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Abstract 
The research outlined in this thesis aims to further our knowledge of the biological 
characteristics underlying the aggressive behaviour by which pancreatic cancer invades 
and metastasises at an early stage and is refractory to most chemotherapeutic drugs. 
Investigation into drug resistance in pancreatic cancer involved pulse-selection of three 
cell lines with epirubicin, taxotere and gemcitabine. The drug-selected cell lines, in 
general, displayed low changes in sensitivity to their respective selecting drugs and no 
obvious cross-resistance profile. However, drug treatment modulated the invasive 
potential of the pulse-selected cell lines.  
Expression of multi-drug resistant proteins (P-gp and MRP-1) was also determined by 
IHC in 45 pancreatic tumour specimens, results suggested a contributory role for P-gp 
expression in pancreatic cancer. 
 
An in vitro pancreatic invasion model was established by single cell cloning of MiaPaCa-
2, yielding sub-clones displaying diverse invasive properties. The malignant phenotypes 
of MiaPaCa-2, Clone #3 (highly invasive) and Clone #8 (poorly invasive) were 
characterised, comparative proteomic profiling by 2-D DIGE, MALDI-TOF MS and 
RNAi revealed three targets, ALDH1A1, VIM and STIP1 with functional involvement in 
the invasion process. ALDH1A1 appeared to play a role in the aggressive invasive 
phenotype; expression was associated with increased invasion, drug resistance and 
decreased adhesion. VIM and STIP expression was also linked to increased invasion and 
decreased adhesion, with STIP1 displaying a role in proliferation, which has not 
previously been described. Factors secreted into conditioned media of Clone #3 and Clone 
#8 was also examined by proteomics. Targets, GSN and ALDH1A1 were chosen for 
functional analysis and their potential involvement in cancer cell invasion assessed. 
 
EGFR/HER2 expression was analysed in 5 pancreatic cancer cell lines, and two cell lines 
which co-expressed EGFR and HER2 were tested with lapatinib. Lapatinib, a dual 
EGFR/HER2 inhibitor in combination with chemotherapeutic drugs showed additive 
interactions, suggesting the possibility of a therapeutic role for lapatinib in combination 
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1.0 Introduction 
1.1 Pancreatic cancer 
 
Pancreatic cancer is a devastating disease and is the tenth most common cause of cancer in 
Europe (Ferlay et al., 2007). Approximately 170,000 new cases of pancreatic cancer 
(2.1% of total cancers) occur worldwide every year (Parkin et al., 1999). In Ireland, 
pancreatic cancer is the 11th most common invasive cancer in men and women, is 
responsible for 5% of cancer related deaths and has the lowest 5-year relative survival for 
patients diagnosed between 1995 and 2000 (National Cancer Registry Ireland, 2000). 
It is the most fatal malignancy; all-stage 5-year survival rate is less than 5% (Jemal et al., 
2002). The lethality of this cancer is related to its rapid growth and tendency to invade 
adjacent organs and metastasise at an early stage. Patients generally present at an 
unresectable stage, due to the asymptomatic nature of the disease. Surgery offers the best 
possibilities for survival; however, fewer than 15% of patients are eligible for resection at 
time of diagnosis. Cancer of the pancreas is more common in males than females and in 
the older individual; the highest incidence has been reported in black American males. 
Several causes and associations have been linked to the occurrence of pancreatic cancer. 
The risk of pancreatic cancer is increased 3-fold by diabetes. Other factors such as 
pancreatitis, pernicious anemia, cystic fibrosis and familial adenomatous polyposis 
increase the risk of contracting the disease (Ghadirian et al., 2003). Smoking is the 
strongest environmental cause of pancreatic cancer with an increased risk of 
approximately 2-fold (Lowenfels and Maisonneuve, 2004). 
Apart from surgical resection at early diagnosis, no therapy has been found to elicit a good 
response. At present radiation and chemotherapy only show a limited effect in fighting 
pancreatic cancer. 
Pancreatic carcinoma appears to be inherently resistant to a wide variety of 
chemotherapeutic agents, which can differ greatly and are unrelated with respect to 
molecular structure and target specificity. 
 
  2 
1.1.1 Genetics of pancreatic cancer 
Pancreatic cancer can occur through the accumulation of inherent and acquired genetic 
alterations. Tumour suppressors and oncogenes contribute to the development of 
pancreatic cancer. Tumour suppressor genes code for proteins which control cell 
proliferation, and loss of these genes through mutations, deletion or chromosomal 
reorganisation leads to deregulated growth. Oncogenes are mutated forms of proto-
oncogenes that cause normal cells to grow out of control and cause cancer. Proto-
oncogenes are the genes that control normal cell division and differentiation. When a 
proto-oncogene mutates into an oncogene, the gene is permanently turned-on or activated 
which leads to increased cell division. 
 
1.1.2 Tumour suppressors in pancreatic cancer 
Pancreatic cancer is associated with several inactivated tumour suppressor genes such as 
p53, p16, p21, SMAD4/DPC4 and p27. Both copies of a tumour suppressor gene must be 
inactivated, i.e. mutations in both alleles must occur for there to be a loss in the gene 
product (Hruban et al., 1998).   
 
The p53 tumour suppressor gene is inactivated in approximately 50% of pancreatic 
cancers (Pellegata et al., 1994; Slebos et al., 2000). P53 controls cell cycle at the G1/S 
interface and plays a vital role in inducing programmed death in response to DNA 
damage. Taghavi et al. (2007) determined that restoration of wild-type p53 function could 
be used to eliminate the tumourigenic phenotype in two pancreatic tumour cell lines; 
CRL1420, which contains elevated levels of mutant p53, and CRL1682, with no 
detectable p53 protein. Expression of wild-type p53 decreased the growth rate of 
CRL1420 and completely suppressed its potential for tumour formation in nude mice. The 
size of the tumours formed in nude mice by CRL1682 was reduced drastically. Neither of 
the cell lines irrespective of the status of p53 was arrested at G1 in response to x-
irradiation. Thus, these results provide functional evidence that the deletion or mutational 
inactivation of the p53 gene represents an important step in the tumourigenicity of 
pancreatic cancer. Cascalló et al. (2005) showed that in a human xenograft model, 
sequential administration of gemcitabine and restoration of p53 resulted in potent tumour 
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growth inhibition. Statistical differences were observed with respect to the growth of 
tumours receiving only gemcitabine or p53. This data indicates that reintroduction of p53 
function in human pancreatic tumours in vivo allows the restoration of molecular 
pathways improving the response to gemcitabine. Eisold et al. (2004) examined whether 
the combination of adenovirus-mediated (Ad) wild-type (wt) p53 gene transfer and 5-
fluorouracil (5FU) chemotherapy effects pancreatic cancer cells with different p53 gene 
status. Human and rat pancreatic cancer cell lines, with p53 mutation, wild-type and null 
were used for in vitro studies. Ad-p53 gene transfer combined with 5-FU significantly 
inhibited tumour cell proliferation and substantially enhanced apoptosis in all cell lines 
with an alteration in the p53 gene compared to cell lines containing (Ad) wt-p53. In vivo 
experiments showed the most effective tumour regression in animals treated with Ad-p53 
plus 5-FU. Both in vitro and in vivo analyses revealed that a sublethal dose of Ad-p53 
increased the apoptotic response induced by 5-FU. These results suggest that Ad-p53 may 
synergistically enhance 5-FU-chemosensitivity most strikingly in pancreatic cancer cells 
lacking p53 function. These findings illustrate that the anticancer efficacy of this 
combination treatment is dependent on the p53 gene status of the target tumour cells. 
 
P16 is an inhibitor of cyclin-dependent kinases (CDKs), which complexes with cyclin-D. 
Loss of p16 function results in release of activated transcription factors and progression of 
the cell cycle through the G1/S checkpoint (Cowgill et al., 2003). P16 acts on 
retinoblastoma (RB1) to form a negative feed-back loop that regulates the ability of RB1 
to prevent cell proliferation. Deletions or mutations in p16 expression can affect the 
relative balance of functional p16 and cyclin-D, resulting in abnormal cell growth 
(Sirivatanauksorn et al., 1998). Liu et al. (1995) observed deletions of both exons 1 and 2 
of MTS-1 (MTS-1 encodes p16, an inhibitor of cyclin-dependent kinase 4 (cdk4) which 
complexes with cyclin D1) in 50% of pancreatic cancer cell lines and an additional 30% of 
pancreatic cancer cell lines show point mutations or microdeletions based on DNA 
sequencing. Loss of p16 expression has been reported in 25-100% of pancreatic cancers 
(Xu et al., 2006; Caldas et al., 1994; Naumann et al., 1996) and is associated with higher 
incidence of lymph node metastasis (Jeong et al., 2005). Loss of p16 expression is 
associated with decreased survival, increased tumour size and risk of metastasis (Garcea et 
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al., 2005). The presence p16 alterations, correlates with a worse prognosis in resected 
pancreatic cancer patients (Gerdes et al., 2002). 
 
SMAD4/DPC4 tumour suppressor gene is deleted/lost in approximately 50% of invasive 
pancreatic cancers (Hahn et al., 1996; Tang et al., 2002). SMAD4 regulates signal 
transduction of the transforming growth factor β (TGFβ) superfamily (Levy et al., 2005). 
SMAD4 mediates down-regulation of E-cadherin induced by TGF-β in the pancreatic 
cancer cell line, Panc-1, at least in part, through Snail and Slug induction (Takano et al., 
2007). Peng et al. (2002) determined the role of SMAD4 in the suppression of tumor cell 
growth and in the regulation of TGF-β-mediated expression of cell-cycle regulatory genes 
p15 (ink4b) and p21(waf1). Over-expression of SMAD4 by adenoviral infection in 
pancreatic cancer cell line, Capan-1 (no SMAD4 expression) reduced anchorage-
independent growth by more than 50%, and inhibited xenograft tumour growth. However, 
over-expression of SMAD4 in CFPac-1 cells (SMAD4 homozygously deleted) did not 
inhibit CFPac-1 growth. Interestingly, SMAD4 induced expression of p15(ink4b), 
p21(waf1), and TGF-β-responsive reporter gene in Capan-1 but not in CFPac-1 cells.  
 
1.1.3 Tumour oncogenes in pancreatic cancer 
Pancreatic cancer is associated with many mutated oncogenes. These oncogenes can be 
classified into groups; growth factors and their receptors, signal transducers, transcription 
factors and programmed cell death receptors. Examples of oncogenes associated with 
pancreatic cancer include c-met, platelet-derived growth factor (PDGF), EGFR and HER2, 
abl and K-ras, myc and bcl-2. 
 
Mutations in K-ras are found in 80-100% of pancreatic cancer patients (Lemoine et al., 
1992; Rozenblum et al., 1997). The ras family of oncogenes encode for proteins with 
GTPase activity and can switch on signal transduction pathways. Ji et al. (2007) reported 
that K-ras activates hedgehog signalling in pancreatic cancer, utilising a down-stream 
effector pathway mediated by RAF/MEK/MAPK but not PI3K/AKT. Brummelkamp et al. 
(2002) used a retroviral RNA interference (RNAi) system to inhibit the expression of 
mutated K-rasv12 while leaving other ras isoforms unaffected. These studies showed that 
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small interfering RNA (siRNA) for K-ras decreases anchorage-independent growth in the 
pancreatic cancer cell line, Capan-1. Fleming et al. (2005) found that silencing mutant K-
ras through RNAi results in alteration of pancreatic cancer tumour cell behaviour in vitro. 
Furthermore, after K-ras RNAi, there was a reduction in angiogenic potential of both 
pancreatic cancer cell lines. Panc-1 cells increased the level of expression of 
thrombospondin-1, an endogenous inhibitor of angiogenesis, whereas MiaPaCa-2 cells 
decreased the production of vascular endothelial growth factor, a primary stimulant of 
angiogenesis in pancreatic tumours. This study suggested that targeting mutant K-ras 
specifically might be effective against pancreatic cancer in vivo. 
Rejiba et al. (2007) examined whether combining K-ras siRNA with gemcitabine has 
therapeutic potential for pancreatic cancer. In vitro, the treatment of tumour cell cultures 
with the corresponding K-ras siRNA resulted in a significant inhibition of endogenous k-
ras expression and cell proliferation. In vivo, tumour xenografts were significantly reduced 
with K-ras siRNA (GAT) delivered by electroporation. The combined treatment with K-
ras siRNA(GAT) plus gemcitabine resulted in strong growth inhibition of orthotopic 
pancreatic tumours. Survival rate was significantly prolonged and the mean tumour 
volume was dramatically reduced in mice receiving the combined treatment compared 
with single agents.  
These recent reports show that targeting mutant K-ras through specific siRNA might be 
effective for K-ras oncogene silencing and tumour growth inhibition.  
 
The oncogene c-Met is a 190 kDa tyrosine kinase receptor, consisting of a heterodimer of 
two disulphide linked chains of 50 kDa (alpha) and 145 kDa (beta) which is synthesised as 
a 170 kDa precursor that is glycosylated and cleaved to give the active protein (Giordano 
et al., 1989). The c-met proto-oncogene encodes a transmembrane tyrosine kinase receptor 
(Met) that has the capacity to modulate cell proliferation and differentiation; it is activated 
by the hepatocyte growth factor (HGF) or scatter factor (SF). 
 Over-expression of c-Met has been reported in biliary tract carcinomas (Nakazawa et al., 
2005) and colorectal cancers (Zeng et al., 2004). Ebert et al. (1994) reported co-over-
expression of c-Met and HGF in pancreatic cancer, indicating that both regulatory proteins 
may participate via an autocrine or paracrine mechanism to promote pancreatic cancer cell 
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invasion. Hansel et al. (2004) examined global gene expression profiles from well-
differentiated non-metastatic (n=5) and metastatic (n=7) pancreatic endocrine neoplasms 
to determine molecular markers that predict disease progression. This study confirmed the 
over-expression of Met in metastatic versus non-metastatic pancreatic endocrine 
neoplasms (5 of 15, 33% versus 4 of 24, 17%), as well as in lymph node metastases (4 of 
7, 57%) and liver metastases (5 of 9, 56%) by immunohistochemistry. 
 
1.1.4 Genetic alterations predisposition for pancreatic cancer  
Familial pancreatic cancer is hereditary predisposition that is responsible for 
approximately 3% of pancreatic cancer cases. Analysis of the family history can help 
individuals to identify risks of developing pancreatic cancer. These include distinct 
hereditary cancer syndromes such as; Peutz-Jeghers syndrome, hereditary pancreatitis, 
familial atypical multiple mole melanoma syndrome, hereditary breast and ovarian cancer 
syndrome and hereditary non-polyposis colorectal cancer.  
BRCA1 and BRCA2 encode proteins that are involved in cell cycle regulation and DNA 
repair (Boulton, 2006). Inherited or germ-line mutations in these genes has been identified 
as predictors of breast and ovarian cancer (Wooster et al., 2003). Recently, Couch et al. 
(2007) suggested that BRCA2 mutations accounts for 6% of moderate and high-risk 
pancreatic cancer families. Other genetic mutations such as STK11/LKB1, CDKN2A/p16, 
PRSS1 are association with pancreatic cancer (Zalatnai, 2006). The identification of 
germline mutations in genes predisposing to pancreatic cancer could be used for a more 
precise risk assessment for the development of pancreatic cancer. This may allow the 
application of screening methods for the detection of early pancreatic cancer in high-risk 
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1.2 Chemotherapy for pancreatic cancer 
 
Chemotherapeutic drugs used in combination assays and proliferation assays throughout 




Epirubicin (Figure 1.2.1), doxorubicin (adriamycin) and daunorubicin are members of the 
anthracycline class of antineoplastic drugs. Doxorubicin is an anthracycline antibiotic 
isolated from Streptomyces peucetius. Epirubicin is the semi-synthetic drug derived from 
doxorubicin; it forms a complex with DNA by intercalation of its planar rings between 
nucleotide base pairs. Intercalation results in complex formation which inhibits DNA, 
RNA and protein synthesis. It also triggers DNA cleavage by topoisomerase II α, resulting 
in initiation of cell death (Minotti et al., 2004). Binding to cell membranes and 
proteasomes may also be involved in the compound's cytotoxic effects. The drug binds to 
the proteasome in the cytoplasm forming an anthracycline-proteasome complex that 
translocates into the nucleas via nuclear pores. The drug then dissociates from the 
proteasome and binds to DNA (Kiyomiya et al., 2001). 
Epirubicin also generates free radicals that cause cell and DNA damage. It inhibits DNA 
helicase activity, preventing the enzymatic separation of double-stranded DNA and 
interfering with replication and transcription. The anti-proliferative and cytotoxic activity 
of epirubicin is thought to result from these or other possible mechanisms. 
Epirubicin is favoured over doxorubicin, the most popular anthracycline, in some 
chemotherapy regimens as it appears to cause less side-effects. Epirubicin has a different 
spatial orientation of the hydroxyl group at the 4' carbon of the sugar, which may account 
for its faster elimination and reduced toxicity. Epirubicin is primarily used against breast 
and ovarian cancer, gastric cancer, lung cancer, and lymphomas. Epirubicin and 
gemcitabine have been tested in combination to treat advanced pancreatic cancer (Neri et 
al., 2002). In a phase II trial, Ianniello et al. (2001) showed how the regime offered a 
feasible approach for the improvement of treatment for advanced pancreatic cancer. 
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Figure 1.2.1 Chemical structure of epirubicin (www.chemblink.com). 
 
Common methods of resistance to epirubicin include increased drug efflux, due to the 
over-expression of MDR-1 gene product P-glycoprotein (Pesic et al., 2006) and multidrug 
resistance associated protein, MRP-1 (Breuninger et al., 1995). 
 
1.2.2 Taxanes 
Docetaxel (taxotere) and paclitaxel (taxol) are members of a group of anti-neoplastic 
chemotherapeutic drugs known as the taxanes. Taxotere (Figure 1.2.2) is a semi-synthetic 
taxane derived from a taxane intermediate extracted from the needles of Taxus baccata, 
while taxol was originally isolated from the yew tree Taxus brecifolia. The anti-tumour 
activity of taxanes is attributed to their ability to disrupt the normal process of microtubule 
assembly and disassembly. Microtubules within a cell support cell shape and can act as a 
transport network. They are essential for the reproduction, growth and spread of tumour 
cells. Microtubules are normally reorganised during the mitosis process to form a spindle. 
Guanosine triphosphate (GTP) is required during the assembly of microtubules from 
tubulin. When mitosis is complete, the spindle disappears and the microtubule network 
reforms. Taxanes have a high binding affinity to tubulin, and taxotere has a higher binding 
affinity than taxol (Georgoulias, 2002). Tubulin-binding promotes polymerisation and 
prevents de-polymerisation of the microtubules in the absence of GTP, forming stable 
microtubules that exhibit resistance to microtubule physiologic disassembly. Taxotere 
accumulates within the tumour cells, inhibiting cell proliferation and promoting cell death 
(Eisenhauer and Vermorken, 1998). 
Taxotere displayed variable activity (0-28% response rate) in the treatment of pancreatic 
cancer and has shown a median survival of > 6 months (Okada et al., 1999; Rougier et al., 
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2000). Taxotere has been combined with gemcitabine for treatment of unresectable 
metastatic pancreatic cancer; results show response rates of 7.4-33% and the best median 
survival of 7 months (Androulakis et al., 1999). 
 
Resistance to taxotere is associated with two major mechanisms: over-expression of P-gp 
(Bradley and Ling, 1994; Gottesman and Pastan, 1993) and altered expression α- and β-
tubulin binding activity (Cabral and Barlow, 1989; Haber et al., 1995). 
 
 
Figure 1.2.2 Chemical structure of taxotere (www.taxotere.com). 
  
1.2.3 Gemcitabine 
Gemcitabine (2', 2'-difluorodeoxycytidine: dFdC), an anti-metabolite, is an S-phase 
nucleoside deoxycytidine analogue. It is a pro-drug that needs to be metabolised before it 
can exert its toxic effects. It has three modes of action: it competes for incorporation into 
DNA, hence inhibiting DNA synthesis (Huang et al., 1991); prevents DNA repair by 
masked termination; and undergoes self potentiation and inhibits ribonucleotide reductase 
(Shore et al., 2003) (Figure 1.2.3). 
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Gemcitabine has been widely used for the treatment of head and neck, non-small lung 
cancer and has now emerged as the keystone of chemotherapy for pancreatic cancer. 
 
 
Figure 1.2.3 Mode of Action of Gemcitabine (Shore et al., 2003). 
Gemcitabine resistance may be caused by increased ribonucleotide reductase activity 
(Jordheim et al., 2005) and decreased dCK activity (Achiwa et al., 2004), which decreases 
the phosphorylation of gemcitabine (Figure 1.2.4). Feng et al. (2006) reported that 
treatment of two human head and neck cancer cell lines with gemcitabine stimulates 
phosphorylation of EGFR. EGFR down-regulation did not occur at the level of 
transcription (RT-PCR), but instead occurred via phosphorylation and ubiquitination of 
the receptor along a proteosome/lysosome-mediated pathway. These results suggest that 
EGFR degradation may be a novel mechanism for gemcitabine-mediated cell death.  
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Figure 1.2.4 A. Schematic diagram of the metabolism of gemcitabine. B. The 
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1.2.4 Platinum compounds 
Cisplatin (cis-diamminedichloro-platinum (II)) (Figure 1.2.5 (A)) and carboplatin (cis-
diammine-1,1-cyclobutandicarboxylateplatinum (II)) (Figure 1.2.5 (B)) are platinum 
compounds commonly used in cancer chemotherapy. These platinum agents form strong 
chemical bonds with thiol sulphurs and amino nitrogens in proteins and nucleic acids. The 
cytotoxicity of platinum agents is due to the formation of intrastrand cross-links in the 
DNA (Brabec and Kasparkova, 2002). The cross-link adducts in the DNA lead to G2 
arrest and apoptosis, due to the inability of the cells to transcribe the Pt-damaged DNA 
and produce mRNA essential for mitosis (Sorenson and Eastman, 1988). 
Cisplatin is mainly used to treat solid tumours such as testicular, germ cell, bladder, head 
and neck cancer. Palmer et al. (2007) performed a randomised phase 2 trial of neoadjuvant 
chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine 
combined with cisplatin. This study concluded that combination therapy with gemcitabine 
and cisplatin is associated with a high resection rate and an encouraging survival rate, 
suggesting that further study is warranted. 
 






Figure 1.2.5 Chemical structure of (A) cisplatin and (B) carboplatin 
(www.dsch.univ.trieste.it) 
 
Mechanisms of platinum resistance include decreased uptake of the drug into the cells, 
inactivation of the drug by cellular thiol compounds, enhanced repair of the platinum-
related DNA damage and the absence of mismatch repair (Papouli et al., 2004), and 
increased GSH-based detoxification (Godwin et al., 1992). 
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1.2.5 Capecitabine (5’dFUrd)                                                                                   
XELODA (capecitabine) is a fluoropyrimidine carbamate with anti-neoplastic activity. It 
is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR or 
5’dFUrd)) which is converted to 5-fluorouracil. 
Capecitabine has substantial activity in patients with locally advanced or metastatic breast 
cancer, after failure of taxane or anthracycline chemotherapy (Blum et al., 1999). 
Capecitabine is metabolised in the liver by carboxylesterase to 5'-deoxy-5-fluorocytidine 
(5’dFCR), and then converted to 5’dFUR. Finally, 5’dFUR is converted to the cytotoxic 5-
FU by thymidine phosphorylase (Figure 1.2.6) in tumour and normal tissue (Ishikawa et 
al., 1998). These metabolites exert their toxic effects by thymidylate synthase (TS) 
inhibition and incorporation into RNA and DNA (Schellens, 2006). TS is bound by 
capecitabine metabolite, FdUMP. This binding complex prevents the formation of 
thymidylate from 2'-deoxyuridylate. TS is essential for the synthesis of 2'-
deoxythymidine-5'-monophosphate, a precursor for DNA synthesis (Rustum, 2004). 
Therefore, deficiency of this compound inhibits cell division. Nuclear transcription 
enzymes can incorporate FUTP in place of UTP during RNA synthesis; this metabolic 
error interferes with RNA processing and protein synthesis (FDA, 2000). 
Capecitabine in combination with gemcitabine, in the treatment of advanced/metastatic 
pancreatic cancer improved the median overall survival, but not significantly compared to 
gemcitabine alone (Herrmann et al., 2007). Capecitabine in combination with trastuzumab 
(Herceptin) caused complete remission of a patient with recurrent breast cancer and liver 
metastasis (Morohashi et al., 2007). The combination of capecitabine and trastuzumab has 
been further validated in a phase II study of HER2 over-expressing advanced/metastatic 
breast cancer. Schaller et al. (2007) showed that the combination of capecitabine and 
trastuzumab is highly active in patients with HER2 over-expressing anthracycline- and/or 
taxane-pretreated breast cancer, with only slight restrictions regarding quality of life. 
These recent studies suggest that the combination of capecitabine and EGFR/HER2 
targeting therapies could possibly be used to treat other cancer at advanced/metastatic 
stage. Geyer et al. (2006) demonstrated in a randomised trial that lapatinib, an 
EGFR/HER2 inhibitor, increases the efficacy of capecitabine, compared to capecitabine 
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alone in patients with advanced or metastatic breast cancer who have developed resistance 
to trastuzumab-based therapy. The median time to progression was 8.4 months in the 
combination-therapy group as compared with 4.4 months in the monotherapy group. 
Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-
positive advanced breast cancer that has progressed after treatment with regimens that 
included an anthracycline, a taxane, and trastuzumab. 
 
 
Figure 1.2.6 Chemical structure of capecitabine and its main metabolites. 
Abbreviations: 5'-DFCR, 5'-deoxy-5-fluorocytidine; 5'-DFUR, 5'-deoxy-5-
fluorouridine; 5-FU, 5-fluorouracil; 5-FUH2, 5-fluorodihydrouracil; FdUMP, 5-
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1.3 Multi-drug resistance 
 
Multi-drug resistance (MDR) is defined as the ability of cancer cells to develop cross- 
resistance to chemotherapeutic drugs. The resistance profile seems to be unrelated to 
molecular structure or target specificity. The multi-drug resistance increases during 
chemotherapy treatment and is multi-factorial, as several pathways and cellular 
mechanisms are involved. The most widely studied MDR mechanisms are the over-
expression of the MDR-1 gene/P-glycoprotein (P-170/P-gp) and the multi-drug 
resistance associated protein (MRP-1). Other factors associated with increased drug 
resistance include, the lung resistance protein (LRP), topoisomerase IIα, glutathione S 
transferase (GST), increased repair of drug-induced DNA damage, blocked apoptosis and 
alterations in cell cycle control and signalling pathways (Filipits et al., 2000). 
The MDR phenotype represents a major obstacle for effective chemotherapy. Such 
resistance may develop during drug treatment, referred to as acquired resistance, or 
maybe an inherent feature of the tumour known as intrinsic resistance.  
 
1.3.1 Drug resistance in pancreatic cancer 
Resistance of pancreatic cancer to multiple drugs is frequently encountered. Such 
resistance may be acquired during drug treatment, or may be an inherent feature of 
pancreatic cancer. This severe resistance is linked with treatment failure and poor 
prognosis. 
Over-expression of the multidrug resistance protein, P-glycoprotein (P-gp) and the 
multidrug resistance protein (MRP-1) in cancer cells have been linked with the 
development of simultaneous resistance to a great variety of cytotoxic drugs. P-
glycoprotein is a 170-kDa integral plasma membrane protein, which contains 12 putative 
transmembrane regions and two ATP binding sites. It confers multidrug resistance by 
functioning as an energy-dependent drug efflux pump (Germann et al., 1993). MRP-1 is 
involved in cancer drug resistance and in the transport of glutathione and glucuronate 
conjugates, as well as anionic drugs out of the cell (Figure 1.3.1). 
This ability of P-gp and MRP-1 to act as drug efflux pumps, transporting 
chemotherapeutic drugs out of the cells, renders the chemotherapy ineffective. 
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Chemotherapy for advanced pancreatic cancer is often considered palliative and due to the 
intrinsic and/or acquired resistance to chemotherapeutic drugs the rate of survival of 
pancreatic cancer is very low. 
 
Lage and Dietel (2002) established a P-glycoprotein-mediated multidrug resistant 
pancreatic cell line induced by daunorubicin (DRB)-selection, and an alternative drug 
resistant phenotype due to treatment with mitoxantrone (MTX) to investigate further the 
complex multimodal mechanisms of resistance in pancreatic cancer. The DRB-variant was 
1,800 times more resistant and the MTX-selected cell line was 8 times more resistant than 
the parental cell line. The DRB-selected variant showed considerable over expression of 
ABC-transporter protein P-gp by Western blot and RT-PCR, while the MTX cell line 
exhibited no enhanced expression of P-gp at either the mRNA or protein level. There was 
however, a constitutive expression of MRP-1 protein in both drug selected cell lines and 
the parent. Accumulation assays were performed to investigate the level of drug uptake in 
these cell lines. The results showed decreased accumulation of drugs, mitoxantrone and 
daunorubicin in the DRB selected variant, which may be explained by the activity and 
presence of P-gp in this cell line. However, in the MTX-variant reduced accumulation of 
the drugs was also observed indicating that an alternative mechanism unrelated to P-
gp/MRP-1 transport proteins is involved in the decreased up-take of drugs in this cell line. 
 
Recently, it has been shown that MRP-1 has been found in some MDR phenotypes in the 
absence of P-gp. The structurally distinct MRP-1 drug resistant protein is similar to P-gp 
as it also causes resistance to a wide variety of hydrophobic drugs. It is located in the 
plasma membrane and causes decreased drug accumulation and increased drug efflux in 
cells (Zamann et al., 1994).  
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Figure 1.3.1: Schematic Diagram of MRP-1 (www.sigmaaldrich.com). 
 
Miller et al.  (1996) examined the expression of both P-gp and MRP-1, and their function 
as drug efflux systems in pancreatic ductal adenocarcinoma (PDA). Functional expression 
of P-gp was examined using Rhodamine 123 (R123), an indicator of P-gp activity; results 
suggested there was no functional P-gp present in the cell lines PANC-1, BxPc-3 and 
AsPc-1 whereas the incidence of MRP-1 expression in the cell lines (3 out of 4 cell lines) 
suggests that MRP-1 is an important contributor to the resistance of pancreatic cancer to 
chemotherapeutic drugs.  
 
Verovski et al. (1996) developed a pancreatic tumour cell line resistant to doxorubicin, 
which displayed multidrug resistance not conferred by P-gp. Over-expression of the 
vesicular marker lung resistance-related protein (LRP) and MRP-1 were associated with 
the MDR phenotype.  
 
However, P-gp may have an important contribution in the development of acquired 
resistance after exposure to drug treatment. 
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Liu et al. (2001) verified the acquired resistance caused by P-gp in a study examining the 
effect of taxotere on the pancreatic carcinoma cell line SUIT-2 and its taxotere selected 
variant S2/TXT, established by drug selection with increasing taxotere concentrations (0.1 
nM to 2 nM). The TXT-variant was 9.5-fold more resistant than the parental cell line. RT-
PCR was used to establish the level of MDR-1 expression in both cell lines. The parental 
line SUIT-2 showed no MDR-1 expression while the S2/TXT line expressed MDR-1. 
However, MDR-1 was also expressed when the parental line was exposed to 0.4 nM 
taxotere for 24 hrs. This shows that the MDR-1 gene is expressed when treated with a 
chemotherapeutic agent and highlights the fact that P-gp may mediate acquired resistance 
to taxotere in pancreatic cancer. 
 
König et al. (2005) studied the expression and localisation of the human MRP family, 
(MRP1-MRP9) and the breast cancer resistance protein, (BCRP) in normal human 
pancreas (n=6) and pancreatic carcinoma (n=31). Quantification of mRNA levels showed 
BCRP, MRP-1, MRP-3, MRP-4 and MRP-5 were most abundantly expressed in 37 tissue 
samples. The expression of BCRP, MRP-1 and MRP-4 mRNA did not show a relationship 
with tumour stage or grading. However, the mRNA level of MRP-3 was up-regulated in 
pancreatic carcinoma samples and correlated with tumour grading. The MRP-5 mRNA 
showed significantly increased expression in pancreatic carcinoma samples compared to 
normal pancreas samples. 
Among the MRP family members, MRP-3 shares the highest amino acid sequence identity 
(58%) with MRP-1 and both localise to the basolateral membranes of polarised cells 
(König et al., 1999). In humans, MRP-3 expression is highest in the adrenal glands and 
the intra-hepatic bile ducts, followed by moderate to low expression in the small intestine, 
kidney and pancreas (Kool et al., 1997). Zelcer et al. (2001) characterised the drug 
specificity of MRP-3, and showed that MRP-3 conferred resistance to etoposide and 
methotrexate. 
MRP-5 is an organic anion transporter, as it pumps efflux anionic fluorochromes. In 
addition, intracellular glutathione levels have been shown to be depressed in MRP5-
transfected cells (Wijnholds et al., 2000). 
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This data suggests that both MRP-3 and MRP-5 may play a considerable role in drug 
resistance in pancreatic carcinoma and that quantitative investigation into their expression 
may prove to be a predictive advantage for patients with pancreatic cancer. 
 
1.4 Multi-drug resistance, invasion and metastasis 
 
The relationship between drug resistance, invasion and metastasis has not been fully 
elucidated. However, there is evidence suggesting a link, as cell lines selected for drug 
resistance are more invasive/metastatic compared to non-resistant parental cells (Liang et 
al., 2002).  
 
1.4.1 Invasion and metastasis 
Metastasis is defined by the ability of tumour cells at the primary site to invade local 
tissue and to cross basement membrane and tissue barriers and to re-establish at distant 
secondary locations. 
Tumour invasion and metastasis are major causes of treatment failure and death in cancer 
patients. Intrinsic aggressiveness of the tumour and histological grade may be responsible 
for the divergence of metastasis in cancers of comparable size. The heterogeneous nature 
of some tumours leads to sub-populations of highly metastatic tumour cells existing at 
very early stages of primary tumour development (Fearon and Vogelstein, 1990).  
Secondary metastases in vivo are commonly more resistant to chemotherapeutic treatment 
compared to the primary tumours (Goswami et al., 2004).  
 
1.4.2 The metastatic cascade 
The process of metastasis is not random. A cascade of complex interactions between the 
cancer cell and its surroundings results in the metastatic cascade (Table 1.4.1). To initiate 
the metastatic cascade, tumour cells must first break signalling contact with neighbouring 
cells, degrade and penetrate the basement membrane and then invade the interstitial 
stroma in order to reach blood/lymph vessels (Ray et al., 1994). Intravasation requires 
penetration of the blood/lymph systems. The tumour cells must then exit the lymph system 
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or blood stream at a new site (extravasation) and proliferate in the secondary organ 
(Deryugine et al., 2006) (Figure 1.4.1). 
It is important to note that although metastasis is an intentional, effective event it is an 
inefficient development, as the majority of invading/metastatic cells do not survive the 
process. Millions of tumour cells are shed into the circulation daily. However only 0.01% 
of circulating tumour cells initiate a successful metastatic focus, the rest having been 
destroyed by a combination of mechanical stresses, proteolytic degradation and 
surveillance by the immune system (Cameron et al., 2000). 
  
1.4.3 Invasion and metastasis in pancreatic cancer 
The process of invasion and metastasis in pancreatic cancer is responsible for 90% of 
pancreatic cancer deaths in patients. At diagnosis, nodal involvement is found in 80% of 
cases and visual metastases are detected in 50% of cases. Among the remaining non-
metastatic patients, approximately 1 in 5 has undetected peritoneal cancer (André et al., 
1998). The most common sites of metastasis of pancreatic adenocarcinoma are the liver, 
the peritoneum (the thin membrane lining of the abdominal cavity) and the lungs 
(Nakahashi et al., 2003; Neoptolemos et al., 2003). 
Numerous in vitro studies and in vivo analyses of animal models have indicated that cells 
isolated from metastases differ greatly (both genetically and phenotypically) from cells 
isolated from their parental primary tumours. Therefore, sub-populations of primary 
tumour cells seem to obtain metastatic properties during later stages of tumour progression 
(Fidler and Kriple, 1977). In contrast, studies also indicate that it is not small sub-
populations of the primary tumour that have metastatic capacity, but rather most of the 
cells in the tumour. Bernards and Weinberg (2001) suggest that the potential for 
metastasis is determined early in tumourigenesis, which explains why most cells in a 
primary tumour express the molecular signature that is associated with metastatic tumours.  
A review by Pantel and Brakenhoff (2004) suggests metastatic spread might follow two 
models; both of which are complementary but take different specific routes. The first 
model is refers to lymph node metastasis. Cancer cells during the early stages of tumour 
growth disseminate from the original primary tumour to the lymphatic or vascular system. 
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In this model, cancer cells form solid metastases in the lymph nodes. Further metastases 
then occur from the lymph nodes to distant sites, and it is possible that this ability was 
gained during the selection of these cells in the lymph-node environment. The second 
model involves the development of solid metastases at distant sites as a result of 
dissemination through the blood. In this model cells do not passage through the lymphatic 
system. Kayahara et al. (2007) investigated the precise pattern of neural invasion and the 
relationship between neural invasion and nodal involvement in pancreatic cancer. 
Histological evaluation of pancreatic cancer specimens revealed a connection between 
cancer cells inside lymph nodes and cancer cells within the perineural space, suggesting 
tumour cells in the perineural space grow in a continuous fashion and may be responsible 
for some cases of lymphatic spread.  
There is increasing evidence that in epithelial malignancies, loss or down-regulation of 
expression of the structures responsible for the maintenance of tissue integrity correlates 
with an increasing tendency for metastatic spread. Such de-adhesion acts as a prelude to 
the cells invading the extracellular matrix (Ahmad and Hart., 1997).   
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Steps       Mechanisms involved 
Transformation and growth Oncogene activation/ suppressor 
inactivation 
Detachment from original tumour and 
attachment to extracellular matrix (ECM) 
components 
Loss of E-cadherin, integrins 
Disruption and invasion through surrounding 
tissue or ECM/basement membrane 
MMP, uPA, cathepsin activity 
Attachment to basement membrane of the 
vascular endothelium of the lymphatic or 
blood vascular channel 
Altered integrin expression 
Intravasculation into the blood/lymph vascular 
channel 
Protease activity 
Adhesion to the blood/lymph wall E-selectin, mucins, V-CAM,       
I-CAM, Integrins 
Survival and transportation through the 
blood/lymph vessels and avoid immune 
mediated destruction 
IGF survival factors, 
Downregulation of intrinsic 
immunogenicity 
Lodgement in the capillary of tissue and 
attachment to the endothelium or basement 
membrane of the tissue 
Integrins, laminin, collagens, 
fibronectin 
Extravasation- exit the vessel wall and enter 
perivascular, interstitial connective tissue 
Protease activity 
Proliferation and induce angiogenesis within 
new environment 
Organ specific growth factors, 
VEGF, HGF,EGFR 
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1.4.4 The extracellular matrix- basement membrane 
The extracellular matrix (ECM) is a complex structural entity surrounding and supporting 
cells and organs within the body.  The main function of the basement membrane is cell 
and tissue support. Epithelial, endothelial and many mesenchymal cells are supported by 
this thin sheet-like ECM structure. It consists of 4 main components; structural proteins, 
collagens and elastin; specialised proteins, fibronectin and laminin; proteoglycans and 
glycosaminoglycans. 
Three main proteins will be discussed, collagens, fibronectin and laminin. 
 
1.4.4.1 Collagen                 
The collagens are the most abundant family of fibrous proteins found in all animals. It is 
the major protein comprising the ECM. Collagens are secreted in the form of propeptides 
and are converted to collagen molecules by specific proteolytic enzymes, which reside 
outside the cells. The collagens then assemble in the extracellular space to form collagen 
fibres. There are at least 12 types of collagen. Type I, II and III are the most abundant and 
form fibrils of similar structure. These collagens are characterised by their long, helical 
structure. Three alpha chains coil together to form a triple superhelix. Collagens are also 
rich in proline and hydroxyproline. The bulky pyrollidone rings of proline reside on the 
outside of the triple helix (Brown et al., 2006). 
Type IV collagen forms a two-dimensional reticulum and is a major component of the 
ECM organised as a thin sheet beneath the epithelia known as the basal lamina (40-120 
nm thick). Collagens are predominantly synthesised by fibroblasts but epithelial cells also 
synthesise these proteins. These basic structures organise the extracellular matrix and give 
it resilience. Molecules of this type of collagen have a more flexible structure then 





  25 
1.4.4.2 Fibronectin 
Fibronectin was the first well-characterised adhesive protein. It is built up of multiple 
domains, each with specific binding sites for other matrix macromolecules and for 
receptors on the surfaces of cells. Fibronectin is a large glycoprotein that is found in all 
vertebrates. It exists as a dimer composed of two very large subunits, 60-70 nm long and 
2-3 nm thick, joined by a pair of disulfide bonds near their carboxyl termini. Each subunit 
is folded into a series of functionally distinct domains separated by regions of flexible 
polypeptide chain. Fibronectin contains at least six folded domains, each with a high 
affinity for collagen, heparin, fibrin and specific integrins on the surfaces of various types 
of cells. Expression of fibronectin has been shown to have a direct influence on the 
establishment and maintenance of the transformed phenotype (Ruoslahti et al., 1999). 
Adhesion to fibronectin mediated by integrin α5β1 is responsible for improved survival of 
different cell lines, including breast carcinoma (Varner et al., 1995) and pancreatic cancer 
(Vogelmann et al., 1999). 
1.4.4.3 Laminin                                                                                                              
Laminin anchors cell surfaces to the basal lamina. Laminins are flexible four-armed, 850 
kDa glycoproteins. Laminin monomers polymerise into 3D structures in a time- and 
concentration- dependent manner. As an initial step in metastasis, many epithelial tumours 
exhibit altered localisation or expression of laminin-binding integrins (e.g. α6β4/α6β1). 
This promotes invasion through the basement membrane and increases motility in the 
stroma, where tumour cells can remodel the matrix by depositing laminin (Hood and 
Cheresh, 2002). Increased expression of laminin binding proteins correlates with 
aggressive growth and with the ability to metastasise in pancreatic tumour tissues 
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1.4.5 The proteases involved in metastasis 
Proteolytic enzymes play a fundamental role in cancer progression. The process of 
invasion is not a passive one due to pressure from excessive cellular proliferation alone 
but is an active, dynamic process that requires protein synthesis and degradation. A critical 
proteolytic event early in the metastatic cascade appears to be the degradation of basement 
membrane (Gobin and West, 2002). 
Tumour cells secrete enzymes to degrade the extracellular matrix barriers in order to 
intravasate successfully. Almost all cells of the tumour and host environment over-express 
one or more of these enzymes. Degradation of the basement membrane is not dependent 
solely on the amount of proteolytic enzymes present but on the balance of activated 
proteases and their naturally occurring inhibitors (Kohn et al., 1995).  
Many proteases are capable of degrading ECM components and can be classified into 4 
major classes: 
 
1. Matrix metallproteinases (MMPs) 
2. Serine proteinases 
3. Cathepsins 
4. Cysteine proteinases. 
 
1.4.5.1 Matrix metalloproteinases 
Matrix metalloproteinases are a family of secreted or transmembrane proteins that are 
capable of digesting basement membrane components. These proteolytic enzymes have 
been involved in the remodelling of connective tissue in many conditions such as 
embryonic growth and development, ovulation, menstruation and wound healing. 
However over-production of these proteases is known to contribute to cancer progression 
(Coussens and Werb 1996). 
Currently there are over 20 known members, which share functional and structural 
characteristics and can be categorised into the collagenases, gelatinases, stromelysin and 
membrane-type MMP sub families (Table 1.4.2). 
 
 
  27 
Table 1.4.2 Family of matrix metalloproteinases (MMPs) 




MMP-3 MMP-1 MMP-2 (MT-MMP1) 
MMP-14 
MMP-18 
MMP-7 MMP-8 MMP-9 (MT-MMP2) 
MMP-15 
MMP-19 
MMP-10 MMP-13   (MT-MMP3) 
MMP-16 
MMP-20 
MMP-11     (MT-MMP4) 
MMP-17 
MMP-21 
MMP-12    MMP-24 MMP-23 
 
MMPs have a zinc-binding domain at their catalytic site; they are secreted as zymogens 
and are regulated through gene transcription, proteolytic cleavage and by their natural 
inhibitors, the tissue-specific inhibitors of matrix metalloproteinases (TIMPs). 
Biologically active agents such as growth factors, hormones, oncogenes and tumour 
promoters transcriptionally regulate MMP activation. TIMPs inhibit MMPs by forming 
tight 1:1 stoichiometric, non-covalent complexes with either the pro-enzyme or the 
activated MMP, or by controlling their autocatalytic activation. Their expression is also 
influenced by local cytokines and growth factors. 
MMP-2 activation involves the membrane bound MMP type I (MT-MMP1). TIMP2 binds 
to the inactive MT-MMP1, which allows proMMP-2 to bind and form a complex on the 
cell surface and then acts as a substrate for a second MT-MMP1 molecule. This results in 
the conversion of MMP-2 into its active form, suggesting that MT-MMP1 expression 
level is closely related to invasion and malignancy of tumours (Sato et al., 2005). 
Four TIMPs have been identified (Brew et al., 2000). TIMP-1, TIMP-2, TIMP-4 are 
secreted proteins while TIMP-3 is anchored in the ECM. 
Studies have demonstrated a positive correlation between MMP expression, invasive 
behaviour and metastatic potential in tumours such as breast (Kim et al., 2006), prostate 
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(Aalinkeel et al., 2004), colon (Murray et al., 2004), lung (Fang et al., 2005), ovarian 
(Herrera et al., 2002) and pancreatic cancers (Bloomston et al., 2002).  
Degradation of extracellular membrane proteins in the basement membrane such as 
collagen type IV is a critical event in early tumour invasion, suggesting that MMP-2 and 
MMP-9, which degrade collagen IV are particularly important. MMP-2 and MMP-9 
expression in pancreatic cell lines correlates with the in vitro invasive potential of cell 
lines (Yang et al., 2001). 
Jones et al. (2004) showed that MMPs 7, 8, 9, 11 and TIMPs 1 and 3 were highly 
expressed in 75 pancreatic adenocarcinomas compared to 10 normal pancreas samples by 
immunohistochemistry and real time RT-PCR. MMP-15 was under expressed in the 
tumours by RT-PCR; however this was not confirmed by immunohistochemistry. MMP-
11 expression is associated with lymph node involvement, while MMP-7 predicted 
survival. MMP-7 up regulation has been identified as an early event in tumour 
development (Yamamoto et al., 2001). MMP-7 expression is limited to epithelial cells, 
rather than the stroma and is produced mainly by the tumour cells and can increase the 
invasive potential of the tumour cells (Powell et al., 1993). 
 
1.4.5.2 Serine proteases 
Serine proteases are characterised by a serine residue at their active site and are produced 
in an inactive form. Members of this family include elastin, cathepsin G and B, thrombin, 
plasmin, plasminogen, tissue-type plasminogen activator (tPA) and urokinase type 
plasminogen-activator (uPA). uPA converts inactive plasminogen to active plasmin. 
Plasmin is capable of degrading a wide variety of ECM components as well as activating 
other proteinases, such as MMPs. uPA is mainly detected in the cell membrane fraction 
and high levels have been found in gastric tumours with metastatic spread occurring 
between normal colonic epithelium and carcinoma (Plebani et al., 1995). 
 
1.4.5.3 Cathepsins 
Cathepsins are lysosomal enzymes involved in cancer due to their proteolytic activity. 
Cathepsin D is an aspartic proteinase, cathepsin B and L are cysteine proteinases and 
cathepsin G is a serine proteinase. 
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Cathepsin D has been extensively studied in tumour invasion and metastasis. Over-
expression of cathepsin D has been shown in several neoplasms including gastric, colon 
and breast, where relapse and metastasis is related to high levels of cathepsin D (Ahamad 
and Hart, 1997). However, in pancreatic cancer expression of cathepsin D did not 
correlate to nodal invasion or metastasis to liver or lung (Ruppert et al., 1997). 
Cathepsin B and L are cysteine-rich proteases, characterised by a cysteine-rich residue at 
their active site and are lysosomol proteases capable of ECM degradation (Ahmad and 
Hart, 1997). Cathepsin B levels in B16 murine melanoma correlated with metastatic 
potential of the tumour (Qian et al., 1989). Cathepsin B expression has been demonstrated 
to have prognostic implications, whereby expression levels correlate with tumour grade, 
lymph node metastasis in some tumours. Ohta et al. (1994) demonstrated that over-





Integrins are a large family of heterodimeric transmembrane glycoproteins that attach cells 
to extracellular matrix proteins of the basement membrane or to ligands on other cells i.e. 
they mediate direct cell-cell recognition and cell-matrix interactions (Hynes, 1992). 
Integrins contain large α (120-170KDa) and small β (90-100KDa) subunits non-covalently 
bound (Figure 1.5.1 A). To date, 24 distinct heterodimers have been described. These 
heterodimers are integral cell membrane receptors that form focal adhesion contacts with 
various ECM-ligands, such as collagens, fibronectin, laminin, vitronectin. Ligand binding 
specificity depends on the specific α and β chains present in the heterocomplex. Members 
of integrin subfamilies bind to many ECM ligands therefore the presence of multiple 
integrins on cells that identify the same ligands allows for overlapping recognition 
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Figure 1.5.1 A. Structure of integrin heterodimer (dan1.medkem.gu.se) and B. The 
integrin family of adhesion receptors and their main ligands (www.chuv.ch). 
 
1.5.1 Integrins in invasion and metastasis 
Malignant transformation is characterised by disruption of the basement membrane, 
cytoskeletal remodelling, decreased adhesion and altered cell motility. Many studies 
suggest that various integrin subunits can contribute either positively or negatively to the 
transformed cell phenotype. Changes in the expression of fibronectin-binding integrins 
have been observed in malignant cells. Integrin α5β1, the main fibronectin receptor, is 
down-regulated in poorly differentiated breast carcinoma. However over-expression of the 
fibronectin receptor in transfected sarcoma S180 cells enhances their motility on 
fibronectin. Increased integrin αvβ3, the vitronectin receptor appears to be positively 
correlated with increased malignancy in melanoma, whereby the integrin complex 
expression is a molecular marker for the change from radial growth phase (RGP) to the 
metastatically competent vertical growth phase (VGP). Hsu et al. (1998) introduced β3 
into RGP melanoma cell lines subsequently converting them to VGP-like melanoma cells. 
Altered expression of α6-containing integrins is found in various tumours. In hepatoma 
cell lines, attachment to laminin is mediated by integrin α6β1 (Torimura et al., 1999). 
This complex was also over-expressed and functionally active in metastatic human 
pancreatic carcinoma cells and participates in metastasis formation through binding to 
laminin (Vogelmann et al., 1999). The expression of the fibronectin-binding subunit α5 
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appears to be decreased in pancreatic tumour tissue. In general, the loss or gain of 
expression of particular integrins appears to be indirectly implicated in malignant 
transformation and may be directly involved in tumour progression and metastasis. 
 
1.5.2 Integrins and proteolytic enzymes 
Integrins are needed in cell movement, but they may also have other roles in cancer 
invasion and metastasis. Importantly, they induce the expression of different ECM 
degrading proteases, especially members of the MMP family. The interplay between 
integrins and the matrix metalloproteinases may be one of the key phenomena in the 
invasion process. Integrin complex α3β1 recognises fibronectin, collagen type IV and 
laminin, and is up-regulated in certain tumours. Sugiura et al. (1999) demonstrated that 
ligation of α3β1, in the breast cell line MDA-MB-231, with monoclonal antibodies 
specifically stimulates production of MMP-2 and induces invasive protusions within 
matrigel. Integrin adhesion to laminin and antibody-induced clustering of integrin α3β1, 
also enhanced the secretion of MMP-2 in rhabdomyosarcoma and glioblastoma cells 
(Kubota et al., 1997; Chintala et al., 1996). Other integrins have been associated with 
tumour progression and metastasis; αvβ3 has been identified as a tumour progression 
marker in melanoma. It co-localises with MMP-2 on the surface of melanoma cells 
thereby facilitating tumour cell invasion by degradation of the ECM (Hofmann et al., 
2000). The signalling pathways that link integrin receptors and MMP activation are poorly 
understood. Up-regulation of collagen by MMP-1 was prevented by tyrosine kinase 
inhibitors in osteosarcoma cells (Riikonen et al., 1995). Klemke et al. (1994) observed 
that the epidermal growth factor (EGF) promotes αvβ5-dependent pancreatic carcinoma 
cell migration on vitronectin and is dependent on the activation of the EGF receptor and 
protein kinase C (PKC). 
 
1.5.3 Integrins and anoikis 
Anchorage-dependent cells that are deprived of the ability to bind immobilised ECM 
undergo apoptosis, a process referred to as anoikis (Frisch and Screaton, 2001).  Anoikis is 
the apoptosis of cells that have lost contact with extracellular matrix, or that interact with 
matrix through an inappropriate integrin-matrix combination. It is important for 
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embryonic development (gastrulation) and mammary gland involution. Anoikis occurs 
through established apoptotic signalling pathways, which depend upon cell type. These 
include caspases of the initiator (caspase-8) and effector (caspase-3, 7) types as well as 
protein kinases such as MEKK- 1. Cells undergoing anoikis display typical apoptopic 
characteristics: nucleosomal DNA ladder formation, cell shrinkage, caspase 
activation/cleavage of caspase substrates and cytochrome c release from mitochondria 
(Marco et al., 2003). Protection against anoikis is afforded by the activation of certain 
other kinases such as FAK and PI3K/Akt. Upon integrin ligation, FAK is phosphorylated 
and begins a signalling complex (Figure 1.5.2). The FAK signalling complex mediates and 
activates pathways such as PI3K and its downstream targets protein kinase B (PKB/AKT), 
the ERK and JNK/MAPK pathway (Grossmann, 2002). Sensitivity to anoikis is frequently 
lost in tumour cells, which probably contributes to their ability to grow independently of 
anchorage and metastasise. This sensitivity can be lost by activation of oncogenes such as 
ras, alterations in intracellular apoptosis components, over-expression of growth factors 
such as EGF, HGF or IGF-related molecules, or breakdown of cadherin-catenin 
complexes. 
 
Figure 1.5.2 Integrin signalling pathways (www.chuv.ch). 
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1.6 The epithelial to mesenchymal transition (EMT) 
 
Epithelial to mesenchymal transition (EMT) is the process by which epithelial cells lose 
their strong intracellular adhesion and their basolateral polarity to gain front-end to back-
end polarity, and the ability to migrate through the ECM (Savagner, 2001). As cells lose 
cell-cell contact, new cell-ECM interactions are generated. Thus, many cell surface-
associated adhesion molecules change function and are the source of signals that activate 
growth, ECM degradation and metastasis (DeClerck, 2004).  
A variety of indicators exist for the EMT phenotype (Figure 1.6.1). Intermediate filament 
proteins provide a convenient and abundant marker, with keratins indicating an epithelial 
phenotype and vimentin indicating a mesenchymal phenotype (Hay, 1995). The epithelial 
state is characterised by the presence of the epithelial cell adhesion molecule E-cadherin 
and/or the associated catenins, forming the adherens junctions. These cell-cell adhesion-
related criteria are almost entirely absent in mesenchymal cells (Birchmeier et al., 1996). 
Several other groups of molecules have been implicated in physiological and pathological 
EMT pathways, including cell-cell adhesion molecules, cell-ECM adhesion molecules, 
proteases, transcription factors, growth factors and cytoskeletal proteins. 
The molecular changes that occur during EMT also include reorganisation of other cell-
cell contact complexes (tight junctions, desmosomes), modification of cell-substrate 
adhesion complexes, synthesis of ECM proteins normally expressed by mesenchymal 
cells, and the expression of several proteases including matrix metalloproteases (MMPs). 
The ability to scatter, migrate and degrade ECM components is associated with a 

















Figure 1.6.1 Molecular traits of the EMT. Epithelial and mesenchymal cells are 
shown schematically, and the differences commonly seen between them are grouped 
into four major categories: Cell-cell contacts, cytoskeleton, ECM synthesis, and 
protease expression (Holland and Frei, 2003). 
EMT plays an important role in tumour invasion and metastases, and its detection may 
have a significant prognostic implication in pancreatic cancer. Yosuico et al. (2006) 
examined the expression of EMT related proteins in resected pancreatic cancers and 
correlated the results with clinical outcome. Pancreatic cancer patients (n=34) who 
underwent pancreatectomy were included. Immunohistochemical staining for vimentin, E-
cadherin, MIB-1 (Ki-67 nuclear fraction) and cytokeratin were performed on formalin 
fixed paraffin-embedded tissues. The results were correlated with clinicopathological 
parameters and survival. There was a significant negative association between vimentin 
and E-cadherin expression. Vimentin expression correlated with histological grade. 
        Mesenchymal 
 
Cell-cell contact 






















Laminin, collagen type IV 
 
Protease expression 
Low or absent 
        MET 
 EMT 
  35 
Therefore, decreased E-cadherin expression (<50% expression) was associated with 
poorer survival, as E-cadherin expression had an inverse correlation with vimentin.  
The role of cadherins (calcium-dependent adhesion molecules) has been investigated as 
inducers of EMT. E-cadherin (epithelial cadherin) has been implicated in EMT, as the loss 
of its expression has been found to correlate with an invasive and undifferentiated 
phenotype in pancreatic carcinoma (Karayiannakis et al., 2001; Joo et al., 2002) as well as 
gastric (Jawhari et al., 1997), prostate (Richmond et al., 1997) and colorectal cancer 
(Karatzas et al., 1999; Hugh et al., 1999). N-cadherin (neural cadherin) over-expression is 
associated with high invasive potential. Nakajima et al. (2004) immunohistochemically 
investigated N-cadherin expression and the role of EMT in pancreatic carcinoma. N-
cadherin expression was observed in 13/30 primary tumours and 8/15 metastatic tumour 
samples. Its expression correlated with neural invasion, histological type, fibroblast 
growth factor expression in primary tumours and with TGF and vimentin expression in 
metastatic tumours. Vimentin, a mesenchymal marker, was observed in a few cancer cells 
of primary tumour but was substantially expressed in liver metastasis. TGF stimulated N-
cadherin and vimentin protein expression and decreased E-cadherin expression of Panc-1 
cells with morphological change. This study provides morphological evidence of EMT in 
pancreatic carcinoma and revealed that over expression of N-cadherin is involved in EMT 
and is affected by growth factors.  
Yin et al. (2006) studied the implication of EMT induced by TGF-β1 in pancreatic cancer 
invasion. TGF-β1 expression was determined in 29 cases of human pancreatic carcinoma 
(PC) by immunohistochemistry and the results were compared with those of pathological 
examination. The effects of TGF-β1 on the phenotype and invasion of pancreatic cancer 
cell line Panc-1 were also investigated. TGF-β1 was detected in 12 cases (41.4 %) of PC. 
Significant correlation was found between the expression of TGF-β1 and lymph node 
involvement and the depth of invasion. TGF-β1 promoted EMT of Panc-1 cell lines and 
their invasion ability was substantially enhanced. TGF-β1 may promote the malignancy of 
pancreatic cancer by triggering EMT. TGF-β1 induces EMT in A549 alveolar epithelial 
cells via Smad2 activation (Kasai et al., 2005). 
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The transcription factors Snail and Slug (zinc-finger proteins) have been linked as 
repressors of E-cadherin expression (Bolos et al., 2003). Barrallo-Gimeno et al. (2005) 
proposed that Snail genes act primarily as survival factors and inducers of cell movement, 
rather than as inducers of EMT. Twist, another transcription factor, is also known to 
trigger EMT. Twist is essential in the expression of N-cadherin in Drosophilia 
embryogenesis (Oda et al., 1998). Studies have shown that up-regulation of Twist is 
associated with the malignant transformation of melanoma and T-cell lymphoma (Yang et 
al., 2006). An increased N-cadherin level in gastric carcinomas is due to Twist over-
expression (Rosivatz et al., 2002). Hotz et al. (2007) reported that Snail and Slug are 
expressed in pancreatic cancer but not normal tissue.  
Recent reports have shown that MMPs can stimulate Snail expression, and consequently 
activate the EMT (Radisky, 2005). Przybylo and Radisky (2007) showed that by exposing 
mouse mammary cells SCp2, to MMP-3 the EMT phenotype is stimulated. Increased cell 
motility, down-regulation of epithelial cytokeratins, expression of Snail and up-regulation 
of mesenchymal marker vimentin were observed. Expression of Snail was dependent on 
MMP-3, as withdrawal of MMP-3 caused a rapid decrease in Snail levels. Yokoyama et 
al. (2003) showed that three E-cadherin negative squamous cell carcinoma (SCC) cell 
lines had a fibroblastic morphology, strong expression of vimentin, and expressed Snail. 
Compared to other E-cadherin positive SCC cells, these cells showed higher invasive 
ability and expression of MMP-2. Over-expression of Snail in A431 cells resulted in the 
loss of E-cadherin expression, the change of their morphology to fibroblastic, and the up-
regulation of vimentin, indicating that an EMT was induced by Snail. Furthermore, these 
cells became more invasive and showed higher levels of MMP-2 activity and its gene 
expression. Luciferase analysis demonstrated that the MMP-2 promoter activity was 
induced by Snail transfection and the promoter region from -262 to -411 relative to the 
transcriptional start site was necessary for this induction. These results indicate that Snail 
is a new inducer of MMP-2 expression and suggest that the EMT contributes to the 
increased invasion not only through the inhibition of cell-cell adhesion but also the up-
regulation of MMP-2 expression in SCC cells. Several signaling pathways have been 
found to be important in EMT, these include tyrosine kinase signaling, the Ras pathway, 
integrin-linked kinase (ILK) and integrin signaling, Wnt/ -catenin, Notch, Rac1b and 
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reactive oxygen species (ROS), and the phosphatidylinositol 3' kinase (PI3K)/AKT 
pathway (Figure 1.6.2) (Larue and Bellacosa, 2005).  
 
Figure 1.6.2 Diagram of the signal transduction pathways involved in the epithelial–
mesenchymal transition (Larue and Bellacosa, 2005). 
 
Activation of the PI3K/AKT signaling cascade is a central feature of EMT. The oncogenic 
serine/threonine kinase AKT is a downstream effector of PI3K (Batlle et al., 2000).          
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AKT is frequently up-regulated and activated in ovarian (Altomare et al., 2004), breast 
(Bakin et al., 2000) and pancreatic tumours (Javle et al., 2007). AKT is involved in many 
basic cellular processes, including cell cycle progression, cell proliferation, cell survival, 
metabolism and EMT (Grille et al., 2003). AKT activation can contribute to the neoplastic 
phenotype. AKT can enhance invasiveness of pancreatic carcinoma cells via up-regulation 
of IGF-I (Tanno et al., 2001). Furthermore, EMT induced by activated AKT involves loss 
of cell–cell adhesion (including down-regulation of E-cadherin) and morphological 
changes, caused by the up-regulation of the mesenchymal marker vimentin (Grille et al., 
2003). Induction of cell motility, enhanced tumour cell invasion, decrease in cell–matrix 
adhesion and suppression of apoptosis link AKT activation to metastatic tumour 
progression (Jallal et al., 2007; Kim et al., 2002). 
During tumour progression loss of cell-cell adhesion leads to the invasive phenotype. 
Integrins, which mediate adhesion to extracellular matrix components, play a critical role 
in directing the migration of cells and these receptors also may have an important role in 
EMT. Bates et al. (2005) found that EMT activated the integrin β6 subunit and 
consequently caused induction of the complex αvβ6 in colon carcinoma. Enhancement of 
tumourigenetic properties were observed, including activation of autocrine TGF-ß and 
migration on interstitial fibronectin. Kaplan-Meier analysis of β6 expressions in 488 
colorectal carcinomas revealed a reduction in median survival time of patients with high 
β6 expression. Cox regression analysis confirmed that this integrin is an independent 
variable for these tumours. These findings define the αvβ6 integrin as an important risk 
factor for early-stage disease and a novel therapeutic candidate for colorectal cancer. 
Promotion of EMT in cancer cells has been shown to be activated by signalling of 
integrins through integrin-linked kinase (ILK), activating rac and downstream pathways 
(Persad and Dedhar, 2003). Over-expression of constitutively active ILK results in loss of 
cell-cell adhesion, anchorage-independent growth and tumourigenicity in nude mice. 
Down-regulation of E-cadherin and loss of β-catenin from cell–cell adherence junctions 
are also induced by activated ILK signalling (Novak et al., 1998). ILK over-expression 
can activate AP-1 transcription factor that regulates genes required for EMT. Sawai et al. 
(2006) demonstrated that ILK and β1-integrin play important roles in the enhancement of 
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adhesive and invasive capabilities of pancreatic cancer cells through p38 MAPK signaling 
pathway and AP-1 activation. Over-expression of ILK enhanced the IL-1α-induced p38 
MAPK phosphorylation more strongly through GSK-3 activation, and subsequently 
induced AP-1 DNA-binding activity, promoting expression of genes involved in 
pancreatic cancer cell adhesion and invasion. 
 
1.7 Proteomic analysis  
Since the successful sequencing and mapping of the human genome, proteomic analysis 
has focused on identification, localisation and functional analysis of protein complements 
expressed by the genome (Neet and Lee, 2000).  
Genomic technologies such as microarrays are used for the detection of specific gene 
changes within, for example, diseased tissue compared to normal tissue. Microarrays are 
artificially constructed grids of DNA in which each element of the grid contains a specific 
oligodeoxynucleotide probe. Microarray experiments rely on the ability of RNA to bind 
specifically to a corresponding sequence-complementary probe. This enables researchers 
to simultaneously measure the expression of thousands of genes in a given sample. High 
throughput sequencing of DNA and the subsequent storage and annotation of the data is 
an advantage of gene profiling. However, interpreting data and adapting the results to a 
particular application remains a challenge. Also, the process is complex and focuses on the 
information of one target molecule, DNA, in the nucleus of cells. Studies have shown that 
differential mRNA expression does not always correlate with protein expression (Gygi et 
al., 1999; Anderson and Seilhamer, 1997) 
Distinct changes may occur during the transformation of a healthy cell to a neoplastic cell 
that may not be apparent in gene changes. The location, structure and function of proteins 
can change dramatically within an organism due to malignant transformation, cell cycle 
and external/internal signalling. Thus, the quantity and complexity of the data derived 
from the sequencing and mapping of the human proteome are estimated to be at least three 
times greater than that involved in the human genome project (Sellers et al., 2003). 
  40 
The field of proteomics is particularly important because most diseases are manifested at 
the level of protein activity. Therefore, proteomics is an invaluable tool in the direct 
correlation of the involvement of specific proteins, protein complexes and their 
modification status to a disease state.  
1.7.1 2D-DIGE MALDI-TOF MS 
Two-dimensional difference gel electrophoresis (2D-DIGE) is a high performance 
proteomic technology, allowing quantitative protein expression profiles across many 
clinical specimens in a reproducible, sensitive and high-throughout manner. Initially 
described by O’Farrell (1975), proteins in a 2D gel are separated by two separate unrelated 
elements. The first dimension step is isoelectric focusing (IEF), which separates proteins 
according to their isoelectric points (pI). The second dimension step, SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE), separates proteins according to their molecular weights.  
Fluorescent spectrally resolvable dyes used to prelabel proteins have added to the 
multiplexing capability of 2D DIGE methodology. The CyDye DIGE Fluor dyes (Cy2, 
Cy3 and Cy5) are matched for mass and charge, but possess distinct excitation and 
emission spectra. The Cy dyes minimally label the lysine residues of proteins; the dyes 
undergo nucleophilic substitution reaction with the epsilon-amino group of lysine residues 
on the protein resulting in the formation of an amide bond. The dye: protein ratio is 
optimised so that only 3-5% of the protein sample is labelled. This method ensures that 
proteins with a single dye molecule are visualised, resulting in co-migration of proteins 
originating from separate samples. Consequently, the same protein labelled with any of 
the dyes will migrate to the same position on the 2D gel. By using different dyes to 
separately label proteins isolated from normal and diseased tissues, multiple samples (up 
to three) can be co-separated and quantitated by three different set of wavelengths (Figure 
1.7.1). The inclusion of a pooled internal standard (Cy2), containing every protein from all 
samples is used to match protein patterns across gels. This feature, counteracts inter-gel 
variation, allows normalisation of individual experiments and accurate quantification of 
differences between samples with significance (Alban et al., 2003; Unlu et al., 1997; 
Gharbi et al., 2002). 










Figure 1.7.1 Outline of 2D DIGE system where three CyDye DIGE Fluor minimal 
dyes are separated in one gel  
The fully optimised system (including CyDye fluorescent dyes, imager, and DeCyder 
Differential Analysis Software) offers increased throughput, ease of use, reproducibility, 
and accurate quantitation of protein expression differences. Reduced system variability 
enables accurate study of protein expression differences against a baseline of biological 
variation. DeCyder biological variation analysis (BVA) processes multiple gel images, 
performs gel-gel spot matching and quantatively compares protein abundance across gels.  
Mass spectrometry identifies the proteins corresponding to any spots observed by 2D-
DIGE and utilises the gene and literature database to interpret the proteomic data. Matrix-
assisted Laser Desorption/Ionisation (MALDI) developed by Karas and Hillenkamp, 
(1988, 1990) involves the precipitation of sample molecules with an excess of matrix 
material (α-cyano-4-hydroxycinnamic acid or dihydroxybenzoic acid), the precipitant is 
then bombarded with a laser pulses and imparts energy. The matrix materials have 
absorbances at the wavelength of the laser, and are subject to desorption and ionisation, 
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accompanied by fragmentation. The MS measures the mass-to-charge ratio (m/z) of the 
protein, peptide or peptide fragments (Figure 1.7.2). The time-of-flight (TOF) analyser 
separates ions according to their m/z ratios by measuring the time it takes for ions to travel 
through a field free region known as the flight or drift tube. The smaller ions possess 
higher velocity relative to larger/heavier ions. Separated ion fractions arriving at the end 
of the drift tube are detected by an appropriate recorder that produces a signal upon impact 
of each ion group. The TOF mass spectrum is a recording of the detector signal as a 
function of time. This peptide mass fingerprint can then be used to search databases to 













Figure 1.7.2 A schematic diagram of the mechanism of MALDI-TOF-MS (Yates, 
2000) 
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1.7.2 Bioinformatics 
Bioinformatic approaches can determine the proteomic signatures responsible for the 
important clinical-pathological features and identify a small number of key proteins, 
which may be candidates for disease markers and therapeutic targets. Bioinformatics is the 
collection, organisation and analysis of large amounts of biological data, using networks 
of computers and databases. General information about proteins can be obtained using 
SWISS-PROT and NCBI. Other proteomic databases, such as Bioinfomatic harvester, 
Open proteomics and Pubmed, search all that is known about a protein’s interactions and 
its related gene. Software packages are available to analyse proteomic data e.g. 
PathwayStudio and Gene Ontology (GO STAT). PathwayStudio is a product aimed at the 
visualisation and analysis of biological pathways, gene regulation networks and protein 
interaction maps. It comes with a comprehensive database that gives a snapshot of all 
information available in PubMed, with the focus on pathways and cell signalling 
networks. This product allows visualisation of results in the context of automatically 
created pathways, gene regulation networks and protein interaction maps. The GO STAT 
consortium provides structural description of protein function that is used as a common 
language for gene annotation in many organisms. Large-scale techniques have generated 
many valuable protein-protein interaction datasets that are useful for the study of protein 
function (Deng et al., 2004).  
Combination between 2D-DIGE, mass spectrometry and bioinformatics approach is a 
powerful tool for disease proteomics. The efforts to understand the overall features of the 
proteome by using a bioinformatics approach to analyse 2D-DIGE data, together with the 
integrated information of the individual proteins identified by 2D-DIGE, will give us 
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1.7.3 Proteomics and cancer  
Genetic mutations within cancer cells can modify protein signalling through expression of 
differential isoforms, post-translational modifications and altered pathways. Therefore, 
cancer proteomics can be characterised into expression proteomics and functional 
genomics. Expression proteomics seeks to identify proteins that are differently displayed 
in tissues that can be used as markers for cancer detection, diagnosis, and in the 
development of novel treatments. Functional proteomics, on the other hand, is related to 
how proteins interact with each other, with DNA and RNA, or as components of larger 
complexes. This approach recognises that proteins are part of a dynamic system, and that 
just identifying individual proteins is not adequate to explain their function. The capability 
of proteomics to identify and determine proteins associated with cancer is enhancing and 
improving molecular classifications of tumours and furthermore, developing more 
sensitive bio-markers for disease prognosis and treatment sensitivity.   
 
Page et al. (1999) carried out an extensive study of the protein expression map (PEM) of 
the normal human breast (luminal and myoepithelial), which can be compared to future 
breast cancer studies. Using 2D gel proteome analysis, 43,302 proteins were detected 
across 20 samples; each cell type comprising a total of 1,738 unique proteins. Differential 
analysis detected 170 proteins that were elevated two-fold or more between the cell types 
indicating the scope of protein abundance between cell types.  
 
A strategy for combining proteomic analysis and microdissection of human normal tissue 
versus tumour tissue was described by Emmert-Buck et al. (2000). Normal squamous 
epithelium and corresponding tumour cells from two patients with esophageal cancer were 
obtained by laser-capture microdissection and studied by two-dimensional polyacrylamide 
gel electrophoresis (2D-PAGE). 50,000 cells resolved approximately 675 distinct proteins 
(or isoforms). Comparison of the microdissection protein profiles identified 17 proteins 
with tumour-specific alterations, including 10 that were unique to tumour cells and 7 that 
were observed only in normal epithelium. Two of the altered proteins were characterised 
by mass spectrometry and immunoblot analysis, and were identified as cytokeratin 1 and 
annexin I. In the future, comparison of 2D-PAGE protein profiles, visualisation of 
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deregulated proteins, and subsequent determination of the identity of selected proteins 
through high-sensitivity MS-MS microdissection protein profiles can be used to analyse 
suspected malignant tumours and diagnose patients with cancer.  
 
The correlation of large-scale protein expression profiles with clinical data could be used 
to gain insights into the molecular aspects of cancer. Voss et al. (2001) systematically 
compared the protein expression patterns by two-dimensional gel electrophoresis with 
clinical features in human B-cell chronic lymphocytic leukaemia (B-CLL), a disease 
characterised by broad clinical variability. Analysis of the pattern from 24 patient samples 
by statistical methods allowed the identification of proteins that clearly discriminated 
between the patient groups with defined chromosomal characteristics or whose expression 
levels did correlate with clinical parameters such as patient survival. The data described 
showed that B-CLL patient populations with shorter survival times exhibited changed 
levels of redox enzymes, heat shock protein 27 and protein disulfide isomerase, suggesting 
a potential role for these molecules in drug resistance. 
1.7.4 Proteomics and pancreatic cancer                                                          
Identification of the pancreatic cancer proteome may help to unravel the molecular events 
that underlie the early invasive/metastatic, inherent chemo-resistant phenotype of this 
disease. Chen et al. (2005) studied the quantitative protein expression of normal pancreas 
versus pancreatic cancer tissue, using isotope-coded affinity tag technology (ICAT) and 
MS. A total of 656 proteins were identified and quantified in two pancreatic cancer 
samples, of which 151 were differentially expressed in cancer by at least 2-fold. Many 
proteins identified provided candidates for future early diagnosis biomarkers and targets 
for therapy. Several differentially expressed proteins were further validated by tissue 
microarray immunohistochemistry. Several of the differentially expressed proteins 
identified were determined to be involved in protein-driven interactions between the 
ductal epithelium and the extracellular matrix that orchestrate tumour growth, migration, 
angiogenesis, invasion, metastasis, and immunologic escape.  
Mikuriya et al. (2007) identified proteins that might be available for early diagnosis and 
effective therapies by proteomic profiling of pancreatic cancer tissues. Pancreatic 
  46 
cancerous and paired non-cancerous tissues were analysed by two-dimensional gel 
electrophoresis. The differential display showed 11 spots whose expression was increased 
in cancerous tissues compared with the paired non-cancerous tissues. The liquid 
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) system identified 
the spots as alpha-enolase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
triosephosphate isomerase, transgelin, calmodulin, superoxide dismutase(Mn) 
mitochondrial precursor, glutathione S-transferase P, cyclophilin A, protein disulfide 
isomerase A3 precursor, and apolipoprotein A-I precursor. Two of the 11 spots were 
detected as GAPDH. Four of 11 spots were enzymes involved in glycolytic pathway. 
Increased glycolysis in cancer cells has been regarded as the effect of intratumoural 
hypoxia and is possibly associated with tumour invasion, metastasis or resistance to 
therapies.  
1.7.4.1 Proteomics and biomarkers in pancreatic cancer  
As pancreatic cancer invades and metastasises at an early stage without symptoms, it is 
vital to develop early detection systems for the diagnosis of pancreatic cancers. Some 
studies have reported proteomic analyses of pancreatic tissue, pancreatic juice as well as 
blood plasma and sera (Kuramitsu and Nakamura, 2006). Molecular markers and 
biomarkers constitute major targets for the early detection of cancer and identification of 
cancer risk (Negm et al., 2002). Proteomics provides an excellent means for analysis of 
body fluids for classifying proteins and identifying biomarkers for early detection of 
cancers. Biomarkers currently available for pancreatic cancer detection, such as CA19-9, 
lack adequate sensitivity and specificity, which may contribute to late diagnosis of this 
deadly disease. Approximately 10% of the population with the Lewis negative genotype 
are not able to produce CA 19-9 due to the lack of the enzyme involved in its synthesis, 
even if they have advanced pancreatic cancer (Goggins, 2005). Honda et al. (2005) 
demonstrated a set of four mass peaks using surface-enhanced laser desorption/ionization 
coupled with hybrid quadrupole time-of-flight mass spectrometry in pancreatic cancer 
plasma, accurately distinguishing their expression from healthy controls in a training 
cohort with a sensitivity of 97.2% and a specificity of 94.4% and in the validation cohort 
with a sensitivity of 90.9% and a specificity of 91.1%. The introduction of this technology 
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has increased the possibility of identifying novel markers with the potential to overtake 
and replace CA 19-9.  
Sun et al. (2007) analysed, by two-dimensional gel electrophoresis (2-DE) and mass 
spectroscopic identification, 10 protein spots significantly changed in pancreatic 
carcinoma and successfully identified 5 proteins including cyclin I, Rab GDP dissociation 
inhibitor beta (GDI2), alpha-1 antitrypsin precursor, Haptoglobin precursor, and 
Serotransferrin precursor. The increased levels of cyclin I and GDI2 found to be 
associated with pancreatic carcinoma were further confirmed by Western blot analyses in 
an independent series of serum samples and/or pancreatic juice samples. Applying 
immunohistochemistry further validated the expression of cyclin I and GDI2 in additional 
pancreatic carcinomas. These results indicate that cyclin I and GDI2 may be potential 
molecular targets for pancreatic cancer diagnostics and therapeutics. 
In a study to characterise the "pancreatic juice proteome" in patients with pancreatic 
adenocarcinoma, Gronborg et al. (2004) identified a total of 170 unique proteins including 
known pancreatic cancer tumour markers (e.g., CEA, MUC1) and proteins over-expressed 
in pancreatic cancers (e.g. hepatocarcinoma-intestine-pancreas/pancreatitis-associated 
protein (HIP/PAP) and lipocalin 2). In addition, novel proteins that had not been 
previously described in pancreatic juice (e.g., tumour rejection antigen (pg96) and 
azurocidin) were detected. The proteins identified in this study could be directly assessed 
for their potential as biomarkers for pancreatic cancer. Hong et al. (2004) identified, by 
proteomic analysis, autoantibodies to calreticulin isoforms in the sera of pancreatic cancer 
patients. The identification of circulating tumour antigens or their related autoantibodies 
provides a means for early cancer diagnosis as well as leads for therapy, as they can arise 
in sera at a relatively early stage of pancreatic cancer. 
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1.8 RNA interference (RNAi) 
 
RNA interference (RNAi) is the mechanism for RNA-guided regulation of gene 
expression, in which the introduction of double-stranded RNA (dsRNA) into a diverse 
range of organisms and cell types causes degradation of the complementary mRNA. Small 
interfering RNAs (siRNA) are double-stranded RNA molecules, 20-25 nucleotides in 
length (Elbashir et al., 2001). The natural role of RNAi is a mechanism for protecting 
against viral infection. The genetic material of most viruses is RNA rather than DNA. 
Eukaryotic cells recognise dsRNA and degrade it into small fragments of 20 nucleotide 
pairs in length by an enzyme known as dicer. These small interfering RNA fragments are 
then used as a template by an enzyme complex called RISC (RNA induced silencing 
complex) to destroy single stranded RNA with the same sequence (Baulcombe, 2006). 
RNAi controls gene expression at the post-transcriptional level, resulting in selective 
silencing of specific proteins (Figure 1.8.1). 
 
Initial evidence of RNAi emerged from work on the genetic modification of petunia 
flowers; over-expression of the gene involved in the purple pigment resulted in loss of 
their original colour and occurrence of white flowers. This was termed ‘cosuppression’ as 
the introduction of extra copies of the transgene caused decreased expression as well as in 
the endogeneous gene (Van der Krol et al., 1990; Napoli et al., 1990). RNAi was first 
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1.8.1 Applications of RNAi 
RNAi is commonly used in biological and biomedical research to study the effect of 
blocking expression of a given gene. Synthetic siRNAs are the most widespread 
application of RNAi; this involves transient transfection of in vitro cultured mammalian 
cells, effectively mediating post-transcriptional gene silencing in cells without inducing 
interferon responses (Elbashir et al., 2001), followed by a downstream assay to monitor 
the RNAi effect. However, the effective delivery of RNAi agents and serum stability in 
vivo is critical for the therapeutic use of siRNA in cancer. SiRNA-mediated RNAi has a 
short duration in vivo; therefore, enhancing the durability of siRNA is essential. 
1.8.2 Delivery of siRNAs in vivo                    
Many different methods for siRNA delivery have been developed,  
• Direct injection delivering siRNA to target organ 
• Viral vector delivery 
• Liposomes  
• Atelocollagen 
Direct delivery of unmodified/naked siRNA in mice is often administrated intravenously 
by hydrodynamic transfection (high pressure tail vein injection). Lewis et al. (2002) co-
injected mice with plasmids expressing luciferase (reporter gene) along with synthetically 
prepared siRNA targeted to luciferase mRNA. Successful suppression of luciferase was 
observed in the liver, spleen, lung, kidney and pancreas. The inherent simplicity and easy 
manipulation of naked RNA makes it an attractive delivery target (Wolff and Budker, 
2005). While this method is widely used and in some cases led to efficient target gene 
inhibition, it may suffer from certain technical and practical limitations at least in a 
therapeutical setting, since it relies on the rapid IV injection of a comparably large volume 
(Aigner, 2006). Alternative strategies for the application of naked siRNAs include various 
delivery routes which, however, often provide a local administration or rely on an 
administration at least close to the target tissue or target organ, thus restricting the number 
of target organs, which may not be relevant for certain diseases. Intranasal administration 
of naked siRNA targeting heme oxygenase-1 (HO-1), a cytoprotective enzyme, led to 
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effective gene suppression and consequently enhanced apoptosis, via increased Fas 
expression and caspase 3 activity, in mouse lung during ischemia-reperfusion (I-R) injury 
(Zhang et al., 2004). 
siRNA delivery by viral vectors utilises 3 main classes of viruses, including the retrovirus, 
adenovirus and lentivirus. Retroviruses were one of the first vectors used to transduct cells 
with plasmids expressing hairpin-shRNA constructs. Despite the relative ease of use in 
vitro, use of the retrovirus in vivo has safety concerns and significant limitations. 
Retroviruses integrate their DNA into the hosts genomic DNA, bringing with it, the risk of 
mutagenesis and carcinogenesis (Xi and Grandis, 2003). Another problem is that retroviral 
transduction is limited to actively dividing cells, which means that the majority of 
mammalian cells will not receive the siRNA.  
Adenoviruses do not commonly integrate DNA into the host’s genome and the effects are 
short-lived, usually lost after several cell divisions. Therefore are used when a short 
duration of action is required, such as tumour-targeting therapy. Zhang et al. (2004) 
intratumourally injected an adenovirus encoding the hypoxia-inducible factor-1 (HIF-1)-
targeted siRNA. Down-regulation of HIF-1 protein in vivo had a small but significant 
effect on tumour growth when combined with ionising radiation. These results suggest 
that an adenovirus-based siRNA gene transfer approach may be a potentially effective 
adjuvant strategy for cancer treatment. However, despite the lowered risk of insertional 
mutagenesis, the adenovirus is associated with significant dose-dependent liver toxicity 
that can severely limit therapy. Another major disadvantage of adenoviral vectors is the 
dependence on specific surface receptors on the target cell which are often absent, 
rendering transduction impossible in many cases.  
Lentiviral vectors are a promising subclass of viruses that lack the risk of insertional 
mutagenesis and are able to transfect primary and non-dividing cells. Lentiviral vectors 
have been shown to successfully transduce and stably express siRNAs in muscle cells 
(Rubinson et al., 2003). Chen et al. (2007) employed lentivirus-mediated siRNA targeted 
to the gene, enhancer of zeste homolog 2 (EZH2). Suppression of EZH2 in hepatocellular 
carcinoma (HCC) cells, reduced their growth rate in vitro and markedly diminished their 
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tumourigenicity in vivo. Moreover, in a mouse model of established large-sized HCC, 
intratumoural injection of lentiviral (Lenti)-shRNA (short hairpin RNA) or siRNA (small 
interfering RNA) targeting EZH2 produced significant tumour regression. 
Non-viral vectors such as liposomes have the advantage of low toxicity, ease of synthesis 
and low immune response over viral vectors. Cationic liposomes and polymer particles 
have been shown to be suitable for the delivery of siRNA. Yano et al. (2004) determined 
that intravenous administration of a liposome complexed with bcl-2 siRNA induced strong 
anti-tumour effects in a mouse model of liver metastasis. Ochiya et al. (2001) developed a 
safe non-vector-based siRNA delivery system, termed atelocollagen. Atelocollagen is a 
biomaterial obtained from type I collagen of calf dermis by pepsin treatment. The 
atelocollagen-based transfer method has great potential for site-specific transportation of 
target siRNAs because the complex of siRNA/atelocollagen becomes solid when 
transplanted and remains so for a defined period in vivo. In addition, an atelocollagen 
complex can be delivered as micro-particles for intravenous injection, making systemic 
delivery of siRNA possible (Sano et al., 2003). 
Minakuchi et al. (2004) determined that atelocollagen complexed with human fibroblast 
growth factor (FGF)-4 siRNA was resistant to nucleases and was efficiently transduced 
into cells, thereby allowing long-term gene silencing. Site-specific in vivo administration 
of an anti-luciferase siRNA/atelocollagen complex reduced luciferase expression in a 
xenografted tumour. Atelocollagen-mediated transfer of siRNA in vivo showed efficient 
inhibition of tumour growth in an orthotopic xenograft model of a human non-
seminomatous germ cell tumour. Clinical applications of siRNA indicate that an 
atelocollagen-based non-viral delivery method could be a reliable approach to achieve 
maximal function of siRNA in vivo. 
RNAi is an invaluable tool, allowing rapid characterisation of the function of known 
genes, as well as aiding the identification of novel genes in disease processes such as the 
cancer invasion/metastatic cascade. 
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1.8.3 RNAi-mediated therapy in pancreatic cancer 
Many molecular alerations play a role in pancreatic tumour progression, early invasion 
and metastasis as well as inherent resistance to chemotherapy and radiation. Therefore, 
challenges exist to identify molecular pathways and genes that are involved in the 
aggressiveness of this cancer.  
Inhibition of target genes through siRNA is an effective therapy to determine the potential 
involvement of specific genes in the pancreatic cancer malignancy. Recent developments 
in RNAi-mediated targeting research in pancreatic cancer are summarised in table 1.8.1. 
 
The k-ras gene is frequently mutated in pancreatic cancer (Lemoine et al., 1992; 
Rozenblum et al., 1997). Brummelkamp et al. (2002) developed a siRNA retroviral vector 
targeting the mutant oncogenic k-ras gene, rather than the wild-type in the pancreatic 
cancer cell line, Capan-1. Down-regulation of k-ras (mut) abolished colony formation in 
vitro and formation of tumours in vivo. In agreement with this study, reduced cell 
proliferation, migration, colony growth and VEGF expression was observed in pancreatic 
cancer cell lines, MiaPaCa-2 and Panc-1 after k-ras knockdown (Flemming et al., 2005). 
 
Targeting the molecules associated with pancreatic cancer progression, including, 
invasion, metastasis and angiogenesis by RNAi represent a powerful tool in anti-cancer 
therapy. Today, numerous genes and proteins have been used to reverse the neoplastic 
phenotype in vitro and in vivo through gene translation silencing. Suppression of genes 
such as, carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) 
(Duxbury et al., 2006), EphA2 (Duxbury et al., 2004), glucose transporter-1 (GLUT-1) 
(Ito et al., 2004) and MUC-1 (Tsutsumida et al., 2006) at the post-transcriptional level 
inhibited tumour cell growth, invasion and metastasis of pancreatic cancer cell lines. 
Nitori et al. (2005) examined the clinicopathologic significance of tissue factor (TF) 
expression in pancreatic ductal adenocarcinoma by immunohistochemistry using a newly 
raised anti-TF monoclonal antibody in 113 patients who had undergone surgical resection 
of pancreatic ductal adenocarcinoma. Increased TF expression correlated with the extent 
of the primary tumour, lymph node metastasis, lymphatic distant metastasis, advanced 
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tumour-node-metastasis stage, and high tumour grade. Multivariate analysis using the Cox 
proportional hazards model showed that high TF expression was an independent negative 
predictor for survival, and patients with TF-negative tumours had a significantly better 
prognosis even if lymph node metastasis was present. Furthermore, this study 
corroborated the clinical data with in vitro TF knockdown by RNA interference. In vitro, 
siRNA targeting TF suppressed the invasiveness of a pancreatic adenocarcinoma cell line, 
suggesting that TF expression may contribute to the aggressiveness of pancreatic ductal 
adenocarcinoma by stimulating tumour invasiveness and that evaluation of the primary 
tumour for TF expression may identify patients with a poor prognosis. 
The inherent drug and radiation resistance of pancreatic cancer is another area for RNAi 
targeted therapy. P-gp, encoded by the MDR-1 gene, has been shown to play a role in 
pancreatic cancer mediated drug resistance (Liu et al., 2001). Nieth et al. (2003) inhibited 
MDR1 expression by RNAi. SiRNA duplexes specifically inhibited MDR1 expression up 
to 91% at the mRNA and protein level in the human pancreatic carcinoma cell line, 
EPP85-181RDB, and resistance against daunorubicin was decreased to 89%. The data 
proved that siRNA-targeting of P-gp expression could be an effective method for reversal 
of drug resistance. The role of survivin, ILK and RRM2 in pancreatic tumour cell 
resistance to chemotherapy and radiation was evaluated by RNAi. Kami et al. (2005) 
silenced survivin at mRNA and protein level in AsPc-1 cells by siRNA, and radiation 
treatment of the cells caused increased capase-3 activity and DNA fragmentation. This 
study is in accordance with others determining that survivin may play a role as a 
radioresistance factor in pancreatic cancer (Asanuma et al., 2000; Rodel et al., 2005; Guan 
et al., 2006). Further studies have implicated survivin in proliferation and apoptosis (Tsuji 
et al., 2005; Guan et al., 2006). 
Enhancing the chemotherapeutic effects of drugs in pancreatic cancer has further been 
evaluated by down-regulated tumourigenetic-related genes which are over-expressed in 
pancreatic cancer. ILK has been previously shown to be linked to the progression of the 
aggressive nature of pancreatic cancer (Sawai et al., 2006). Yau et al. (2005) reported that 
the ILK inhibitor QLT0254 blocked tumour growth and enhanced gemcitabine-induced 
apoptosis in a pancreatic cancer xenograft. This study was further validated, whereby ILK 
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siRNA-mediated knockdown in pancreatic cancer cells induced chemosensitisation to 
gemcitabine via increased caspase 3-mediated apoptosis, suggesting a role for ILK as a 
determinant of pancreatic cancer resistance to gemcitabine (Duxbury et al., 2005). 
Activation of RRM2 which catalyses the conversion of ribonucleotide 5'-diphosphate to 
2'-deoxynucleotide, is associated with chemoresistance to gemcitabine and with the 
invasive potential of pancreatic cancer cells (Jung et al., 2001; Zhou et al., 1998). 
Duxbury et al. (2004) determined that suppression of RRM2 by RNAi resulted in 
enhanced gemcitabine-induced cytotoxicity in vitro, as well as reduced tumour growth, 
increased tumour apoptosis and inhibition of metastasis in pancreatic cancer xenografts in 
vivo. This study demonstrates that systemic delivery of siRNA-based therapy can enhance 
the efficacy of gemcitabine. 
Investigation of potential therapeutic targets in pancreatic cancer has demonstrated that 
RNAi technology can be directed against specific characteristics of this malignant disease. 
Selective and efficient knockdown of genes enables researchers to monitor the specificity 
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Therapeutic effects Reference 
Oncogene K-ras Reduction of cell proliferation, migration and 
VEGF expression 
Brummelkamp et al. (2002) 
Fleming et al. (2005) 
Tumour progression, 
angiogenesis and apoptosis 
CEACAM6 Inhibition tumour growth, angiogenesis and 
enhancement of apoptosis 
Duxbury et al. (2006) 
 TF Suppression of invasion Nitori et al. (2005) 
 EphA2 Inhibition of tumour growth and metastasis Duxbury et al. (2004) 
 GLUT-1 Inhibition of metastasis Ito et al. (2004) 
 MUC-1 Decreased proliferation and reduction of 
metastasis 
Tsutsumida et al. (2006) 
 Notch-1 Decreased cell invasion through reduced MMP-2, 
NF-kappa and VEGF expression in vitro 
Wang et al. (2006) 
Chemo-resistance P-gp Enhancement of chemotherapy Nieth et al. (2003) 
 Survivin Increased caspase-3 and apoptosis Kami et al. (2005); Asanuma et al, (2000)  
Rodel et al. (2005); Guan et al. (2006) 
 ILK Increased capase-3-mediated apoptosis Duxbury et al. (2005) 
 RRM2 Enhanced gemcitabine induced toxicity 
Reduced tumour growth and increased apoptosis 
Duxbury et al. (2004) 
Table 1.8.1 Summary of potential targets by RNAi for developing therapeutic in pancreatic cancer 
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1.9 Epidermal growth factor receptor tyrosine kinase family 
 
Receptors of the epidermal growth factor (erbB) family play principal roles in mediating 
the proliferation and differentiation of normal cells and are expressed in a wide variety of 
tissues. The role of growth factors in the pathogenesis of cancers has been increasingly 
studied as they have been shown to function in cell proliferation, survival, adhesion, 
migration and differentiation (Yarden, 2001). 
The ErbB family consists of four closely related transmembrane receptors, erbB-1 
(EGFR/HER1), erbB-2 (HER2), erbB-3 (HER3) and erbB-4 (HER4). All four receptors 
share the same basic structure composed of three regions; an extracellular region 
consisting of glycosylated domains- two of which are cysteine-rich, a transmembrane 
domain containing a single hydrophobic anchor sequence, and an intracellular region 
containing the catalytic tyrosine kinase domain which is responsible for the regulation of 
intracellular signalling (Schlessinger, 2000). The receptors share 40-50% sequence 
identity in their extracellular domains, 60-80% similarity in their kinase domains and 10-
30% in their tails (Yarden et al., 1991). EGFR binds the ligands, epidermal growth factor 
(EGF), transforming growth factor α (TGF-α) and amphiregulin (AR). Betacellulin 
(BTC), heparin binding EGF-like growth factor (HB-EGF) and epiregulin bind to both 
EGFR and HER4. However the latter two ligands also bind to HER3.  Neuregulins -1, -2 
and heregulins are ligands for HER3 and HER4. HER4 also binds neuregulin -3 and 4 
(Figure 1.9.1). These ligands activate the receptor by binding to the extracellular domain 
and inducing the formation of receptor homodimers or heterodimers allowing the 
receptors to signal. Although HER2 does not act as a receptor, the ligands induce tyrosine 
phosphoylation by triggering heterodimerisation and cross-phosphorylation. The major 
partner of EGFR is HER2. These complexes containing HER2 are more stable than other 
dimers containing members of the EGF receptor family. HER3 lacks tyrosine kinase 
activity and is activated by the tyrosine kinases on other receptors. HER4 isoforms differ 




Figure 1.9.1 Structure of erbB family and their cognate ligands (Horizons in cancer 
therapeutics, 2001). 
 
1.9.1 Epidermal growth factor receptor (EGFR) 
EGFR is a 170 kDa cell surface molecule that mediates signal transduction from the cell 
surface to the cytoplasm (Xiong et al., 2002). When activated, EGFR phosphorylates and 
activates other intracellular proteins, including the Ras/Raf/MAPK pathway and the AKT 
pathway, which affects cell signalling pathways, cellular proliferation, control of apoptosis 
and angiogenesis (Figure 1.9.2). EGFR plays an important role in tumour development 
and maintenance. EGFR over-expression occurs in 30% to 65% of pancreatic ductal 
adenocarcinomas (Fjällskog et al., 2003; Dancer et al., 2007) and EGFR over-expression 
is thought to confer a poor prognosis in several malignancies. It often correlates with 
poorly differentiated histology and a more advanced stage of cancer. Tobita et al. (2003) 
investigated the expression of EGFR in 77 cases of invasive ductal adenocarcinoma of the 
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pancreas. They detected EGFR on 42% of cancer cell membranes by IHC. EGFR 
expression correlated with the histological differentiation and metastatic status of the 
TNM tumour classification, but was not related to other clinicopathological features. 
EGFR status in pancreatic cancer may therefore be a potential marker for differentiation 
and liver metastasis in cancer cells rather than tumourgenesis. Recent studies have 
described a relationship between EGFR and metastasis and suggest that EGFR expression 
may be useful as a predictive marker for invasion and metastasis in cancer (Wang et al., 
2007; Festuccia et al., 2005). 
Therefore EGFR is an attractive target for treatment because of its presence and over-
expression in many tumour types.  
 
 
Figure 1.9.2 EGF Receptor Signal Transduction Pathway (www.sigmaaldrich.com). 
 
1.9.2 HER2  
HER2 is a proto-oncogene that encodes a transmembrane glycoprotein with tyrosine 
kinase activity, which is closely related to EGFR. Although HER2 is a more potent 
oncoprotein than other members of the erbB family, it has no high affinity ligands. EGFR 
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and HER2 can form heterodimeric complexes; HER2 has also been linked with the 
formation of heterodimeric complexes with HER3 and HER4. Up-regulation or 
amplification of the HER2 gene has been associated with a poor prognosis in breast cancer 
and in 30% of ovarian cancers (McKenzie et al., 1993). Approximately 30% of prostate, 
20% of gastric, 2% of colorectal cancer have been reported to over-express HER2 
(Markogiannakis et al., 1997). Safran et al. (2001) establish the frequency of over-
expression of HER2 in patients with pancreatic adenocarcinoma in order to determine the 
potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. IHC 
staining revealed HER2 over-expression in 21% of samples (n=154), indicating that HER2 
over-expression occurs in a subset of pancreatic cancer patients. Over-expression is more 
common in well and moderately differentiated tumours. Yamanaka et al. (1993) examined 
the expression of HER2 in normal pancreas and pancreatic cancer tissue. Immunostaining 
was observed in acinar and ductal cells of normal pancreas, where as HER2 expression 
was observed in 45% of pancreatic carcinomas. A slight correlation existed between well-
differentiated tumours and HER2 expression. HER2 over-expresison in pancreatic cancer 
has also been determined to reduce survival times. Lei et al. (1995) reported that over-
expression of HER2 was found in 10 of 21 (47.6%) pancreatic cancers of ductal origin and 
in 2 of 6 (33.3%) ampullary adenocarcinomas. Over-expression of HER2 was closely and 
inversely related to the survival of the patients with pancreatic cancer of ductal origin: 
19.1 ± 11.7 months for those not over-expressing compared to 7.3 ± 3.8 months for the 
over-expressing patients. Among the pancreatic cancer group, 11 patients underwent 
cancer resection. The average survival for the 7 with non over-expressing cancer was 21.4 
± 14.3 months compared to 10.5 ± 3.6 months for those with over-expressing tumour. 
Among the 4 patients not undergoing resection, the average survival with non over-
expressing cancer was 15.0 ± 3.8 months as contrasted to 5.2 ± 2.1 months for the over-
expressers.  
The oncogene HER2 is variably expressed in pancreatic cancer cases, between 17-82% 
(Bũchler et al., 2001; Dancer et al., 2007). Therefore, it may be a target for therapeutic 




1.9.3 HER3 and HER4 
HER3 and HER4 are structurally related family members of the erbB receptor family. 
HER3 lacks tyrosine kinase activity and is activated by the tyrosine kinases on other 
receptors. HER4 isoforms differ in the composition and structure of their membrane 
regions and C-terminal tails, which contain key phosphorylation sites responsible for 
binding with downstream targets.  
The formation of erbB homodimers and heterodimers, following ligand binding and 
receptor aggregation causes the activation of intrinsic tyrosine kinase activity of the 
receptor via phosphorylation and generates a cascade of downstream events. HER3 and 
HER4 proteins have been increasingly referred to in literature as potential prognostic 
markers in pancreatic cancer. Expression of HER3, in particular was shown to be 
expressed in 47% (27/58) of pancreatic cancer. This expression of HER3 was associated 
with advanced tumour stage and shorter survival postoperatively. The study concluded 
that a significant quantity of human pancreatic cancers over express HER3, and that the 
presence of HER3 might contribute to disease progression (Friess et al., 1995). 
A study was conducted to investigate the presence of HER4 in pancreatic cancer. Graber 
et al. (1999) showed that mRNA expression of HER4 is decreased (6 fold) in non-
metastatic pancreatic cancer when compared to tumours with lymph node or distant 
metastasis or to the normal pancreas. IHC showed that the HER4 antigen is predominantly 
located in the cell membrane and cytoplasm of ductal and acinar cells. 61 out of 75 
pancreatic samples showed weak to moderate expression of HER4. However, the level of 
HER4 in pancreatic cancer had no influence on patient survival, yet may be an important 










1.9.4 Clinical implications of the mechanism of EGFR family inhibitors in cancer 
Novel therapeutic agents that target the epidermal growth factor receptor family and 
signalling pathways represent an important addition to the therapy for the treatment of a 
variety of cancers. 
Inhibitors of the EGFR family can be divided into two categories: 
1. Monoclonal antibodies 
2. Small molecule inhibitors 
 
1.9.4.1 Erlotinib/ Tarveca 
Erlotinib (tarveca) is an oral anti-cancer drug under development by OSI Pharmaceuticals, 
Genentech and Roche (Figure 1.9.3). It is a member of the epidermal growth factor 
receptor (EGFR) inhibitor class of agents, approved in 2004 by the FDA for the treatment 
of patients with local or advanced metastatic NSCLC and in 2005 as a first line treatment 
of locally advanced, unresectable or metastatic pancreatic cancer, in combination with 
gemcitabine. Furthermore, Moore et al. (2007) recently published a phase III trial of 
erlotinib plus gemcitabine compared with gemcitabine alone in 569 patients with 
advanced pancreatic cancer. Overall survival based on an intent-to-treat analysis was 
significantly prolonged on the erlotinib/gemcitabine arm; median survival 6.24 months v 
5.91 months. One-year survival was also greater with erlotinib plus gemcitabine (23% v 
17%). Progression-free survival was significantly longer with erlotinib plus gemcitabine. 
Objective response rates were not significantly different between the arms, although more 
patients on erlotinib had disease stabilisation.  
 
Figure 1.9.3 Structure of erlotinib (Tsao et al., 2005) 
6,7-bis(2-methoxy-ethoxy)-quinazolin-4-
yl-(3-ethylnylphenyl) amine  
Chemical formula C22H23N3O4HCl. 
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Erlotinib is a member of the quinazoline family. It is a reversible, ATP-competitive 
inhibitor of the internal tyrosine kinase domain of EGFR. Erlotinib is capable of inducing 
cell cycle arrest with an accumulation of cells in G0/G1, loss of the hyperphosphorylated 
form of the retinoblastoma protein and accumulation of p27Kip1 (Moyer et al., 1997). 
Durkin et al. (2003) investigated the effect of erlotinib on pancreatic cell lines in vitro. 
Five out of six cell lines showed growth inhibition at 72 hrs at both 50 μM and 100 μM 
concentrations of erlotinib. No significant difference in cell growth was noted between the 
two concentrations. This may suggest that saturation of the EGF receptor was achieved at 
the lower concentration and no additional benefits were observed at greater 
concentrations. This study promotes the use of EGFR blockade as a targeted therapeutic 
strategy for the treatment of pancreatic cancer using small molecule tyrosine inhibitors 
such as erlotinib. 
EGFR-mediated signal transduction pathways are important in cellular response to 
ionizing radiation. High EGFR expression on cancer cells may contribute to 
radioresistance. Kim et al. (2005) evaluated the radiosensitising effect of erlotinib in three 
human cancer cell lines with different EGFR expression, A431 (very high expression), 
H157 (moderate expression) and H460 (low expression). A431 was the most radioresistant 
and the most sensitive to erlotinib, while H460 was the most radiosensitive and the most 
resistant to erlotinib. H157 had intermediate sensitivity to radiation and erlotinib. 
Treatment with erlotinib for 24 hr at 300 nM increased G1 arrest by 18.6, 2.0 and 4.8% in 
A431, H157 and H460, respectively. Erlotinib-induced apoptosis was augmented by 
radiation in A431 cells only. In conclusion, high EGFR expression may result in a high 
degree of radiosensitiation when treated with erlotinib combined with radiation. The 
extent of erlotinib-induced radiosensitisation was proportional to EGFR expression, as 
well as autophosphorylation of the human epidermal growth factor receptor. 
1.9.4.2 Iressa/Gefitinib 
Gefitinib is an oral anti-cancer drug developed by AstraZeneca (Figure 1.9.4). It is a 
member of the quinazoline family. The drug works by competitively inhibiting ATP 
binding to the ATP binding site of the internal tyrosine kinase domain of EGFR. The drug 
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causes numerous effects on tumour cells over expressing EGFR, such as blocking receptor 
autophosphorylation, inducing cell cycle arrest and reducing cell proliferation. This 
tumour growth inhibition is associated with up-regulation of the CDK2 inhibitor p27Kip1, 
which accounts for the cell cycle arrest in the G1 phase (Di Gennaro et al., 2003). 
 
Figure 1.9.4 Structure of gefitinib (Barker et al., 2001) 
 This EGFR tyrosine kinase inhibitor has shown clinical activity against EGFR-expressing 
tumours. Li et al. (2004) investigated the potential role of gefitinib in pancreatic cancer in 
vitro. Gefitinib inhibited EGF-induced cell growth and eradicated EGF-induced 
phosphorylation of EGFR and MAP kinase. Gefitinib inhibited basal and EGF-induced 
anchorage-dependant cell growth and invasion through EGFR-dependent pathways. 
Gefitinib has been indicated as offering a new treatment option for pancreatic cancer. 
Czito et al. (2006) initiated two phase I clinical trials assessing the combination of 
gefitinib, capecitabine and radiation on patients with localised pancreatic or rectal cancer. 
This combination resulted in increased patient toxicity and further investigation of this 
combination is needed. Gefitinib use in clinical trials is now limited due to its 
unfavourable outcome in many NSCLC trials.  
1.9.4.3 Lapatinib/Tykerb                                                                                        
Lapatinib is a dual EGFR and HER2 tyrosine kinase inhibitor (Figure 1.9.5). Its dual 
mode of action distinguishes it from existing TKIs, which are selective EGFR inhibitors. 
Dual inhibition of EGFR and HER-2 tyrosine kinases has been found to exert greater 
biologic effects in the inhibition of signalling pathways promoting cancer cell proliferation 




Figure 1.9.5 Structure of lapatinib (Arora et al., 2005) 
Rusnak et al. (2001) developed potent quinazoline and pyrido-[3,4- d]-pyrimidine small 
molecules that are dual inhibitors of the EGFR and HER2. These dual inhibitors 
demonstrated in vitro inhibition of EGFR and HER2 kinase domains. Cell lines over-
expressing EGFR and HER2 showed significant inhibition of growth at concentrations of 
<0.5 μM. Dose-responsive inhibition was observed in tumour growth in mouse 
subcutaneous xenograft models of BT-474 and NH5 breast cancer cell lines. This data 
highlighted the potential use of dual EGFR and HER2 inhibitors in cancers over 
expressing EGFR and HER2. 
The novel dual EGFR/HER2 tyrosine kinase inhibitor lapatinib (GlaxoSmithKline; 
Research Triangle Park, NC) has been shown to inhibit tumour cell growth in vitro and in 
xenograft models for a variety of human tumours. Lapatinib reduced the tyrosine 
phosphorylation of EGFR and HER2, and cell survival and proliferation in vitro. 
Downstream effectors, Erk1/2 and AKT were also inhibited. In vivo mouse xenograft 
models of BT-474 and NH5 were used to show that activation of EGFR, HER2, Erk1/2 
and AKT were inhibited by treatment with lapatinib (Xia et al., 2002). 
Phase I clinical trials using lapatinib to treat solid tumours were performed. Preliminary 
data showed good response and no grade 4 toxicities. Phase IB trial of lapatinib in 
 66
pretreated metastatic cancer patients using varied doses showed stable disease in most 
cancer types and partial/minor response in breast cancer previously treated with 
Herceptin-containing regimens (Burris H.A, 2004). 
More clinical trials are ongoing for the treatment of breast cancer with lapatinib in various 
regimens, including Herceptin, plus paclitaxel and lapatinib together with letrozole. 
Recently, lapatinib in combination with capecitabine has gained FDA approval for the 
treatment of patients with HER2 positive, advanced, metastatic breast cancer. Geyer et al. 
(2006) treated women with HER2-positive, locally advanced or metastatic breast cancer 
that had progressed after treatment with regimens that included an anthracycline, a taxane, 
and trastuzumab (Herceptin) with capecitabine alone or in combination with lapatinib. 
Results show that the median time to progression was 8.4 months in the combination 
therapy group compared to 4.4 months in the monotherapy group. These improvements 
were achieved without an increase in serious toxic effects or symptomatic cardiac events. 
The trial was stopped and women receiving capecitabine alone were allowed transfer to 
the combination therapy arm and continue treatment. Overall survival data is not currently 
available.  
The positive results from these trials have opened up more combinations of lapatinib to 
treat different types of cancers over expressing EGFR and HER2. Lapatinib has not yet 
been tested in pancreatic cancer. 
1.9.4.4 Erbitux/ Cetuximab 
Erbitux is a human-mouse chimerised IgG1 monoclonal antibody with a high affinity to 
EGFR, derived from the murine anti-EGFR monoclonal antibody 225. 
Erbitux inhibits EGF receptor activity by blocking the binding of EGFR ligands such as 
EGF and the transforming growth factor-α (TGF-α), resulting in the increased activity of 
pro-apoptotic molecules, inhibition of cyclin dependent kinase-2 (CDK-2) activity and 
enhancement of the cytotoxicity of chemotherapeutic drugs and radiation. 
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Erbitux inhibits tumour growth in vivo and cell proliferation in vitro. The mechanisms 
involved include inhibition of angiogenesis, invasion and metastasis, activation of immune 
responses, arrest in cell cycle progression, activation of pro-apoptotic agents and increased 
sensitivity to chemotherapeutic drugs (Mendelsohn, 2001). 
Buchsbaum et al. (2002) investigated the treatment of pancreatic cell lines and mouse 
xenografts with combinations of erbitux, gemcitabine and radiation. Erbitux inhibited 
EGF-induced tyrosine kinase phosphorylation of EGFR in cell lines, MiaPaCa-2 and 
BxPc-3. The combination of erbitux, gemcitabine and radiation in the cell lines showed 
high apoptosis and inhibition of proliferation in vitro. While in vivo the combination 
showed 100% complete regression of MiaPaCa-2 tumours for 250 days and the greatest 
growth inhibition for BxPc-3 compared to single treatment of erbitux, gemcitabine or 
radiation alone. 
 Xiong et al. (2004) carried out a phase II trial to evaluate the combination of erbitux and 
gemcitabine in the treatment of advanced pancreatic cancer. This trial included 41 patients 
who had not received prior chemotherapy. Following treatment, 12% of patients achieved 
a partial response and 63% achieved stabilisation of their cancer. The average duration of 
survival for the entire group of patients was 7 months, with a one-year survival of over 
30%. The most common side effect of treatment was rash, which occurred in 87% of 
patients. 
 
The researchers concluded that the addition of erbitux to gemcitabine appears promising 
for the treatment of pancreatic cancer and may improve survival in patients with advanced 









1.10 Aims of Thesis: 
The aims of this thesis were as follows; 
 
• To investigate the sensitivity of a panel of pancreatic cancer cell lines to a panel of 
chemotherapeutic drugs. 
• To develop drug-resistant variants of pancreatic cancer cell lines and investigate 
the occurrence of cross-resistance to other structurally and functionally unrelated 
drugs; and also to investigate any correlation between acquired drug resistance and 
invasion.  
• To study the incidence of multi-drug resistance pumps (P-gp and MRP-1) in 
pancreatic cancer tissue sections by immunohistochemistry.  
 
• To investigate clonal variation within a pancreatic cancer cell line with respect to 
invasion, adhesion and drug resistance.   
• To identify key target proteins by proteomic analysis, followed by functional 
analysis such as gene expression knockdown using siRNA, in order to investigate 
the mechanisms of invasion, adhesion, anoikis, proliferation and drug resistance 
within human pancreatic cancer cell lines.  
 
• To investigate and characterise the role of secreted factors in the conditioned 
media (CM) in in vitro invasion, adhesion and anoikis assay.  
 
• To determine the role of the tyrosine kinase inhibitor, lapatinib, in EGFR/HER2 






2.0 Materials & Methods 
 
2.1 Cell Culture 
Cell culture procedures were strictly adhered to as outlined in NICB SOP. 
 
2.1.1 Cell lines 
Table 2.1 outlines details and sources of the human pancreatic tumour cell lines used in 
this thesis. All cells were maintained under standard culture conditions, 5% CO2 at 37 
oC. Table 2.2 outlines the media components and serum concentration for the cell 
lines. All cell lines are mycoplasma free; testing was carried out in-house by Michael 
Henry. 
Table 2.1 Cell lines used in this thesis 
Cell Line Details-Histology Source 
AsPc-1 Pancreatic adenocarcinoma from metastatic ascites ATCC 
BxPc-3 Pancreatic adenocarcinoma ATCC 
Bx/Epi Epirubicin-selected variant of BxPc-3 NICB 
Bx/Gem Gemcitabine-selected variant of BxPc-3 NICB 
KCI-MOH1 Pancreatic adenocarcinoma DSMZ 
KCI/Epi Epirubicin-selected variant of KCI-MOH1 NICB 
KCI/Txt Taxotere-selected variant of KCI-MOH1 NICB 
KCI/Gem Gemcitabine-selected variant of KCI-MOH1 NICB 
MiaPaCa-2 Pancreatic carcinoma ECACC 
Mia/Epi Epirubicin-selected variant of MiaPaCa-2 NICB 
Mia/Txt Taxotere-selected variant of MiaPaCa-2 NICB 
Mia/Gem Gemcitabine-selected variant of MiaPaCa-2 NICB 
Clone #3 Clonal population of MiaPaCa-2 NICB 
Clone #8 Clonal population of MiaPaCa-2 NICB 
Panc-1 Pancreatic ductal carcinoma ATCC 
NICB, National Institute for Cellular Biotechnology, DCU, Dublin, Ireland 
ATCC, American Type Culture Collection, Rockville, MD, USA. 
DSMZ, Deutsche Sammlung von Mikroorganism und Zellkulturen GmbH (German 
Collection of Microorganisms and Cell Cultures), Braunschweig, Germany. 
ECACC, European Collection of Animal Cell Cultures, Salisbury, Wiltshire, UK. 
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Table 2.2 Additional components in media. 
Cell Line Basal Media FCS (%) Additions 
AsPc-1 RPMI 1640 5 Sodium pyruvate 
BxPc-3 RPMI 1640 5 Sodium pyruvate 
KCI-MOH1 RPMI 1640 5 Sodium pyruvate 
MiaPaCa-2 DMEM 5 N/A 
Panc-1 DMEM 5 N/A 
 
2.2 Isolation of sub-populations by clonal dilution 
 
Clonal populations were isolated by plating cells in 96-well plates at a concentration of 
1 cell per 3 wells (15 cells/ml). After 1 day, the 96-well plates were monitored for 
single cells in wells. Single cell wells were marked and then allowed to grow until they 
reached levels that allowed them to be scaled up initially into 24-well plates.  
 
2.2.1 Collection of conditioned media 
Cells were cultured until 50-60% confluent. Cells were washed x3 in serum-free (SF) 
media. Cells were incubated in SF media (5 ml/T25 cm2 flask) for 60 min. After this 
time, cells were washed again x3 in SF media. SF media was added to the cells and 
incubated for 72 hrs. After such time, conditioned media (CM) was collected, 
centrifuged for 5 min at 1000 rpm, filtered through 0.22 μm filter and stored at –80 oC. 
 
Experiments varying the pH of CMs were carried out by the addition of differing 
volumes of HCL (acidic pH) and NaOH (alkaline pH) and pH determined using a pH 
meter.  Aliquots of pH altered CMs were left at RT for 2 hrs then brought back to their 
original pH and added into the invasion chamber as outlined in section 2.5.2. 
 
2.2.1.1 Proteomic analysis of conditioned media 
CM was collected as outlined in section 2.2.1. CM was concentrated using 10,000 
molecular weight cut-off concentrators (Millipore); samples were cleaned-up using 
ready-prep 2D clean-up kit (BioRad) and protein quantification was carried out on 
precipitates as outlined in section 2.9.2 
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2.3 In vitro proliferation assays 
 
Cells in the exponential phase of growth were harvested by trypsinisation. Cell 
suspensions containing 1x104 cells/ml were prepared in cell culture medium. 100 
μl/well of the cell suspension was added to 96-well plates (Costar, 3599). Plates were 
agitated gently in order to ensure even dispersion of cells over the surface of the wells. 
Cells were then incubated overnight. Cytotoxic drug dilutions were prepared at 2X 
their final concentration in cell culture medium. 100 μl of the drug dilutions were then 
added to each well. Plates were then mixed gently as above. Cells were incubated for a 
further 6-7 days until the control wells had reached approximately 80-90% confluency. 
Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (section 2.3.2). The concentration of drug which caused 50% cell 
kill (IC50 of the drug) was determined by using CalcuSyn software (Biosoft, version 
2.0). Results were graphed as percentage survival (relative to the control cells) versus 
cytotoxic drug concentration.  
 
2.3.1 Combination toxicity assays 
Cells were set up as for in vitro proliferation assays (section 2.3).  Following overnight 
incubation, a volume of 50 μl of 3x lapatinib dilutions was added to appropriate wells, 
24 hrs prior to addition of 50 μl of the 5x chemotherapeutic drug. All wells contained a 
total final volume of 250 μl in each well (including controls). All agents were 
dissolved in DMSO, ethanol or media. Cells were incubated for a further 6 days. Cell 
number was assessed using the acid phosphatase assay (section 2.3.2). The 
concentration of drug, which caused the greatest efficiency in cell kill, was determined 
by using CalcuSyn software (Biosoft, version 2.0). Results were plotted as the 
percentage survival (relative to the control cells) versus cytotoxic drug concentration.  
 
2.3.2 Assessment of cell number - Acid Phosphatase assay 
A. Acid Phosphatase in 96-well plate format. 
1. Following an incubation period of 6-7 days, media was removed from the 
plates. 
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2. Each well on the plate was washed with 100 μl PBS. This was removed and 
100 μl of freshly prepared phosphatase substrate (10 mM p-nitrophenol 
phosphate (Sigma 104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton 
X-100 (BDH, 30632), pH 5.5) was added to each well. The plates were 
wrapped in tinfoil and incubated in the dark at 37°C for 1.5 hours. 
3. The enzymatic reaction was stopped by the addition of 50 μl of 1 M NaOH to 
each well. 
B. Acid Phosphatase in 6-well plate format. 
1. Following an incubation period of 72 hours, media was removed from the 
plates. 
2. Each well on the plate was washed with 1 ml PBS. This was removed and 2ml 
of freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate 
(Sigma 104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 
(BDH, 30632), pH 5.5) was added to each well. The plates were wrapped in 
tinfoil and incubated in the dark at 37°C for 2 hours. 
3. The enzymatic reaction was stopped by the addition of 1 ml of 1 M NaOH to 
each well. 




CalcuSyn Version 2.0 software uses the median effect method to quantify the effects 
of drug combinations to determine whether they give greater effects together that 
expected from a simple summation of their individual effects (Chou and Talalay, 
1984). CalcuSyn analysed dose effects for single and multiple drugs. Data was 
processed for non-mutually exclusive (drugs that are non-competitive inhibitors of 
each other), constant ratio combinations for two compounds. The programme graphs 
the data and produces reports of summary statistics for all drugs and detailed analysis 
of drug interactions including the Combination Index (CI) and effective dose (ED) 
values. CI<0.8 indicates synergism, CI > 0.8 but < 1.2 indicates an additive effect and 
CI > 1.2 indicates antagonism (van Waardenburg et al., 2004). 
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2.4 Pulse selection of parent cell lines 
 
A number of drug resistant variants were established from the cell lines BxPc-3, KCI-
MOH1 and MiaPaCa-2 by pulse-selection with epirubicin, taxotere and gemcitabine. 
 
2.4.1 Determination of drug concentration for pulse selection 
Cells were seeded into twelve T25 cm2 flasks at 1.5 × 105 cells per flask and allowed 
to attach overnight. The following day media was removed from the flask and a range 
of concentrations of appropriate drug was added to the flasks in duplicate. Complete 
media was added to two flasks as a 100% survival control. Flasks were returned to the 
incubator for a 4-hour incubation, after which the drug was removed. The flasks were 
rinsed and fed with fresh complete media. The flasks were then incubated for 5-7 days 
until the cells in the control flasks had reached approximately 80% confluency. At this 
point, medium was removed from the flasks and cells were trypsinised and counted in 
duplicate. The concentration of drug that caused appropriate cell kill was determined 
from a plot of the percentage survival relative to the control cells versus cytotoxic drug 
concentration. Concentrations chosen for pulse selection of BxPc-3, KCI-MOH1 and 
MiaPaCa-2 gave a 50-60% kill, i.e. IC50 – IC60 (Table 2.3). 
 
Table 2.3 Concentrations for pulse-selection 
Cell Line Epirubicin (ng/ml) Taxotere (ng/ml) Gemcitabine (ng/ml) 
BxPc-3 50 2 60 
KCI-MOH1 100 2 50 
MiaPaCa-2 64 1.2 20 
 
 
2.4.2 Pulse selection  
Cells at low confluency in T75 cm2 flasks were exposed to the chosen concentration of 
epirubicin, taxotere or gemcitabine for 4 hours. After this period, the drug was 
removed and the flasks were rinsed and fed with fresh complete media. The cells were 
then grown in drug-free media for 6 days, refeeding every 2-3 days. This was repeated 
once a week for ten weeks. Some drug-selected variants could not be selected for 10 
pulses as low viability was observed.  
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2.5     Extracellular matrix assays 
 
2.5.1 Reconstitution of ECM proteins 
Matrigel (Sigma, E-1270) was diluted to a working stock of 1 mg/ml in serum free 
DMEM. Collagen type IV (Sigma, C-5533), fibronectin (Sigma, F-2006) and laminin 
(Sigma, L-2020) were reconstituted in PBS to a stock concentration of 500 μg/ml. 
Each of the ECM proteins, collagen type IV, fibronectin and laminin were diluted to a 
working stock concentration of 25 μg/ml in PBS. Collagen type I (Sigma, C4361) at a 
stock concentration of 3.1 mg/ml was used at a working concentration of 10 μg/ml in 
PBS. Aliquoted stocks were stored at –20oC.  
 
2.5.2 In vitro invasion assays 
Invasion assays were performed using the method of Albini et al. (1987). 100 μl of 
matrigel, laminin, fibronectin and collagen type IV and I were placed into each insert 
(Falcon 3097) (8.0μm pore size, 24 well format) and kept at 4 oC for 24 hours. The 
insert and the plate were then incubated for one hour at 37 oC to allow the proteins to 
polymerise. Cells were harvested and resuspended in culture media containing 5% 
FCS at 1 × 106 cells/ml. Excess media/PBS was removed from the inserts, and they 
were rinsed with culture media. 100 μl of the cell suspension was added to each insert. 
A further 100 μl of culture media was added to each insert and 500 μl of culture media 
containing 5% FCS was added to the well underneath the insert. Cells were incubated 
for 24 hours. After this time period, the inside of the insert was wiped with a cotton 
swab dampened with PBS, while the outer side of the insert was stained with 0.25% 
crystal violet for 10 minutes and then rinsed in distilled water (dH2O) and allowed to 
dry. The inserts were then viewed and photographed under the microscope. The 
invasion assays were quantified by counting cells in 10 random fields within a grid at 
20x objective and graphed as the total number of cells invading at 200x magnification. 
 
For conditioned media experiments, CM (diluted 1:1 in fresh media) was added above 
and below the insert and assayed as above. 
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2.5.3 Motility assay 
Motility assays were carried out as described in section 2.5.2, without the addition of 
extracellular proteins.  
 
2.5.4 Adhesion assay 
Adhesion assays were performed using an adapted method of Torimura et al. (1999). 
250 μl aliquots of ECM proteins were placed into wells of a 24-well plate. The plates 
were gently mixed to ensure the base of each well was completely covered with the 
solution. The plates were then incubated overnight at 4 oC. The excess solution was 
then removed from the wells and washed twice with sterile PBS. To reduce non-
specific binding, 0.5 ml of sterile 0.1% BSA/PBS solution was dispensed into each 
well. The plates were incubated at 37 oC for 20 minutes and then rinsed twice again 
with sterile PBS. 
Cells were harvested and resuspended in media at a concentration of 2.5x104 cells/ml. 
1 ml of cells were plated onto 24 wells plates in triplicate and incubated for 60 
minutes. Wells that had been coated with ECM proteins but contained no cells were 
used as blanks. Wells containing cells but not coated with ECM proteins were used as 
positive controls. After 60 minutes, the medium was removed from the wells and 
rinsed gently with sterile PBS. Cell number attached was assessed using the acid 
phosphatase assay (section 2.3.2 B). 
 
2.5.5 Preincubation of cells with matrigel coated flasks 
Matrigel was coated onto flasks (1 ml/25 cm2) at a concentration of 1 mg/ml. Flasks 
were shaken gently to ensure complete coverage of the bottom of the flask. The coated 
flasks were then placed at 4 oC overnight to allow the matrigel settle. Before seeding 
flasks with cells, the flasks were placed into an incubator at 37 oC for approximately 2 
hours to allow the matrigel polymerise. The excess media in the flasks was then 
removed and fresh complete media containing the cell suspension was added. Cells 
attached to the matrigel on the bottom of the flask and after 24 hrs were removed with 
0.5 ml/25 cm2 dispase (BD Biosciences, 354235). Dispase is a bacillus derived neutral 
metalo protease that recovers cells cultured on matrigel. 
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2.6 Soft agar assays 
 
1.548 g of agar (Bacto Difco, 214040) was dissolved in 100 ml of ultra pure water and 
autoclaved. This agar was then melted in a microwave oven immediately prior to use 
and incubated at 44 oC. RPMI-1640 10x medium (Sigma, R1145) and DME 10x 
medium (Sigma, D5271) were diluted to 2x stock in dH2O, filter sterilised and pH 
adjusted. Agar Medium (AgM) was prepared by adding equal parts agar and 2x 
medium. This solution was then dispensed onto 35 mm sterile petri dishes (Lux 
Scientific Corp., 5217). The agar was allowed to set at room temperature and the 
remaining AgM was returned to the water bath with the temperature reduced to 41 oC. 
The thermo-labile serum was added last to the Agar Medium.  
Cells were harvested and resuspended in medium without serum, ensuring that a single 
cell suspension was obtained. The cells were diluted to give a concentration of 2 x 104 
cells/ml in a total of 5 ml. 5 ml of Agar Medium was then added to each suspension, 
mixed well and 1.5 ml was dispensed onto each pre-set agar plate, in triplicate, giving 
a final concentration of 1.5 x 104 cells/plate. The plates were placed on trays 
containing a small volume of water to prevent the agar from drying out and incubated 
at 37 oC, 5% CO2 for 10 days. Percentage colony forming efficiency (%CFE) was 
evaluated by counting the number of single cells in ten random fields on day 1 at 40x 
magnification. Colonies greater than 50 μm were counted on day 10, and the 
percentage of cells forming colonies determined.  
 
2.7 Anoikis assay 
 
Poly- (2-hydroxyethyl methacrylate) (poly-HEMA, Sigma, P3932) was dissolved at 12 
mg/ml in 95% ethanol. To coat 24-well plates, 100 μl of poly-HEMA solution was 
added and allowed to dry in a laminar flow cabinet. After full evaporation, the coating 
step was repeated. Once evaporation was complete, wells were washed twice with 
sterile PBS. Cells (1x105cells/ml/well) were then plated onto standard 24-well tissue 
plates (adherent controls) or poly-HEMA-coated plates (non-adherent) and incubated 
for 24 hrs at 37oC in 5% CO2. After this time, 100 μl of alamar blue vital dye (Serotec, 
BUF012B) was added to the 24-well plates to quantitatively measure cell survival. The 
plate was read in a dual beam plate reader at 570 nm with a reference wavelength of 
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600 nm. The level of anoikis was assessed as the percentage cell death relative to 
adherent controls over 24 hours. 
 
2.8 Tissue samples 
 
Formalin-fixed paraffin-embedded tissue was kindly provided by the Histopathology 
Department of St. Vincent’s Hospital, Dublin. 5 μm sections of tissue blocks were cut 
using a microtome, mounted onto poly-l-lysine coated slides. Slides were stored at 
room temperature until required. 
 
2.8.1  Immunohistochemistry 
All immunohistochemical studies on formalin-fixed paraffin-embedded tissue sections 
were performed following the method of Hsu et al. (1981) using an avidin-biotin 
horseradish peroxidase (HRP) conjugated kit (ABC) plus an appropriate secondary 
antibody. 
Paraffin-embedded tissue samples were dewaxed in xylene (2 x 5 minutes), rehydrated 
in grading alcohols, 100%, 90% and 70% (2 x 3 minutes), and placed in Tris Buffered 
Saline (TBS/0.05% Tween-20). Endogenous peroxidase activity was quenched by 
placing tissue sections in 3% (vol/vol) H202/distilled water for 5-7 minutes at room 
temperature. All slides were blocked for non-specific staining with 20% normal rabbit 
serum (Dako, X-902)/TBS for 20 minutes at room temperature. Primary antibodies 
were applied to each sample optimally diluted in TBS/0.05% Tween-20 (antibody 
MDR-1, 6/1C: ascites diluted 1:40; MRP-1: neat supernatant) (Table 2.4). Primary 
antibodies were incubated overnight at 4oC. Samples were then washed (3 x 5 minutes) 
with TBS/0.05% Tween-20; this was followed by a 30 minute incubation with 
biotinylated secondary antibody (rabbit anti-mouse IgG (1/300 dilution in TBS/0.05% 
Tween-20) (Dako, E345) or rabbit anti-rat (1/500 dilution in TBS/0.05% Tween-20). 
Finally, following another 3 x 5 minute wash step, Vectastain Elite ABC reagent (HRP 
conjugated) (Vector Laboratories, UK PK-7100) was applied for 25 minutes at room 
temperature. The peroxidase substrate, 3’,3-daminobenzidine tetrahydrochloride 
(DAB) containing 0.02% H202 (Vector Laboratories, UK SK-4100) was added for 5-10 
minutes at room temperature. All slides were then washed (3 x 5 minutes) TBS/0.05% 
Tween-20. Tissue sections were then lightly counter stained with haematoxylin 
(Vector Laboratories, H-3401). Slides were then dehydrated in grading alcohols, 70%, 
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90% and 100% (2 x 3 minutes). Samples were then cleared in xylene and mounted in 
DPX (BDH, UK). Negative control samples in which primary antibody were replaced 
by 1x TBS/0.05% Tween-20 were included in all experiments. Positive controls 
(normal kidney and lung tissue) using the same experimental conditions were included 
in all experiments. 
 
Table 2.4 Antibodies used in Immunohistochemical analysis 












Aliquots of 100 μl of 1x106 cells/ml from actively growing cultures were plated 
directly onto coated slides. Cells were allowed to attach overnight under culture 
conditions. After such time, slides were washed 3x in PBS and allowed to air dry. 
Slides were then foil wrapped and stored at -80 oC until required. Cells were later 
thawed and fixed in ice-cold acetone for 5-10 minutes and allowed to air dry for 15 
min prior to immunostaining. Slides were blocked for non-specific staining with 20% 
(v/v) normal rabbit serum for 20 min. The primary antibody was added and incubated 
for 1 hr at RT. Cells were washed 3x in PBS and secondary antibody, fluorescein 
isothicyanate-linked (FITC) anti-goat (Sigma) was added for 30 min at RT. Secondary 
antibody was removed and cells washed as outlined. Slides were mounted with 
Vectashield (Vector Laboratories, U.K) mounting medium and covered using a glass 
cover slip. Cells were viewed and photographed using a Nikon phase contrast 









2.9 Western blotting techniques 
 
2.9.1 Whole cell extract preparation 
Cells were grown to 80-90% confluency in cell culture grade petri dishes. Media was 
removed and cells were washed twice with ice cold PBS. All procedures from this 
point forward were performed on ice. Cells were lysed with 200-300 μl of NP-40 lysis 
buffer and incubated on ice for 20 minutes.  Table 2.5 below provides the details of the 
lysis buffer. Immediately before use, 10 μl of the 100X protease and phosphatase 
inhibitors listed in table 2.6 were added to 1 ml of lysis buffer. 
 
Table 2.5 NP-40 lysis buffer 
Addition required per 500ml stock Final concentration 
425 ml dH2O water - 
25 ml 1 M Tris-HCl (pH 7.5) 50 mM Tris-HCl (pH 7.5) 
15 ml 5 M NaCl 150 mM NaCl 
2.5 ml NP-40 0.5% NP-40 
 
Table 2.6 NP-40 lysis buffer 100X stocks 
100X stock  Preparation instructions 
100 mM DTT 154 mg in 10 ml dH2O 
100 mM PMSF 174 mg in 10 ml 100% ethanol 
100X Protease inhibitors 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin, 15 mg/ml 
benzamidine and 1 mg/ml trypsin inhibitor in dH2O 
 
Cells were then removed with a cell scraper and further homogenised by passing 
through a 21 G syringe. Sample lysates were centrifuged at 14000 rpm for 10 minutes 
at 4 oC. Supernatant containing extracted protein was transferred to a fresh chilled 
eppendorf tube. Protein concentration was quantified using the Biorad assay as 
detailed in Section 2.9.2. Samples were then stored in aliquots at -80°C. 
 
2.9.2 Protein Quantification  
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 500-
0006) as follows. A 2 mg/ml bovine serum albumin (BSA) solution (Sigma, A9543) 
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was prepared freshly in lysis buffer. A protein standard curve (0, 0.2, 0.4, 0.6, 0.8 and 
1.0 mg/ml) was prepared from the BSA stock with dilutions made in lysis buffer. The 
Bio-Rad reagent was diluted 1:5 in dH2O water. 8 μl of protein standard dilution or 
sample (diluted 1:10) was added to 392 μl of diluted dye reagent and the mixture 
vortexed. The protein standards and samples were added in triplicate onto a 96-well 
plate. After 5 minutes incubation, absorbance was assessed at 570 nm. The 
concentration of the protein samples was determined from the plot of the absorbance at 
570 nm versus concentration of the protein standard. 
 
2.9.3 Gel electrophoresis 
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). The stacking and resolving gels were prepared as 
illustrated in table 2.7 or precast 7.5% gels were used (Lonza). 
 
Table 2.7 Preparation protocol for SDS-PAGE gels (2 x 0.75mm gels) 
Components 10% Resolving Gel 5% Stacking Gel 
Acrylamide stock 4.6 ml 670 μl 
dH2O 5.6 ml 2.7 ml 
1.875 M Tris-HCl pH 8.8 3.5 ml - 
1.25 M Tris-HCl pH 6.8 - 500 μl 
10% SDS 140 μl 40 μl 
10% NH4- persulfate 140 μl 40 μl 
TEMED 5.6 μl 4 μl 
 
The acrylamide stock in table 2.7 consists of a 30% (29:1) ratio of acrylamide:bis-
acrylamide (Sigma, A2792). In advance of samples being loaded in to the relevant 
sample wells, 20-40 μg of protein was diluted in 10x loading buffer. Molecular weight 
markers (Sigma, C4105) were loaded alongside samples. The gels were run at constant 
amplitude (45mA) until the bromophenol blue dye front reached the end of the gel, at 





2.9.4 Western blotting 
Western Blotting was performed by the method of Towbin et al. (1979). Once 
electrophoresis was complete, the SDS-PAGE gel was equilibrated in transfer buffer 
(25 mM Tris (Sigma, T8404), 192 mM glycine (Sigma, G7126), pH 8.3-8.5) for 
approximately 15 minutes. Six sheets of Whatman 3 mm filter paper were soaked in 
freshly prepared transfer buffer. These were then placed on the cathode plate of a semi-
dry blotting apparatus (Bio-rad). Air pockets were then removed from between the 
filter paper. Nitrocellulose membrane (GE Healthcare, RPN 303D), which had been 
equilibrated in the same transfer buffer, was placed over the filter paper on the cathode 
plate. Air pockets were once again removed. The gels were then aligned on to the 
membrane. Six additional sheets of transfer buffer soaked filter paper were placed on 
top of the gel and all air pockets removed. The anode was carefully laid on top of the 
stack and the proteins were transferred from the gel to the membrane at a current of 34 
mA at 15 V for 30-40 minutes, until all colour markers had transferred.  Following 
protein transfer, membranes were stained using PonceauS (Sigma, P7170) to ensure 
efficient protein transfer. The membranes were then blocked overnight using 5% 
skimmed milk powder in PBS at 4 °C. Membranes were incubated with primary 
antibody for 2-3 hours at RT (Table 2.8) and a negative control where the membrane 
was exposed to antibody diluent was also performed. Antibodies were prepared in 1% 
skimmed milk powder in PBS. Primary antibody was removed after this period and the 
membranes rinsed 3 times with PBS containing 0.5% Tween 20 (Sigma P1379) for a 
total of 15-30 minutes. Secondary antibody (1 in 1,000 dilution of anti-mouse IgG 
peroxidase conjugate (Sigma, A4914)) in PBS, was added for 1.5 hour at room 
temperature. The membranes were washed thoroughly in PBS containing 0.5% Tween 
for 15 minutes. 
 
Table 2.8 List of primary, secondary antibodies and dilutions 
Primary Antibody Dilution  
MDR-1/P-gp 1/100 sc-59589, Santa Cruz Biotechnology 
MRP-1 1/100 sc-59607, Santa Cruz Biotechnology 
Integrin Beta 1 1/500 MAB1951Z-20, Chemicon 
Integrin Alpha 4 1/500 MAB1945, Chemicon 
Integrin Alpha 5 1/500 AB1949, Chemicon 
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Integrin Alpha 6 1/200 MAB1982, Chemicon 
Aldehyde dehydrogenase 1A1 1/500 Ab9893, Abcam 
Vimentin 1/500 V4630, Sigma 
Cytokeratin 18 1/200 sc-6259, Santa Cruz Biotechnology 
Triosephosphatase 1  1/500 Ab28760, Abcam 
Stress-induced phosphoprotein 1 1/200 sc-15276, Santa Cruz Biotechnology 
GAPDH 1μg/ml AM4300, Ambion 
Gelsolin 1/500 G4896, Sigma 
Galectin 1 1/500 Ab25138, Abcam 
Nucleotide diphosphate kinase 1/200 Ab37627, Abcam 
Bip 1/200 610978, BD Bioscience 
β-actin  1:10,000 A5441, Sigma 
α-Tubulin 1/1000 T6199, Sigma 
EGFR 1/100 Ab-15, Lab Vision 
HER2 1/1000 OP15, Oncogene Research Products 
Secondary Antibody Dilution  
Anti-mouse 1/1000 A6782, Sigma 
Anti-rat 1/1000 R5130, Sigma 
Anti-rabbit 1/500 18772, Sigma 
Anti-goat 1/500 Sc2098, Santa Cruz Biotechnology 
 
2.9.5 Enhanced chemiluminescence (ECL) detection 
Immunoblots were developed using Luminol (Santa Cruz), which facilitated the detection 
of bound peroxidase-conjugated secondary antibody. Following the final washing 
membranes were incubated with Western blot Luminol reagent (Santa Cruz, sc-2048). 
3 ml of a 50:50 mixture of Luminol reagent was used to cover the membrane. The 
membrane was wrapped in clingfilm. The membrane was then exposed to 
autoradiographic film (Kodak, X-OMATS) for various times (from 10 seconds to 30 
minutes depending on the signal). The exposed autoradiographic film was developed for 
3 minutes in developer (Kodak, LX-24). The film was then washed in water for 15 
seconds and transferred to a fixative (Kodak, FX-40) for 5 minutes. The film was then 
washed with water for 5-10 minutes and left to dry at room temperature. 
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2.10 Proteomic analysis  
 
2.10.1 Sample preparation 
Cells were grown to 60-70% confluency in 175cm2 flasks, trypsinised and allowed to 
attach to matrigel for 24 hrs and managed according to section 2.5.5. Cell pellets were 
then washed twice in ice cold PBS and twice in sucrose buffer and the resulting pellet 
was stored at -80 oC.  
 
2.10.2 Total protein extraction 
All proteomic analysis detailed in this thesis was carried out by Dr. Paul Dowling. 
Cell pellets were reconstituted with 1ml of the following complete lysis buffer: (4% 
w/v CHAPS, 7 M urea, 2 M thiourea, 10 mM Tris-HCL, 5 mM magnesium acetate pH 
8.5). Immediately before use, 10μl of 100x stocks of DNase and RNase were added to 
1ml of lysis buffer. The lysate was then homogenised by passing though a 25-gauge 
needle 6 times. The cell lysate was placed on an orbital shaker and shaken for 1 hour at 
room temperature. The protein lysate was then transferred to an eppendorf and 
centrifuged at 14,000 rpm for 20 minutes at 10 oC to remove insoluble material. The 
resulting supernatant was transferred to a fresh microcentrifuge tube and its pH was 
checked to ensure it was between pH 8.0-9.0 by spotting 3 μl onto a pH indicator strip. 
The sample was then divided into smaller aliquots and stored at –80 oC. The protein 
concentration was quantified using the Biorad method. Biological replicates (n=3) of 
each cell line were prepared.  
 
2.11 Protein sample labelling  
 
2.11.1 Preparation of dye stock solution (1 nmol/μl) 
The three CyDye DIGE Fluor Minimal dyes (Cy3, Cy5 and Cy2 (GE Healthcare, 25-
8010-65) were thawed from –20 oC to room temperature for 5 minutes. To each 
microfuge tube dimethylformamide (DMF) (Aldrich, 22,705-6) was added to a 
concentration of 1 nmol/μl. Each microfuge tube was vortexed vigorously for 30 sec to 
dissolve the dye. The tubes were then centrifuged for 30 sec at 14,000 rpm in a 




2.11.2 Preparation of 10 μl working dye solution (200 pmol/μl) 
On thawing, the dye stock solutions were centrifuged in a microcentrifuge for 30 
seconds. To make 10 μl of the three working dye solutions, 8 μl of DMF was added to 
2 µl of 1 nmol/µl stock of Cy2, Cy3 and Cy5 i.e. 200 pmol/µl working stock. The dyes 
were stored at -20 oC in tinfoil in the dark for 3 months. 
 
2.11.3  Protein labelling                                                                                                
The comparative protein samples equivalent to 50 μg was placed into eppendorf tubes 
and labelled with the Cy3 and Cy5 minimal dyes. Each tube was mixed by vortexing, 
centrifuged and then left on ice for 30 minutes in the dark. The reaction was quenched 
with a 50-fold molar excess of free lysine to dye for 10 minutes on ice in the dark. The 
labelled samples were stored at –80 oC. The Cy2 pool for each gel (50 μg) contained 
an equal concentration aliquot of each of the protein samples. To this 1 µl of each dye 
(200 pmol/µl) was added to 50 µg of protein sample. An equal volume of 2x sample 
buffer (2.5 ml rehydration buffer stock solution (7 M urea, 2 M thiourea, 4 % 
CHAPS), pharmalyte broad range pH 4-7 (2%) (GE Healthcare, 17-6000-86), DTT 
(2%) (Sigma, D9163)) was added to the labelled protein samples. The mixture was left 
on ice for at least 10 minutes then applied to Immobiline DryStrips for isoelectric 
focussing. 
 
2.12 First dimension separation - isoelectric focussing  
 
2.12.1 Strip rehydration  
Immobiline 24 cm linear pH gradient (GE Healthcare, IPG) strips, pH 3-11 were 
rehydrated in rehydration buffer solution (7 M urea, 2 M thiourea, 4% CHAPS, 0.5% 
IPG buffer, 50 mM DTT). Each strip was overlaid with about 3 ml IPG Cover Fluid 
(GE Healthcare, 17-1335-01) and allowed to rehydrate overnight (or at least 12 hours) 
at RT. 
 
2.12.2 Isoelectric focussing  
IEF was performed using an IPGphor apparatus (GE Healthcare). The cover of the 
IPGphor unit was closed and the desired programme selected (40 kV/h at 20 oC with 
resistance set at 50 mA). On completion of the IEF run, the strips were drained of the 
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cover fluid and stored in glass tubes at –80 oC or used directly in the second 
dimension.  
 
2.13 Second Dimension – SDS polyacrylamide gel electrophoresis 
 
2.13.1 Equilibration of focussed Immobiline DryStrips 
Strips were equilibrated for 20 min in 50 mM Tris-HCL, pH 8.8, 6 M urea, 30% v/v 
glycerol, 1% w/v SDS containing 65 mM DTT and then for 20 min in the same buffer 
containing 240 mM iodoacetamide. The 12.5 % acrylamide gel solution was prepared 
in a glass beaker (acrylamide/bis 40 %, 1.5 M Tris pH 8.8, 10 % SDS). Prior to 
pouring, 10 % ammonium persulfate and 100 µl neat TEMED were added. The gels 
were overlaid with 1 ml saturated butanol. The gels were left to set for at least three 
hours at RT. Equilibrated IPG strips were transferred onto 24 cm 12.5% uniform 
polyacrylamide gels poured between low fluorescence glass plates. Strips were 
overlaid with 0.5% w/v low melting point agarose in running buffer containing 
bromophenol blue. Gels were run at 2.5 W/gel for 30 min and then 100 W total at 10 
oC until the dye front had run off the bottom of the gels. All the images were collected 
on a Typhoon 9400 Variable Mode Imager (GE Healthcare).  
 
2.13.2 Scanning DIGE labelled samples 
The appropriate emission filters and lasers were then selected in the Typhoon Variable 
Mode Imager (GE Healthcare) for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 
580 BP30 Green (532) and Cy5 670 BP 30 Red (633)). Gels were scanned at 100 pixel 
resolution, resulting in the generation of three images, one each for Cy2, Cy3 and Cy5. 
Once the scanning was completed, the gel images were imported into the ImageQuant 
software. All gels were cropped identically to facilitate spot matching in the Decyder 
BVA module. 
 
2.14 Analysis of gel images 
 
2.14.1 Differential in-gel analysis (DIA) 
The DIA module processes a triplet of images from a single gel. The internal standard 
is loaded as the primary image followed by the secondary and tertiary image, derived 
from, for example, a control and treated sample. Spot detection and calculation of 
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spots properties were performed for each image from the same gel. The software 
determined the margins of the spots, quantified the spot intensities and calculated the 
relative spot intensity as the ratio between the total intensity of the gel and the intensity 
of each individual spot. The protein spots were then normalised using the in-gel linked 
internal standard. The data from the first gel was XML formatted and exported into the 
Biological Variation Analysis (BVA) software for further analysis. This procedure was 
repeated for each gel in the experiment.  
 
2.14.2 Biological variation analysis (BVA) 
Once all gels from the experiment were loaded into the BVA module, the experiment 
design was set up and the images were assigned into three groups (standard, control 
and treated). The spots on the gels were then matched across all gels in the experiment.  
This module detects the consistency of the differences between samples across all the 
gels. The software standardises the relative spot intensity of the Cy5 image to that of 
the Cy3 image in the same gel. The standardised spot intensity was then averaged 
across the triplicate gels. The BVA module detected the consistency of the differences 
between samples across all the gels and applied statistics to associate a level of 
confidence for each of the differences. The protein spots with statistically significant 
protein expression changes were designated “proteins of interest” and placed in a pick 
list. 
Preparative gels for spot picking with 300 μg of protein/gel were focussed and run out 
on SDS-PAGE gels. The gels were then stained with colloidal coomassie and deep 
purple (section 2.14.3, 2.14.4). Spots that showed differential protein expression were 
picked with the ETTAN Spot Picker (section 2.14.3).  
 
2.14.3 Staining- Brilliant blue G Colloidal coomassie and Deep purple staining of 
preparative gels for spot picking  
After electrophoresis, the smaller lower plates with the gels attached were placed in the 
gel boxes containing fixing solution (7% glacial acetic acid in 40% (v/v) methanol 
(Aldrich, 200-659-6)) for at least 1 hour. During this step a 1X working solution of 
Brilliant Blue G colloidal coomassie (Sigma, B2025) was prepared by adding 800ml 
UHP to the stock bottle. When the fixing step had nearly elapsed a solution containing 
4 parts of 1X working colloidal coomassie solution and 1 part methanol was made, 
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mixed by vortexing for 30 seconds and then placed on top of the gels. The gels were 
left to stain for 2 hours. To destain, a solution containing 10% acetic acid in 25% 
methanol was poured over the shaking gels for 60 seconds. The gels were then rinsed 
with 25% methanol for 30 seconds and then destained with 25% methanol for 24 
hours. Alternatively, after fixing solution, gels were washed 3x in wash buffer (35 mM 
sodium hydrogen and 300 mM sodium carbonate in water) and further washed in 
water. Deep purple stain (GE Healthcare, RPN6305) was then added to the gels, 
diluted 1/200 in water, and incubated for 1 hr. Gels were destained in 7.5% (v/v) acetic 
acid in the dark for 15 min and repeated. The glass surface was dried and two reference 
markers (GE Healthcare) attached to the underside of the glass plate before scanning. 
The resulting image was imported into the ImageMaster software (GE Healthcare) and 
the spots were detected, normalised and the reference markers selected. All spots of 
interest were manually selected. The resulting image was saved and exported into the 
Ettan Spot Picker software.  
 
2.14.4 Spot picking 
The stained gel was placed in the tray of the Ettan Spot Picker (GE Healthcare, 18-
1145-28) with reference markers (GE Healthcare, 18-1143-34), aligned appropriately 
and covered with UHP. The imported pick list was opened, the syringe primed and the 
system was set up for picking the spots from the pick list. The spots were robotically 
picked and placed in 96-well plates (Greiner), which were stored at 4oC until spot 
digestion. 
 
2.14.5 Spot digestion  
The 96-well plate was placed in the Ettan Digester (GE Healthcare, 18-1142-68) to 
digest the protein. The gel plugs were washed 3x for 20 minutes each with 50µl 50mM 
ammonium bicarbonate (Sigma, A6141) in 50% methanol, followed by 3x wash for 15 
min with 50µl 70% acetonitrile (Sigma, 34967). The gel plugs were left to dry. After 
drying, the individual gel pieces were rehydrated in 10µl digestion buffer (12.5ng 
trypsin (Promega, V5111) per µl of 10% acetonitrile, 40mM ammonium bicarbonate). 
Exhaustive digestion was carried out overnight at 37oC. A volume of 40µl of 0.1% 
trifluoroacetic acid (Sigma, 302031) in 50% acetonitrile was added to the wells, mixed 
and left for 20 minutes. A volume of 60µl of this solution was transferred to a fresh 96-
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well plate. A volume of 30 µl of 0.1% trifluoroacetic acid in 50% acetonitrile was 
added to the wells, mixed and left for 20 minutes. A volume of 50µl of this solution 
was transferred to the fresh 96-well plate. The liquid in the plate was vacuum-dried in 
a Maxi dry plus (Speed Vac, MSC, Dublin). After drying, the 96-well plate was placed 
in the Ettan Spotter (GE Healthcare, 18-1142-67) for spotting onto the target plates. A 
volume of 3 µl of 0.5% trifluoroacetic acid in 50% acetonitrile was added to the 
desiccated peptides and mixed 5 times. A volume of 0.3 µl of this mixture was spotted 
onto the target plate after which a volume of 0.3 µl matrix solution [7.5 mg/ml a-
cyano-4-hydroxycinnamic acid (LaserBio labs, 28166-41-8) in 0.1% trifluoroacetic 
acid in 50% acetonitrile] was added.  
 
2.14.6 Identification of proteins with MALDI-TOF 
The target plate was placed in the MALDI-ToF (GE Healthcare, 11-0010-87) 
instrument. Mass spectra were recorded operating in the positive reflectron mode at the 
following parameters: accelerating voltage 20 kV; and pulsed extraction: on (focus 
mass 2500). Internal calibration was performed using trypsin autolysis peaks at 
842.509 m/z, 2211.104 m/z and external calibration was performed using PepMix 4 
respectively. Calibration using Pep4 was performed. The mass spectra generated for 
each of the proteins were analyzed using MALDI evaluation software (GE 
Healthcare). Protein identification was achieved with the PMF Pro-Found search 
engine for peptide mass fingerprints. 
 
2.15 PathwayStudio of identified proteins 
 
PathwayStudio 4.0 is a bioinfomatic product aimed at the visualisation and analysis of 
biological pathways, gene regulation networks and protein interaction maps. It comes 
with a comprehensive database that gives a snapshot of all information available in 
PubMed, with the focus on pathways and cell signalling networks. PathwayStudio 
permits the identification of biological interactions among genes and proteins of 
interest from the published literature, and provides links to the supporting sentences in 
the matching journal article citations (for articles available online in PubMed). The 
software can also connect two genes/proteins with the shortest possible path, import a 
list of genes/proteins, which can then be arranged into a pathway and finally find 
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common upstream and downstream regulators of a gene/protein. Graph drawing, 
layout optimisation, data filtering, pathway expansion and classification and 
prioritisation of proteins were all possible. PathwayStudio workes by identifying 
relationships among genes, small molecules, cell objects and processes and builds 
pathways based on these relationships. 
 





















2.16 RNA interference (RNAi) 
 
RNAi using small interfering RNAs (siRNAs) was carried out to silence specific 
genes. The siRNAs used were chemically synthesised (Ambion Inc). These siRNAs 
were 21-23 bps in length and were introduced to the cells via reverse transfection with 
the transfection agent siPORTTM NeoFXTM (Ambion Inc., 4511).  
Figure 2.1: PathwayStudio® A. Eight different types of ‘nodes’ are represented in a 
unique graphical form. Each ‘node’ details the molecule name, alias, description, 
HUGO ID, Swiss Prot ID, MGI ID, OMIM ID, Locuslink ID, RGD ID, Unigene ID, 
Gene Ontology terms, and organism name. B. ‘Controls’ are represented as arrows with 
different colours in the network, each representing a type of control/interaction.  The 
dots on each 'control' arrow is clickable to obtain the description of an interaction and 
the relevant MedLine articles. 
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2.16.1 Transfection optimisation 
In order to determine the optimal conditions for siRNA transfection, optimisation with 
kinesin siRNA (Ambion Inc., 16704) was carried out for each cell line. There were a 
number of different parameters that had to be determined to establish an optimised 
protocol for the siRNA transfection of MiaPaCa-2 and its single cell population clones. 
Cell suspensions were prepared at 1x105, 3x105 and 5x105 cells per ml. Solutions of 
negative control and kinesin siRNAs at a final concentration of 30 nM were prepared 
in optiMEM (GibcoTM, 31985). NeoFX solutions at a range of concentrations were 
prepared in optiMEM in duplicate and incubated at room temperature for 10 minutes.  
After incubation, either negative control or kinesin siRNA solution was added to each 
neoFX concentration. These solutions were mixed well and incubated for a further 10 
minutes at room temperature. 100 μl of the siRNA/neoFX solutions were added to 
each well of a 6-well plate. 1 ml of the relevant cell concentrations were added to each 
well. The plates were mixed gently and incubated at 37°C for 24 hours. After 24 hours, 
the transfection mixture was removed from the cells and the plates were fed with fresh 
medium.  The plates were assayed for changes in proliferation at 72 hours using the 
acid phosphatase assay (Section 2.3.2 B).  Optimal conditions for transfection were 
determined as the combination of conditions which gave the greatest reduction in cell 
number after kinesin siRNA transfection and also the least cell kill in the presence of 
transfection reagent.   
Optimisation of siRNA for GAPDH was also carried out using the above parameters to 
determine accurate transfection knock down at the protein level. Western blot analysis 
was used to establish the optimum conditions for a siRNA transfection. The optimised 
conditions for the cell lines are shown in Table 2.11. 
 
Table 2.11 Optimised conditions for siRNA transfection 
Cell line Seeding 






per 96 well (μl) 
Volume NeoFX 
per 6 well (μl) 
MiaPaCa-2  2.5 x 103 3 x 105 0.2 2 
Mia clone #3 2.5 x 103 3 x 105 0.2 2 
Mia clone #8 2.5 x 103 3 x 105 0.2 2 
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2.16.2 siRNA functional analysis of targets MiaPaCa-2 and its sub-populations 
Clone #3 and Clone #8 
Three pre-designed siRNAs were chosen for each of the protein/gene targets and 
transfected into cells. Two siRNAs were used if a validated siRNA was available. 
Validated siRNAs have been verified by real-time RT-PCR to reduce gene expression 
of >70% 48 hours post-transfection. For each set of siRNA transfections carried out, 
control, non-transfected (NT) cells and a scrambled (SCR) siRNA transfected control 
were used. Scrambled siRNA are sequences that do not have homology to any 
genomic sequence. The scrambled non-targeting siRNA used in this study is 
commercially produced, and guarantees siRNA with a sequence that does not target 
any gene product. It has also been functionally proven to have no significant effects on 
cell proliferation, morphology and viability. For each set of experiments investigating 
the effect of siRNA, the cells transfected with target-specific siRNAs were compared 
to cells transfected with scrambled siRNA. This took account of any effects due to the 
transfection procedure, reagents, and also any random effects of the scrambled siRNA. 
Kinesin was used as a control to assess the efficiency of the siRNA transfection. 
Kinesin plays an important role in cell division; facilitating cellular mitosis. Therefore, 
transfection of siRNA kinesin resulted in cell cycle arrest and confirmed efficient 
transfection. Western blots (section 2.9) were used to determine if siRNA had an 
efficient knock-down effect at a protein level. Table 2.12 outline the list of siRNAs 
and IDs used in this thesis. 
 
Table 2.12 List of siRNAs used 




Integrin Beta 1 #1 109877 (validated) 
Integrin Beta 1 #2 109878 
Integrin Beta 1 #3 109879 
Integrin Alpha 5 #1 111113    
Integrin Alpha 5 #2 106729 
Integrin Alpha 5 #3 106728 
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Integrin Alpha 6 #1 103827 (validated)  
Integrin Alpha 6 #2 8146 
ALDH1A1 #1 106197    
ALDH1A1 #2 106196 
ALDH1A1 #3 106195 
VIM #1 13111    
VIM #2 138994 
VIM #3 138993 
STIP1 #1 136103    
STIP1 #1 136104 
STIP1 #1 18523 
GSN #1 8127 
GSN #2 8031 
 
2.16.3 Invasion assays on siRNA transfected cells 
Using the optimised conditions in Table 2.11, each of the siRNAs was tested to see 
changes in invasion of the cells after transfection. Two-three separate siRNAs were 
used for each target gene (Table 2.12). All siRNAs were purchased from Ambion Inc.   
To assay for changes in invasive capacity, siRNA experiments in 6-well plates were 
set up using 2 μl NeoFx to transfect 30 nM siRNA at a cell density of 3x105 per well of 
a 6-well plate. Transfection medium was removed after 24 hours and replaced with 
fresh growth medium. The transfected cells were assayed for changes in invasion 
capacity at 48 hours using the in vitro invasion assay described in Section 2.5.2. All 
experiments were carried out independently at least three times. 
 
2.16.4 Adhesion assays on siRNA transfected cells 
To assay for changes in adhesion abilities, siRNA experiments in 6-well plates were 
set up using 2 μl NeoFx to transfect 30nM siRNA in a cell density of 3x105 per well of 
a 6-well plate. Transfection medium was removed after 24 hours and replaced with 
fresh growth medium. The transfected cells were assayed for changes in adhesion 
abilities at 48 hours using the optimised in vitro adhesion assay described in section 
2.5.3. All experiments were carried out independently at least three times. 
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2.16.5 Anoikis assays on siRNA transfected cells 
Forty-eight hrs post transfection (as previously described, table 2.11) in 6-well plates, 
cells were tested in anoikis assays (section 2.6) to determine changes in the ability to 
survive in suspension conditions. All experiments were carried out independently at 
least three times. 
 
2.16.6 Proliferation assays on siRNA transfected cells 
As described in table 2.11, cells were seeded using 0.2 μl Neofx to transfect 30 nM 
siRNA in a cell density of 2.5x103 per well of a 96-well plate. After 24 hrs, 
transfection medium was replaced with fresh media and cells were allowed to grow 
until they reached 80-90% confluency, a total of 5 days. Cell number was assessed 
using the acid phosphatase assay (section 2.3.2). All experiments were carried out 
independently at least three times. 
 
2.16.7 Chemosensitivity assay on siRNA transfected cells 
Assays were set up as described above (section 2.12.6). 24 hrs after addition of fresh 
media, appropriate concentrations (2x) of chemotherapeutic drugs were added to the 
wells in duplicate and incubated for 3 days. Drug was aspirated and cells washed 3x 
with PBS. Cells were then trypsinised and resuspended to 150 μl in fresh media. From 
the suspension, 30 μl was transferred to a fresh 96-well plate in the presence of fresh 
media. The plates were assayed for changes in proliferation at 96 hrs using the acid 
phosphatase assay (Section 2.3.2).  
 
2.16.8 Transfection of Clone #8 with ALDH1A1 cDNA 
The target cell line was trypsinised in 6-well plates and set up at 50-70% confluency. 
Following incubation overnight at 37oC, transfection mixtures were prepared and 
combined as outlined in table 2.13, and incubated for 15 minutes at RT. Control wells 
were untreated and empty vector controls contained transfection mixture without 
cDNA in the presence of empty plasmid, pCMV6-XL5 (Figure 2.3) (Origene). The 
transfection mixture was added directly onto cells in 6-well plate and incubated for a 
further 48 hrs. Western blotting (section 2.9) and invasion assays (section 2.5.2) were 
then carried out. 
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Table 2.13 Volumes for efficient cDNA transfection 
Vessel type Optimem Transfection 
reagent 
Optimem ALDH1A1 cDNA 
expression plasmid  





Figure 2.3 Schematic of plasmid vector 
 
2.17 Statistical analysis  
 
Analysis of the difference of comparisons, as well as untreated versus siRNA treated 
mean invasion and motility counts, adherence absorbance, anoikis and percentage 
survival calculated, were performed using a student t-test (two-tailed with unequal 
variance), on Microsoft Excel. In the siRNA experiments, siRNA scrambled 
transfected cells were used as control compared to siRNA treated samples. This was to 
ensure no ‘off-target’ effects of the transfection procedure. Non-treated controls were 
used to ensure scrambled siRNA was having no effects and to normalise data. 
 
*, A p value of ≤ 0.05 was deemed significant 
**, A p value ≤ 0.01 was deemed more significant 
***, A p value ≤ 0.005 was deemed highly significant 
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3.0 Results 
3.1 Chemosensitivity profile of BxPc-3, KCI-MOH1 and MiaPaCa-2 
cell lines 
In order to determine the relative resistance of the pancreatic cancer cell lines to a range of 
structurally distinct and molecularly different chemotherapeutic drugs, proliferation assays 
were performed (Chapter 2.3). The cell lines were analysed using an in vitro proliferation 
assay to determine the IC50 (concentration of drug that inhibits proliferation of 50% of the 
cell population) of the following drugs: epirubicin, taxotere, gemcitabine, taxol, 5-
fluorouracil, vincristine, VP-16, adriamycin, carboplatin and cisplatin. 
There was a considerable difference in sensitivity between the cell lines to the panel of 
chemotherapeutic drugs studied. BxPc-3 showed high resistance to epirubicin and VP-16 
compared to both KCI-MOH1 and MiaPaCa-2. MiaPaCa-2 also displayed sensitivity to 
adriamycin and vincristine. The chemo-sensitivity profiles for several drugs are similar in 
the three pancreatic cell lines, such as taxotere, taxol, carboplatin and cisplatin. However, 
there are significant differences in sensitivity to certain drugs, for example, gemcitabine, 
which is the drug of choice for pancreatic cancer. The KCI-MOH1 cell line appears to be 
more sensitive to gemcitabine than either BxPc-3 or MiaPaCa-2. Interestingly BxPc-3 
appears to be less sensitive to epirubicin, although not to adriamycin or to VP-16 as 
compared to the other two cell lines (Table 3.1.1).  
In conclusion, the pancreatic cancer cell lines generally displayed a modest inherent 
resistance to the panel of ten chemotherapeutic drugs analysed. In some cases, the 
resistance profile seems to indicate the same mechanistic mode of resistance, whereby 





Table 3.1.1 IC50 values of pancreatic cell lines to a panel of chemotherapeutic 
agents (results are expressed as IC50 ± SD, n=3). 
Chemotherapeutic agent 
(ng/ml) 
BxPc-3 KCI-MOH1 MiaPaCa-2 
Epirubicin 37.2 ± 6.7 5.6 ± 0.7 14 ± 2.2 
Gemcitabine 1.7 ± 0.2 0.5 ± 0.1 1.3 ± 0.1 
5-Fluorouracil (μg/ml) 0.5 ± 0.04 0.17 ± 0.02 0.5 ± 0.1 
Taxotere 0.4 ± 0.05 0.43 ± 0.1 0.4 ± 0.04 
Taxol 1.4 ± 0.2 1.8 ± 0.7 1.7 ± 0.1 
Adriamycin 42.3 ± 3.0 40.3 ± 4.4 16.7 ± 2.3 
Carboplatin (μg/ml) 2.8 ± 0.3 4.3 ± 0.4 6.1 ± 0.4 
Cisplatin (μg/ml) 0.2 ± 0.05 0.2 ± 0.01 0.4 ± 0.05 
VP-16 477.4 ± 49.5 33.2 ± 3.7 171.5 ± 9.4 







3.1.1 Pulse selection of cell lines 
Three pancreatic cancer cell lines, BxPc-3, KCI-MOH1 and MiaPaCa-2 were chosen for 
drug treatment. The cell lines were pulsed with epirubicin, taxotere and gemcitabine for 
four hours, once a week for 10 weeks (Chapter 2.4.2). These drugs are clinically relevant 
and were used at different concentrations based on cell line sensitivity to the 
chemotherapeutic drugs as outlined in table 3.1.2. All drug concentrations were within the 
range of physiological achievable concentration in vivo. 
Table 3.1.2 Concentrations for pulse-selection 
Cell line Epirubicin (ng/ml)  Taxotere (ng/ml) Gemcitabine (ng/ml)
BxPc-3 50 n/a 60 
KCI-MOH1 100 2 50 
MiaPaCa-2 64 1.2 20 
(n/a refers to the unsuccessful establishment of taxotere-selected BxPc-3 variant) 
3.1.1.1 Changes in resistance to chemotherapeutic drugs in selected variants  
Pulse selection of the above cell lines with epirubicin, taxotere and gemcitabine resulted in 
the establishment of nine novel cell lines. Cell lines selected with epirubicin, taxotere and 
gemcitabine were denoted “/Epi”, “/Txt” and “/Gem” respectively. 
After the 10 pulses, the pulse selected cell lines exhibited a modest increase in resistance 





3.1.2 Cross-resistance profile of pulse-selected variants 
When cell lines are repeatedly exposed to a chemotherapeutic drug, they may develop 
resistance to the selecting drug and also develop to a variety of other chemotherapeutic 
drugs which are unrelated in molecular structure and target specificity; this is termed 
cross-resistance. To investigate this phenomenon, the cross-resistance profiles to a variety 
of drugs were tested in the BxPc-3, KCI-MOH1 and MiaPaCa-2 selected variants.   
3.1.2.1 BxPc-3 pulse-selected variants 
The IC50 concentrations, fold resistance information and p values of the BxPc-3 pulse-
selected variants are shown in table 3.1.3. 
Bx/Epi was generated after 10 pulses with 50 ng/ml epirubicin. The epirubicin variant 
exhibits a modest 1.4-fold increase in resistance to epirubicin and cross-resistance to 
adriamycin (1.7-fold) and vincristine (1.5-fold). The cell line showed similar sensitivity to 
gemcitabine, taxol and VP-16 as the parental cell line. Bx/Epi exhibited cross-sensitivity 
to 5-fluorouracil, taxotere, carboplatin and cisplatin. 
The gemcitabine-selected variant was established after 10 pulses with 60 ng/ml 
gemcitabine. Bx/Gem exhibited no increase in resistance to gemcitabine or VP-16. 
However, cross-resistance was observed with epirubicin (1.7-fold) and vincristine (1.2-
fold). Increased sensitivity was observed to 5-fluorouracil and taxotere. Carboplatin 
sensitivity was increased whereas resistance to cisplatin was increased 1.3-fold. 






Table 3.1.3 IC50 concentrations and fold resistance of BxPc-3 drug selected 
variants (results are expressed as IC50 ± SD, n=3). 
Chemotherapeutic 
agent (ng/ml) 
BxPc-3   
IC50 










Epirubicin 38.7 ± 6.3 52.3 ± 26.0 1.4 54.7 ± 26.1 1.7 
Gemcitabine 1.7 ± 0.2 1.5 ± 0.1 0.8 1.7 ± 0.1 1.0 
5-Fluorouracil 
(μg/ml) 0.5 ± 0.04 0.2 ± 0.2 0.4 0.3 ± 0.1 0.6** 
Taxotere 0.4 ± 0.3 0.3 ± 0.04 0.7* 0.2 ± 0.2 0.8 
Taxol 1.4 ± 0.2 1.5 ± 0.1 1.2 1.5 ± 0.1 1.1*** 
Adriamycin 42.3 ± 3.0 72.2 ± 17.0 1.7* 65.3 ± 30.8 1.1 
Carboplatin 
(μg/ml) 3.3± 0.7 2.1 ±0.05 0.6 2.6 ± 0.6 0.9** 
Cisplatin (μg/ml) 0.2 ± 0.04 0.2 ± 0.01 0.8 0.28 ± 0.08 1.3* 
VP-16 (μg/ml) 0.5 ± 0.05 0.4 ± 0.1 0.9 0.5 ± 0.09 1.0 
Vincristine 2.3 ± 0.2 3.5 ± 0.3 1.5 2.6 ± 1.0 1.2*** 




3.1.2.2 KCI-MOH1 pulse-selected variants 
The IC50 concentrations, fold resistance information and p values denoted by; * ≤ 0.05, ** 
≤ 0.01, *** ≤ 0.005 of the KCI-MOH1 pulse-selected variants are shown in table 3.1.4. 
KCI/Epi was established after 10 pulses with 100 ng/ml epirubicin. The selected variant 
displayed 8-fold resistance to epirubicin compared to the parental cell line. Cross-
resistance profiling showed that an increase in resistance was also observed for 
gemcitabine (2.1-fold), taxol (1.5-fold), carboplatin (1.4-fold) and VP-16 (2.5-fold). A 
significant decrease in response to adriamycin and vincristine was demonstrated 
suggesting an alternative mode of multidrug resistance other than MDR-1 and MRP-1. 
The gemcitabine-selected variant was generated after 10 pulses with 50 ng/ml 
gemcitabine. A significant increase in resistance of 2608-fold was observed to the 
selecting drug. KCI/Gem also displayed cross-resistance to epirubicin (7.3-fold), taxol 
(2.6-fold) and VP-16 (3.0-fold). A slight increase in resistance to taxotere and cisplatin 
was observed. Resistance to 5-fluorouracil, adriamycin, carboplatin and vincristine were 
decreased. 
The taxotere-selected variant, KCI/Txt was established after 10 pulses with 2 ng/ml 
taxotere. No resistance was developed against the selecting drug; in fact the cells 
displayed a marked sensitivity to taxotere. Cells also showed a decrease in resistance to 
adriamycin, cisplatin, and vincristine. An increase in resistance was observed for 
epirubicin (9.0-fold), gemcitabine (2.5-fold), 5-fluorouracil (1.5-fold), taxol (2.4-fold), 























Epirubicin 5.6 ± 0.7 45.1 ± 4.7 8.0*** 41.1 ± 5.2 7.3** 50.2 ± 8.8 9.0 
Gemcitabine 0.5 ± 0.1 1.1 ± 0.2 2.1* 1394 ± 219 2608** 1.3 ± 0.2 2.5 
5-Fluorouracil 
(μg/ml) 0.17 ± 0.02 0.2 ± 0.2 1.1 0.1 ± 0.01 0.5** 0.3 ± 0.03 1.5* 
Taxotere 0.43 ± 0.1 0.2 ± 0.002 1.1 0.5 ± 0.03 1.1 0.3 ± 0.1 0.8* 
Taxol 1.8 ± 0.7 2.6 ± 0.2 1.4 4.5 ± 0.8 2.5** 4.2 ± 0.4 2.3** 
Adriamycin 40.3 ± 4.4 25.1 ± 3.6 0.6** 25.1 ± 1.7 0.6* 28.6 ± 1.3 0.7 
Carboplatin (μg/ml) 4.3 ± 0.4 5.8 ± 0.1 1.4** 2.6 ± 0.1 0.6** 6.1 ± 1.0 1.4 
Cisplatin (μg/ml) 0.2 ± 0.01 0.2 ± 0.05 1.1 0.3 ± 0.05 1.5* 0.2 ± 0.02 0.9 
VP-16 33.2 ± 3.7 82.2 ± 8.3 2.5*** 99.1 ± 9.0 3.0*** 99.1 ± 7.4 3.0* 
Vincristine 2.6 ± 0.3 1.7 ± 0.3 0.6** 1.8 ± 0.2 0.7* 1.8 ± 0.1 0.7 
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3.1.2.3 MiaPaCa-2 pulse-selected variants 
The IC50 concentrations, fold resistance information and p values denoted by; * ≤ 0.05, ** 
≤ 0.01, *** ≤ 0.005 of the MiaPaCa-2 pulse selected variants are shown in table 3.1.5. 
 
Mia/Epi was established after 10 pulses with 64 ng/ml epirubicin. The selected variant 
displayed a significant 1.7-fold increase in resistance to epirubicin compared to the 
parental cell line. Cross-resistance profiling showed an increase in resistance to 
gemcitabine (1.6-fold), taxotere (1.4-fold), adriamycin (2.6-fold), carboplatin (1.4-fold), 
cisplatin (1.5-fold), VP-16 (2.3-fold) and vincristine (2.8-fold). No change in resistance 
was observed for taxol. 
 
The taxotere-selected variant, Mia/Txt was established after 10 pulses with 1.2 ng/ml 
taxotere. Table 2.3.3 shows that resistance to taxotere was increased 1.2-fold, while taxol 
resistance was similarly increased (1.2-fold). Cross-resistance profiling showed modest 
increases in resistance to gemcitabine (2.5-fold), cisplatin (1.5-fold) and carboplatin (1.2-
fold). A decrease in resistance was observed for epirubicin, 5-fluorouracil, adriamycin, 
VP-16 and vincristine. 
 
Mia/Gem established through 10 pulses with 20 ng/ml gemcitabine displayed a significant 
increase in resistance to gemcitabine (1.3-fold). Cross-resistance was also observed to 5-
fluorouracil (1.2-fold), epirubicin (1.2-fold), taxotere (1.3-fold), taxol (1.4-fold), 
adriamycin (2.6-fold), VP-16 (1.3-fold) and vincristine (2.8-fold). Cells displayed a 
modest increase in resistance to carboplatin while, a slight decrease in resistance to 
cisplatin was observed. 
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Epirubicin 14 ± 2.2 24.3 ± 2.1 1.7*** 17.9 ± 1.5 1.2* 3.9 ± 0.5 0.3*** 
Gemcitabine 1.3 ± 0.1 2 ± 0.1 1.6*** 1.7 ± 0.1 1.3** 3.1 ± 0.3 2.5* 
5-Fluorouracil (μg/ml) 0.5 ± 0.1 0.5 ± 0.1 1.1 0.6 ± 0.0.4 1.2 0.2 ± 0.0.3 0.5*** 
Taxotere 0.4 ± 0.04 0.5 ± 0.01 1.4** 0.5 ± 0.1 1.3 0.5 ± 0.2 1.2 
Taxol 1.7 ± 0.1 1.6 ± 0.2 1.0 2.3 ± 0.3 1.4 2.0 ± 0.2 1.2 
Adriamycin 16.7 ± 2.3 44.0 ± 2.9 2.6*** 42.8 ± 7.0 2.6* 6.0 ± 1.0 0.4*** 
Carboplatin (μg/ml) 6.1 ± 0.4 8.6 ± 0.7 1.4 6.6 ± 1.3 1.1 7.4 ± 1.3 1.2 
Cisplatin (μg/ml) 0.4 ± 0.05 0.7 ± 0.02 1.5* 0.4 ± 0.1 0.9 0.6 ± 0.09 1.5* 
VP-16 171.5 ± 9.4 400.8 ± 57.7 2.3* 222.8 ± 14.2 1.3*** 82.2 ± 12.8 0.5*** 
Vincristine 0.6 ± 0.1 1.7 ± 0.3 2.8* 1.7 ± 0.1 2.8*** 0.5 ± 0.3 0.9 
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3.1.3 P-gp and MRP-1 expression in pulse-selected variants 
 
Expression of two drug resistance pumps (P-gp and MRP-1) were investigated by Western 
blot in our panel of drug selected cell lines (Chapter 2.9). Figure 3.1.1 (A) shows no 
detection of P-gp in our panel of pulse-selected variants. (B) MRP-1 protein was detected 
at very low levels in the BxPc-3 cell line; however, there is no distinguishable difference 
in MRP-1 expression between parental BxPc-3 and epirubicin and gemcitabine-selected 

















Figure 3.1.1 Western blot analysis of (A) P-gp and (B) MRP-1 in our panel of drug-
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3.1.4 Invasion assays 
 
Invasion assays were performed on the drug selected variants to investigate the possible 
association between drug resistance and invasion. Invasion assays were performed on 
epirubicin, taxotere and gemcitabine selected variants of BxPc-3, KCI-MOH1 and 
MiaPaCa-2 as outlined in Chapter 2.5.2. 
 
3.1.4.1 Invasion assay of parental cell lines 
The invasion assays performed on the parental cell lines show variable degrees of 
invasion. BxPc-3 displays the highest level of invasion through matrigel-coated invasion 
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3.1.4.2 Invasion of drug-selected cell lines 
The BxPc-3 parent cell line was the most invasive cell line used in this study. After pulse-
selecting the cells with epirubicin and gemcitabine, the variants showed increased 
invasion activity compared to the parental line (Figure 3.1.3). Bx/Epi displayed a 
significant increase in invasion (p=0.002), while Bx/Gem also displayed a slight but 
significant increase in invasion (p=0.05). 
 
The KCI-MOH1 cell line showed modest invasion through the matrigel-coated insert, 
however, the epirubicin and gemcitabine-selected variants showed a significant increase in 
invasion compared to the parental cell line (p ≤ 0.001). The taxotere-selected cell line, 
KCI/Txt showed a slight decrease in invasion (Figure 3.1.4).  
 
MiaPaCa-2 displayed the lowest level of invasion. After pulse-selecting the cells with 
epirubicin and gemcitabine, the selected variants became significantly more invasive than 
the parent cell line (p ≤ 0.001). Mia/Txt showed no significant change in invasion capacity 
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(A) 

































Figure 3.1.3 (A) Invasion assay of (i) BxPc-3, (ii) Bx/Epi, (iii) Bx/Gem through 
matrigel. Magnification, 200x. Scale bar, 200 μm. (B) Quantified invasion assay of 
BxPc-3, Bx/Epi and Bx/Gem. 





 108  
(A) 






































Figure 3.1.4 A. Invasion of (i) KCI-MOH1, (ii) KCI/Epi, (iii) KCI/Gem through 
matrigel. Magnification, 200x. Scale bar, 200 μm. B. Quantified invasion assay of 
KCI-MOH1, KCI/Epi, KCI/Gem and KCI/Txt. 
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005 Student’s t-test. 
*** 
***
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(A) 








































Figure 3.1.5 A. Invasion of (i) MiaPaCa-2, (ii) Mia/Epi, (iii) Mia/Gem and (iv) 
Mia/Txt through matrigel. Magnification, 200x. Scale bar, 200 μm. B. Quantified 
invasion assay of MiaPaCa-2, Mia/Epi, Mia/Gem and Mia/Txt 
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005 Student’s t-test. 
*** 
*** 
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3.2 MDR-associated protein expression in pancreatic carcinoma 
patients 
 
Drug resistance is one of the major obstacles in the treatment of pancreatic cancer. 
Increased export of cytotoxic drugs from tumour cells is one of the key mechanisms of 
drug resistance. Many of the proteins responsible in this drug efflux belong to the family 
of ABC transporters. 
 
Primary pancreatic carcinoma specimens from 45 patients were included in this study. 
Formalin-fixed paraffin embedded tumour samples from the 45 patients were analysed by 
means of immunohistochemistry for expression of MDR-1/P-gp and MRP-1 using 
monoclonal antibodies (MAbs) (Chapter 2.8.1, table 2.3.1). Tumours stained with 
appropriate MAbs were scored and presented as the percentage of positive tumour cells 
and intensity (Table 3.2.1). 
Relevant histopathological information was available for 42 cases (Table 3.2.2). 
Information on patient age at diagnosis was available for 37 cases; age ranged from 32 to 
73 years and the median age was 62 years. Data on tumour type was available for 42 
cases; 34 tumours were classified as adenocarcinoma, 4 were endocrine/neuro-endocrine, 
3 were cholangiocarcinoma and one was a retro-pancreatic malignant GIST. Six tumours 
were poorly differentiated, twenty-five were moderately differentiated and seven were 
well differentiated (data was unavailable for 7 cases). Table 3.2.3 outlines the grade 
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Table 3.2.1 Percentage and intensity grade of staining 
Percentage grade of staining Intensity grade of staining 
1= 10<25% Level 1 = weak staining 
2= 25-50% Level 2 = strong staining 
3= 50<75% Level 3 = intense staining 
4= 75<100%  
 
Table 3.2.2 Summary of histopathological information for 42 patients 
Age (years) Tumour type  Differentiation status 
Range, 32-73 Adenocarcinoma, 34 Poorly differentiated, 6 
Median, 62 Endocrine/neuro-endocrine, 4 Moderately differentiated, 25 
 Cholangiocarcinoma, 3 Well differentiated, 7 
 Retro-pancreatic malignant, GIST 1  
 
 
Table 3.2.3 Histological grading of tumours 
Histopathological grade Classification  
Grade X Cannot be assessed 
Grade I 
Well differentiated (greater than 95% of 
tumour composed of glands) 
Grade II 
Moderately differentiated (50-95% of 
tumour composed of glands 
Grade III 
Poorly differentiated (40% or less of 
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3.2.1 MDR-1/P-glycoprotein protein expression 
 
MDR-1/P-glycoprotein (P-gp) protein expression was studied in 45 pancreatic tumour 
specimens. Immunohistochemical analysis results are presented in table 3.2.4. 
Representative tumours stained with the P-gp specific MAb, 6/1C (Moran et al., 1997) are 
shown in figure 3.2.1. 
Our findings show that P-gp was expressed in 93% (42/45) of pancreatic tumours (Table 
3.2.4). Approximately 12% (5/42) scored 1+, 10% (4/42) scored 2+, 24% (10/42) scored 
3+, while 55% (23/42) scored 4+. Weak staining was observed in 10% (4/42) of cases, 
intermediate staining in 52% (22/42) and strong staining in 38% (16/42) of cases. Three 
cases showed no P-gp expression. 
Table 3.2.5 shows the distribution and percentage of P-gp positive tumours in relation to 
age at diagnosis, tumour size, histological grade and nodal status. The majority of patients 
in this study were over 50 and displayed a higher expression of P-gp positivity (93%) than 
patients under 50 (89%). A weak association between P-gp expression and larger tumour 
size was displayed; higher P-gp expression levels (93%) were observed in larger size 
tumours (≥ 2cm), while 67% of smaller tumours (≤ 2cm) displayed P-gp positivity. 
Histological grade II appeared to be more strongly associated with P-gp expression 
(100%). In node positive patients, 94% of specimens expressed P-gp, while 87% of 
samples from node negative patients expressed P-gp. It is important to note that no 
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             Intensity grade of staining 
 Strong (+3)  Intermediate (+2) Weak     (+1) 
 
0 3 ------------- ------------- ------------- 
1+ 
(1<25%) 
5 -------------- 3 2 
2+ 
(25-50%) 
4 -------------- 4 -------------- 
3+ 
(50<75%) 
10 3 6 1 
4+ 
(>75%) 
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Table 3.2.5 P-gp expression in pancreatic carcinomas and association with age at 
diagnosis, tumour size, histological grade and nodal status (n=45) 
 Number positive Percentage positive 
Age   
<50 years 8/9 89% 
>50 years 26/28 93% 
Unknown n=8   
   
Tumour size   
≤2 cm 2/3 67% 
≥2 cm 26/28 93% 
Unknown n=14   
   
Histological grade   







Unknown n=7   
   
Nodal status   
Node positive patients  16/17 94% 
Node negative patients  13/15 87% 
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Figure 3.2.1 Immunohistochemical analysis of P-gp expression  
A. Intense P-gp positivity is observed in the pancreatic tumour sample (4+3), stained 
with anti- MDR-1, 6/1C. B. Negative control specimen. Magnification, 400x, scale 
bar, 100 μm.  
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3.2.2 MRP-1 protein expression 
 
MRP-1 protein expression was studied in 45 specimens from pancreatic tumour patients. 
Immunohistochemical analysis results are presented in table 3.2.6. Representative tumours 
stained with the MRP-1 specific MAb, (Alexis, ALX-801-007-C250) are represented in 
figure 3.2.2. 
We found that MRP-1 protein was expressed in 31% of pancreatic tumours (Table 3.2.6). 
Approximately 14% (2/14) scored 1+, 14% (2/14) scored 2+, 57% (8/14) scored 3+ and 
14% (2/14) scored 4+. Weak staining was observed in 36% (5/14) of cases, intermediate 
staining in 29% (4/14) and strong staining in 36% (5/14). 
Sixty-nine percent (31/45) of tumours did not show MRP-1 protein expression. 
Patients over 50 years displayed a higher percentage of MRP-1 expression (46.5%) than 
patients under 50 (11%). A weak association between MRP-1 expression and larger 
tumour size was observed; higher MRP-1 expression levels (39%) were observed in larger 
tumours (≥ 2 cm) compared to smaller tumours (≤ 2 cm) of which all specimens were 
MRP-1 negative. Histological grade II appeared to be more strongly associated with MRP-
1 expression (40%). In specimens from node positive patients, 29% of samples expressed 
MRP-1, while 53% of samples from node negative patients expressed MRP-1 (Table 
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             Intensity grade of staining 
 Strong (+3)        Intermediate (+2)     Weak     (+1) 
 
0      31 ------------- ------------- ------------- 
1+ 
(1<25%) 
2 1 -------------- 1 
2+ 
(25-50%) 
2 1 --------------- 1 
3+ 
(50<75%) 
8 2 3 3 
4+ 
(>75%) 
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Table 3.2.7 MRP-1 expression in pancreatic cancer and association with age at 
diagnosis, tumour size, and histological grade and nodal status (n=45) 
 Number positive Percentage positive 
Age   
<50 years 1/9 11% 
>50 years 13/28 46.5% 
Unknown n=8   
   
Tumour size   
≤2 cm 0/3 0% 
≥2 cm 11/28 39% 
Unknown n=14   
   
Histological grade   







Unknown n=7   
   
Nodal status   
Node positive patients  5/17 29% 
Node negative patients  8/15 53% 

































Figure 3.2.2 Immunohistochemical analysis of MRP-1 expression  
A. Intense MRP-1 positivity is observed in the pancreatic tumour sample (3+3), 
stained with anti-MRP-1. B. Negative control specimen. Magnification, 400x. Scale 
bar, 100 μm.  
 
 120  
3.2.3 MDR-1/P-gp and MRP-1 protein expression 
 
Table 3.2.8 outlines the co-expression of P-gp and MRP-1 observed in the samples. In this 
study, 31% of samples stained positive for both P-gp and MRP-1. However from section 
3.3.1-3.3.2, P-gp expression (93%) is found more frequently in pancreatic cancer than 
MRP-1 expression (31%). Interestingly, 62% of patients stained positive for P-gp and 
negative for MRP-1. Only, three cases (6.7%) expressed neither P-gp nor MRP-1. No 
cases of MRP-1 positive, P-gp negative were observed. 
   
Table 3.2.8 Summary slide number stained positive and negative for P-gp and 
MRP-1. 
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3.3 Investigation into clonal variation in the invasive phenotype in 
sub-populations of MiaPaCa-2 
 
An objective of this thesis was to establish pancreatic cancer cell line models differing in 
invasion status from single cell clonal populations of the cell line, MiaPaCa-2 (Chapter 
2.2). Initially clonal populations were screened using in vitro invasion assays to determine 
intrinsic differences in the invasive phenotype (Chapter 2.5.2).  
Invasion through specific extracellular matrix proteins was assessed using laminin, 
fibronectin, collagens type IV and I.  
 
3.3.1 Isolation of sub-clonal populations of the pancreatic cancer cell 
line, MiaPaCa-2 
 
Single cell cloning was performed as described in chapter 2.2. The cell line, MiaPaCa-2 
was chosen as other cell lines did not culture well in single cell colonies. Four clones were 
isolated and successfully established as cell lines from MiaPaCa-2. The invasion status of 
the clones was tested on matrigel (Figure 3.3.1). Two sub-populations, Clone #3 and 
Clone #8 showing a large increase and decrease in invasion were chosen for further 
analysis. 
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3.3.2 Invasion assays through matrigel, laminin, fibronectin, collagens 
type IV and I 
 
The invasion assays were carried out using a range of extracellular matrix proteins: 
matrigel, laminin, fibronectin, collagens type IV and I (Figures 3.3.2-6). Motility assays 
were also performed without extracellular matrices (Figure 3.3.7). The assays were 
performed in triplicate and each figure illustrates a representative experiment. Invasion 
and motility assay results are summarised in figure 3.3.8.  
 
Clone #3 is a highly invasive clonal population displaying significantly increased invasion 
through matrigel (p=0.001) compared to the parent MiaPaCa-2. Invasion is also increased 
through laminin and fibronectin, although not significantly. Clone #3 also displays 
significantly increased motility compared to the parental cell line (p=0.00005). 
Clone #8 shows a significant decrease in invasion through matrigel (p=0.00001), laminin 
(p=0.002), fibronectin (p=0.008), and collagens type IV (p=0.02) and I (p=0.03). Motility 
of Clone #8 is similar to MiaPaCa-2. 
 
Overall, the highest level of invasion was observed through fibronectin for each of the cell 
lines. In contrast, the lowest level of invasion displayed by the cell lines was through the 
collagens, type IV and I. This lack of invasion through the collagens could be explained 
by the reduced expression of collagen receptors, integrin α1, in the pancreatic cancer cell 
line, MiaPaCa-2 (Grzesiak and Bouvet, 2007).
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Figure 3.3.2 Invasion of (A) MiaPaCa-2 (B) Clone #3 and (C) Clone #8, through 
matrigel. Magnification, 100x. Scale bar, 200μm. 




























Figure 3.3.3 Invasion of (A) MiaPaCa-2 (B) Clone #3 and (C) Clone #8, through 
laminin. Magnification, 200x. Scale bar, 100μm. 
 


























Figure 3.3.4 Invasion of (A) MiaPaCa-2 (B) Clone #3 and (C) Clone #8, through 
fibronectin. Magnification, 200x. Scale bar, 100μm. 



























Figure 3.3.5 Invasion of (A) MiaPaCa-2 (B) Clone #3 and (C) Clone #8, through 
collagen type IV. Magnification, 200x. Scale bar, 100μm. 
 
































Figure 3.3.6 Invasion of (A) MiaPaCa-2 (B) Clone #3 and (C) Clone #8, through 
collagen type I. Magnification, 200x. Scale bar, 100μm. 




























Figure 3.3.7 Motility of (A) MiaPaCa-2 (B) Clone #3 and (C) Clone #8. 
Magnification, 200x. Scale bar, 100μm. 
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Figure 3.3.8 Invasion of MiaPaCa-2, Clone #3 and Clone #8 through ECM proteins 
and motility assay. Results are displayed as the total number of cells invading as 
counted at 200x magnification ± SD (n = 3). Ten random fields were counted, 
averaged and the total no. of cells invading calculated and statistical analysis was 
carried out using the student t-test.  
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3.3.3 Adhesion properties of MiaPaCa-2 and sub-populations Clone #3 
and Clone #8 
 
The sub-populations, Clone #3 and Clone #8 were characterised further by assessing the 
adhesive abilities of the clones to ECM proteins, matrigel, laminin, fibronectin, collagen 
type IV and I compared to the parental cell line, MiaPaCa-2 (Chapter 2.5.4).  
 
Figure 3.3.9 illustrates the level of adhesion of the pancreatic cell line, MiaPaCa-2 and its 
sub-clones, Clone #3 and Clone #8. The more invasive cell line, Clone #3 displays 
significantly decreased adhesion to matrigel (p=0.01), laminin (p=0.02), fibronectin 
(p=0.01) and collagen type IV (p=0.01) compared to the parental line. In contrast, a 
significant increase in adhesion was observed to collagen type I (p=0.003), although the 
level of adhesion to the collagens was lower than to laminin or fibronectin.  
The less invasive cell line, Clone #8 shows significantly increased adhesion to matrigel 
(p=0.04) and laminin (p=0.002). The adhesion to fibronectin and collagen type I were also 
increased, but not significantly. In contrast, adhesion to collagen type IV was decreased 
significantly (p=0.001). 
Interestingly, it is evident from figure 3.3.9, that there is no difference in adherence to 
collagens type IV and I between Clone #3 and Clone #8. Adhesion to collagen type IV is 
significantly decreased for both clonal populations compared to the parental cell line, 
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Figure 3.3.9 Adhesion of MiaPaCa-2, Clone #3 and Clone #8 to extracellular matrix 
proteins. Results are expressed as absorbance at 405nm with a reference wavelength 
of 620nm. Data shown is mean ± standard deviation (n = 3). 
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3.3.4 Anchorage independent growth of MiaPaCa-2 and sub-
populations Clone #3 and Clone #8 
 
The ability of MiaPaCa-2, Clone #3 and Clone #8 to form colonies under anchorage 
independent conditions was evaluated in order to further characterise the inherent 
differences in the sub-populations, Clone #3 and Clone #8 (Chapter 2.6).  
 
Figure 3.3.10 illustrates the different appearance of the colonies after 10 days of 
anchorage independent growth. MiaPaCa-2 shows modest colony formation with an 
average colony size of 75 μm, Clone #3 forms more and larger colonies with an average 
size of 120 μm. In contrast, Clone #8 in single cell suspension had the ability to form very 
few colonies; single cells appeared to undergo apoptosis, possibly due to the lack of cell-
ECM or cell-cell attachment as pictured in figure 3.3.11. The average size of Clone #8 
colonies was 60 μm. The parental cell line, MiaPaCa-2 has a percentage colony forming 
efficiency (%CFE) of 48%; however Clone #3, the cell line that has shown increased 
invasion and decreased adhesion displays a %CFE of 69% (Figure 3.3.11). In contrast, 
Clone #8, which displays decreased invasion and increased adhesion, shows a 
significantly reduced ability (32% CFE) to form colonies (p=0.006). 
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Figure 3.3.10 Colony formation after 10 days of MiaPaCa-2 (A) and (B), Clone #3 
(C) and (D) and Clone #8 (E) and (F). Magnification, 100x (A,C,E) and 400x (B,D,F). 
Scale bar, 200μm. 
 




























Figure 3.3.11 Percentage colony forming efficiency (%CFE) of MiaPaCa-2, Clone #3 
and Clone #8 under anchorage independent conditions. Data shown is mean ± 
standard deviation (n = 3). 
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3.3.5 Anoikis induction in MiaPaCa-2 and sub-populations Clone #3 
and Clone #8 
Anoikis is a specific form of apoptosis induced by the loss or alteration of cell-cell or cell-
matrix anchorage. An in vitro anoikis assay was used to assess sensitivity to anoikis of 
MiaPaCa-2 and its sub-populations Clone #3 and Clone #8 (Chapter 2.7). 
Figure 3.3.12 shows the percentage survival of non-adherent cells (24 hrs poly-HEMA 
treated plastic) relative to adherent cells (non-treated plastic). The evaluation of survival in 
suspension shows that Clone #3 displays increased resistance in anoikis compared to the 
parental cell line, although this difference did not reach statistical significance (p=0.07). 
Clone #8 demonstrates a significant sensitivity to anoikis (p=0.02) compared to the 
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Figure 3.3.12 Percentage survival of MiaPaCa-2, Clone #3 and Clone #8 in 
suspension compared to adherent cells.  Data shown is mean ± standard deviation (n 
= 3). Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test). 
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3.3.6 Analysis of the expression of integrins β1, α2, α5 and α6 in 
MiaPaCa-2 and sub-populations Clone #3 and Clone #8 
 
Altered changes in invasion and adhesion to fibronectin and laminin were observed in 
Clone #3 and Clone #8. Therefore, expression of integrins β1, α2, α5 and α6 which are 
associated with the adhesion to fibronectin and laminin were examined by Western blot 
analysis in the cell lines (Chapter 2.9).  
 
Figure 3.3.13 (A) illustrates the Western blot of integrin β1 (130kDa) in MiaPaCa-2, 
Clone #3 and Clone #8. Integrin β1 is highly expressed in the low-invasive, Clone #8 
compared to the parent cell line, MiaPaCa-2. Clone #3 and MiaPaCa-2 showed low 
expression of integrin β1.  
 
Integrin α2 (130 kDa) protein was expressed at low levels, the expression was unaltered 
between MiaPaCa-2, Clone #3 and Clone #8 (Figure 3.3.13 B). 
 
Integrin α5 (135kDa) expression in Clone #8 was increased compared to MiaPaCa-2, 
while a significant decrease in expression of Clone #3 was observed (Fig 3.3.13 C.).  
 
Integrin α6 shows higher protein expression in Clone #8 compared to the parental 
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Figure 3.3.13 Western blot of (A) Integrin β1 (130kDa) (B) Integrin α2 (130 kDa) (C) 
Integrin α5 (135 kDa) (D) Integrin α6 (120 kDa) and β-actin (42 kDa) (below) used as 
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3.3.6.1 Effect of siRNA transfection of integrin β1 on Clone #8 
Integrin β1 was shown to be abundantly expressed in the Clone #8 cell line compared to 
the parental cell line, MiaPaCa-2 and its high invasive sub-population Clone #3. Figure 
3.3.14 shows a representative Western blot of the knockdown of integrin β1 in Clone #8 

















Figure 3.3.14 Knockdown of integrin β1 in Clone #8 cells confirmed by Western blot 
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3.3.6.2 Effect of integrin β1 siRNA transfection on invasion and motility 
The role of integrin β1 in the low invasive, highly adhesive cell line, Clone #8 was 
assessed using siRNA (Figure 3.3.15). Forty-eight hours following transfection of two 
independent siRNAs, cells were subjected to invasion and motility assays as described 
previously in chapter 2.16.3 and 2.16.4. Integrin β1 siRNA transfected into Clone #8 
resulted in a significant increase in invasion through matrigel (p=0.005 and p=0.04), 
however invasion through laminin was not significantly altered. Invasion through 
fibronectin significantly increased (p=0.04 and p=0.02). Motility of Clone #8 after siRNA 
β1 transfection was also significantly increased (p=0.01 and p=0.03) compared to the 











Figure 3.3.15 Invasion and motility of Clone #8 control, treated with scrambled 
siRNA and two independent integrin β1 siRNA targets through matrigel, laminin 
and fibronectin.  Experiments were performed 48 hours post-transfection with two 
different exon targeted siRNA integrin β1. Untransfected- and scrambled siRNA 
transfected- cell lines were the controls for this experiment.  
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test). 
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3.3.6.3 Effect of integrin β1 siRNA transfection on adhesion 
The role of adhesion in Clone #8 cells transfected with integrin β1 siRNA was also 
assessed (Figure 3.3.16). A significant decrease in adhesion to matrigel (45% and 47% 
decrease) was observed (p=0.02 and p=0.002) compared to the scrambled control. 
Adhesion to fibronectin (p=0.02 and p=0.04) was also decreased with the integrin β1 
siRNA treatment (49% and 37%). Adhesion to laminin was not altered after transfection 
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Figure 3.3.16 Adhesion of Clone #8 control, treated with scrambled siRNA and two 
independent integrin β1 siRNA targets to matrigel, laminin and fibronectin.  
Experiments were performed 48 hours post-transfection with two different exon 
targeted siRNA integrin Beta 1. Untransfected- and scrambled siRNA transfected- 
cell lines were the controls for this experiment.  
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test). 
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3.3.6.4 Effect of integrin β1 siRNA transfection on anoikis 
Anoikis assays were also carried out to investigate whether the knockdown of integrin β1 
had any effect on the survival of Clone #8 in suspension (Chapter 2.16.5). Figure 3.3.17 
shows a significant increase in the percentage of cells surviving in suspension, when 
treated with integrin β1 siRNA compared to cells treated with scrambled control relative 
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Figure 3.3.17 Anoikis assay of Clone #8 control, treated with scrambled siRNA and 
two independent integrin β1 siRNA targets. Experiments were performed 48 hours 
post-transfection with two different exon targeted siRNA integrin Beta 1 and in 
triplicate. Untransfected- and scrambled siRNA transfected- cell lines were the 
controls for this experiment.  


























































3.3.6.5 Effect of integrins α5 and α6 siRNA transfection in Clone #8 
Integrins α5 and α6 were shown to be expressed in the Clone #8 cell line compared to the 
parental cell line, MiaPaCa-2 and its sub-population Clone #3. Figure 3.3.18 shows a 
representative Western blot of the knockdown of integrins α5 (ITGA5) and α6 (ITGA6) in 
Clone #8 cells after integrins α5 and α6 siRNA transfection.  
















Figure 3.3.18 Knockdown of integrin α5 and integrin α6 in Clone #8 cells confirmed 
by Western blot 48 hours post transfection. SiRNAs ITGA5 #1, #2 and #3 were 
chosen as target integrin α5 siRNAs.  SiRNAs ITGA6 #1 (validated) and #2 were 
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3.3.6.6 Effect of integrins α5 and α6 siRNA transfection on invasion  
Transfection of integrin α5 siRNA into Clone #8 resulted in significant increase in 
invasion through matrigel (p=0.0003, p=0.005 and p=0.005), laminin (p=0.07, p=0.008 
and p=0.0002) and fibronectin (p=0.0002, p=0.0001 and p=0.008) compared to the 
scrambled control.   
Transfection of siRNA α6 into Clone #8 also resulted in significant increase in invasion 
through matrigel (p=0.00009 and p=0.02), no significant increase in invasion through 
laminin, but significantly increased invasion through fibronectin (p=0.004 and p=0.04) 
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Figure 3.1.19 Invasion of Clone #8 control, treated with scrambled siRNA and three 
independent integrin α5 siRNA targets and two integrin α6 target siRNAs through 
matrigel, laminin and fibronectin. Experiments were performed 48 hours post-
transfection and in triplicate. Untransfected- and scrambled siRNA transfected- cell 
lines were the controls for this experiment.  
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test). 
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3.3.6.7 Effect of integrins α5 and α6 siRNA transfection on motility  
Transfection of integrin α5 siRNA into Clone #8 resulted in a significant increase in 
motility. Integrin α5 siRNA (1) resulted in a 1.7-fold increased in motility (p=0.03), 
integrin α5 siRNA (2) increased motility by 1.9-fold (p=0.0007) and integrin α5 siRNA 
(3) also increased motility 1.7-fold (p=0.06) compared to scrambled siRNA transfected 
control. 
Transfection of integrin α6 siRNA (1) into Clone #8 also resulted in a 1.4-fold increase in 
motility (p=0.2) and integrin α6 siRNA (2) showed a significant 1.6-fold increase in 
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Figure 3.3.20 Motility of Clone #8 control, treated with scrambled siRNA and three 
independent integrin α5 siRNA targets and two integrin α6 target siRNAs. 
Experiments were performed 48 hours post-transfection and in triplicate. 
Untransfected- and scrambled siRNA transfected- cell lines were the controls for this 
experiment.  Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test). 
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3.3.6.8 Effect of integrins α5 and α6 siRNA transfection on adhesion  
Figure 3.3.21 shows the percentage adhesion relative to untreated control cells. A decrease 
in adhesion to matrigel and laminin was observed although not significantly, while a more 
pronounced reduction of 40%, 29% and 38% in adhesion to fibronectin was seen after 
integrin α5 siRNA treatment (p=0.02, p=0.03 and p=0.02).  
Adhesion to matrigel and fibronectin was not altered with integrin α6 siRNAs treatment; 





































Figure 3.3.21 Adhesion of Clone #8 control, treated with scrambled siRNA, three 
independent integrin α5 siRNA targets and two integrin α6 siRNA targets to 
matrigel, laminin and fibronectin. Experiments were performed 48 hours post-
transfection and in triplicate. Untransfected- and scrambled siRNA transfected- cell 
lines were the controls for this experiment.  





 147  
3.3.6.9 Effect of integrins α5 and α6 siRNA transfection on anoikis  
Anoikis assays were also carried out to investigate the role of integrins α5 and α6 on the 
survival of Clone #8 in suspension. No significant increase in resistance to anoikis was 
observed after either integrins α5 and α6 siRNA transfection compared to cells treated 














Figure 3.3.22 Anoikis of Clone #8 control, treated with scrambled siRNA, three 
independent integrin α5 siRNA targets and two integrin α6 siRNA targets.  
Experiments were performed 48 hours post-transfection and in triplicate. 
Untransfected- and scrambled siRNA transfected- cell lines were the controls for this 
experiment.  
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test). 
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3.3.7 Drug resistance of MiaPaCa-2 and sub-populations, Clone #3 and 
Clone #8  
To determine if there is any link between altered invasion, adhesion, anchorage 
independent survival and drug resistance, proliferation assays were performed to compare 
drug sensitivity in MiaPaCa-2 and its sub-populations, Clone #3 and Clone #8 (Chapter 
2.3).  
 
The IC50 values of each of the chemotherapeutic agents were determined for the parental 
cell line and its sub-populations, Clone #3 and Clone #8 (Table 3.3.1). Clone #3 exhibited 
a significantly higher level of resistance to taxotere (p=0.02) and VP-16 (p=0.05), while 
resistance levels to epirubicin (p=0.13), adriamycin (p=0.06) and vincristine (p=0.08) 
were also increased compared to MiaPaCa-2, although not significantly. No increase in 
resistance was observed for 5-FU, taxol, cisplatin and carboplatin. Interestingly, a 
significant sensitivity to gemcitabine was observed (p < 0.005). Clone #8 displayed an 
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Figure 3.3.23 Fold resistance levels of MiaPaCa-2, Clone #3 and Clone #8 to a panel of 10 drugs. Cell viability was determined 
by acid phosphatase assay, read at 405nm with a reference wavelength of 620nm.  
Statistics, * p ≤ 0.05, ** p ≤ 0.01 *** p ≤ 0.005 Student’s t-test. 
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Table 3.3.1 Comparison of chemo-sensitivity and IC50 results between MiaPaCa-2 
and sub-clones, Clone #3 and Clone #8. Mean IC50 values from triplicate 





MiaPaCa-2 Clone #3 Fold 
resistance
Clone #8 Fold 
resistance
Epirubicin 14 ± 2.3 18.3 ± 3.1 1.3 7.2 ± 0.3 0.5*** 
Gemcitabine 1.3 ± 0.1 0.6 ± 0.0 0.5*** 1.0 ± 0.1 0.8* 
5-FU (ug/ml) 0.5 ± 0.1 0.4 ± 0.0 0.9 0.1 ± 0.0 0.1*** 
Taxotere  0.4 ± 0.0 0.6 ± 0.1 1.5* 0.2 ± 0.0 0.4*** 
Taxol  1.7 ± 0.1 1.2 ± 0.4 0.7 0.6 ± 0.1 0.4*** 
Adriamycin 16.7 ± 2.3 26.9 ± 5.2 1.6 7.6 ± 1.5 0.5*** 
Carboplatin  6140 ± 392 5243 ± 762 0.9 2820 ± 556 0.5*** 
Cisplatin 431.6 ± 53.7 413.1 ± 26.1 1.0 303.5 ± 52.9 0.7* 
VP-16 171.5 ± 9.4 267.5 ± 42.2 1.6* 55.1 ± 10.3 0.3*** 
Vincristine  0.6 ± 0.1 1.0 ± 0.2 1.6 0.4 ± 0.1 0.7 
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Table 3.3.2 Summary of different characteristics between Clone #3 and Clone #8 
compared to the parental cell line, MiaPaCa-2. 
 Clone #3 Clone #8 
Motility Increased Unchanged 
Invasion through matrigel Increased Decreased 
Invasion through laminin Slightly increased Decreased 
Invasion through fibronectin Slightly increased Decreased 
Invasion through collagen IV Slightly increased Decreased 
Invasion through collagen I Slightly increased Decreased 
Adhesion to matrigel Decreased Increased 
Adhesion to laminin Decreased Increased 
Adhesion to fibronectin Decreased Slightly increased 
Adhesion to collagen IV Decreased Decreased 
Adhesion to collagen I Increased Slightly increased 
Colony growth Slightly increased Decreased 
Anoikis Slightly increased Decreased 
Integrin β1 expression Unchanged Increased 
Integrin α2 expression Unchanged Unchanged 
Integrin α5 expression Decreased Increased 
Integrin α6 expression Slightly increased Increased 
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3.4 Proteomic analysis of MiaPaCa-2 and sub-populations Clone #3 
and Clone #8 by two-dimensional difference in-gel 
electrophoresis (2-D DIGE) 
 
Adhesion and degradation of the extracellular matrix (ECM) or basement membrane is 
one of the first critical steps during the invasive/metastatic cascade in vivo (Hood and 
Cheresh, 2002). Cell-ECM interaction can lead to the activation of essential signalling 
pathways, therefore to study these stimulated mechanisms, MiaPaCa-2, Clone #3 and 
Clone #8 were grown on matrigel for 24 hrs (Chapter 2.5.5).  
During control conditions, Clone #3 displays a 2.5-fold increase in invasion, while 
Clone #8 has a 6-fold decrease in invasion compared to the parental cell line, 
MiaPaCa-2 (Figure 3.4.1). However, pre-incubation of the cells to matrigel for 24 
hours prior to the in vitro invasion assay induced a further increase in the invasive 
potential of the cells and a new phenomenon termed superinvasion was also observed 
(Chapter 3.5). Superinvasion is defined as a process by which cells invade through the 
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Figure 3.4.1 Total number of cells invading under control conditions and also 
after 24 hrs incubation on matrigel. Line graph displays the total number of 
superinvading cells counted after 24 hrs incubation on matrigel of Clone #8, 
MiaPaCa-2 and Clone #3. 
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To determine expression differences between the parental cell line and the sub-
populations Clone #3 and Clone #8, proteomic analysis was carried out on MiaPaCa-2, 
Clone #3 and Clone #8 (Chapter 2.10) grown on matrigel for 24 hrs. Investigations 
into differential protein expression between the cell lines grown on matrigel in relation 
to their altered invasive phenotype could potentially identify significant functions of 
proteins and the complexities of cell-ECM interactions and may be critical for 
developing effective diagnostic techniques and early invasive detection markers for 
pancreatic cancer.  
 
3.4.1 Experimental outline for 2D-DIGE analysis of the samples 
 
2D-DIGE protein separation is performed by separating proteins first by isoelectric 
point and then by molecular weight. Protein spots in a gel are visualised using 
fluorescent markers (Görg et al., 2004). 2-D DIGE enables the incorporation of the 
same internal standard on every 2-D gel. The internal standard is a pool of all the 
samples within the experiment, and therefore contains every protein from every sample 
(e.g. MiaPaCa-2, Clone #3 and Clone #8). Duplicate technical repeats were also 
carried out as well as reverse labelling. Once proteins are separated and quantified, 
they are identified by MALDI-TOF MS (Chapter 1.7.1). Identification of proteins 
enables lists to be generated detailing differentially regulated proteins between 
samples. 
Gel number Cy2 Cy3 Cy5 
Gel 1 Pool MiaPaCa-2 (1) Clone #3 (1) 
Gel 2 Pool MiaPaCa-2 (2) Clone #3 (2) 
Gel 3 Pool MiaPaCa-2 (3) Clone #3 (3) 
Gel 4 Pool Clone #3 (1) Clone #8 (1) 
Gel 5 Pool Clone #3 (2) Clone #8 (2) 
Gel 6 Pool Clone #3 (3) Clone #8 (3) 
Gel 7 Pool Clone #8 (1) MiaPaCa-2 (1) 
Gel 8 Pool Clone #8 (2) MiaPaCa-2 (2) 
Gel 9 Pool Clone #8 (3) MiaPaCa-2 (3) 
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Figure 3.4.2 Normalised pool comprising all the samples from all samples 
(MiaPaCa-2, Clone #3 and Clone #8) is labelled with Cy2 dye. Each 2D-DIGE gel 
comprises pool (Cy2), condition 1 (Cy3/Cy5) and condition 2 (Cy3/Cy5) samples. 
The three scanned images from each 2D-DIGE are further analysed by DeCyder 
Image analysis software to generate the differentially regulated protein spots. The 
differentially regulated protein spots, as depicted in the 2D gel, are further 
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3.4.1.1 Identification of differentially regulated proteins  
Differential protein expression between triplicate biological replicates of MiaPaCa-2, 
Clone #3 and Clone #8 (exposed to matrigel for 24 hrs) were examined using 2D-
DIGE. DeCyderTM 6.5 software was used to identify differentially regulated proteins in 
each comparison. Biological variation analyses of these spots showing greater that 1.2-
fold change in expression with a t-test score of less that 0.05 were identified.  
 
To evaluate the differentially expressed proteins in the cell lines MiaPaCa-2, Clone #3 
and Clone #8, three comparative protein lists were generated. A total number of 113 
protein spots were identified in each comparison. Of these, 52 proteins were changed 
in the comparison of MiaPaCa-2 versus Clone #8; Clone #3 versus MiaPaCa-2 resulted 
in 37 differentially regulated proteins, and in the comparison of Clone #3 versus Clone 
#8, 60 proteins were identified as differentially regulated (Chapter 7.0, Appendix).  
 
In order to further determine the biological relevance of these differentially expressed 
proteins, the design analysis was laid out to specifically identify protein changes 
(either up-regulated or down-regulated) that consistently correlated with the invasion 
status of the cell lines, that is from high to low invasion (MiaPaCa-2 versus Clone #8 
and Clone #3 versus MiaPaCa-2 and Clone #3 versus Clone #8). The three protein lists 
were overlaid, determining unique and common proteins between lists, as outlined in 
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3.4.1.2 Identification of unique proteins differentially regulated with the 
invasion status of the cell lines 
The unique proteins abundantly expressed between each of the comparison lists 
(MiaPaCa-2 versus Clone #8 and Clone #3 versus MiaPaCa-2 and Clone #3 versus 
Clone #8) were determined to assess the potential role of uniquely expressed proteins 
in each comparison. 
 
The fold change in spot intensity in each comparison was determined from the 
Cy5/Cy3/Cy2 images of replicate repeats. The cell lines are compared from high to 
low invasion, therefore, proteins that are up-regulated, are increased in the more 
invasive cells lines and are represented as positive fold changes. The proteins that are 
down-regulated have negative fold changes, as these proteins are lowly expressed in 
the invasive cell lines compared to the less invasive cell lines. 
 
Table 3.4.1 outlines the 12 unique expressed proteins in the comparison of MiaPaCa-2 
to Clone #8. Among these proteins, 5 were up-regulated while 7 were down-regulated. 
 
In the comparison of Clone #3 to MiaPaCa-2, 9 proteins were identified as uniquely 
expressed (Table 3.4.2). This list identified 8 up-related protein and 1-down regulated 
proteins. 
 
Table 3.4.3 displays 13 unique differentially expressed proteins in the comparison of 
Clone #3 to Clone #8. Of these 13 proteins, 12 proteins were up-regulated, while 1 
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Aldolase ALDOA gi|4930291| 8.8/39.7 28.9 -1.4 ** 
14-3-3 Protein Epsilon  YWHAE gi|67464424| 4.6/29.1 27.3 -1.3 * 
Heat shock protein 60 
(b) 
HSPD1 gi|77702086| 5.7/61.4 35.5 -1.5 * 
Peroxiredoxin 2 PRDX2 gi|33188452| 6.1/16.0 25.9 -1.4 *** 
Heat shock protein 60 
(c) 
HSPD1 gi|77702086| 5.7/61.4 31.3 -1.3 * 
Aldehyde 
dehydrogenase 1 
family; member B1 
ALDH1B1 gi|2183299| 6.4/57.7 25.9 -1.3 * 
Glutathione 
synthetase  
GSS gi|8248826| 5.7/52.5 27.8 -1.2 * 
Beta actin (d) ACTB gi|15277503| 5.6/40.5 21.7 1.2 * 
Heat shock 70kDa 
protein 1A 
HSPA1A gi|5123454| 5.5/70.3 33.5 1.3 *** 
Nucleoside 
diphosphate kinase 
NDPK gi|1421614| 5.3/46.4 12.8 1.7 *** 
Gamma actin (b) ACTG1 gi|17511847| 8.8/17.3 43.7 2.0 *** 
Beta actin (b) ACTB gi|15277503| 5.3/42.1 45.6 2.3 *** 
 
The theoretical isoelectric point (pI) and molecular weight (Mw) were calculated from 
the sequence of the protein in the database. Isoforms of the same protein are referred to 
as (a), (b) etc. The percentage coverage is the amount of the protein sequence covered 
by the matched peptides. Statistical analysis between replicates is referred to as; * p ≤ 
0.05, *** p ≤ 0.01, *** p ≤ 0.005. For protein identification, all proteins were digested 
and identified at least twice from separate gels with MALDI-TOF MS. An expectation 
value of <0.02 was used for all reported identifications, which indicates a 0.2% chance 
that the identification is random. 
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90kDa heat shock 
protein 








GAPDH gi|31645| 8.7/36.2 22.1 1.2 * 
Transketolase TKT gi|37267| 6.5/58.8 33.6 1.3 * 
Triosephosphate 
Isomerase (Tim) (b) 
TPI1 gi|66360366| 6.5/26.8 19.4 1.3 ** 
ATP synthase 5 alpha  
1 protein (a) 
ATP5A1 gi|34782901| 9.2/48.9 27.8 1.3 *** 
ATP synthase beta 
subunit 








9.6/51.6 31.6 1.5 ** 
Beta actin (a) ACTB gi|15277503| 5.6/40.5 17.2 1.7 ** 
The theoretical isoelectric point (pI) and molecular weight (Mw) were calculated from 
the sequence of the protein in the database. Isoforms of the same protein are referred to 
as (a), (b) etc. The percentage coverage is the amount of the protein sequence covered 
by the matched peptides. Statistical analysis between replicates is referred to as; * p ≤ 
0.05, *** p ≤ 0.01, *** p ≤ 0.005. For protein identification, all proteins were digested 
and identified at least twice from separate gels with MALDI-TOF MS. An expectation 
value of <0.02 was used for all reported identifications, which indicates a 0.2% chance 
that the identification is random. 
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Clone #3  
versus 
Clone #8 
Heat shock 70kDa 
protein 8 isoform (b) 
HSPA8 gi|62897129| 4.9/26.9 23.5 -1.3 ** 
Eukaryotic translation 
elongation factor 2 
EEF2 gi|33869643| 9.1/65.4 13.6 1.2 * 
Malate dehydrogenase 2 MDH2 gi|49168580| 9.4/36.0 49.7 1.4 ** 
Tubulin; beta 
polypeptide (a) 
TUBB gi|18088719| 4.7/50.1 33.1 1.3 ** 
Tubulin; beta 
polypeptide (b) 
TUBB gi|18088719| 5.0/50.5 29.4 1.4 ** 
Tubulin alpha 6 variant TUBA6 gi|62897609| 5.0/46.5 29 1.4 ** 
Protein disulfide 
isomerise protein 5 
PDIA5 gi|1710248| 5.3/71.1 30.5 1.4 *** 
Heat shock 70kDa 
protein 8 isoform (b) 
HSPA8 gi|62897129| 6.1/47.1 27 1.3 * 
Translation initiation 
factor 
EIF4A3 gi|496902| 4.7/50.2 32.9 1.5 *** 
Beta-tubulin TUBB gi|18088719| 5.9/57.2 26.9 1.5 *** 
ER-60 protein (b) PDIA3 gi|2245365| 8.1/18.1 30.3 1.7 *** 
Cyclophilin A 
complexed with 2-Thr 
cyclosporine A 
PPIA gi|3659980| 5.0/50.5 18.9 1.7 ** 
Stress induced 
phosphoprotein (b) 
STIP1 gi|54696884| 6.4/63.3 11.6 1.8 *** 
The theoretical Pi and Mw were calculated from the sequence of the protein in the 
database. Isoforms of the same protein are referred to as (a), (b) etc. The % coverage is 
the amount of the protein sequence covered by the matched peptides. Statistical 
analysis between replicates is referred to as; * p ≤ 0.05, *** p ≤ 0.01, *** p ≤ 0.005. 
An expectation value of <0.02 was used for all reported MS identifications. 
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3.4.1.3 Identification of common proteins differentially regulated with the 
invasion status of the cell lines by overlapping two lists 
Proteins commonly expressed between the cell lines, MiaPaCa-2, Clone #3 and Clone 
#8 were examined. The three generated protein comparison lists (MiaPaCa-2 versus 
Clone #8, Clone #3 versus MiaPaCa-2 and Clone #3 versus Clone #8) were then 
overlaid to identify common proteins expressed in two lists. 
 
Each generated comparison (from high to low invasion) was overlapped with another 
comparison to identify key differentially regulated proteins common to both proteins 
lists. Proteins that are up-regulated are increased in the more invasive cells lines due to 
high invasion status and have positive fold changes. The proteins that are down-
regulated have negative fold changes, as these proteins are lowly expressed in the 
invasive cell lines compared to the less invasive cell lines. To further define the 
involvement of the overlapping proteins in each comparison, the proteins with 
consistent expression (either positively or negatively) in each comparison were 
considered consistently expressed and deemed more associated with invasion trend of 
the cell lines.  
 
Two comparison lists, MiaPaCa-2 versus Clone #8 and Clone #3 versus MiaPaCa-2 
were overlapped. Table 3.4.4 displays the 4 proteins that were identified as commonly 
regulated between the lists. The 4 proteins identified were inconsistently expressed in 
this comparison .i.e. the expression (fold change) did not consistently correlate to the 
invasive trend of the cell lines. 
 
The comparison of Clone #3 versus MiaPaCa-2 and Clone #3 versus Clone #8 resulted 
in 11 differentially regulated proteins (Table 3.4.5). Of these 11 proteins, 10 proteins 
were up-regulated and 1 protein was down-regulated. All proteins were consistently 
expressed in both comparisons. 
 
Table 3.4.6 outlines the 23 proteins commonly differentially expressed between the 
comparison of MiaPaCa-2 versus Clone #8 and Clone #3 versus Clone #8. Of these 23 
proteins, 17 were up-regulated and 6 were down-regulated. All proteins were 
consistently expressed in both comparisons. 
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Table 3.4.4 Proteins commonly expressed in the comparison of MiaPaCa-2 to 


















Peroxiredoxin PRDX1 gi|55959887| 6.4/19.1 38.6 -1.4 *** 1.2 ** 
14-3-3 
Protein Theta 
YWHAQ gi|71042777| 5.2/29.4 24.2 -1.4 *** 1.5 *** 




ANXA2 gi|62896643| 6.9/38.9 25.7 1.6 *** -1.3 * 
 
The theoretical isoelectric point (pI) and molecular weight (Mw) were calculated from 
the sequence of the protein in the database. Isoforms of the same protein are referred to 
as (a), (b) etc. The percentage coverage is the amount of the protein sequence covered 
by the matched peptides. Statistical analysis between replicates is referred to as; * p ≤ 
0.05, *** p ≤ 0.01, *** p ≤ 0.005. For protein identification, all proteins were digested 
and identified at least twice from separate gels with MALDI-TOF MS. An expectation 
value of <0.02 was used for all reported identifications, which indicates a 0.2% chance 
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Table 3.4.5 Proteins commonly expressed in the comparison of Clone #3 to 















 versus    
Clone #8 
Heat shock 
70kDa protein 8 
isoform 1 
variant (c)  
HSPA8 gi|62897129| 5.3/71.1 18.3 -1.2 * -1.3 ** 
Mortalin (a) HSPA9 gi|21040386| 6.0/74.1 38.5 1.2 *** 1.2 * 
Aldolase (b) ALDOA gi|4930291| 8.8/39.7 27.8 1.3 * 1.3 * 
Mortalin (b) HSPA9 gi|292059| 6.0/74.1 17.5 1.4 *** 1.6 *** 
Aconitase 2, 
mitochondrial 
ACO2 gi|49168620| 7.2/86.2 11.9 1.4 *** 1.3 * 
Annexin I (b) ANXA1 gi|442631| 7.9/35.3 14.6 1.5 *** 1.3 * 
ER-60 protein PDIA3 gi|2245365| 5.9/57.2 25.5 1.5 * 1.7 *** 
Translation 
initiation factor 
EIF4A3 gi|496902| 6.1/47.1 27 1.5 *** 1.5 *** 
ATP synthase  
5 alpha 1 (b) 
ATP5A1 gi|34782901| 8.4/54.6 36.2 1.5 ** 1.5 * 
Translation 
elongation 
factor 1 alpha 
1-like 14 (b) 
EEF1A1 gi|15277711| 9.1/43.3 12.1 1.6 * 2.2 *** 
Elongation 
factor 1 alpha 1 
(a) 
EEF1A1 gi|28848610| 5.3/43.2 10.1 2.0 ** 2.4 *** 
The theoretical pI and Mw were calculated from the sequence of the protein in the 
database. Isoforms of the same protein are referred to as (a), (b) etc. The % coverage is 
the amount of the protein sequence covered by the matched peptides. Statistical 
analysis between replicates is referred to as; * p ≤ 0.05, *** p ≤ 0.01, *** p ≤ 0.005. 
An expectation value of <0.02 was used for all reported MS identifications. 
Fold change
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Table 3.4.6 Proteins commonly expressed in the comparison of MiaPaCa-2 to Clone #8 and Clone #3 to Clone #8 





versus Clone #8 
 
Clone #3 versus     
Clone #8 
Glyceraldehyde dehydrogenase (a) GAPDH gi|31645| 8.4/36.2 16.1 -1.7 *** -1.9 *** 
Profilin PFN1 gi|30582841| 8.7/15.2 24.3 -1.6 *** -1.4 ** 
Heat shock protein 60 (a) HSPD1 gi|77702086| 5.7/61.4 42.8 -1.6 *** -1.5 *** 
Beta Actin (c) ACTB gi|15277503| 5.6/40.5 20.0 -1.5 *** -1.6 ** 
Ubiquinol-cytochrome c reductase 
complex core protein I 
UQCRC1 gi|731047| 5.9/53.3 20.0 -1.3 *** -1.3 *** 
Stomatin-like 2 STOML2 gi|6841440| 6.9/38.6 23.6 -1.3 ** -1.2 * 
Alpha tubulin  TUBA gi|340021| 4.9/50.8 32.6 1.3 * 1.4 ** 
Tubulin alpha 6 variant TUBA6 gi|62897609| 5.0/50.5 28.7 1.3 ** 1.4 *** 
Heat shock 70kDa protein 8 isoform 1 
variant (d) 
HSPA8 gi|62897129| 5.6/53.6 41.4 1.5 *** 1.7 *** 
Dissociation inhibitor 2 GDI2 gi|285975| 5.9/51.1 31.7 1.6 *** 1.8 *** 
Enolase 1 variant ENO1 gi|62897945| 7.0/47.5 31.8 1.6 *** 1.9 *** 
Heat shock 70kDa protein 8 isoform 1 
variant (a) 
HSPA8 gi|62897129| 5.3/71.1 28.2 1.6 *** 1.9 *** 
Fold change
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Pyruvate kinase 3 isoform 1 variant (a) PKM2 gi|67464392| 8.8/58.5 44.8 1.6 *** 1.9 *** 
Pyruvate kinase 3 isoform 1 variant (b) PKM2 gi|67464392| 7.8/58.5 41.8 1.6 ** 2.4 *** 
GARS GARS gi|12652637| 8.2/85.4 19.7 1.7 *** 1.8 *** 
Chaperonin TCP1, subunit 5 (epsilon) CCT5 gi|58257644| 5.5/61.5 38.3 1.7 *** 1.8 *** 
Vimentin (d) VIM gi|57471646| 5.2/49.7 18.1 1.8 *** 2.0 *** 
Vinculin VCL gi|24657579| 5.8/117.3 15.6 1.8 *** 2.2 *** 
Heat shock 70kDa protein 4 isoform a 
variant 
HSPA4 gi|62087882| 5.4/88.8 10.5 2.0 *** 2.4 *** 
Eukaryotic translation elongation 
factor 1 alpha 1 variant (c) 
EEF1A1 gi|62897525| 9.3/50.5 16.5 2.0 *** 1.8 * 
Eukaryotic translation elongation 
factor 2 
EEF2 gi|33869643| 6.5/58.2 17.6 2.1 *** 2.0 *** 
Vimentin (b) VIM gi|57471646| 5.2/49.7 33.2 2.2 *** 2.8 *** 
Aldehyde dehydrogenase 1 (c) ALDH1A1 gi|2183299| 6.3/55.4 28.5 3.8 *** 5.3 *** 
 
The theoretical pI and Mw were calculated from the sequence of the protein in the database. Isoforms of the same protein are referred to as (a), 
(b) etc. The % coverage is the amount of the protein sequence covered by the matched peptides. Statistical analysis between replicates is referred 
to as; * p ≤ 0.05, *** p ≤ 0.01, *** p ≤ 0.005. An expectation value of <0.02 was used for all reported MS identifications. 
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3.4.2 Identification of common proteins differentially regulated with 
the invasion status of the cell lines by overlapping three lists 
 
The three generated protein comparison lists (MiaPaCa-2 versus Clone #8, Clone #3 
versus MiaPaCa-2 and Clone #3 versus Clone #8) were then overlaid to determine the 
common proteins in all the lists.  
 
Table 3.4.7 outlines the list of proteins, in which 13 proteins were commonly regulated 
between all the lists generated. Of these 13 proteins, 9 proteins were consistently 
changed across all the lists either increasing/decreasing in expression relative to the 
invasion status of the cell lines. These 9 proteins are highlighted in bold, KRT19, 
GAPDH, STIP1, GANAB, UBE1, VIM, TPI1 and ALDH1A1 (a) (b). 
Keratin 18 (KRT18) and GAPDH are expressed at lower levels in the high invasive 
cell line, Clone #3, and expression of these two proteins are increased in the low 
invasive cell line Clone #8. Their expression in all three lists (going from high to low 
invasion) is consistently down-regulated as the invasion status of the cell lines 
increases. 
Seven proteins, ALDH1A1 isoforms (a) and (b), TPI1 isoform (a), VIM isoform (a), 
UBE1, GANAB and STIP1 isoform (a) were all expressed at higher levels in the 
invasive cell line, Clone #3 compared to the low invasive cell line, Clone #8. Their 
expression is consistently up-regulated as the invasive status of the cell lines increases. 
Figure 3.4.3 represents protein expression map of common differentially regulated 
proteins between all three list comparisons. 
Validation by Western blot was carried out on proteins, ALDH1A1, VIM, TPI1, 
KRT18, GAPDH, TPI1, ALDH1A1, STIP1 and VIM. Immunofluorescence was also 
carried out on KRT18 and VIM. 
 
Further functional analysis was carried out on the proteins aldehyde dehydrogenase 




 166  
Table 3.4.7 Overlapping proteins spots between the comparisons MiaPaCa-2 versus Clone #8 and Clone #3 versus MiaPaCa-2 























Antiquitin (b) ALDH7A1 gi|34783121| 6.2/55.9 17.6 -4.7 *** 2.2 *** -2.2 *** n/a 




GAPDH gi|31645| 8.4/36.2 29.6 -1.9 *** -1.3 ** -2.6 *** decreasing 
Keratin 18 KRT18 gi|12653819| 5.4/48.0 37.7 -1.6 * -1.8 * -2.9 *** decreasing 
Gamma actin (a) ACTG1 114865 5.3/42.1 40.3 -1.2 * -1.3 ** 1.5 * n/a 
Stress-induced-
phosphoprotein 1 (a) 
STIP1 gi|54696884| 6.4/63.3 17.9 1.3 * 1.5 * 2.0 *** increasing 
Glucosidase II GANAB gi|2274968| 5.7/107 11.3 1.4 *** 1.6 *** 2.2 *** increasing 
Ubiquitin-activating 
enzyme E1 
UBE1 gi|57209338| 5.5/119 4.9 1.6 ** 1.6 ** 2.6 *** increasing 
Human Tryptophanyl-
Trna Synthetase 
WARS gi|50513261| 7.1/43.6 35.2 1.8 *** 1.3 ** 1.4 *** n/a 
Fold change
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Vimentin (a) VIM gi|57471646| 5.2/49.7 37.9 2.2 *** 2.5 *** 5.5 *** increasing 
Chain B; Human 
Triosephosphate 
Isomerase (a) 
TPI1 gi|66360366| 6.5/26.8 19.4 2.2 *** 1.8 ** 4.0 *** increasing 
Aldehyde 
dehydrogenase 1 (a) 
ALDH1A1 gi|2183299| 6.3/55.4 21.8 5.3 *** 1.7 *** 8.9 *** increasing 
Aldehyde 
dehydrogenase 1 (b) 
ALDH1A1 gi|2183299| 5.2/49.7 33.2 6.8 *** 1.2 * 8.4 *** increasing 
 
The theoretical isoelectric point (pI) and molecular weight (Mw) were calculated from the sequence of the protein in the database. 
Isoforms of the same protein are referred to as (a), (b) etc. The percentage coverage is the amount of the protein sequence covered by the 
matched peptides. n/a refers to expression not consistent between protein lists. Statistical analysis between replicates is referred to as; * p 
≤ 0.05, *** p ≤ 0.01, *** p ≤ 0.005. For protein identification, all proteins were digested and identified at least twice from separate gels 
with MALDI-TOF MS. An expectation value of <0.02 was used for all reported identifications, which indicates a 0.2% chance that the 
identification is random.
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Figure 3.4.3 Protein expression map of MiaPaCa-2, Clone #3 and Clone #8. 
Arrows highlight 13 proteins commonly differentially regulated in three 
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3.4.3 Bioinformatic analysis of differentially regulated proteins 
 
Bioinformatic analysis was carried out on all differentially regulated proteins identified 
in our proteomic comparison of MiaPaCa-2, Clone #3 and Clone #8. Figure 3.4.4 
represents a Venn diagram outlining the distribution of proteins between the three 
generated lists, MiaPaCa-2 versus Clone #8, Clone #3 versus MiaPaCa-2 and Clone #3 
versus Clone #8. 
 
Using DAVID gene ID tool software (http://david.abcc.ncifcrf.gov), the proteins 
differentially regulated in our model were converted to their gene IDs. Gene ontology 
(GO STAT) (http://gostat.wehi.edu.au/cgi-bin/goStat.pl) was then used to classify the 
proteins and their corresponding genes into gene categories. Enrichment of a particular 
ontology term, for significantly expressed genes in response to the process under 
study, means that the ontology term is likely to be involved in the process. In our 
study, the process refers to invasion in pancreatic cancer. Using the over-expression 
function of the software and false discovery rate (Benjamini) stats, 52 GO terms were 
found significantly enriched. The “cytoplasm” term achieved the highest degree of 
significance in the up-regulated gene class (p = 1.40E-09), with “glycolysis” (p = 
4.05E-07) and “nucleotide binding” (p = 1.04E-06) also highly significant terms. In the 
down-regulated class, “oxioreductase activity” (p = 0.0006), “aldehyde dehydrogenase 
activity” (p = 0.003) and “mitochondrion” (p = 0.03) were also significantly enhanced. 
Figure 3.4.5 outlines the top ten ranked functional categories using GO terms in the 
differentially expressed proteins in the pancreatic cancer model. 
 
Pathway studio is a bioinformatics tool that allows the visualisation and analysis of 
biological pathways, gene regulation networks and protein interaction maps of groups 
of genes or proteins (Chapter 2.15). Direct interactions between the differentially 




















Figure 3.4.4 Venn diagram of outlining overlapping proteins between the three 
lists generated (Clone #8 versus MiaPaCa-2 and MiaPaCa-2 versus Clone #3 and 










 MiaPaCa-2 vs Clone #8 Clone #3 vs MiaPaCa-2
(52 proteins)              (37 proteins)
HSPA1A ACTB (d) HSP90ab1 ATP5A1 (a)
PRDX2 HSPD1 (c) GOT2 GAPDH (d)
HSPD1 (b) NDPK 12 4 9 HADHB ACTB (b)
YWHAE ACTG1 (b) TPI1 (b) ATPB




GAPDH (a) HSPA8 (d) HSPA4 23 11 EEF1A1 (ATP5A1 (aANXA1 (b)
PFN1 GDI2 EEF1A1 (c) HSPA8 (cALDOA (a)ACO2
HSPD1 (a) ENO1 EEF2 (a) PDIA3 (aEIF4F
ACTB (c) HSPA8 (a) VIM (b)
UQCRC1 PKM2 (a) ALDH1A1 (c) 13
STOML2 PKM2 (b) VCL UBE1 ALDH1A1 (a)
TUBA GARS VIM (d) WARS ALDH1A1 (b)
PDIA3 (b) CCT5 VIM (a) ALDH7A1 (b)
KRT18 ALDH7A1 (a)
PPIA STIP1(a)GAPDH (b)
TUBB (a) EEF2 (b) GANAB ACTG1 (a)
PDIA5 HSPA8 (b)  Clone #3 vs Clone #8 TPI1 (a)
EIF4A3 STIP1 (b)         (60 proteins)
TUBB (b) TUBB
MDH2 TUBA6 (a)
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Figure 3.4.5 Representation of the 10 top-ranked functional categories, using GO 
terms that are enriched in all significantly differentially expressed proteins 
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Figure 3.4.6 Pathway studio analysis of direct 
interaction between all differentially regulated 
proteins in MiaPaCa-2, Clone #3 and Clone #8. Each 
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3.4.4 Protein validation 
 
The identified proteins showing consistent expression in terms of the invasion status of 
the cell lines (Table 3.4.7) were further analysed by literature searches, Western blot 
and/or fluorescence validation before final targets for functional analysis were chosen. 
 
3.4.4.1 Western blot and immunofluorescence confirmation of proteomic data 
analysis 
Western blot and immunofluorescence analysis of six proteins was carried out. The 
proteins highlighted in bold in table 3.4.7 were subjected to validation across the three 
cell lines exposed to matrigel for 24 hrs, MiaPaCa-2, Clone #3 and Clone #8. 
Western blot verification was carried out on ALDH1A1, VIM, STIP1, KRT18, TPI1 
and GAPDH. Immunofluorescence was performed on VIM and KRT18 to illustrate the 
localisation of the protein within the cells (Chapter 2.8.2). 
Aldehyde dehydrogenase 1A1, vimentin, stress-induced phosphoprotein 1, cytokeratin 
18 and glyceraldehyde-3-phosphate dehydrogenase confirmed the trends indicated in 
the proteomic analysis. However, Western blot analysis of triosephosphate isomerase 1 
did not fully correspond to the trend of expression identified in the 2D proteomic 
analysis of the cell lines. This discrepancy may be due to the many isoforms caused by 
post-transcriptional modifications of the protein (Figures 3.4.7-3.4.12).  
 
Three proteins, aldehyde dehydrogenase 1A1, vimentin and stress-induced 
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Figure 3.4.7 3D spot images from 2D DIGE gels (Decyder BVA module) and 
Western blot images of aldehyde dehydrogenase 1A1 protein expression in 
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A. MiaPaCa-2 B. Clone #3                               C. Clone #8 
                              
                                




















Figure 3.4.8 Immunofluorescence, 3D spot images from 2D DIGE gels (Decyder 
BVA module) and Western blot images of vimentin protein expression in A. 







3.4.4.4 Stress-induced phosphoprotein 1 
















Bip (loading control)    
78 kDa 
Vimentin 55 kDa 














Figure 3.4.9 3D spot images from 2D DIGE gels (Decyder BVA module) and 
Western blot images of STIP1 protein expression in MiaPaCa-2, Clone #3 and 
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Figure 3.4.10 3D spot images from 2D DIGE gels (Decyder BVA module) and 
Western blot images of triosephosphate isomerase protein expression in 































Clone #3                    Clone #8 Bip (loading control)  
78 kDa 
 178  
 




















Figure 3.4.11 Immunofluorescence, 3D spot images from 2D DIGE gels (Decyder 
BVA module)  and Western blot images of cytokeratin 18 protein expression in A. 









3.4.4.7 Glyceraldehyde-3-phosphate dehydrogenase  
Bip (loading control) 
78 kDa 
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Figure 3.4.12 3D spot images from 2D DIGE gels (Decyder BVA module) and 
Western blot images of glyceraldehydes-3-phosphate dehydrogenase protein 
expression in MiaPaCa-2, Clone #3 and Clone #8. Western blot is representative 
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SiRNA targets specific to invasion were chosen based on proteomic analysis of 
MiaPaCa-2, Clone #3 and Clone #8 grown on matrigel for 24 hrs. The conditions for 
siRNA transfection were optimised in 96- and 6-well plates using GAPDH and kinesin 
as positive controls, and scrambled siRNA as a siRNA transfection control.  
Three siRNAs were selected for each of the 3 targets chosen and transfected into cells 
(Chapter 2.16.2). For each set of siRNA transfections carried out, a non-transfected 
cell line (control) and a scrambled (SCR) siRNA transfected control were used. 
Kinesin (Kin) was used as a control for efficient transfection as Kin siRNA reduces 
proliferation in the cells. 
 
The three chosen targets, aldehyde dehydrogenase 1A1 (ALDH1A1), vimentin (VIM) 
and stress-induced phosphoprotein 1 (STIP1) were all up-regulated in the high 
invasive Clone #3, and therefore knockdown of these targets was expected to reduce 
the level of invasion.  
 
Invasion assays (Chapter 2.16.3) were carried out to confirm whether or not these 
targets played an important role in invasion, as suggested by proteomic analysis.  
Further functional analyses, including adhesion, anoikis, proliferation and 
chemosensitivity were assessed to investigate the potential role of these targets in 
characterising the malignant phenotype. In these experiments, all data was normalised 
to non-treated control cells and statistical analysis to determine significance was 
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3.4.5 Investigation into the role of ALDH1A1 in pancreatic cancer 
cell invasion 
 
Aldehyde dehydrogenase was identified as a protein potentially involved in invasion in 
our in vitro pancreatic cancer cell line model. The analysis showed that ALDH1A1 
was 9-fold up-regulated in the more invasive sub-population, Clone #3 compared to 
the low invasive cell line, Clone #8 (Table 3.4.7).  
 
3.4.5.1 Effect of ALDH1A1 siRNA transfection on Clone #3 
The protein aldehyde dehydrogenase 1A1 was shown to be up-regulated as the 
invasion status of the cell lines increased, therefore the more invasive cell line, Clone 
#3 expressed an abundance of the protein. Clone #3 was used for siRNA knockdown 
and further functional analysis. 
 
Figure 3.4.13 shows by Western blot, the efficient knockdown of ALDH1A1 in three 
siRNA transfected Clone #3 cells compared to non-treated control and siRNA 




































































































Figure 3.4.13 Western blot of siRNA ALDH1A1 knockdown in Clone #3. Three 
independent target siRNA of ALDH1A1 were transfected into Clone #3 cells.  
Protein was harvested 48 hrs post-transfection and used to determine an 
ALDH1A1-siRNA specific decrease at protein level in response to siRNA 
transfection by Western blot. α-tubulin antibody was used to demonstrate even 
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3.4.5.2 Effect of ALDH1A1 siRNA on invasion  
Fourty-eight hours post-transfection with ALDH1A1 siRNA, invasion assays were 
performed. The total number of cells invading was reduced in Clone #3 cells 
transfected with ALDH1A1 siRNA. Figure 3.4.14 (A) shows representative pictures of 
invading cells, and (B) highlights the total number of cells invading. ALDH1A1 
siRNA transfection reduced the invasive capabilities of the cells. Invasion was 
significantly reduced by 2.2-fold (p=0.0013) with siRNA ALDH1A1 (1), 1.8-fold 




3.4.5.3 Effect of ALDH1A1 siRNA on adhesion  
Adhesion assays were also carried out to assess the involvement of ALDH1A1 in 
adhesion to matrigel. Figure 3.4.15 shows that ALDH1A1 siRNA transfection in Clone 
#3 cells increased the percentage of adhesion relative to untreated control cells. 
Adhesion was increased by all three ALDH1A1 siRNA targets. Adhesion was 
increased 27% with siRNA ALDH1A1 (1) (p=0.04), 23% with siRNA ALDH1A1 (2) 
(p=0.07) and 32% with siRNA ALDH1A1 (3) (p=0.001) to matrigel, compared to 
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Figure 3.4.14 (A) Invasion assays of Clone #3 (i) under control conditions (ii) 
transfected with scrambled siRNA (iii) transfected with ALDH1A1 siRNA (1) (iv) 
transfected with ALDH1A1 siRNA (2) (v) transfected with ALDH1A1 siRNA (3), 
48 hrs post transfection. Magnification, 200x. Scale bar, 200μm. (B) Total number 
of Clone #3 cells invading post ALDH1A1 siRNA transfection. 
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test) to scrambled controls 
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Figure 3.4.15 Percentage adhesion of Clone #3 untreated, scrambled and treated 
with three target ALDH1A1 siRNAs to matrigel 48 hrs after transfection. Results 
are expressed as % adhesion relative to untreated control cells. Data shown is 
mean ± standard deviation (n = 3). 
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3.4.5.4 Effect of ALDH1A1 siRNA on anoikis  
To determine the effect of ALDH1A1 knockdown on suspension survival in Clone #3, 
anoikis assays were performed with ALDH1A1 siRNAs. Figure 3.4.16 shows that 
anoikis is modestly induced in siRNA ALDH1A1 (1) and (2) transfected cells 
compared to scrambled treated cells. Treatment with ALDH1A1 siRNA (3) 
statistically induces anoikis (p=0.03) compared to the scrambled control. However, no 
significant difference is observed in anoikis of cells transfected with ALDH1A1 



































Figure 3.4.16 Percentage survival of Clone #3, untreated, scrambled and 
transfected with three independent ALDH1A1 siRNA targets in suspension 
compared to adherent cells.  Data shown is mean ± standard deviation (n = 3). 
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3.4.5.5 Effect of ALDH1A1 siRNA on proliferation  
 
Proliferation assays were carried out over 5 days after transfection of ALDH1A1 
siRNAs into Clone #3 cells. Figure 3.4.17 displays the percentage survival of 
transfected cells relative to untreated control. Kinesin was used as a control for 
efficient transfection. There was no significant difference in proliferation of siRNA 
ALDH1A1 treated cells compared to control cells, therefore loss of ALDH1A1 did not 

























Figure 3.4.17 Percentage survival of Clone #3 transfected with ALDH1A1 target 
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3.4.5.6 ALDH1A1 cDNA transfection in the low invasive cell line, Clone #8 
Proteomic data and Western blot validation confirmed that ALDH1A1 expression was 
highest in the invasive sub-population, Clone #3 and lowest in the lesser invasive sub-
population, Clone #8. To determine whether increasing ALDH1A1 expression in 
Clone #8 would have an effect on invasion, ALDH1A1 cDNA was transfected into 
Clone #8. Figure 3.4.18 displays ALDH1A1 expression in Clone #8 control, empty 
vector and ALDH1A1 cDNA transfected cells. Western blot analysis clearly shows 
that ALDH1A1 expression was induced in the ALDH1A1 cDNA transfected Clone #8 
cells confirming efficient transfection. Two time points, 48 and 72 hrs post transfection 
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Figure 3.4.18 Western blot analysis of ALDH1A1 cDNA transient transfection in 
Clone #8. Two time points of 48 hrs and 72 hrs post cDNA transfection were used 
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3.4.5.6.1 Evaluation of ALDH1A1 cDNA transient transfection of Clone #8 on 
invasion 
The effect of increasing ALDH1A1 expression in the poorly invasive Clone #8 was 
examined. Invasion assay analysis was performed 48 hrs post transfection. Figure 
3.4.19 (A) shows representative pictures of invading cells, and (B) highlights the total 
number of invading cells of Clone #8 control (untreated), Clone #8 transfected with 
empty vector and Clone #8 transfected with ALDH1A1 cDNA. ALDH1A1 
transfection of Clone #8 cells increased the invasive capacities of the cells, compared 
to empty vector control. 
Invasion was significantly increased 2.1-fold (p=0.01) in Clone #8 ALDH1A1 cDNA 
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Figure 3.4.19 Invasion assays of (A) (i) Clone #8 under control conditions (ii) 
Clone #8 transfected with empty vector (EV) (iii) Clone #8 transfected with 
ALDH1A1 cDNA. Magnification, 200x. Scale bar, 200μm.  (B) Invasion assay of 
Clone #8 of total number of cells invading 48 hrs post ALDH1A1 cDNA 
transfection. 
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3.4.5.7 Correlation of ALDH1A1 expression on drug resistance 
Chemosensitivity assays were carried out in the three cell lines, MiaPaCa-2, Clone #3 
and Clone #8. 4-hydroxycyclophosphamide (4-HC) and mafosfamide are known to be 
detoxified by ALDH1A1. 4-diethylaminobenzaldehyde (DEAB) is a specific inhibitor 
of ALDH1A1 and ALDH1A1 converts retinal to retinoic acid. The high invasive cell 
line, Clone #3 is more resistant to the cytotoxic effects of cyclophosphamide 
metabolite, 4-HC and analogue, mafosfamide. However, the parental cell line, 
MiaPaCa-2 and the low invasive cell line, Clone #8 are more sensitive to the drugs 
(Table 3.4.8).  
 
 
Table 3.4.8 IC50 of MiaPaCa-2, Clone #3 and Clone #8 
Drug (μg/ml) MiaPaCa-2 Clone #3 Clone #8 
4-hydroxycyclophosphamide 0.5±0.02 0.8±0.1 0.4±0.02 
Mafosfamide 7.2±3.1 10.3±5.2 6.2±2.6 
Diethylaminobenzaldehyde 14.4±2.0 16.8±1.0 15.0±1.4 
All trans Retinoic Acid 
(ATRA) 
3.4±0.3 6.2±0.6 2.3±0.6 
 
IC50s calculated represent half maximal inhibitory concentration of each drug in 
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3.4.5.7.1 Effect of ALDH1A1 siRNA on drug resistance  
Chemosensitivity assays were performed on Clone #3 cells transfected with 
ALDH1A1 siRNA to determine whether ALDH1A1 silencing sensitised the cells to 
the toxic effects of 4-HC. Figure 3.4.20 shows that ALDH1A1 siRNA slightly 
increased sensitivity to 4-HC and may be associated with 4-HC resistance in pancreatic 
cancer cells. Table 3.4.9 outlines the IC50s of Clone #3 untreated control, scrambled 






















Figure 3.4.20 Percentage survival of Clone #3, untreated, scrambled and 
transfected with three independent ALDH1A1 siRNA targets in 4-HC 
chemosensitivity assay.  Data shown is mean ± standard deviation (n = 3). 
 
 
Table 3.4.9 IC50 of Clone #3 control, scrambled and ALDH1A1 siRNA treated 
cells to 4-HC 
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3.4.5.8 Effect of ATRA treatment on Clone #3 and Clone #8 
ALDH1A1 acts as a catalyst irreversibly converting retinaldehyde to retinoic acid 
(RA). Analyses were performed to investigate whether accumulation of intracellular 
retinoic acid may lead to the suppression of ALDH expression (Moreb et al., 2005). 
Clone #3 and Clone #8 were incubated with 1.5 µg/ml (5 μM) of ATRA to assess a 
possible feedback loop of high levels of retinoic acid on ALDH1A1 expression. This 
effect was measured by Western blot, invasion assays and morphological changes in 
the cells. 
 
3.4.5.8.1 Western blot analysis of ALDH1A1 expression in Clone #3 cells 
incubated with ATRA 
ALDH1A1 expression was determined by Western blot in Clone #3 cells treated with 
5 μM ATRA for 48 hrs and continuous 5 µM ATRA treatment. Figure 3.4.21 shows 


















Figure 3.4.21 Western blot of Clone #3 control, treated with 5 µM ATRA for 48 








































ALDH1A1 55 kDa 
 
β-actin 42 kDa 
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3.4.5.8.2 Invasion assays of Clone #3 and Clone #8 cells incubated with 
ATRA 
Invasion assays were performed in Clone #3 and Clone #8 cells after 48 hrs treatment 
with 5 μM ATRA. Initial experiments were negative as invasion was not altered in 
either cell line after ATRA treatment. However, after long-term continuous treatment 
of 5 μM ATRA for 8 days, Clone #3 displayed unchanged invasion levels, yet invasion 
of Clone #8 was significantly increased (p=0.03) (Figure 3.4.22 (A) and (B)).  
(A) 

















Clone #3          
+ 5 uM ATRA
Clone #8
control
Clone #8          














Figure 3.4.22 (A) Invasion of (i) Clone #3 and (ii) Clone #8 after 8 days continuous 
exposure to 5 µM ATRA. (B) Total number of cells invading. 
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test) to control 
 
*
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3.4.5.8.3 Morphology of Clone #3 and Clone #8 cells incubated with ATRA 
Figure 3.4.23 (i) displays the morphology of control Clone #3 cells, while (ii) 
highlights the morphology of these cells after continuous exposure to ATRA. These 
results show that the morphology is unchanged. 
Clone #8 under control conditions is depicted in (iii), while (iv) represents the 
morphology of the cells after long-term treatment with ATRA. The typical phenotype 
of the cells is obviously different. The cells are spread out, spindle-shaped and 
elongated compared to colony-type rounded phenotype of the control cells. 
 
 
















Figure 3.4.23 Morphology of Clone #3 (i) under normal culture conditions (ii) 5 
μM ATRA treatment (iii) Clone #8 under normal culture conditioned and (iv) 5 
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3.4.6 Investigation into the role of vimentin in pancreatic cancer cell 
invasion  
 
Vimentin (VIM) was identified as a protein involved in invasion in our in vitro 
pancreatic cancer cell line model. The analysis showed that VIM was 5.5-fold up-
regulated in the more invasive sub-clone, Clone #3 compared to the low invasive cell 
line, Clone #8 (Table 3.4.7).  
 
 
3.4.6.1 Effect of VIM siRNA transfection on Clone #3 
The protein vimentin was shown to be up-regulated as the invasion status of the cell 
lines increased, therefore the more invasive cell line, Clone #3 expressed high levels of 
the protein. Clone #3 was used for siRNA knockdown and further functional analysis. 
Figure 3.4.24 shows by Western blot the efficient knockdown of VIM in Clone #3 
cells transfected with three VIM siRNAs compared to non-treated control and siRNA 





































Figure 3.4.24 Western blot of siRNA VIM knockdown in Clone #3. Three 
independent target siRNA of VIM were transfected into Clone #3 cells.  
Protein was harvested 48 hrs post-transfection and used to determine a VIM-
siRNA specific decrease at protein level in response to siRNA transfection by 
Western blot. α-tubulin antibody was used to demonstrate even loading between 
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3.4.6.2 Effect of VIM siRNA on invasion  
Fourty-eight hours post-transfection with VIM siRNA, invasion assays were 
performed. The total number of cells invading was reduced in Clone #3 cells 
transfected with VIM siRNA. Figure 3.4.25 (A) shows representative pictures of 
invading cells, and (B) highlights the total number of cells invading. VIM siRNA 
transfection reduces the invasive capabilities of the cells, by 4-fold (p=0.00036) with 
VIM siRNA (1), 6-fold (p=0.00031) with VIM siRNA (2) and 6-fold (p=0.0004) with 
VIM siRNA (3) transfection. The loss of VIM expression through siRNA knockdown 
in Clone #3 cells reduces invasion and confirms proteomics results. 
 
 
3.4.6.3 Effect of VIM siRNA on adhesion  
Adhesion assays were also carried out to assess the involvement of vimentin in 
adhesion of Clone #3 to matrigel. Figure 3.4.26 shows the percentage adhesion relative 
to untreated control cells. siRNA VIM (1) transfection increased the percentage of 
adhesion (35%) relative to cells treated with scrambled control (p=0.08). Percentage 
adhesion was significantly increased by 25% with VIM (2) and 32% with VIM (3) 
siRNAs (p=0.02 and p=0.02) compared to scrambled siRNA transfected control cells. 
Therefore, these results suggest that siRNA VIM (2) and (3) are more efficient 
inhibitors of VIM protein translation and that VIM expression is involved in adhesion 
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  i.                         ii.  
 
   
 
 






 Figure 3.4.25 (A) Invasion assays of Clone #3 (i) under control conditions (ii) 
transfected with scrambled siRNA (iii) transfected with VIM siRNA (1) (iv) 
transfected with VIM siRNA (2) (v) transfected with VIM siRNA (3). 
Magnification, 200x. Scale bar, 200μm. 
 (B) Invasion assay of Clone #3 of total number of cells invading post siRNA 
vimentin transfection.  
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Figure 3.4.26 Percentage adhesion of Clone #3 control, scrambled and treated 
with three target VIM siRNAs to matrigel. Results are expressed as % adhesion 
relative to scrambled cells. Data shown is mean ± standard deviation (n = 3). 
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3.4.6.4 Effect of VIM siRNA on anoikis  
Anoikis assays showed that VIM siRNA (3) caused a slight but statistically significant 
decrease in anoikis resistance compared to scrambled control (p=0.02) (Figure 3.4.27). 
Sensitivity to anoikis was slightly induced in VIM siRNA (1) and (2) transfected cells 
but only significant in siRNA VIM (3) compared to the scrambled control, indicating 
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Figure 3.4.27 Percentage survival of Clone #3, untreated, scrambled and 
transfected with three independent VIM siRNA targets in suspension compared 
to adherent cells.  Data shown is mean ± standard deviation (n = 3). 
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3.4.6.5 Effect of VIM siRNA on proliferation  
The effect of silencing VIM protein expression on proliferation was studied. Figure 
3.4.28 displays the percentage survival of Clone #3 cells transfected with VIM 
siRNAs. Loss of VIM did not affect proliferation in Clone #3 cells, and VIM is not 





















Figure 3.4.28 Proliferation assay of Clone #3 control, scrambled and transfected 
with siRNA VIM (1), (2) and (3). Results graphed as % survival relative to non-
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3.4.6.6 Effect of VIM siRNA on epithelial to mesenchymal transition (EMT)  
EMT is characterised by morphological and behavioural changes in cells (Maeda et al., 
2005). Investigations into the involvement of VIM, a mesenchymal marker (Leader et 
al., 1987) were determined. Figure 3.4.29 (i-iii) shows the morphological changes of 
Clone #3 and Clone #8 compared to the parental cell line, MiaPaCa-2 under normal 
culture conditions. Clone #3 exhibits a more fibroblast phenotype with spindle shaped 
elongated cells. Clone #8 cells appear rounded and grow in clusters. Clone #3 
transfected with siRNA VIM exhibits a rounded phenotype as observed in Clone #8 
cells. The morphological changes of Clone #3 after loss of VIM expression may 
implicate the role of vimentin in the epithelial to mesenchymal transition.  















Figure 3.4.29 Morphology of (i) MiaPaCa-2, (ii) Clone #3 and (iii) Clone #8 and 
after transfection (iv) Clone #3 control (v) Clone #3 scrambled (vi) Clone #3 
siRNA kinesin (vii) Clone #3 transfected with VIM (1) (viii) Clone #3 transfected 
with VIM (2) and (ix) Clone #3 transfected with VIM (3) 48 hours post-
transfection. Magnification at 20x, scale bar, 200μm. 
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3.4.7 Investigation into the role of stress-induced phosphoprotein 1 in 
pancreatic cancer cell invasion 
 
STIP1 was identified as 2-fold up-regulated in the high invasive sub-population, Clone 
#3, compared to the low invasive sub-population, Clone #8 (Table 3.4.7). The 
expression of STIP1 increased as the invasion status of the cells increased suggesting it 
may correlate to invasion in pancreatic cancer.  
 
 
3.4.7.1 Effect of STIP1 siRNA transfection on Clone #3  
The protein stress-induced phosphoprotein 1 was shown to be up-regulated as the 
invasion status of the cell lines increased, therefore the more invasive cell line, Clone 
#3 expressed high levels of the protein. Clone #3 was used for siRNA knockdown and 
further functional analysis. 
Figure 3.4.30 showed by Western blot the efficient knockdown of STIP1 in siRNA 








































Figure 3.4.30 Western blot of siRNA STIP1 knockdown in Clone #3. Three 
independent target siRNA of STIP1 were transfected into Clone #3 cells.  
Protein was harvested 48 hrs post-transfection and used to determine a STIP1-
siRNA specific decrease at protein level. α-tubulin antibody was used to 
demonstrate even loading between the samples. This is a representative picture of 































































STIP1 (60 kDa) 
 
 
α-tubulin (loading control) 50 kDa 
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3.4.7.2 Effect of STIP1 siRNA on invasion  
Invasion assays were carried out on Clone #3 cells untreated, treated with scrambled 
siRNA and three independent siRNA targets for STIP1. Figure 3.4.31 displays (A) 
representative pictures of the level of invasion and (B) the total number of cells 
invading. STIP1 siRNA transfection reduced the invasive capabilities of Clone #3 
cells. Invasion was significantly reduced 3-fold (p=0.0002) with STIP1 siRNA (1), 2-
fold (p=0.0002) with STIP1 siRNA (2) and 2-fold (p=0.0003) with STIP1 siRNA (3) 
transfection. These results confirm proteomic analysis suggesting STIP1 is involved in 
invasion of Clone #3 cells. 
 
 
3.4.7.3 Effect of STIP1 siRNA on adhesion  
Figure 3.4.32 shows the percentage adhesion to matrigel of STIP1 siRNA transfected 
cells relative to untreated cells. Adhesion was increased by 31% compared to 
scrambled controls with all STIP1 targeted siRNAs. Adhesion was significantly 
increased with siRNA STIP1 (2) and STIP1 (3) (p=0.02 and p=0.03). These results 
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Figure 3.4.31 (A) Invasion assays of Clone #3 (i) under control conditions (ii) 
transfected with scrambled siRNA (iii) transfected with STIP1 siRNA (1) (iv) 
transfected with STIP1 siRNA (2) (v) transfected with STIP1 siRNA (3).  
Magnification, 200x. Scale bar, 200μm. (B) Invasion assay of Clone #3 of total 
number of cells invading post siRNA STIP1 transfection. 
Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-test) to scrambled control. 

































                      
Figure 3.4.32 Percentage adhesion of Clone #3 control, scrambled and treated 
with three target siRNA STIP1 to matrigel. Results are expressed as % adhesion 
relative to untreated cells. Data shown is mean ± standard deviation (n = 3).  
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3.4.7.4 Effect of STIP1 siRNA on anoikis  
The percentage survival relative to adherent cells of Clone #3 treated with STIP1 
siRNAs compared to scrambled controls is displayed in figure 3.4.33. Results show a 
modest decrease in anoikis resistance with STIP1 siRNA transfection; however, this 
decrease in survival was not significant, relative to scrambled control cells. Therefore, 
































Figure 3.4.33 Percentage survival of Clone #3, untreated, scrambled and 
transfected with three independent STIP1 siRNA targets in suspension compared 
to adherent cells.  Data shown is mean ± standard deviation (n = 3). 
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3.4.7.5 Effect of STIP1 siRNA on proliferation  
Proliferation assays were carried out to assess the role of STIP1 on proliferation in 
Clone #3 cells. Figure 3.4.34 shows the percentage survival of Clone #3 cells, 
scrambled control and transfected with STIP1 siRNAs (1), (2) and (3). The percentage 
survival is statistically significantly reduced in STIP1 siRNA (1) and (2) transfected 
cells. Inhibition of growth is reduced 13% (p=0.04) and 27% (p=0.003). Proliferation 
was not reduced with siRNA STIP1 (3). These results suggest that siRNA (1) and (2) 
are more efficient at STIP1 knockdown and that STIP1 may play a role in proliferation 
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Figure 3.4.34 Proliferation assay of Clone #3 control, scrambled and transfected 
with siRNA STIP1 (1), (2) and (3). Results graphed as percentage survival relative 
to non-treated control (n=3). Statistics: p ≤ 0.05*, 0.01**, 0.005*** (unpaired t-
test) compared to scrambled control. 
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3.5 Analysis of effects of conditioned media from Clone #3 (CM#3) 
and Clone #8 (CM#8)  
 
Conditioned media from the clonal populations CM#3 and CM#8 was investigated to 
assess its role as an autocrine stimulatory and inhibitory factor of pancreatic cancer cell 
invasion. Conditioned media without serum was obtained from Clone #3 (CM#3) and 
Clone #8 (CM#8) after 72 hrs incubation. The CM was centrifuged and filtered 
through a 0.22 μm filter to remove any cell debris (Chapter 2.2.1). Invasion, adhesion 
and anoikis assays were carried out as described in chapter 2.5 and 2.6, with the 
addition of either conditioned media CM#3 or CM#8 diluted at a ratio of 1:1 with fresh 
media, above and below the invasion chamber insert at equal dilution to ensure no 
gradient for invasion assays. 
 
3.5.6 Effect of CM#3 and CM#8 on invasion of MiaPaCa-2 and sub-
populations, Clone #3 and Clone #8 
CM#3 enhanced invasion of MiaPaCa-2 by 2.2-fold (p=0.001) compared to an 
invasion assay control containing fresh medium. MiaPaCa-2 containing CM#8 in the 
invasion assay shows a 3.33-fold decrease in invasion (p=0.002) (Figure 3.5.1). 
Conditioned media from Clone #3 and Clone #8 were also tested on Clone #3 and 
Clone #8. Figure 3.5.2 shows the enhanced effect of CM#3 on invasion of the cell line, 
Clone #3. The significant increase in invasion is 1.8-fold (p=0.0008) compared to an 
invasion assay control containing fresh medium. Clone #3 containing CM#8 in the 
invasion assay shows a 3.33-fold decrease in invasion (p <0.001). 
 
CM#3 also significantly increased the invasion, 4.2-fold (p=0.005) of Clone #8 
compared to an invasion assay control containing fresh medium (Figure 3.5.3). CM#8 
caused a very slight (1.1-fold) decrease in invasion of Clone #8 (p=0.7). 
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Figure 3.5.1 (A) Invasion assays of MiaPaCa-2 (i) under control conditions (ii) 
with CM #3 (iii) with CM #8. Magnification, 100x. Scale bar, 200μm.  (B) 
Invasion assay of parental cell line, MiaPaCa-2 containing conditioned media 
from Clone #3 and Mia clone #8.  
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Figure 3.5.2 (A) Invasion assays of Clone #3 (i) under control conditions (ii) with 
CM #3 (iii) with CM #8. Magnification, 100x. Scale bar, 200μm. (B) Invasion 
assay of the high invasive cell line, Clone #3 containing conditioned media from 
Clone #3 and Clone #8. 
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Figure 3.5.3 (A) Invasion assays of Clone #8 (i) under control conditions (ii) with 
CM #3 (iii) with CM #8. Magnification, 100x. Scale bar, 200μm. 
(B) Invasion assay of the low invasive cell line, Clone #8 containing conditioned 
media from Clone #3 and Clone #8. 
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3.5.1.2 Effect of CM#3 and CM#8 on adhesion  
Adhesion assays of MiaPaCa-2, Clone #3 and Clone #8 were performed in the 
presence of CM#3 and CM#8 to matrigel. Figure 3.5.4 shows the level of adhesion of 
the cell lines to matrigel by absorbance readings. The incubation of CM#3 in the 
assays decreased the percentage adhesion of MiaPaCa-2, Clone #3 and Clone #8, 
(18%, 19% and 12%) whereas CM#8 enhanced the percentage adhesion by 24%, 22% 
and 27 % in MiaPaCa-2, Clone #3 and significantly in Clone #8 (p=0.03). 
 
3.5.1.3 Effect of CM#3 and CM#8 on anoikis  
CM#3 and CM#8 were also included in anoikis assays to assess whether secreted 
factors from the CM had an effect on apoptosis due to loss of anchorage (Figure 3.5.5). 
CM#3 slightly increased resistance to anoikis in MiaPaCa-2, Clone #3 and Clone #8. 
CM#8 induced sensitivity to anoikis in MiaPaCa-2 and Clone #3, and significantly 
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Figure 3.5.4 Effect of conditioned media from Clone #3 (CM#3) and Clone #8 
(CM#8) on adhesion of MiaPaCa-2 and its sub-populations, Clone #3 and Clone 
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Figure 3.5.5 Effect of conditioned media from Clone #3 (CM#3) and Clone #8 
(CM#8) on anoikis of MiaPaCa-2 and its sub-populations, Clone #3 and Clone #8. 
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005 Student’s t-test. 
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3.5.1.4 Effect of 24 hour pre-incubation with CM#3 and CM#8 on invasion of 
MiaPaCa-2 
MiaPaCa-2 was incubated with conditioned media for 24 hours and invasiveness 
assessed. The level of invasion is significantly increased after 24 hours pretreatment of 
the parental cell line, MiaPaCa-2 with CM#3 (p=0.02), compared to cells not exposed 
to CM#3. Invasion induced by pre-treatment with CM#3 was similar to that seen when 
CM#3 was added to the invasion assay (Figure 3.5.6). In contrast, CM#8 pre-treatment 
of MiaPaCa-2 significantly reduces the level of invasion (p=0.02), again similar to 
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Figure 3.5.6 Invasion assay of MiaPaCa-2 cells incubated with CM#3 and CM#8 
for 24 hrs prior to invasion assay.  








     * 
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3.5.2 Effect of pre-incubation on matrigel of MiaPaCa-2 and sub-
populations, Clone #3 and Clone #8 on invasion 
 
Adhesion to the extracellular matrix (ECM) is one of the first steps of invasion. The 
cell utilises different mechanisms to disrupt the basement membrane or ECM. In order 
to further stimulate these mechanisms that the cells use to degrade the extracellular 
matrix, the cells were grown on matrigel for 24 hours prior to invasion assays (Chapter 
2.5.5). 
 
The invasion and superinvasion of MiaPaCa-2 after pre-incubation for 24 hours on 
matrigel in the presence of CM#3 and CM#8 were assessed. Figure 3.5.7 (A) shows 
the number of cells invading is higher for the cells grown on matrigel in the presence 
of normal fresh media. Superinvasive cells were also observed after pre-incubation of 
the cells on matrigel. Superinvasion is defined as cells that invade through the matrigel 
and attach to the bottom of the plate (Glynn et al., 2005). However, the invasion of the 
cell line, MiaPaCa-2 is increased even further when grown on matrigel in the presence 
of CM#3. The superinvasion of the cell line also increased. In the presence of CM#8, 
invasion is decreased compared to cells grown in media alone and superinvasion is 
also significantly decreased (p=0.01). Figuure 3.5.7 (B) represents the number of 
Clone #3 cells invading through the matrigel insert, after pre-incubation on matrigel 
for 24 hours. Clone #3 pre-incubated on matrigel displays a slight increase in invasion 
compared to the control cells not pre-incubated on matrigel. The numbers of cells 
invading cells are increased, and the superinvading cells are significantly increased 
(p=0.006) after preincubation on matrigel in the presence of CM#3. Clone #3 shows 
decreased invasion and superinvasion when preincubated with CM#8, though not 
significantly. 
Figure 3.5.7 (C) shows the low invasive potential of Clone #8 under normal invasion 
assay conditions. When the cell line is grown on matrigel for 24 hours, invasion 
increases and superinvasion is also observed. The cell line grown on matrigel in the 
presence of CM#3 displays further increased invasion and superinvasion, whereas after 
preincubation with CM#8, the invasion and superinvasion are decreased slightly.  
 
 











































































































        







































































































Figure 3.5.7 Invasion and superinvasion levels of (A) MiaPaCa-2 (B) Clone 
#3 (C) Clone #8 under normal control conditions, grown on matrigel and 
grown on matrigel in the presence of CM#3 and CM#8. Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005 Student’s t-test. 
 
Untreated Grown on matrigel
Untreated Grown on matrigel
Untreated Grown on matrigel
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3.5.3 Characterisation of CM#3 and CM#8 
Conditioned media from both Clone #3 and #8 were collected over time and pooled to 
generate a stock of conditioned media. This CM was characterised by temperature, 
dilution and pH stability in order to determine the stability of the CM.  
3.5.3.1 Temperature stability of CM#3 and CM#8 
To investigate the temperature stability of the conditioned media, invasion assays were 
performed on MiaPaCa-2 to evaluate the CM stored at 4o C, -20o C and –80o C over 3 
months. 
Conditioned media, CM#3 and CM#8 was diluted at a 1:1 ratio with fresh media, 
above and below the insert. Therefore no gradient was present in the experiments.  
 
The conditioned media CM #3 showed little variability, in terms of inducing increased 
invasion on the pancreatic cell line MiaPaCa-2 (Figure 3.5.8), when stored at different 
temperatures. However, storage of CM#3 at –800C yielded slightly better results. 
 
Figure 3.5.9 shows that conditioned media CM #8 stored at -800C displayed better 
stability in terms of effectiveness on MiaPaCa-2 in invasion assays. Therefore for all 




















Control (+4 degrees) (-20 frozen) (-80 frozen)















Figure 3.5.8 Invasion assay of MiaPaCa-2 with conditioned media from clone #3 







Control (+4 degrees) (-20 frozen) (-80 frozen)














Figure 3.5.9 Invasion assay of MiaPaCa-2 with conditioned media from clone #8 
stored at different temperatures. 
The control column is based on the average number of invading cells of MiaPaCa-2 
under normal fresh media conditions. 
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3.5.3.2 Effect of dilution of CM#3 and CM#8 on invasion of MiaPaCa-2 
Conditioned media from Clone #3 and #8 stored at –80 oC was used in invasion assays 
of MiaPaCa-2 diluted at 1:4, 1:8 and 1:16 with fresh media to determine the maximum 
dilution factor.  
Figure 3.5.10 shows that a dilution factor of 1:4 of CM#3 is optimal to achieve 
increased induction of invasion of MiaPaCa-2 through the matrigel-coated inserts. 
Dilution of the CM#3 to 1:8 or 1:16 with fresh media dilutes the invasion inducing 
factors present in the conditioned media thereby reducing the increased invasive 
effects.  
Figure 3.5.11 shows that a dilution factor of 1:4 of CM#8 is also optimal to achieve 
decreased invasion of MiaPaCa-2 through the matrigel-coated inserts. Dilution of the 
CM#8 to 1:8 or 1:16 with fresh media dilutes the inhibitory effects of the conditioned 
media thereby reverts the level of invasion similar to the control containing fresh 
media.  
All future experiments were carried out using the conditioned media diluted with fresh 































Figure 3.5.10 Invasion assay of parental cell line, MiaPaCa-2 with conditioned 





















Figure 3.5.11 Invasion assay of parental cell line, MiaPaCa-2 with conditioned 
media from Clone #8 at variable dilution factors. 
The control column represents the average number of invading cells of MiaPaCa-2 
under normal fresh media conditions. 
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3.5.3.3 Characterisation of pH stability of CM#3 and CM#8 on invasion 
Serum-free conditioned media from both Clone #3 and Clone #8 were collected over 
time and pooled (as previously described). To investigate the pH stability of the 
conditioned media compared to fresh media (treated under the same conditions); 
invasion assays were performed on MiaPaCa-2 to evaluate stability of the CMs at 
different pHs. 
 
Figure 3.5.12 shows a summary of the level of invasion in MiaPaCa-2 under control 
conditions and with the addition of CM#3 and CM#8, as previously observed in figure 
3.5.1. 
 
To alter the pH of the media, CM#3 and CM#8, aliquots of media were exposed to 
acid/base to a range of pHs, kept at new pH for 2 hrs and brought back to pH 7 
(original pH) (Chapter 2.2.1). 
Fresh media was treated under the same conditions as CM#3 and CM#8 to ensure that 
the effect of altering the pHs of CMs was not due to the addition of acid/base. Figure 
3.5.13 shows invasion of MiaPaCa-2 relative to fresh media treated at the same pH as 
CM#3 and CM#3. The level of invasion is slightly decreased when media is treated at 
different pHs. The highest level of invasion observed in control media treatment was in 
cells treated with media @ pH 3-7. The lowest level of invasion was shown in 
MiaPaCa-2 treated cells with media at pH 9-7. This results confirms that the addition 
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Figure 3.5.12 (A) Invasion assays of (i) MiaPaCa-2 under control conditions, (ii) 
addition of CM#3 into the invasion insert and (iii) addition of CM#8 into the 
invasion insert. Scale bar, 200 μm. (B) Total number of cell invading in invasion 
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Figure 3.5.13 (A) Invasion assays of MiaPaCa-2 (i) with media @ pH 5-7 (ii) with 
media @ pH 3-7 (iii) with media @ pH 9-7 (iv) with media @ pH 11-7. 
Magnification, 200x. Scale bar, 200μm.  
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3.5.3.3.1 Characterisation of pH stability on CM#3 invasion stimulatory activity 
Conditioned media from Clone #3 (obtained as previously described) was exposed to 
differing pH for 2 hours at room temperature and then readjusted back to original pH 
of the CM#3. Unconditioned media samples were also pH adjusted and treated as 
controls (Figure 3.5.13). Invasion assays were performed using the parental cell line, 
MiaPaCa-2. The CM#3 was used at a 1:1 dilution with fresh media. 
 











HCL (20 ul) 5 NaOH (20 μl) 7.2 +++++ Invasion + Invasion 
HCL (50μl) 3 NaOH (50 μl) 7.2 ++++ Invasion ++ Invasion 
NaOH (30 μl) 9 HCL (30 μl) 7.2 +++ Invasion + Invasion 
NaOH (60 μl) 11 HCL (60 μl) 7.2 +++ Invasion + Invasion 
 
These experiments indicate that the invasion stimulatory effects of CM#3 are enhanced 
with acid treatment and readjustment. Slight base sensitivity was observed, although 
residual activity remained between pH 9 and 11 (Table 3.5.1). pH treatment on control 
media had greater inhibitory effects on invasion compared to CM#3 (Figure 3.5.14). 
 
The pH stability was also examined by exposing the CM#3 to a range of pH values 
without readjustment. CM#3 displayed no invasion effect at pH 3 and moderate 
invasion at pH 9. A higher level of invasion was observed at pH 7.8 (Table 3.5.2). This 
may be due to the fact that the original pH of CM#3 is slightly more acidic compared 
to control media. 
 





3 - Invasion + Invasion 
7.8 ++ Invasion + Invasion 
9 + Invasion + Invasion 
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Figure 3.5.14 (A) Invasion assays of MiaPaCa-2 (i) with CM #3 @ pH 5-7 in 
invasion chamber (ii) with CM #3 @ pH 3-7 in invasion chamber (iii)  with CM #3 
@ pH 9-7 in invasion chamber (iv) with CM #3 @ pH 11-7 in invasion chamber. 
Magnification, 200x. Scale bar, 200μm.  
(B) Invasion assay MiaPaCa-2 containing conditioned media from CM #3 @ 
varying pH.  
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3.5.3.3.2 Characterisation of pH stability CM#8 invasion inhibitory activity 
Conditioned media from Clone #8 (obtained as previously described) was exposed to 
differing pH for 2 hours at room temperature and then readjusted back to original pH 
of the CM#8. Unconditioned media samples were also pH adjusted and treated as 
control (Figure 3.5.13). Invasion assays were performed using the parental cell line, 
MiaPaCa-2. The CM#8 was used at a 1:1 dilution with fresh media. 
 
Table 3.5.3 Stability of CM#8 after pH treatment and readjustment on invasion 
Volume 
added 




HCL (20 μl) 5 NaOH (20 μl) 7.4 ++ Invasion + Invasion 
HCL (50 μl) 3 NaOH (50 μl) 7.4 + Invasion ++ Invasion 
NaOH (30 μl) 9 HCL (30 μl) 7.4 +  Invasion + Invasion 
NaOH (30 μl) 11 HCL (60 μl) 7.4 + Invasion + Invasion 
These experiments indicate that the invasion inhibitory effects of CM#8 are enhanced 
with basic treatment and readjustment. Slight acid sensitivity was observed, whereby 
the invasion levels increased similar to that of the untreated control media at pH 5-7 
(Table 3.5.3). pH treatment on control media had less inhibitory effects on invasion 
compared to CM#8, optimal CM#8 inhibitory effects were observed at higher pH 
range between 9-11 (Figure 3.5.15). 
The pH stability was also examined more closely by exposing the CM#8 to a range of 
pH values without readjustment. CM#8 displayed no invasion effect at pH 2 and 
moderate invasion at pH 8. A higher level of invasion was observed at pH 7.2 (Table 
3.5.4) and inhibitory effects optimal at pH8. This may be due to the fact that the 
original pH of CM#8 is slightly more basic compared to control media. 
 





2 - Invasion + Invasion 
7.2 ++ Invasion + Invasion 
8 + Invasion + Invasion 
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Figure 3.5.15 (A) Invasion assays of MiaPaCa-2 (i) with CM #8 @ pH 5-7 in 
invasion chamber (ii) with CM #8 @ pH 3-7 in invasion chamber (iii) with CM #8 
@ pH 9-7 in invasion chamber (iv) with CM #8 @ pH 11-7 in invasion chamber. 
Magnification, 200x. Scale bar, 200μm.  
 
(B) Invasion assay MiaPaCa-2 containing conditioned media from CM #8 @ 
different pH.  
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3.5.4 Analysis of fractionation samples of CM#3 and CM#8 on    
invasion of Clone #3 
 
Serum-free conditioned media from Clone #3 and Clone #8 were concentrated to five 
molecular weight cut off fractions. Approximately 11 ml of CM#3 and CM#8 were 
concentrated to fractions of below 10 kDa, between 10-30 kDa, 30-50 kDa, 50-100 
kDa and above 100 kDa. These concentrated samples were then re-established to their 
original volume. CM#3 and CM#8 fractions were then used in invasion assays to 
assess whether a secreted factor in the media causing the promotion or inhibition of 
invasion was concentrated in a specific CM fraction.  
 
Invasion assays of Clone #3 in the presence of CM#3 fractions were performed. 
Invasion at the lower concentration cut off showed a decrease in invasion, (p=0.01 and 
p=0.02), while invasion levels of Clone #3 including fractions, 30-50 kDa,  50-100 
kDa and 100 kDa  increased significantly (p=0.001, p=0.0002 and p=0.0001) (Figure 
3.5.16). 
 
Figure 3.5.17 shows the invasion of Clone #3 in the presence of the different isolated 
fractions of CM#8. Control invasion was monitored using normal media. The addition 
of CM#8 at fractions 10 kDa and 10-30 kDa showed the largest reduction in invasion 
(p=0.002 and p=0.03). As the molecular weight cut off points began to increase, so did 
the invasion. Invasion increased back to control levels and at 100 kDa invasion was 
increased 1.1-fold (p=0.05). 
 
These results suggest that important fractions are secreted into Clone #8, acting as an 
inhibitory factor at lower concentrations, while CM#3 seems to contain high molecular 
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Figure 3.5.16 (A) Invasion of Clone #3 (i) under control conditions (ii) with CM #3 
fraction 10 kDa (iii) with CM #3 fraction 10-30 kDa (iv) with CM #3 fraction 30-
50 kDa (v) with CM #8 fraction 50-100 kDa (vi) Clone #3 with CM #3 fraction 100 
kDa. Magnification, 200x. Scale bar, 200μm. 
(B) Invasion of Clone #3 containing CM#3 fractions.  
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Figure 3.5.17 (A) Invasion assays of Clone #3 (i) under control conditions (ii) with 
CM #8 fraction 10 kDa (iii) with CM #8 fraction 10-30 kDa (iv) with CM #8 fraction 
30-50 kDa (v) with CM #8 fraction 50-100 kDa (vi) with CM #8 fraction 100 kDa. 
Magnification, 200x. Scale bar, 200μm. 
(B) Invasion assay of Clone #3 containing CM#8 fractions.  
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3.6 Proteomic analysis of conditioned media from MiaPaCa-2 and 
sub-populations Clone #3 and Clone #8 by two-dimensional 
difference gel electrophoresis (2-D DIGE) 
 
Proteomic analysis was carried on the conditioned media (CM) of MiaPaCa-2, Clone #3 
and Clone #8. Differential protein expression was investigated by 2-D DIGE in the CM 
samples (Chapter 2.10). 
 
CM #3 and CM #8 were added into the in vitro invasion assay model to assess the 
potential effects of secreted factors on invasion (Chapter 3.5). 
CM#3 enhanced invasion of MiaPaCa-2 by 2.2-fold, Clone #3 by 1.8-fold and also 
significantly increased the invasion, 4.2 fold, of Clone #8 compared to an invasion assay 
control containing fresh medium. 
 
In contrast, the addition of CM#8 into the invasion chamber caused a reduction in the 
invasive potential of the cell lines. MiaPaCa-2 containing CM#8 in the invasion assay 
showed a 3.3-fold decrease in invasion. CM#8 added onto Clone #3 in the invasion assay 
showed a 3.3-fold decrease in invasion and added onto Clone #8, a 1.1-fold decrease in 
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3.6.1 Experimental outline for 2-D DIGE analysis of the samples 
 
Differential secreted proteins between CM Mia, CM#3 and CM#8 were analysed by 2-D 
DIGE as outlined in Chapter 3.4. Triplicate biological repeats with duplicate technical 
repeats were reverse labelled with Cy3 and Cy5. All samples used in the experiment were 
pooled and labelled with the internal dye Cy2. Each sample was compared internally to 
the same standard, to account for any gel-to-gel variation.  
 
3.6.1.1 DeCyder analysis 
Differential protein expression between CM of MiaPaCa-2, Clone #3 and Clone #8 was 
observed using 2D-DIGE. DeCyder image analysis merged the Cy2, Cy3 and Cy5 images 
for each gel and detected spot boundaries for the calculation of normalised protein 
abundance. All paired images were then matched to generate comparative cross-gel 
statistical analysis. DeCyderTM software revealed a total of 54 secreted protein spots 
identified in each comparison of CM Mia versus CM #8, CM #3 versus CM Mia and CM 
#3 versus CM #8. 
Biological variation analysis of these spots showing greater that 1.2-fold change in 
expression with a t-test score of < 0.05 revealed 37 proteins which are significantly 
changed between CM Mia versus CM #8, while 32 proteins changed between CM #3 
versus CM Mia, and 41 proteins were significantly differentially regulated between CM 
#3 versus CM #8. Protein expression maps (PEM) of all identified proteins between 
CM#3 and CM#8 are shown in figure 3.6.1 (Position number corresponds to table 3.6.3).  
 
3.6.1.2 Protein identification 
For protein identification, all proteins were digested and identified at least twice from 
separate gels with MALDI-TOF MS. An expectation value of <0.02 was used for all 
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3.6.2 Secreted protein list generation 
 
To evaluate the differentially expressed secreted proteins in the conditioned media of 
MiaPaCa-2, Clone #3 and Clone #8, three comparative protein lists were generated. 
 
Table 3.6.1 outlines the 37 differentially regulated secreted proteins altered between CM 
of Mia versus CM #8. In this comparison, 5 secreted proteins are up-regulated and 32 
secreted proteins are down-regulated with respect to fold change in protein secretion in 
CM Mia.  
 
Table 3.6.2 outlines the 32 differentially regulated secreted proteins between the 
comparison of CM #3 versus CM #Mia. Of the 32 secreted proteins, 22 secreted proteins 
are up-regulated and 10 secreted proteins are down-regulated in relation to CM #3. 
 
The third list compares the secreted proteins between CM #3 and CM #8 (Table 3.6.3). 41 
proteins are significantly secreted, 14 secreted proteins are up-regulated and 27 secreted 
proteins are down-regulated in relation to CM #3. 
 
Figure 3.6.1 displays a representative protein expression map of differentially abundant 
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Table 3.6.1 Secreted proteins significantly expressed in CM Mia versus CM #8 











Gelsolin isoform b (a) GSN gi|38044288| 5.6/80.9 17.9 -2.6 *** 
Gelsolin isoform b (b) GSN gi|38044288| 5.6/80.9 24.4 -2.4 *** 
Gelsolin isoform b (c) GSN gi|38044288| 5.6/80.9 18.6 -2.3 *** 
Gelsolin isoform b (d) GSN gi|38044288| 5.6/80.9 18.3 -1.9 *** 
Proteasome activator Reg  PSME1 gi|2780883| 7.1/16.3 44.3 -1.9 *** 
Beta actin (a) ACTB gi|15277503| 5.6/40.5 36.6 -1.9 *** 
Phosphoglycerate kinase 1 
(a) 
PGK1 gi|48145549| 8.6/44.9 25.7 -1.8 *** 
Phosphoglycerate kinase 1 
(b) 
PGK1 gi|48145549| 8.6/44.9 34.8 -1.8 *** 
Phosphoglycerate kinase 1 
(c) 
PGK1 gi|48145549| 8.6/44.9 27.3 -1.7 *** 
Beta actin (b) ACTB gi|15277503| 5.6/40.5 24.2 -1.7 *** 
Nucleoside-diphosphate 
kinase 2 isoform 1 
NDPK gi|66392203| 9.3/30.3 21.7 -1.7 *** 
Heat shock 70kDa protein 
8 isoform 2 variant (a) 
HSPA8 gi|62896815| 5.6/53.6 28.8 -1.7 *** 




4.9/85.0 24.5 -1.6 *** 
Gelsolin isoform b (e) GSN gi|38044288| 5.6/80.9 12.7 -1.6 * 
Heat shock 70kDa protein 
8 isoform 2 variant (b) 
HSPA8 gi|62896815| 5.6/53.6 16.8 -1.6 *** 
S-adenosylhomocysteine 
hydrolase 
AHCY gi|178277| 6.0/48.2 10.6 -1.6 *** 
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Malate dehydrogenase 
cytosolic 
MDH1 gi|74311531| 5.9/36.6 20.1 -1.5 *** 
Transketolase TKT gi|31417921| 8.4/50.3 18.2 -1.5 *** 
Thioredoxin peroxidase  PRDX2 gi|9955016| 5.7/21.6 28.4 -1.5 *** 
Gelsolin (amyloidosis: 
finnish type) 
GSN gi|55960299| 5.9/86.0 9.5 -1.5 ** 
NM23-H1 NM23-H1 gi|29468184| 5.4/19.8 27.1 -1.5 *** 
Heat shock 70kDa protein 
8 isoform 2 variant (c) 
HSPA8 gi|62896815| 5.6/53.6 19.7 -1.5 *** 
Peroxidase enzyme 1PRXB gi|55959887| 6.0/24.9 53.2 -1.4 *** 
Beta actin (c) ACTB gi|15277503| 5.6/40.5 24.4 -1.4 * 
Beta actin (d) ACTB gi|15277503| 5.6/40.5 27.3 -1.4 ** 
Protein disulfide 
isomerase 
PDI gi|860986| 6.1/57.0 16.0 -1.4 *** 
Beta tubulin TUBB gi|16198437| 4.8/30.6  14.7 -1.3 *** 
Aldolase (a) ALDOA gi|4930291| 8.8/39.7 32.0 -1.2 *** 
Aldolase (b) ALDOA gi|4930291| 8.8/39.7 35.8 -1.2 *** 
Pi glutathione transferase GSTP1 gi|34811304| 5.7/23.4 36.4 -1.2 ** 
Triosephosphate 
isomerase 
TPI1 gi|999893| 6.5/26.8 29.0 -1.2 * 
Glycerate-3-phosphate 
dehydrogenase (a) 
GAPDH gi|31645| 8.4/36.2 19.4 -1.2 * 
Alpha enolase ENO1 gi|2661039| 7.0/47.4 15.5 1.2 ** 
Glycerate-3-phosphate 
dehydrogenase (b) 
GAPDH gi|31645| 8.4/36.2 23.6 1.3 *** 
Beta actin (e) ACTB gi|15277503| 5.6/40.5 24.4 1.4 * 
Mu-protocadherin isoform 
1 
MUCDHL gi|62020550| 4.8/88.4 18.2 1.7 *** 
Aldehyde dehydrogenase 
1A1 
ALDH1A1 gi|2183299| 6.3/55.4 18.4 11.4 *** 
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Table 3.6.2 Secreted proteins significantly expressed in CM #3 versus CM #Mia 








CM #3  
versus 
CM Mia 
Gelsolin isoform b (a) GSN gi|38044288| 5.6/80.9 17.9 -8.0 *** 
Gelsolin isoform b (b) GSN gi|38044288| 5.6/80.9 24.4 -6.3 *** 
Gelsolin isoform b (c) GSN gi|38044288| 5.6/80.9 18.6 -4.7 *** 
Gelsolin isoform b (f) GSN gi|38044288| 5.6/80.9 15.2 -3.8 *** 
Gelsolin isoform b (e) GSN gi|38044288| 5.6/80.9 12.7 -2.1 ** 
Pro-MMP-2TIMP2 
complex 
TIMP2 gi|22218678| 6.5/22.4 30.9 -1.9 *** 
Gelsolin isoform b (d) GSN gi|38044288| 5.6/80.9 18.3 -1.8 * 
Gelsolin (amyloidosis: 
finnish type) 
GSN gi|55960299| 5.6/86.0 9.5 -1.7 ** 
Mu-protocadherin isoform 
1 
MUCDHL gi|62020550| 4.8/88.4 18.2 -1.3 *** 
Glycerate-3-phosphate 
dehydrogenase (b) 
GAPDH gi|31645| 8.4/36.2 23.6 -1.2 ** 
Glyoxalase I GLO1 gi|562056| 5.1/20.9 28.3 1.2 *** 
Heat shock 70kDa protein 
8 isoform 2 variant (c) 
HSPA8 gi|62896815| 5.6/53.6 19.7 1.2 *** 
Sadenosylhomocysteine 
hydrolase 
AHCY gi|178277| 6.0/48.2 10.6 1.2 *** 
Heat shock 70kDa protein 
8 isoform 2 variant (b) 
HSPA8 gi|62896815| 5.6/53.6 16.8 1.2 *** 
Malate dehydrogenase 
cytosolic 
MDH1 gi|7431153| 5.9/36.6 20.1 1.2 *** 
Proteasome activator Reg  PSME1 gi|2780883| 7.1/16.3 44.3 1.2 *** 
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Phosphoglycerate kinase 1 
(c) 
PGK1 gi|48145549| 8.6/44.9 27.3 1.3 *** 
Alpha enolase (a) ENO1 gi|2661039| 7.0/47.4 15.5 1.3 *** 
Human rab GDI GDIA gi|285975| 5.9/51.1 38.7 1.3 *** 
Phosphoglycerate kinase 1 
(a) 
PGK1 gi|48145549| 8.6/44.9 25.7 1.3 *** 
Heat shock 70kDa protein 
8 isoform 2 variant (a) 
HSPA8 gi|62896815| 5.6/53.6 28.8 1.3 *** 
Phosphoglycerate kinase 1 
(b) 
PGK1 gi|62896815| 8.6/44.9 16.8 1.3 *** 
Protein disulfide 
isomerase 
PDI gi|8609861| 6.1/57.0 16.0 1.3 *** 
Glycerate-3-phosphate 
dehydrogenase (a) 
GAPDH gi|31645| 8.4/36.2 19.4 1.4 *** 
Peroxiredoxin 1 PRDX1 gi|55959887| 6.4/19.1 53.2 1.4 *** 
Alpha enolase (b) ENO1 gi|2661039| 7.0/47.4 28.6 1.4 *** 
Galectin-1 LGALS1 gi|56554350| 5.1/14.8 38.1 1.4 ** 
Pi glutathione transferase GSTP1 gi|34811304| 5.7/23.4 36.4 1.6 *** 
Human peroxidase 
enzyme 
1PRXB gi|3318842| 6.0/24.9 40.2 1.6 *** 
Mitochondrial malate 
dehydrogenase 
MDH2 gi|12804929| 9.4/35.9 37.0 1.6 *** 
Transkelolase TKT gi|31417921| 8.4/50.3 18.2 1.7 *** 
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Table 3.6.3 Secreted proteins significantly expressed in CM #3 versus CM #8 




PI/MW % Cov Fold 
change 
CM #3  
versus 
CM #8 
1 Gelsolin isoform b (a) GSN gi|38044288| 5.6/80.9 17.9 -21.0 ***
2 Gelsolin isoform b (b) GSN gi|38044288| 5.6/80.9 24.4 -15.2 ***
3 Gelsolin isoform b (c) GSN gi|38044288| 5.6/80.9 18.6 -10.7 ***
4 Gelsolin isoform b (f) GSN gi|38044288| 5.6/80.9 15.2 -6.4 *** 
5 Gelsolin isoform b (d) GSN gi|38044288| 5.6/80.9 18.3 -3.8 *** 
6 Gelsolin isoform b (g) GSN gi|38044288| 5.6/80.9 18.5 -3.4 *** 
7 Gelsolin (amyloidosis: 
Finnish type) 
GSN gi|55960299| 5.9/86.0 9.5 -2.5 *** 
8 Pro-MMP-2TIMP2 
complex 
TIMP2 gi|22218678| 6.5/22.4 30.9 -1.8 *** 
9 Beta actin (a) ACTB gi|15277503| 5.6/40.5 36.6 -1.7 *** 
10 Nucleoside-
diphosphate kinase 2 
isoform 
NDPK2 gi|66392203| 9.3/30.5 21.7 -1.7 ** 
11 Beta actin (c) ACTB gi|15277503| 5.6/40.5 24.4 -1.6 *** 
12 Proteasome activator 
Reg(Alpha) 
PSME1 gi|2780883| 7.1/16.3 44.3 -1.5 *** 
13 Beta actin (b) ACTB gi|15277503| 5.6/40.5 24.2 -1.5 *** 
14 Heat shock protein 
HSP 90-alpha (HSP86) 
HSP86 gi|92090606| 
 
4.9/85.0 24.5 -1.5 *** 
15 Phosphoglycerate 
kinase 1 (a) 
PGK1 gi|48145549| 8.6/44.9 25.7 -1.4 *** 
16 Thioredoxin peroxidase PRDX2 gi|9955016| 5.7/21.6 28.4 -1.4 *** 
17 Phosphoglycerate PGK1 gi|48145549| 8.6/44.9 25.7 -1.4 *** 
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kinase 1 (b) 
18 Phosphoglycerate 
kinase 1 (c) 
PGK1 gi|48145549| 8.6/44.9 27.3 -1.4 *** 
19 Heat shock 70kDa 
protein 8 isoform 2 
variant (b) 
HSPA8 gi|62896815| 5.6/53.6 16.8 -1.3 *** 
20 Beta actin (d) ACTB gi|15277503| 5.6/40.5 27.3 -1.3 *** 
21 NM23-H1 NME1 gi|29468184| 5.4/19.8 27.1 -1.3 *** 
22 Triosephosphate 
isomerase 
TPI1 gi|999893| 6.5/26.8 29.0 -1.3 *** 
23 Heat shock 70kDa 
protein 8 isoform 2 
variant (a) 




AHCY gi|178277| 6.0/48.2 10.6 -1.3 *** 
25 Malate dehydrogenase 
cytosolic 
MDH1 gi|7431153| 5.9/36.6 20.1 -1.2 *** 
26 Heat shock 70kDa 
protein 8 isoform 2 
variant (c) 
HSPA8 gi|62896815| 5.6/53.6 19.7 -1.2 *** 
27 Nucleoside 
phosphorylase 
PNP gi|58176568| 6.5/32.2 36.1 -1.2 *** 
28 CAPZA1 CAPZA1 gi|12652789| 5.4/33.0 39.9 1.2 *** 
29 Beta actin (g) ACTB gi|15277503| 5.6/40.5 30.6 1.2 * 
30 Beta actin (f) ACTB gi|15277503| 5.6/40.5 24.4 1.2 * 
31 Glycerate-3-phosphate 
dehydrogenase (a) 
GAPDH gi|31645| 8.4/36.2 19.4 1.2 ** 
32 Beta actin (e) ACTB gi|15277503| 5.6/40.5 24.5 1.2 * 
33 Galectin-1 LGALS1 gi|56554350| 5.1/14.8 38.1 1.3 *** 





gi|62020550| 4.8/88.4 18.2 1.3 *** 
35 Pi glutathione 
transferase 
GSTP1 gi|34811304| 5.7/23.4 36.4 1.3 *** 
36 Elongation factor EEF1A1 gi|15277711| 9.3/46.5 12.1 1.4 *** 
37 Alpha enolase (b) ENO1 gi|2661039| 7.0/47.4 28.6 1.5 *** 
38 Peroxiredoxin 1 PRDX1 gi|55959887| 6.4/19.1 53.2 1.5 *** 
39 Alpha enolase (a) ENO1 gi|2661039| 7.0/47.4 15.5 1.5 *** 
40 Mitochondrial malate 
dehydrogenase 





gi|2183299| 6.3/55.4 18.4 21.0 *** 
 
The nominal isoelectric point (pI) and molecular weight (Mw) were calculated from the 
sequence of the protein in the database. Isoforms of the same protein are referred to as (a), 
(b) etc. The percentage coverage is the amount of the protein sequence covered by the 
matched peptides. Statistical analysis between replicates is referred to as; * p ≤ 0.05, *** p 
≤ 0.01, *** p ≤ 0.005. For protein identification, all proteins were digested and identified 
at least twice from separate gels with MALDI-TOF MS. An expectation value of <0.02 
was used for all reported identifications, which indicates a 0.2% chance that the 
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Figure 3.6.1 Protein expression map of CM Mia, CM#3 and CM#8. Numbers 
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3.6.3 Bioinformatic analysis of differentially regulated secreted proteins 
 
Bioinformatic analysis was carried out on all differentially identified secreted proteins in 
our proteomic comparison of the conditioned media of MiaPaCa-2, Clone #3 and Clone 
#8. 
 
As outlined in section 2.8, DAVID gene ID tool software (http://david.abcc.ncifcrf.gov) 
was used to generate gene ID matching the significant secreted proteins in our model. 
Gene ontology (GO STAT) (http://gostat.wehi.edu.au/cgi-bin/goStat.pl) was then used to 
classify the proteins and their corresponding genes into gene categories. Using the over-
expression function of the software and false discovery rate (Benjamini) stats, 91 GO 
terms were found significantly enriched. The “cytoplasm” term achieved the highest 
degree of significance in the up-regulated gene class (p = 0.0013), with “glycolysis” (p = 
5.4E-07) and “glucose/alcohol catabolic process” (p = 9.05E-07/9.5E-07) also highly 
significant terms. In the down-regulated class, “cytoplasm” (p = 0.0076) and “glycolysis” 
(p = 1.8E-09) were also significantly enhanced. Figure 3.6.2 outlines the top eight ranked 
functional categories using GO terms in the differentially expressed proteins in the 
pancreatic cancer model. 
 
Pathway studio is a bioinformatics tool that allows the visualisation and analysis of 
biological pathways, gene regulation networks and protein interaction maps of groups of 
genes or proteins (Chapter 2.15). Direct interactions between the differentially regulated 
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Figure 3.6.2 Term-ranking GO categories. Representation of the 8 top-ranked 
functional categories, using GO terms that are enriched in all significantly 





























Figure 3.6.3 Pathway studio analysis of direct 
interactions between all secreted proteins in conditioned 
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3.6.4 Identification and validation of target secreted proteins  
 
Table 3.6.3 outlines the comparison of the conditioned media from Clone #3 to the 
conditioned media of Clone #8. This comparison represents the greatest difference in 
invasion status as the addition of CM #3 and CM #8 into the invasion chamber had the 
greatest effect on invasion (either increasing or decreasing). 
 
Four secreted proteins have been chosen for further analysis. Of these 4 secreted proteins, 
2 are up-regulated and 2 are down-regulated in the comparison. 
 
Gelsolin (GSN) is -21-fold down-regulated in the CM of Clone #3 compared to CM #8. 
Nucleotide-diphosphate kinase 2 (NDPK) is -1.7-fold less expressed in CM#3 compared 
to CM#8. 
Of the up-regulated secreted proteins, galectin (LGALS1) is 1.3-fold, while aldhehyde 
dehydrogenase 1A1 (ALDH1A1) expression is 21-fold more highly secreted in CM #3 
versus CM #8.  
 
Western blotting was carried out to confirm the expression of the proteins, as indicated 
from the proteomic data. Figure 3.6.4 (A, B, D) validates the secretion of GSN, NDPK 
and ALDH1A1. However, secretion of LGALS1 was difficult to confirm, as the proteins 
seemed to be over-secreted and the antibody and Western blot technique were not 
sensitive enough to differentiate between expression levels in CM#3 compared to CM#8 
(Figure 3.6.4, C). 
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Figure 3.6.4 Western blot validation and 3D spot images of A. GSN, B. NDPK, C. 
LGALS1, D. ALDH1A1, E. BiP (loading control) in conditioned media of MiaPaCa-
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3.6.5 Investigation into the role of secreted gelsolin in pancreatic cancer 
invasion 
 
Gelsolin was identified as a secreted protein potentially involved in invasion in our in 
vitro pancreatic cancer cell line model. The analysis showed that GSN was up-regulated 




3.6.5.1 Effect of GSN siRNA transfection on invasion 
The secretion of gelsolin was shown to be up-regulated in the conditioned media of the 
less invasive cell line, Clone #8. Using two siRNA targets for GSN, the secreted 
expression of GSN was knocked down in the conditioned media of Clone #8. CM#8 was 
used for siRNA knockdown and further functional analysis. Figure 3.6.4 shows by 
Western blot the efficient knockdown of GSN in the CM#8 using two GSN target siRNAs 
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Figure 3.6.5 Western blot of siRNA GSN knockdown in CM#8. Two independent 
target siRNAs for GSN were transfected into Clone #8 cells. SFCM was harvested 72 
hrs post-transfection and used to determine GSN-siRNA specific decrease of secreted 
protein compared with non-treated and scrambled controls. Bip antibody was used 
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3.6.4.2 Effect of siRNA GSN CM#8 on invasion  
Conditioned media derived from Clone #8 cells treated with GSN siRNA was added into 
invasion assays of Clone #8 to assess the potential involvement of GSN in invasion. GSN 
siRNA CM#8 was added above and below the insert at equal dilution to ensure no 
gradient was present in the assay. Clone #8 was chosen; as this cell line is low invasive 
and any increase in invasion could be easily observed. Figure 3.6.6 represents (A) pictures 
of the invasion level after addition of CM#8 untreated control, scrambled and GSN (1) and 
(2) transfected siRNA. Figure 3.6.6 (B) displays the total number of invading cells. GSN 
knockdown in CM#8 resulted in increased invasion through matrigel. Invasion was 
increased 1.3-fold (p=0.01) with siRNA GSN (1) in CM#8 and 1.5-fold (p=0.2) with 




































































Figure 3.6.6  (A) Invasion assay pictures of Clone #8 cells with the addition of (i) 
untreated control CM#8, (ii) scrambled transfected CM#8, (iii) GSN siRNA (1) 
CM#8 and (iv) GSN siRNA (2) CM#8. Magnification, 200x. Scale bar, 200 μm.  (B) 
Total number of invading cells (n=3). Statistics; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.005. 
**
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3.6.4.3 Cytoplasmic GSN expression  
Figure 3.6.7 shows by Western blot the expression of GSN in the whole cell lysates of 
MiaPaCa-2, Clone #3 and Clone #8. GSN is expressed at low levels in Clone #8; however, 
the expression of GSN is increased in Clone #8 when the cells are grown on matrigel for 
24 hrs. This suggests that GSN expression is induced when the cells are exposed to 
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Figure 3.6.7 Western blot of GSN expression in MiaPaCa-2, Clone #3 and Clone #8 
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3.6.5.4 Effect of GSN siRNA on invasion  
Invasion assays were performed on Clone #8 cells transfected with GSN siRNA. Figure 
3.6.8 (A) shows representative pictures of the level of invasion observed in Clone #8 non-
treated and scrambled control cells and cells transfected with GSN siRNA, (B) displays 
the total number of cells invading. Loss of GSN expression through siRNA induces 
increased invasion in Clone #8 cells. Invasion was significantly increased 2.6–fold with 
GSN siRNA (1) (p=0.02) and 2.4-fold with GSN siRNA (2) (p=0.05). 
 
These results suggest that silencing of GSN cytoplasmic expression within the cells has 
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(A) 
  

































     *                         *
 
Figure 3.6.8 (A) Invasion assay pictures of Clone #8 (i) untreated control, (ii) 
scrambled transfected, (iii)  GSN siRNA (1) and (iv) GSN siRNA (2) transfected cells. 
Magnification, 200x. Scale bar, 200 μm.  (B) Total number of invading cells (n=3). 
Statistics; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.005. 
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3.6.6 Investigation into the role of secreted aldehyde dehydrogenase 1A1 
in pancreatic cancer invasion 
 
ALDH1A1 was identified as a secreted protein potentially involved in invasion in our in 
vitro pancreatic cancer cell line model. The analysis showed that ALDH1A1 was up-
regulated (21-fold) in the more invasive sub-population, Clone #3 compared to the low 
invasive cell line, Clone #8.  
 
3.6.6.1 Effect of ALDH1A1 siRNA CM#3 on invasion  
Figure 3.6.9 shows efficient knockdown of secreted ALDH1A1 in conditioned media of 
Clone #3 after ALDH1A1 siRNA transfection. Invasion assays were then carried out with 
the addition of CM#3 untreated control, scrambled, and three independent ALDH1A1 
siRNAs into the invasion chamber above and below to ensure no gradient.  
 
Figure 3.6.10 (A) highlights the representative pictures of invasion, and (B) displays the 
total number of invading cells. Invasion is significantly decreased after siRNA knockdown 
of ALDH1A1 secretion.  
ALDH1A1 siRNA (1) in CM#3 reduced invasion 4.2-fold (p=0.01), ALDH1A1 siRNA 
(2) in CM#3 decreased invasion 2.7-fold (p=0.003) and ALDH1A1 siRNA (3) in CM#3 
also significantly reduced the invasive abilities of Clone #3 2.5-fold (p=0.02), compared 





























Figure 3.6.9 Western blot of ALDH1A1 knockdown in CM#3 untreated control, 





























































 Bip 78 kDa (loading control) 
 
ALDH1A1 55 kDa 
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(A) 











Figure 3.6.10 (A) Invasion assays of Clone #3 with addition of (i) CM#3 media 
(control) (ii) CM#3 media with scrambled (iii) CM#3 treated with ALDH1A1 siRNA 
(1) (iv) CM#3 treated with ALDH1A1 siRNA (2) (v) CM#3 treated with ALDH1A1 
siRNA (3). SFCM was collected 72-96 hrs post transfection.  Magnification, 200x. 
Scale bar, 200μm.  (B) Invasion assay of Clone #3 showing total number of cells 
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3.7 Investigation of EGFR and HER2 expression in pancreatic cancer 
 
3.7.1 EGFR expression 
EGFR levels were investigated by Western blot and ELISA in a panel of five pancreatic 
cancer cell lines (Chapter 2.9). Figure 3.7.1 (A) shows the protein expression of EGFR. 
(B) Quantitatively measures the level of EGFR (pg/µl total protein). EGFR is highly 






















Figure 3.7.1 EGFR expression in panel of pancreatic cancer cell lines (A) Western 
blot of EGFR and (B) ELISA quantification of EGFR pg/µl total protein.  
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3.7.2 HER2 expression 
HER2 expression levels were investigated by Western blot in a panel of five pancreatic 
cancer cell lines. Figure 3.7.2 shows the protein expression of HER2. HER2 is expressed 
in BxPc-3, AsPc-1 and expressed in lower levels in KCI-MOH1 and Panc-1. No 










                                                    
 
 
Figure 3.7.2 HER2 expression in panel of pancreatic cancer cell lines by Western 










































HER2 185 kDa 
 
 
β-actin 42 kDa 
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3.7.3 Chemosensitivity profile of BxPc-3 and KCIMOH1  
The dual EGFR and HER2 inhibitor, lapatinib, was tested in two of the EGFR/HER2 
positive cell lines, BxPc-3 and KCIMOH1. Table 3.7.1 shows the IC50s for lapatinib in the 
pancreatic cancer cell lines compared to two lapatinib sensitive breast cancer cell lines, 
which express low levels of EGFR (+) and over-express HER2 (+++++).  
 
The chemosensitivity profile of BxPc-3 and KCIMOH1 was also analysed using an in 
vitro proliferation assay (Chapter 2.3) to determine the IC50 (concentration of drug that 
inhibits proliferation of 50% of the cell population) of cisplatin, gemcitabine, taxotere and 
5’dFUrd (Table 3.7.2). 
 
Table 3.7.1 Lapatinib IC50 values for pancreatic and breast cancer cell lines 
(results are expressed as IC50 ± SD, n=3). 
 EGFR HER2 Lapatinib IC50 
BxPc-3 +++ ++ 1.4 ± 0.1 µg/ml 
KCIMOH1 + + 1.4 ± 0.2 µg/ml 
BT474 + +++++ 142 ± 28 ng/ml 
SKBR3 + +++++ 113 ± 38 ng/ml 
 
Table 3.7.2 IC50 values of pancreatic cell lines to chemotherapeutic agents    
(results are expressed as IC50 ± SD, n=3). 
(ng/ml) BxPc-3 KCI-MOH1 
Cisplatin 225.6 ± 56.3 226.4 ± 10.7 
Gemcitabine 1.4 ± 0.6 0.5 ± 0.01 
Taxotere 0.4 ± 0.05 0.4 ±0.1 
5’dFUrd (µg/ml) 2.9 + 0.2 8.3 ± 1.1 
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3.7.4 Scheduling combination assays 
Combination assays assessing the drug effect/combination index analysis of lapatinib, a 
dual EGFR/HER2 tyrosine kinase inhibitor, in combination with chemotherapeutic agents, 
cisplatin, gemcitabine, taxotere and 5’dFUrd against BxPc-3 and KCIMOH1, two 
EGFR/HER2 expressing pancreatic cancer cell lines in vitro were performed.  
The combination assays were carried out using a fixed ratio of lapatinib:chemotherapeutic 
drug. Initial experiments combined lapatinib and chemotherapeutic drug together during 
assays, however antagonism was observed. Figure 3.7.3 displays a representative graph of 



















Figure 3.7.3 Percentage survival of KCIMOHI in combination with lapatinib and 
cisplatin 
 
However, when cells were pre-treated with lapatinib for 24 hours before addition of 
chemotherapeutic drugs, more efficacy of the combination was observed. Therefore, all 
combinations were performed using this method of scheduling (Chapter 2.3.1). 
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Combination indices (CI) were calculated using the model of Chou and Talalay for drug 
combinations and the CalcuSyn software package. CI < 0.8 denotes synergy, CI > 0.8 but 
< 1.2 denotes additivity and CI > 1.2 denotes antagonism. 
 
3.7.4.1 Drug effect/combination index analysis of lapatinib in combination with 
cisplatin against BxPc-3 and KCI-MOH1, EGFR/HER2 expressing pancreatic 
cancer cell lines in vitro 
Lapatinib was added to the cells 24 hours prior to the addition of cisplatin, this was to 
ensure the EGFR/HER2 inhibitory effects of lapatinib were maximised. The combinations 
of lapatinib and cisplatin were carried out at a constant ratio of 1:0.1, lapatinib:cisplatin to 
obtain a complete dosage range in both cell lines. 
 
Figure 3.7.4 (A) and (B) outlines the percentage survival of BxPc-3 and KCIMOH1 with 
lapatinib and cisplatin alone and in combination. 
 
Synergism was observed between cisplatin and lapatinib in BxPc-3 cells at lower 
concentrations of lapatinib and cisplatin with a CI value at ED25 of 0.60 ± 0.09. At the 
ED50 concentrations, the interaction was additive and at ED75, the interaction became 
antagonistic (Table 3.7.3). 
Synergism was also observed in KCIMOH1 at ED50 (CI value, 0.65 ± 0.05), and at ED25 
















































































Figure 3.7.4 Percentage survival of lapatinib and cisplatin combinations in (A) 
BxPc-3 and (B) KCIMOH1 (n=3). 
 
Table 3.7.3 Mutually non-exclusive CI values at ED25, ED50 and ED75   
  (results are expressed as ED ± SD, n=3) 
Drug Combination Index Values 
Lapatinib:Cisplatin , 1:0.1 ED25 ED50 ED75 
BxPc-3  0.60 ± 0.09 0.97 ± 0.18 1.17 ± 0.16 
KCI-MOH1 0.81 ± 0.23 0.65 ± 0.05 0.88 ± 0.20 
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3.7.4.2 Drug effect/combination index analysis of lapatinib in combination with 
gemcitabine against BxPc-3 and KCIMOH1, EGFR/HER2 expressing pancreatic 
cancer cell lines in vitro 
BxPc-3 and KCIMOH1 cells were pre-incubated with lapatinib 24 hours prior to the 
addition of gemcitabine, this was to ensure the EGFR/HER2 inhibitory effects of lapatinib 
were maximised. The combinations of lapatinib and gemcitabine were carried out at a 
constant ratio of 1:0.02, lapatinib:gemcitabine to obtain a complete dosage range in both 
cell lines. 
 
Figure 3.7.5 (A) and (B) outlines the average percentage survival of BxPc-3 and 
KCIMOH1 with lapatinib and gemcitabine alone and in combination. 
 
The combination of lapatinib and gemcitabine in BxPc-3 was additive at ED25-75, with 
CI values in the range of 0.9-1.0 (Table 3.7.4). 
 
The relationship between lapatinib and gemcitabine in the KCIMOH1 cell line displayed 
additivity at ED25 (CI value, 0.93 ± 0.10). The combination was additive at ED50 and at 









































































Figure 3.7.5 Percentage survival of lapatinib and gemcitabine combinations in (A) 
BxPc-3 and (B) KCIMOH1 (n=3). 
 
Table 3.7.4 Mutually non-exclusive CI values at ED25, ED50 and ED75   
  (results are expressed as ED ± SD, n=3) 
Drug Combination Index Values 
Lapatinib:Gemcitabine , 1:0.02 ED25 ED50 ED75 
BxPc-3  0.79 ± 0.23 0.89 ± 0.28 1.07 ± 0.41 
KCI-MOH1 0.93 ± 0.10 1.00 ± 0.17 1.12 ± 0.35 
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3.7.4.3 Drug effect/combination index analysis of lapatinib in combination with 
taxotere against BxPc-3 and KCI-MOH1, EGFR/HER2 expressing pancreatic 
cancer cell lines in vitro 
Lapatinib was added to the cells 24 hours prior to the addition of taxotere, this was to 
ensure the EGFR/HER2 inhibitory effects of lapatinib were maximised. The combination 
of lapatinib and taxotere were carried out at a constant ratio of 1:0.01, lapatinib:taxotere to 
obtain a complete dosage range. 
 
Figure 3.7.6 (A) and (B) displays the average percentage survival of BxPc-3 and 
KCIMOH1 with lapatinib and taxotere alone and in combination. These results show that 
taxotere is a very potent drug and that pancreatic cancer cell lines, BxPc-3 and KCIMOH1 
are sensitive at very low concentrations. The high toxicity of taxotere masked any anti-
proliferative effects of lapatinib. Therefore, as an accurate dose response curve was not 













































































Figure 3.7.6 Percentage survival of lapatinib and taxotere combinations in (A) 
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3.7.4.4 Drug effect/combination index analysis of lapatinib in combination with 
5’dFUrd against BxPc-3 and KCIMOH1, EGFR/HER2 expressing pancreatic 
cancer cell lines in vitro 
Lapatinib was added to the cells 24 hours prior to the addition of 5’dFUrd, this was to 
ensure the EGFR/HER2 inhibitory effects of lapatinib were maximised. The combination 
of lapatinib and 5’dFUrd were carried out at a constant ratio of 1:2, lapatinib:5’dFUrd to 
obtain a complete dosage range. 
 
Figure 3.7.7 (A) and (B) displays the average percentage survival of BxPc-3 and 
KCIMOH1 with lapatinib and 5’dFUrd alone and in combination. 
 
The interaction of lapatinib and 5’dFUrd in BxPc-2 at lower concentrations, ED25-50 is 
synergistic to additive. However, at ED75, the CI value is 1.12 ± 0.24 and displays an 
antagonistic effect (Table 3.7.5). 
 
 In KCIMOH1 cells, the relationship between lapatinib and 5’dFUrd is antagonistic at 
ED25, and displays an additive to synergistic interaction at ED50-75. Table 3.7.5 displays 






















































































Figure 3.7.7 Percentage survival of lapatinib and 5’dFUrd combinations in (A) 
BxPc-3 (n=3) and (B) KCIMOH1 (n=3).  
 
Table 3.7.5 Mutually non-exclusive CI values at ED25, ED50 and ED75   
  (results are expressed as ED ± SD, n=3) 
Drug Combination Index Values 
Lapatinib:5’dFUrd , 1:2 ED25 ED50 ED75 
BxPc-3  0.73 ± 0.22 0.88 ± 0.03 1.12 ± 0.24 
KCI-MOH1 1.17 ± 0.20 1.00 ± 0.21 0.95 ± 0.40 
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4.0 Discussion 
4.1 Establishment of drug-selected variants 
 
Multi-drug resistance (MDR) in invasive and metastatic cancer are major causes of death 
for patients with cancer. The relationship between drug resistance and invasion/metastasis 
in cancer is not fully elucidated. In this thesis, three pancreatic cell lines, BxPc-3, KCI-
MOH1 and MiaPaCa-2, each with differing degrees of sensitivity to chemotherapeutic 
drugs were chosen for pulse selection with epirubicin, taxotere and gemcitabine in order to 
investigate any relationship between invasion and drug response. 
The level of resistance observed to the selecting drugs is low compared to the high levels 
of resistance that have been previously shown when selecting continuously with a 
chemotherapeutic drug. The tumour resistance observed in patients is approximately 3- to 
6-fold to the agent of therapy (Wolf et al., 1987). However, the pulse selection method 
outlined in chapter 2.4.6 is more closely related to the in vivo situation, whereby patients 
receiving chemotherapy are treated every 1-3 weeks and also uses clinically relevant doses 
of the drugs. 
 
4.1.1 Epirubicin selections 
Epirubicin is a member of the anthracycline family of chemotherapeutic drugs. The use of 
this drug for the treatment of advanced pancreatic cancer is currently undergoing clinical 
trials. Reni et al. (2006) demonstrated that dose intense cisplatin, epirubicin, 5-fluorouracil 
and gemcitabine in a randomised controlled phase III clinical trial regime appeared more 
suitable than gemcitabine alone for the treatment of advanced pancreatic cancer. 
Multi-drug resistance is a common problem in the treatment of cancer, in particular 
pancreatic cancer. MDR may occur intrinsically or may be acquired after drug treatment. 
P-gp is intrinsically expressed in paraffin embedded sections of untreated pancreatic 
cancer tumours (Suwa et al., 1996) and in cell lines (Zhao et al., 2004).  
Epirubicin is a P-gp substrate and other mechanisms of resistance to anthracyclines 
include: increased glutathione peroxidase and/or glutathione S-tranferase, MRP-1 and 
 273  
decreased topoismoerase II α expression (Uchiyama-Kokubu et al., 2001; Bader et al., 
1998; Kuriyama et al., 1997). 
 
In an attempt to identify the mechanisms of MDR in epirubicin-selected pancreatic cell 
lines, and to investigate the effect of acquired epirubicin resistance on invasion, cross-
resistance proliferation assays were carried out. Invasion status was also assessed. 
 
Bx/Epi was generated after 10 pulses with 50 ng/ml epirubicin. The epirubicin-variant 
exhibited a modest 1.4-fold increase in resistance to epirubicin and a significant cross-
resistance to adriamycin and vincristine. The cell line exhibited cross-sensitivity to 5-
fluorouracil and taxotere. KCI/Epi was established after 10 pulses with 100 ng/ml 
epirubicin. The selected-variant displayed 8-fold resistance to epirubicin compared to the 
parental cell line. Cross-resistance profiling showed that a significant increase in 
resistance was also observed for gemcitabine, carboplatin and VP-16. A significant 
decrease in cross-resistance to adriamycin and vincristine was demonstrated suggesting an 
alternative mode of multi-drug resistance other than MDR-1 and MRP-1. Mia/Epi was 
established after 10 pulses with 64 ng/ml epirubicin. The selected-variant displayed a 
significant 1.7-fold increase in resistance to epirubicin compared to the parental cell line. 
Cross-resistance profiling showed an increase in resistance to gemcitabine, taxotere, 
adriamycin, carboplatin, cisplatin, VP-16 and vincristine.  
 
Both Bx/Epi and Mia/Epi displayed significant cross-resistance to adriamycin and 
vincristine. Epirubicin, adriamycin and vincristine are classified as MDR-related drugs 
and this resistance may be consistent with a P-gp or MRP-1 drug resistant phenotype. 
However, the cross-resistance profile for the epirubicin-selected pancreatic cell lines is 
varied. Takeshita et al. (2000) highlighted the involvement of sub-populations within an 
ADR-resistant osteosarcoma cell line. The ADR-resistant cell line and its sub-population 
displayed cross-resistance to P-gp substrates, doxorubicin, vincristine and etoposide, while 
the sub-populations also exhibited resistance to cisplatin and methotrexate, indicating that 
intrinsic resistance to multiple drugs exists within resistant cell lines.   
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Anthracycline-induced resistance in cells can often show cross-resistance to other 
members of the family. Pesic et al. (2006) established a resistant doxorubicin NSCL 
cancer cell line that displayed cross-resistance to VP-16, taxol, vinblastine and epirubicin, 
which was mediated by P-gp expression and not MRP-1 and LRP. Marks et al. (1996) 
developed an 8-fold epirubicin resistant haemopoietic cell line, which displayed cross-
resistance to vinblastine, paclitaxel, etoposide and cisplatin demonstrating an extended 
MDR phenotype. The cells showed P-gp expression, although the P-gp was not functional 
as decreased drug accumulation was not restored in the presence of verapamil. Therefore, 
the induction of an extended MDR phenotype may explain why the pancreatic cell lines 
pulsed with epirubicin displayed cross-resistance to drugs of different families. 
 
In our study, all epirubicin selected variants showed very low, non-significant cross-
resistance to 5-fluorouracil. This sensitivity may have clinical relevance, whereby tumours 
that develop low to moderate resistance to epirubicin may be treated with 5-fluorouracil in 
order to hinder the development of an MDR tumour.  
 
To investigate the relationship between invasion and epirubicin acquired resistance in 
pancreatic carcinoma, the invasive status of the epirubicin-selected cell lines was assessed 
(Chapter 3.1.4). Pancreatic cancer cell lines pulse-selected with epirubicin, displayed a 
significant increase in invasion relative to untreated parental cells.  
Table 4.1.1 summarises the association between epirubicin drug resistance and invasion in 
the selected pancreatic cell lines. There is no literature available on acquired epirubicin 
resistance and its effect on invasion. From our results it is clear that exposure to epirubicin 
increases invasion through matrigel, to varying degrees. This may be caused by selecting 
the more invasive cell populations or by inducing genetic/translational alterations that lead 





 275  
Table 4.1.1 Summary of fold drug resistance and invasion status of epirubicin 
selected pancreatic cancer variants 
Cell line Drug Fold resistance Fold invasion 
BxPc-3 Epirubicin 1.4 1.3 
MiaPaCa-2 Epirubicin 1.7 3 
KCI-MOH1 Epirubicin 8.0 1.7 
 
 
4.1.2 Taxotere-selections and effects on cell invasion 
Taxotere is a semi-synthetic microtubule inhibitor belonging to the family of taxanes. The 
mechanisms of taxotere resistance in vivo and in vitro are still poorly understood. Taxotere 
is a substrate for the multi-drug resistance P-glycoprotein (P-gp) which confers cross-
resistance to a wide variety of chemotherapeutic substances. Many reports have found that 
cells selected with taxotere display an increased cross-resistance to other chemo-drugs and 
elevated levels of P-gp (Liu et al., 2001). Liang et al. (2004) investigated the mechanism 
of taxotere resistance in the human lung carcinoma cell line, DLKP. The taxotere-selected 
cell line established was 36-fold more resistant than the parental cell line. This new 
resistant “Txt” variant displayed high levels of MDR-1/P-gp and MRP-1 shown by 
Western blot and RT-PCR suggesting taxotere resistance is mediated in part through 
MDR-1/P-gp and MRP-1. 
Brown et al. (2004) investigated a novel mechanism of taxotere resistance in breast cancer 
cells. Two taxotere resistant breast cancer cell lines (MCF-7 and MDA-MB-231) were 
created and analysed by microarray to identify genes associated with taxotere resistance. 
A reduction in the expression of p27, the cyclin-dependent kinase inhibitor was observed 
in the taxotere resistant cell lines. Other studies implicate that alterations in the β-tubulin 
isotypes are associated with acquired taxotere resistance in breast cancer cells (Shalli et 
al., 2005). 
 
Three pancreatic cancer cell lines, BxPc-3, KCI-MOH1 and MiaPaCa-2, were chosen for 
pulse selection with varying concentrations of taxotere (Chapter 3.1). 
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The taxotere-selected variant, KCI/Txt was established after 10 pulses with 2 ng/ml of 
taxotere. No resistance was observed to the selecting drug; in fact a marked sensitivity to 
taxotere was displayed. Adriamycin, cisplatin, and vincristine also showed a decrease in 
resistance. An increase in cross-resistance was observed for epirubicin, gemcitabine, 5-
fluorouracil, taxol, carboplatin and VP-16. In this cell line, pulse selection exposure to 
taxotere did not lead to the development of taxotere resistance. Perhaps, clinically this 
tumour would have responded to taxotere treatment. It would be interesting to study the 
inherent differences in cell lines that develop resistance and those that do not, as it may 
result in the identification of predictive markers. 
  
The taxotere-selected variant, Mia/Txt was established after 10 pulses with 1.2 ng/ml 
taxotere. Resistance to taxotere was increased 1.2-fold, while taxol resistance was also 
increased. Cross-resistance profiling showed a modest increase in resistance to 
gemcitabine, cisplatin and carboplatin. A decrease in resistance was observed for 
epirubicin, 5-fluorouracil, adriamycin, VP-16 and vincristine. 
 
Taxotere promotes the polymerisation of tubulin. Microtubules are involved in many 
aspects of cell functions such as cell division, cell movement and intracellular protein 
translocation, and therefore acquired resistance of cells to taxotere may induce an altered 
in vitro invasive phenotype. Taxotere has been shown to up- or down-regulate the 
expression of metastasis-associated proteins and genes such as metalloproteinases, 
urokinase-type plasminogen activator and E-cadherin. Guo et al. (2003) demonstrated that 
treatment of colon cancer cell lines with non-toxic concentrations of taxotere resulted in a 
decrease in expression of MMP-2 and -9 and induced a reduction in their activities. MMP-
2 and MMP-9 play a vital role in the degradation of collagen type IV in the basement 
membrane, which is a crucial event in the metastatic cascade. 
 
To investigate the relationship between taxotere resistance and invasion, the invasion 
status of the taxotere selected cell lines was assessed. Table 4.1.2 summarises the 
connection between taxotere acquired resistance and invasion. 
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Table 4.1.2 Summary of fold drug resistance and invasion status of taxotere   
selected pancreatic cancer variants 
Cell line Drug Fold resistance Fold invasion 
MiaPaCa-2 Taxotere 1.2 1.0 
KCI-MOH1 Taxotere 0.8 0.9 
 
Invasion assays of the taxotere-selected pancreatic cell lines, MiaPaCa-2 and KCI-MOH1, 
indicated no change in invasion status. These findings may be due to the low level of 
taxotere resistance observed in the selected cell lines. Many other reports show taxotere 
treatment has inhibitory effects on tumour cell invasion. Liu et al. (2001) investigated the 
role of acquired and intrinsic resistance of the pancreatic cell line, SUIT-2 to taxotere. The 
study showed resistance to taxotere was mediated mainly by P-gp and concluded that 
taxotere inhibits the invasive ability of drug-sensitive cells but not drug resistant cells. 
Glynn et al. (2004) also observed decreased invasion in a taxol-resistant variant. 
 
4.2.3 Gemcitabine-selection and effects on cell invasion 
Gemcitabine [2′-deoxy-′, 2′-difluorocytidine monohydrochloride], a pyrimidine nucleoside 
analogue, is the most common principal agent used to treat advanced pancreatic cancer. 
However, acquired resistance to gemcitabine, a clinical trait, may result in treatment 
failure. To investigate the mechanisms involved in gemcitabine resistance, three 
pancreatic cell lines were pulse-selected with varying concentrations of gemcitabine for 4 
hours once a week for 10 weeks as described in Chapter 2.4.2. 
 
Molecular markers relating to gemcitabine chemo-resistance that have been described 
include genes involved in cell cycle regulation, proliferation and apoptosis.  However, the 
genes most frequently associated with gemcitabine resistance are related to nucleoside 
transport and metabolism, which may be involved in the intracellular activation of 
gemcitabine in vivo.  
 
Apoptotic factors have been implicated in the development of resistance to gemcitabine in 
carcinoma cell lines. Nakai et al. (2005) investigated genes relating to gemcitabine 
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sensitivity by using gene expressions profiles from gemcitabine resistant human 
pancreatic cell lines under continuous gemcitabine exposure. Fas ligand (TNFSF6), a gene 
related to Fas mediated apoptosis signalling was down-regulated at the mRNA and protein 
level in a gemcitabine-resistant cell line. The TNFSF6 protein has also been implicated in 
cisplatin resistance, whereby cells unable to up-regulate the protein displayed reduced 
levels of apoptosis in response to cisplatin. 
BNIP3 (Bcl2/adenovirus E1B 19 kDa protein interacting protein), which is a member of 
the BH3-only subfamily of Bcl-2 proteins and is known to promote apoptosis, was 
expressed at lower levels in gemcitabine-resistant cell lines. Silencing of BNIP3 with 
siRNA resulted in a marked reduction of gemcitabine-induced toxicity in vitro (Akada et 
al., 2005). 
 
In NSCLC (non small cell lung cancer), increased hENT1 (human equilibrative nucleoside 
transporter 1) expression is a determinant of gemcitabine sensitivity and decreased dCK 
(deoxycytidine kinase) expression has been shown to be associated with resistance in a 
gemcitabine-resistant cell line (Achiwa et al., 2004). However, Bergman et al. (2005) 
determined that decreased dCK activity in vivo was not as important to gemcitabine 
resistance as RRM1 (ribonucleotide reductase subunit M1) expression (Jordheim et al., 
2005). 
 
We induced acquired gemcitabine resistance in the cell lines KCI-MOH1 and MiaPaCa-2. 
Pulse selection with gemcitabine in the BxPc-3 cell line did not induce acquired resistance 
after ten consecutive pulses.  
 
The KCI-MOH1 gemcitabine-selected variant was generated after 10 pulses with 50 ng/ml 
gemcitabine. A significant increase in resistance of 2608-fold was observed to 
gemcitabine. KCI/Gem also displayed significant cross-resistance to epirubicin, taxol and 
VP-16. Slight increases in resistance to taxotere and cisplatin were observed. Resistance to 
5-fluorouracil, adriamycin, carboplatin and vincristine were decreased.  
The cross-resistance profile of the KCI-MOH1 gemcitabine variant correlates with other 
studies investigating gemcitabine cross-resistance. Bergman et al. (2000) developed a 
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30,000-fold gemcitabine resistant ovarian cell line with no dCK activity and investigated 
the cross-resistance profile. Large increase in resistance was observed to taxol, taxotere 
and epirubicin. Slight cross-resistance was displayed for 5-fluorouracil, cisplatin, VP-16 
and adriamycin. 
KCI/Gem showed some cross-resistance to taxotere and taxol, which may be related to 
toxicity associated with the taxanes; however, no P-gp protein expression was observed in 
this gemcitabine-selected cell line.  
KCI/Gem displayed a high level of resistance to gemcitabine but was not resistant to 5-
fluorouracil. Shi et al. (2002) showed that pancreatic cell lines are intrinsically resistant to 
5-fluorouracil and more sensitive towards gemcitabine. The precise mechanisms of 
gemcitabine and 5-fluorouracil chemo-resistance in cancer patients are still unknown. 
Gemcitabine and 5-fluorouracil have similar molecular structures, mechanisms and 
metabolic characteristics. Both drugs interfere with DNA and RNA synthesis. However 
the drugs target multiple mechanisms, and therefore resistance to either drug is 
multifactorial. Over-expression of thymidylate synthase (TS) (5-FU initiates apoptosis by 
inhibiting TS) and down-regulation of key enzymes (thymidine kinase and pyrimidine 
nucleoside phosphorylase) are involved in 5-FU resistance (Wang et al., 2004). 5-FU 
sensitivity is also dependent on expression of dihydropyrimidine dehydrogenase, p53 
status and DNA mismatch-repair genes (Longley et al., 2003). Shi et al. (2002) 
investigated the role of apoptosis genes in 5-FU/gemcitabine resistance in pancreatic 
cancer cell lines. Following long term exposure to 5-FU and gemcitabine, some pancreatic 
cell lines displayed acquired resistance to the drugs, partially mediated by the up-
regulation of apoptosis inhibitors bcl-xL and mcl-1. This study also showed that the ratio of 
bax/bcl-2 is predictive of sensitivity toward 5-FU and gemcitabine. These results suggest 
that common anti-apoptotic genes between 5-FU and gemcitabine may play an important 
role in predicting cross-resistance.  
Unfortunately, our KCI/Gem cell line could not be cultured further as frozen stocks were 
not viable. 
Mia/Gem was established after 10 pulses with 20 ng/ml gemcitabine and showed a 1.3-
fold increase in resistance. Cross-resistance was observed to adriamycin, VP-16 and 
vincristine. Increasing knowledge of cross-resistance profiles of gemcitabine resistance 
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tumour cells may help to increase our knowledge on future chemotherapeutic 
combinations. 
 
To study the relationship between gemcitabine resistance and invasion, the invasion status 
of the gemcitabine-selected variants was investigated. Acquired drug resistance after 
gemcitabine treatment of pancreatic cancer is often encountered and may lead to further 
more aggressive metastasis. Verma et al. (2006) showed that elevated levels of tissue 
transglutaminase (TG2) in pancreatic ductal adenocarcinoma (PDAC) cells can add to the 
development of gemcitabine drug resistance and invasive phenotypes by activation of the 
FAK/phosphatidylinositol 3-kinase (PI3K)/AKT pathway. 
Table 4.1.3 summarises the relationship between gemcitabine drug resistance and 
invasion. BxPc-3 did not acquire resistance to gemcitabine after pulse selection and 
therefore, did not show any increase in invasion. However, interestingly MiaPaCa-2 and 
KCI-MOH1 displaying different levels of gemcitabine resistance showed the same rate of 
increased invasion. This suggests that even low levels of gemcitabine resistance may 
contribute to enhanced invasion. 
 
Table 4.1.3 Summary of fold drug resistance and invasion status of gemcitabine 
selected pancreatic cancer variants 
Cell line Drug Fold resistance Fold invasion 
BxPc-3 Gemcitabine 1.0 1.0 
MiaPaCa-2 Gemcitabine 1.3 2.5 
KCI-MOH1 Gemcitabine 2608 2.5 
 
In summary, pulse-selection treatment of pancreatic cancer cell lines with epirubicin, 
taxotere and gemcitabine did not result in major multi-drug resistance phenotypes. Our 
method of selection reflected clinical conditions and exposure was efficient enough to 
observe a significant effect on invasion. Further selection with continuous 
chemotherapeutic exposure has previously resulted in stable resistant cell lines (Frei et al., 
1985); however this is not representative of clinical settings. 
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This may be an important finding, in terms of pancreatic cancer patient treatment as 
adjuvant treatment with anti-invasive molecules and chemotherapy may have a more 
efficient outcome than drug treatment alone.   
 
4.2  Investigation of MDR associated protein expression in pancreatic 
carcinoma patients 
 
Intrinsic and acquired drug resistance to a wide variety of molecularly diverse and 
structurally different chemotherapeutic drugs is a clinical phenomenon that is mainly 
responsible for the high mortality rates among patients with pancreatic cancer.  
The two main drug efflux pump transport families involved in multi-drug resistance 
(MDR) are multi-drug resistant gene P-glycoprotein (MDR-1/P-gp) and multi-drug 
resistance protein (MRP-1).  
The expression of P-gp has been found in neoplastic and normal tissues such as the 
kidney, liver (Silverman et al., 1995), pancreas, large intestine, and heart (Abu-Qare et al., 
2003) as well as in several cancer cell lines before or after treatment with cytotoxic agents.  
 
The expression of multi-drug resistant gene 1 (MDR-1/P-gp) and MRP-1 are the major 
factors for failure of chemotherapy in cancer patients. Studies of the prevalence of these 
drug efflux pumps in pancreatic tumours are limited and contradictory. This study is the 
first of its kind to measure the expression of both MDR-1/P-gp and MRP-1 in pancreatic 
tumours. 
 
Conflicting results have been reported in studies regarding P-gp in pancreatic cancer. 
Miller et al. (1996) examined the expression of P-gp and its function as a drug efflux 
system in pancreatic cancer. They found no functional P-gp present in pancreatic cancer 
cell lines, Panc-1, BxPc-3 and AsPc-1, suggesting that intrinsic MDR in pancreatic cancer 
may be in part mediated by MRP-1 and not MDR-1/P-gp. This observation was also 
supported by Izquierdo et al. (1996) whereby MRP-1 was detected in 97% and 87% of 
pancreatic tumour cell lines. 
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However, as P-gp is central in multi-drug resistance, it may have a role in the development 
of acquired resistance after exposure to drug treatment. Liu et al. (2001) verified the 
acquired resistance caused by P-gp in a study examining the effect of taxotere on the 
pancreatic carcinoma cell line SUIT-2 and its taxotere-selected variant S2/Txt, established 
by exposure to increasing taxotere concentrations. The Txt variant was 9.5-fold more 
resistant that the parental cell line. The parental cell line showed no MDR-1 expression 
while the S2/Txt line expressed MDR-1 mRNA. This shows that P-gp may mediate 
acquired resistance in pancreatic cancer. 
 
Suwa et al. (1996) also investigated the role of P-gp in 103 paraffin embedded sections of 
previously untreated pancreatic cancer patients. MDR-1 was detected in all tumours at a 
significantly higher levels compared to normal pancreas tissue. Higher MDR-1/P-gp 
expression levels correlated significantly with better prognosis of patients with ductal 
carcinoma. Among patients with ductal carcinoma, the group with high P-gp staining 
revealed a 3.5-fold better prognosis compared with the low staining group. They 
concluded that MDR-1 gene/P-gp expression in pancreatic cancer without chemotherapy 
inversely correlates with biological aggressiveness and is an independent indicator of 
favourable prognosis. 
 
MRP-1 (multi-drug resistance-associated protein) is a drug efflux pump that actively 
transports selected chemotherapeutic agents out of the cell. The potential importance of 
MRP-1 in pancreatic carcinoma is as yet unknown. A recent study analysed the mRNA 
expression of MRP 1-9 in normal pancreatic tissue and pancreatic carcinoma. MRP-1 
mRNA levels were found not to change significantly between normal pancreatic tissue 
and pancreatic carcinoma samples with different grading. Furthermore, MRP-1 protein 
was localised only in the fibroblasts and not in the acinar cells or pancreatic carcinoma 
cells and expression did not correlate with tumour stage or grading (König et al., 2005). 
 
The potential involvement of MDR-1/P-gp and MRP-1 in pancreatic cancer and the 
implications of their expression in the clinical setting have not been fully defined. 
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In this study, we detailed the expression of both MDR-1/P-gp and MRP-1 expression in 
pancreatic tumours. MDR-1/P-gp expression was detected in 93% of tumours stained, 
while MRP-1 was expressed in 36% of pancreatic carcinomas. Co-expression of multi-
drug proteins was observed in 36% of specimens, no cases were observed where MRP-1 
was expressed independently of MDR-1/P-gp. However, 61% stained MDR-1/P-gp 
positive and MRP-1 negative. Only 6.7% of cases expressed neither drug efflux pumps. 
 
The results from this study show that MDR-1/Pgp and MRP-1 are frequently co-expressed 
in pancreatic tumours. We suggest that these efflux pumps contribute in part to the chemo-
resistance phenotype observed in pancreatic cancer. However as the pre-operative 
chemotherapy history of these patients is unknown, we can not identify whether this 
resistance is inherent or acquired. 
The frequent over-expression of MDR-1/P-gp in particular highlights the need to 
investigate the functional roles of drug efflux pumps in pancreatic cancer, and inhibition 
of multiple drug efflux pumps may be essential for the complete control of multi-drug 
resistance in pancreatic cancer. Future work may involve examining the functional role of 
P-gp and MRP-1 in pancreatic cancer. Targeting these drug efflux pumps with siRNA or 
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4.3 Analysis of the malignant characteristics of MiaPaCa-2 and sub-
populations, Clone #3 and Clone #8 
 
Current therapies are unsuccessful in the treatment of metastatic cancer, mainly due to the 
advanced stage of the cancer at diagnosis. Other rationale behind the high mortality rate of 
metastatic cancers may be the location and specific organ environment, which may alter 
the efficiency of chemotheraptic drugs. The heterogeneous composition of tumours is 
another underlying cause for ineffective treatment as the process of metastasis is highly 
selective. Heterogenic neoplasms contain a variety of sub-populations, which have 
differing metastatic potential (Fidler and Kripke, 1977).    
 
4.3.1 Analysis of invasion, adhesion, anoikis and anchorage independent growth in 
the malignant phenotype 
In this thesis, sub-populations of the human pancreatic cancer cell line, MiaPaCa-2 were 
successfully isolated by single cell cloning to effectively obtain homogeneous clonal 
populations with differing degrees of invasion. Two of these clones, Clone #3 and Clone 
#8, showed the most divergent invasive abilities compared to the parent cell line. In vitro 
invasion assays were carried out using the extracellular matrix proteins, matrigel, laminin, 
fibronectin and collagen type IV and I. A high level of invasion through matrigel, laminin, 
fibronectin was observed for Clone #3. Invasion through collagens type IV and I showed a 
modest increase compared to the parent cell line, MiaPaCa-2. Motility for this cell line 
was also highly increased. In contrast, Clone #8 showed a significant reduction in invasion 
through matrigel, laminin, fibronectin and collagens type IV and I. Motility of this cell 
line was similar to the parental cell line.  
Tumour cell invasion through the basement membrane is central to the metastatic process. 
One of the first events during cancer cell invasion is the loss of junctional contact between 
adjacent cells in the epithelial tissue by disruption of the cell-cell and/or cell-ECM 
association. Loss of tissue cohesiveness involves alterations in adhesion molecules. Cell 
adhesion to the ECM is mediated in part by the integrin family of transmembrane receptor 
proteins. It is understood that adhesion molecules prevent cell migration and invasion via 
the cell-ECM association. However, disruption of these connections may lead to increased 
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motility of the tumour cells that have the ability to detach from the original tumour. 
Therefore, cell surface adhesion molecules play a significant function in cell invasion, 
migration and metastasis. Changes in the integrin expression during malignant 
transformation are dependent on the type of cancer. Vodelmann et al. (1999) demonstrated 
altered adhesion properties and integrin expression in a human pancreatic metastatic cell 
line and a non-metastatic cell line derived from the same original tumour. The metastatic 
cell line exhibited decreased adhesion to fibronectin, collagens type IV and I. However, an 
increase in adhesion was observed to laminin. The non-metastatic cell line displayed an 
increase in adhesion to the ECM proteins, fibronectin, collagens type IV and I. A decrease 
in adhesion was also observed to laminin. Altered integrin expression on these cell lines 
was determined by flow cytometry. The metastatic cell line displayed a higher expression 
of α6 (binding to laminin). The non-metastatic cell line highly expressed integrins α3 
(collagen), α5 (fibronectin) and integrins β1 and β3. 
 
Adhesion of the pancreatic clonal populations of MiaPaCa-2 to the ECM proteins, 
matrigel, laminin, fibronectin and collagens type IV and I, was investigated. The results in 
this thesis agree in part with the above findings, whereby the highly invasive cell line 
Clone #3 displayed significantly reduced adhesion to matrigel, fibronectin, laminin and 
collagen type IV. The low invasive cell line, Clone #8, exhibited a significant increase in 
adhesion to matrigel and laminin. Adhesion to fibronectin and collagen type I was also 
increased, though not significantly. Adhesion to the ECM proteins, especially fibronectin 
and laminin represents an important step in metastasis (Shaw et al., 1996).  
The effect of anoikis in our pancreatic cell line model was also investigated to determine 
whether detachment from cell-cell or cell-ECM/adherent matrix had an effect on cell 
survival. Clone #3 displayed increased resistance to anoikis, while Clone #8 displayed 
significant sensitivity to anoikis compared to the parental cell line. Transformed cells 
often display anchorage independent growth that results in increased motility and 
invasion. Changes in cell morphology are common characteristics of malignant 
transformation in many tumour cells. A feature of transformation is the ability of the cells 
to grow in the absence of cell anchorage, as revealed by their ability to grow in soft agar. 
To determine whether anoikis patterns correlated with the ability of the cell lines, 
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MiaPaCa-2, sub-populations, Clone #3 and Clone #8 to grow in an anchorage-independent 
environment, the in vitro soft agar assay was used. Clone #3 showed an increased ability 
to form colonies compared to the parental cell line. Clone #8 displayed a significant 
reduction in colony formation.  
Previous studies in other cancer types have also shown a correlation between increased 
invasion, decreased adhesion, resistance to anoikis and anchorage independent growth. 
Minard et al. (2006) demonstrated a relationship between reduced cellular adhesion and 
resistance to anoikis mediated by Tiam1 (T-lymphoma invasion and metastasis gene 1) in 
colon tumour cells. Abraham et al. (2003) showed that prostate cancer cells transfected 
with maspin (a member of the serine protease inhibitor family) displayed decreased 
metastasic potential in vivo and this correlated with increased adhesion to laminin and 
fibronectin, decreased invasion as well as anchorage independent growth in vitro. Zhu et 
al. (2001) selected an anoikis resistant melanoma cell line, which displayed increased 
proliferation and higher invasive and metastatic abilities than the anoikis sensitive parent.  
 
In pancreatic cancer, links have been established between increased invasion and 
decreased adhesion to ECM proteins in vitro and to high metastatic potential in vivo. Satoh 
et al. (2000) reported that MUC-1 expression in S2-013, a human pancreatic cell line 
population of SUIT-2, resulted in increased invasion and motility and decreased adhesion 
to ECM proteins. Duxbury et al. (2004) described that resistance to anoikis facilitates 
tumourigenesis and metastasis in pancreatic cancer studies. Over-expression of certain 
genes, such as CEACAM6 and FAK, are common in pancreatic cancer, and knockdown of 
such genes by siRNA have successfully resulted in increased anoikis. 
 
4.3.2 Role of integrin expression  
Tumour progression and metastasis is associated with changes in a multitude of integrin 
signalling cascades. Transformed cells are often characterised by the loss/reduction of 
integrin expression. ECM-ligand binding to an integrin initiates signals which are 
transmitted via different yet interconnecting pathways and elicit various cell functions 
such as morphological changes, adhesion, migration and gene activation. All of these 
functions take part in the metastatic cascade of tumour progression. Investigations into the 
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role of integrin expression in our pancreatic cancer cell line model were based on the 
variable invasive and adhesive differences to ECM components in the cells. Integrins β1, 
α5 and α6 were investigated (Chapter 3.3) and are associated with binding to fibronectin 
and laminin (Lefcort et al., 1992; Shaw et al., 1996).   
We therefore examined the expression of α2, α5, α6 and β1 integrin receptors in our 
pancreatic cancer cell lines by Western blot and determined whether their expression 
could account for differences in adhesion and invasion. In our model, the integrins β1, α5 
and α6 subunits were over-expressed in the low invasive/high adhesive pancreatic cell line 
Clone #8, suggesting a role for this integrin in increasing adhesion and inhibiting invasion 
in pancreatic cancer. Integrin β1 is the unique partner for α5 and also forms heterodimers 
with integrins α2 and α6.  
 
4.3.2.1 Role of integrin β1 siRNA transfection in Clone #8 cells 
Efficient functional siRNA knockdown of integrin β1 in Clone #8 was determined by 
Western blot. Significantly increased invasion through matrigel and fibronectin was 
observed, but there was no significant change in invasion through laminin. The adhesion 
of this cell line to matrigel and fibronectin were also reduced with treatment of integrin β1 
siRNAs; however no decrease in adhesion to laminin was observed. These results suggest 
that integrin β1 plays a role in the adherence of Clone #8 to matrigel and fibronectin, and 
the knockdown of integrin β1 resulted in reduction of the adhesiveness of the cell line and 
subsequently increased the cells ability to become motile, invade and transverse the 
matrigel coated membrane. We therefore investigated changes in migration in the integrin 
β1 siRNA transfected Clone #8 cells. Motility of the cells was significantly increased due 
to the loss of integrin β1 expression.  
Our results suggest that integrin β1 plays a role in promoting adhesion and inhibiting 
invasion/motility in the Clone #8 population, while the decreased expression of integrin 
β1 in Clone #3 may also contribute to the more invasive phenotype of these cells. 
Ellerbroek et al. (1999) determined that inhibition of integrin β1 through aggregation 
induced pro-activation of MMP-2 in ovarian cancer cells. In fact other studies have 
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reported that anti-integrin β1 antibodies stimulate collagenase activity in keratinocytes 
(Larjava et al., 1993) and melanoma (Seftor et al., 1993).  
The involvement of integrin β1 in anoikis was also investigated by RNAi. Decreasing the 
expression of integrin β1 in Clone #8 revealed a more anoikis resistant phenotype. 
Interaction of the ECM proteins and integrin receptors are known to activate proliferation 
and survival signals. Once ECM-cell or cell-cell detachment occurs, survival mechanisms 
are down-regulated, proliferation ceases and cells undergo anoikis (Frisch and Screaton, 
2001). Our findings suggest that loss of integrin β1 signalling resulted in enhanced 
invasion through matrigel, decreased adhesion to matrigel and increased anoikis 
resistance. These findings correlate with a recent study, which determined that drug 
selected resistant variants of a breast cancer cell line showed increased invasion status and 
anoikis resistance through the loss of integrin β1 expression (Morozevich et al., 2006). 
Integrin β1 expression in melanoma metastases has been shown to forecast a longer 
disease-free period (Vihinen et al., 2000). In prostate cancer the integrin β1 splice variant 
of β1A, β1C, has been shown to inhibit proliferation by regulating the cell cycle inhibitor, 
p27(Kip1). β1C integrin has been shown by immunohistochemistry to be down-regulated 
in prostate cancer cells compared to benign prostate tissue (Fornaro et al., 1996). 
Ramachandra et al. (2002) showed that increased p21 and integrin β1 expression reduced 
colony formation efficiency in soft agar, and that anoikis sensitivity was due to SMAD4 
expression in a SMAD4-transfected cell line, which in turn restores transforming growth 
factor beta (TGF-β) signalling.  
Howlett et al. (1995) established a rapid 3-D assay for discrimination of normal and 
malignant human breast epithelial cells where normal epithelial cells differentiate into 
well-organised acinar structures, whereas tumour cells produce large, disordered colonies. 
Immunocytochemical analysis showed that normal cells expressed integrins α1, α2, α3, 
α6, β1 and β4 integrin subunits, whereas breast carcinoma cells show variable losses, 
disordered expression, or down-regulation of these subunits. Function-blocking analysis 
using anti-β1 or anti-α3 antibodies showed a > 5-fold inhibition of the formation of acinar 
structures by normal cells, whereas anti-α2 or -α6 antibodies had little or no effect. In 
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experiments where collagen type I gels were used instead of basement membrane, acinar 
morphogenesis was blocked by anti-β1 and -α2 antibodies but not by anti-α3. These data 
suggest a specificity of integrin utilisation dependent on the ECM ligands encountered by 
the cell and that loss of proper integrin-mediated cell-ECM interaction may be critical to 
breast tumour formation. 
Plath et al. (2000) demonstrated that p16INK4a induces anoikis via up-regulation of α5β1, 
fibronectin receptor in the pancreatic cell line, Capan-1. Addition of soluble fibronectin 
completely inhibits the p16INK4a mediated anoikis. Further investigations showed that with 
the added addition of a monoclonal integrin α5 antibody, the fibronectin-mediated 
inhibition of anoikis was abolished. Integrin α5 and β1 were up-regulated in our low 
invasive, anoikis sensitive clonal population, Clone #8. This may suggest that by 
inhibiting integrin β1 (unique partner for α5 to form the α5β1 receptor) by siRNA, α5 and 
β1 integrins are unable to partner, and therefore the anoikis induction is lost in our cell 
line model resulting in resistance to anoikis.  
 
4.3.2.2 Role of integrins α5 and α6 siRNA transfection in Clone #8 cells 
Expression of the α5 subunit, which binds to fibronectin, was elevated in Clone #8, the 
less invasive/more adhesive cell line. Functional knockdown of integrin α5 expression by 
siRNA in Clone #8 resulted in a significant increase in invasion through matrigel, laminin 
and fibronectin. The level of motility was also increased after integrin α5 siRNA 
transfection. Adhesion to fibronectin was statistically significantly reduced, while 
adhesion to matrigel and laminin was slightly reduced. Resistance to anoikis was slightly 
increased in integrin α5 siRNA transfected cells compared to Clone #8 cells transfected 
with scrambled siRNA, although not significantly. Our findings confirm other reports 
suggesting that the expression of integrin α5 may be related to loss of tumourigenicity. By 
reducing integrin α5 protein expression, a more invasive, less adhesive, anoikis resistant 
phenotype was observed, similar to the more invasive clone, Clone #3. Recent research 
indicates that altered α5β1 expression may inhibit tumour development and metastasis 
(Felding-Habermann, 2003). Chintala et al. (1996) determined that loss of integrins α3β1 
and α5β1 increased the invasiveness of glioma cells through up-regulation of MMP-2.  
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Hall et al. (1991) examined the incidence of integrin α5β1 in pancreatic cancer sections. 
Pancreatic adenocarcinomas and ampullary tumours showed expression of integrins α2, 
α3, α6 and β1, β4 and the vitronectin receptor (integrin αv associated with integrin β1 or 
β5). However, no staining of integrin α5 was observed. Loss of integrin complex α5β1 
(fibronectin receptor) facilitates the tumourigenicity of transformed colon cells. The 
capacity to form tumours in nude mice was significantly lower for α5 positive than α5 
negative clones of the cell line, HT 29 (Stallmach et al., 1994). Giancotti and Ruoslahti 
(1990) showed that in transformed CHO cells, co-expression of integrin α5 and β1 made 
the cells non-tumourigenic.   
We also characterised the involvement of integrin α6, which functions as an adhesive 
receptor for laminin (Mercurio et al., 1995). We functionally knocked down integrin α6 
expression. Invasion assays showed a moderate increase in invasion through matrigel and 
laminin; however, invasion through fibronectin was significantly increased. Adhesive 
properties to laminin were reduced (20-34%), while adhesion to matrigel and fibronectin 
were unchanged. Resistance to anoikis was unaltered suggesting that loss of integrin α6 
results in increased invasion, with decreased adhesion to laminin and no change in anoikis. 
The role of integrin α6 in our pancreatic cancer cell line model may be more associated 
with interactions with specific components of the ECM. The expression and distribution 
patterns of integrins and ECM molecules in chronic pancreatitis (CP) and pancreatic 
adenocarcinoma (PC) compared with normal pancreas (NP) were investigated by 
Shimoyama et al. (1995). Integrins α2, α3, and α6 were strongly expressed and diffuse, 
while no α5 expression was seen in PC. Continuous staining in CP was observed in the 
basement membrane (BM), whereas it showed discontinuous/absent staining in PC with 
anti-collagen type IV, laminin, and vitronectin antibodies. Some carcinoma cells showed 
reverse correlation between expression of integrins α2, α3, and α6 and type IV collagen 
and laminin expression. Weinel et al. (1992) studied the expression of integrins α2, α3, 
α5 and α6 by IHC in tissue samples from ductal PC, CP, NP and in 8 cell lines of ductal 
human pancreatic cancer. Pancreatic carcinoma showed intense staining for integrins α2 
and α6 with redistribution, which may reflect a loss of spatial arrangement of tumour cells 
and their ability to interact randomly with extracellular matrix structures during invasion 
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and metastasis. Furthermore, adhesion assays on purified extracellular matrix (ECM)-
compounds were used to define the function of α2, α3, α5 and α6 in pancreatic cancer 
cell lines (PC 3 and PC 44). Monoclonal antibodies (MAbs) against α6 (GoH3) inhibited 
tumour-cell adhesion to laminin (52%-86%) in both cell lines. These results suggest that 
α6 is a laminin-binding site in pancreatic cancer cells. Weinel et al. (1995) performed in 
vitro adhesion, migration, and invasion experiments to investigate the role of α6 in 
pancreatic cancer. Integrin α6 was differentially expressed in NP and PC. 
Immunoprecipitation of different pancreatic carcinoma cell lines revealed that integrin α6 
was expressed together with the β4 subunit as α6β4 complex. However, adhesion of 
pancreatic cancer cells to laminin was inhibited by anti-α6 and anti-β1 integrin antibodies 
but not by anti-β4 integrin antibodies. Migration of the cells through laminin was almost 
completely inhibited by anti-β1 antibody but not by other anti-integrin antibodies. Tumour 
cell invasion through a matrigel was only slightly inhibited by anti-α6 antibodies. In 
contrast, a marked inhibition was observed using anti-β1 antibody, anti-α2, anti-α5 
antibodies, and RGDS. We have also shown that the integrin α6 is a laminin adhesion 
receptor in pancreatic carcinoma cells, and could possibly be involved in tumour invasion 
and adhesion through the basement membrane. 
 
4.3.3 Drug resistance 
To characterise the relationship between invasion and drug resistance, toxicity assays were 
carried out using a panel of ten chemotherapeutic drugs. The IC50 values of each of the 
chemotherapeutic agents were determined for the parental line and its sub clones, Clone 
#3 and Clone #8 (Chapter 3.3.7, table 3.3.1). Clone #3 exhibited a significantly higher 
level of resistance to taxotere and VP-16, while resistance levels to epirubicin, adriamycin 
and vincristine were also increased compared to MiaPaCa-2. No increase in resistance was 
observed for 5-FU, taxol, cisplatin and carboplatin. Interestingly, a significant sensitivity 
to gemcitabine was observed.  
The general drug resistance of Clone #3 was in fact quite small, less than 2-fold however 
this level of inherent resistance may have important implications in vivo. Clinically, many 
patients develop drug resistance, where the tumour resistance is approximately 3- to 6-fold 
(Wolf et al., 1987). Therefore, the study of low level resistance in invasive tumours may 
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be more relevant than the study of acquired resistance after long term exposure to 
chemotherapeutic agents (Belvedere et al., 1996). Clone #8 displayed an increase in 
sensitivity to all ten chemotherapeutic drugs compared to the parental cell line. 
An important aspect of the toxicity profile of Clone #3 and Clone #8 compared to the 
parental cell line may be the cross-resistance to chemotherapeutic agents of the same 
family. Clone #3 showed no resistance to the platinum family, cisplatin and carboplatin. 
The main mechanisms of resistance to platinum compounds are decreased cellular 
transport of the drug, enhanced repair of platinum-related DNA damage, absence of 
mismatch repair and increased expression of glutathione and glutathione-S-transferase. 
However, Clone #8 displayed a significant sensitivity to the platinum family; this may 
suggest that there may be a more defined link between low invasion and inherent platinum 
sensitivity compared to the high invasion and lack of platinum resistance status of Clone 
#3. Interestingly, Clone #3 and Clone #8 are sensitive to gemcitabine and 5-fluorouracil. 
These drugs are members of the anti-metabolite family; both drugs have similar molecular 
structures, mechanisms and metabolic characteristics. Recent pharmacogenetic studies 
focuses on genes encoding proteins directly involved in anti-metabolite activity, showing 
the role of thymidylate synthase and human equilibrate nucleoside transporter-1 as 
prognostic factor in 5-FU and gemcitabine treated patients, respectively (Giovannetti et 
al., 2006). Gemcitabine and 5-FU interfere with DNA and RNA synthesis; however, the 
drugs target multiple mechanisms, therefore resistance to either drug is multifactorial. 
Clone #3 showed significant increased sensitivity to gemcitabine compared to Clone #8. 
This may suggest that the toxicity potential of gemcitabine is exerted more efficiently to 
invasive pancreatic cancer cells. 
Clone #3 displayed a typical multidrug resistance (MDR) phenotype, whereby increased 
resistance was observed for taxotere, VP-16, epirubicin, adriamycin and vincristine 
compared to MiaPaCa-2 parental cells. These drugs are substrates for P-gp and MRP-1, 
which are drug efflux pumps that mediate drug transport from the cell. However, no 
inherent resistance was observed for taxol. Taxotere and taxol are microtubule inhibitors 
belonging to the family of taxanes. The two taxanes share major part of their structure and 
mechanisms of action, but differ in other aspects. There are differences in their tubulin 
polymer generation and taxotere is twice as active in the inhibition of depolymerisation. 
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Ishitobi et al. (2001) demonstrated the treatment of resistant metastatic breast cancer, 
whereby, resistance to anthracycline and taxotere could be successfully treated with taxol. 
In vitro studies have also confirmed the lack of cross-resistance between the taxanes, and 
that some human tumour cell lines resistant to taxol are not resistant to taxotere; thus, 
resistance to taxol does not automatically indicate resistance to taxotere (Untch et al., 
1994). The clinical implications for the results in this thesis suggest that treatment with 
chemotherapeutic drugs could potentially select for the invasive cells. However, the 




In summary, this chapter discusses the occurrence of sub-populations within a pancreatic 
cancer cell line, displaying variable invasion abilities and correlates the invasive 
phenotype with malignant transformation. Clone #3 displayed an inherent increased 
invasive potential, high motility, distinct reduction in adhesion to ECM proteins, anoikis 
resistance, and the ability to form colonies in soft agar. Integrins β1, α5 and α6 were 
undetectable in this cell line by Western blot, suggesting a role for the loss of their 
expression in invasion and adhesion in pancreatic cancer. Functional knockdown of 
integrins β1, α5 and α6 protein expressions in Clone #8 revealed a more aggressive 
phenotype with increased invasive and motility abilities corresponding to a decrease in 
cell attachment to ECM. The role of integrins in anoikis was less clear, as integrin β1 
knockdown significantly increased anoikis resistance. However, loss of either integrins α5 
or α6 revealed no significant change in the induction of anoikis. Clone #3 corresponding 
to the more invasive/less adhesive phenotype, displayed increased drug resistance 
compared to the parental cell lines, whereas Clone #8, corresponding to the low 
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4.4 Proteomic analysis of MiaPaCa-2 and sub-populations, Clone #3 
and Clone #8 grown on matrigel 
 
Characterisation of MiaPaCa-2, Clone #3 and Clone #8, previously determined a 
relationship between invasion and the malignant transformation. Differing invasive 
abilities within the cells corresponding to an aggressive phenotype is a complex process, 
requiring an organised interaction between proteins, signalling pathways and genetic 
mutations. The tumour microenvironment plays an essential role in cancer progression, 
invasion and metastasis. The microenvironment consists of many features including 
stromal fibroblasts, inflammatory cells, vasculature components, normal epithelial cells 
and the extracellular matrix (ECM). Tumour-tumour cell interaction, tumour-stromal cell 
interaction, as well as tumour-ECM interaction, all contribute to "cross-talk" among 
tumour cells through the release of growth factors, cytokines, proteases, and other 
bioactive molecules (Ariztia et al., 2006). Therefore, to stimulate the interaction of 
MiaPaCa-2, Clone #3 and Clone #8 to the ECM, the cells were grown on matrigel 
(reconstituted ECM) for 24 hrs prior to analysis. Proteomic analysis was applied to 
investigate crucial events underlying in vitro pancreatic cancer invasion tumourigenesis 
and to exploit this knowledge for early detection and better intervention. 
 
4.4.1 Generation of protein lists 
Three lists of differentially expressed proteins between MiaPaCa-2 versus Clone #8 (list 
1), Clone #3 versus MiaPaCa-2 (list 2) and Clone #3 versus Clone #8 (list 3) were 
established. The generated protein lists and analysis was from high to low invasion status 
of the cell lines. Therefore, in order to further determine the significance of these 
differentially changed proteins, the design analysis was laid out to specifically identify 
proteins that were consistently altered (either up-regulated or down-regulated) 
corresponding with the invasion status of the cell lines.  
The three generated differentially expressed protein lists were overlaid, determining 
unique and common expressing proteins between lists. Common proteins consistently 
expressed (positively or negatively) between all three lists, associated with the invasive 
position of the cells were determined (Chapter 3.4, table 3.4.7). 
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4.4.2 Invasion specific proteins chosen for siRNA functional analysis 
Three proteins were chosen for siRNA silencing based on specificity to invasion in our 
proteomic profiling results (Chapter 3.4), relevance to cancer/invasion in the literature, 
fold difference and p-value. Table 4.4.1 summarises fold difference between each 
comparison to the chosen target proteins. 
 
Table 4.4.1 Proteins commonly and consistently expressed between the 
comparisons, MiaPaCa-2 vs Clone #8, Clone #3 versus MiaPaCa-2 and 
Clone #3 versus Clone #8 chosen for further analysis 
Protein Description MiaPaCa-2 
vs Clone #8 
Clone #3 vs 
MiaPaCa-2 
Clone #3   
vs Clone #8 
ALDH1A1 Aldehyde dehydrogenase 1A1 5.3 1.7 8.9 
VIM Vimentin 2.2 2.6 5.5 
STIP1 Stress-induced phosphoprotein 1 1.3 1.5 2.0 
 
There is increasing evidence that siRNAs can affect the expression of multiple genes 
(Jackson et al., 2003). These non-specific results are termed “off-target” effects; therefore 
it is vital that appropriate controls are used during siRNA experiments. In our analysis, 
each set of siRNA experiments included accurate controls of siRNA target sequencing, in 
each experiment the siRNA targeted the same mRNA using three different siRNA 
sequences. Consequently, any changes induced by one siRNA and not the other two could 
be attributed to off-target effects and multiple non-homologous siRNAs are most likely to 
be responsible for specific target suppression/knockdown. Three non-homologous 
ALDH1A1, VIM and STIP1 siRNAs were used in this set of experiments, each targeting 
different regions of the transcript.  
Western blots were used to analyse the efficiency of target siRNA knockdown of protein 
expression in our model; however, it is worth noting the role of monitoring mRNA 
knockdown validation. With an effective siRNA, target reduction should be observed at 
both protein and mRNA level, however, this may not always be true. Reduction in mRNA 
levels without corresponding reduction in protein levels could indicate slow protein 
turnover. Pai et al. (2006) demonstrated that the targeting of proteins with a long half-life 
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may not produce the desired phenotypic effect because silencing at the level of 
transcription will not affect pre-existing proteins, suggesting further optimisation of time 
points may be required.  In contrast, protein reduction without a decrease in mRNA could 
signify a siRNA mediating its effects at the translational level as microRNA (miRNA). 
siRNAs trigger mRNA degradation through the RNAi pathway, however, miRNA can 
inhibit translation without affecting mRNA levels.  
Appropriate controls were used during each siRNA experiment; comparing non-treated 
control to scrambled siRNA (nonsense target) treated cells revealed changes specifically 
caused by siRNA delivery ensuring that siRNA results are due to efficient targeted RNAi 
molecules and not an artefact of the delivery. siRNA delivery through transfection can 
result in temporary changes in the cell, and in some cases cells may become resistant to 
conditions of delivery, to further ensure optimal target knockdown siPORT™ NeoFX™, a 
lipid-based agent was used to minimise serum RNase digestion of siRNA and to maximize 
delivery of siRNA to the cells. 
All experiments also included efficient transfection control/positive control, kinesin 11 
(Kif11). Kinesin facilitates cellular mitosis, therefore silencing kinesin causes cellular 
arrest. Weil et al. (2002) showed that a siRNA targeting the mRNA of the Kif11 induces a 
rapid mitotic arrest and provides a convenient assay for the optimisation of siRNA 
transfection in mammalian cells. Examination of cell morphology and reduced cell 
proliferation after transfection indicated a successful transfection. 
The duration of gene silencing varies greatly between cells with slow growing cells still 
showing the effects of siRNA after several weeks, but more rapidly dividing cells not 
seeing an effect for longer than 1 week (Ryther et al., 2005). This was important to 
consider when choosing time points for protein, invasion, adhesion, and anoikis assays. 
All assays were carried out within a maximum of 72 hrs post transfection. Proliferation 
and chemosensitivity assays were carried out within 5 days of the initial transfection to 





 297  
4.4.3 Aldehyde dehydrogenase 1A1 (ALDH1A1) 
Aldehyde dehydrogenase 1A1 (ALDH1A1) is an enzyme, belonging to the aldehyde 
dehydrogenase family of proteins which are involved in the conversion of aldehydes to 
their corresponding acids by NAD(P)+ dependent reactions (Yoshida et al., 1998). Three 
major liver isoforms of this enzyme exists, cytosolic (1), mitochondrial (2), cytosolic and 
mitrochondrial (3) and can be distinguished by their electrophoretic mobilities, kinetic 
properties, and subcellular localisations. ALDH1A1 is a cytosolic enzyme ubiquitously 
distributed in many tissues, including brain (Bhave et al., 2006) and red blood cells 
(Collard et al., 2007). 
 
ALDH1A1 was chosen as a target for siRNA based on the comparative proteomic data 
analysis which compared protein expression in MiaPaCa-2, Clone #3 and Clone #8. 
ALDH1A1 was expressed at higher levels in the parent MiaPaCa-2 than Clone #8 (5.3-
fold) and at higher levels in Clone #3 compared to either the parent or Clone #8 (1.7- and 
8.9-fold, repectively). As the comparisons generated were from high to low invasion, the 
overall status of ALDH1A1 expression is increasing as the invasive status of the cell lines 
increase. Validation analysis was carried out by Western blot and results confirmed that 
Clone #3 showed the highest expressed of ALDH1A1. 
 
4.4.3.1 Effect of ALDH1A1 siRNA in Clone #3 
RNAi technology was used to study ALDH1A1 protein expression; therefore, using three 
independent ALDH1A1 siRNA target sequences, ALDH1A1 protein expression was 
specifically down-regulated in Clone #3 cells and its role in invasion, adhesion, anoikis, 
proliferation and drug resistance was investigated. 
We suggest that as our model has significant altered ALDH1A1 expression consistently 
correlating with differences in invasion, ALDH1A1 may potentially play a role in 
pancreatic cancer invasion and the transformed phenotype. Invasion assays performed 48 
hrs post-transfection showed significant inhibition of invasion in Clone #3 cells. The 
invasive abilities of the ALDH1A1 siRNA (3) transfected Clone #3 cells were reduced up 
to 2.8-fold compared to scrambled control cells.  
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Adhesion to matrigel was significantly increased (23-32%) after knockdown of 
ALDH1A1 protein expression in Clone #3 cells. Anoikis sensitivity was only induced by 
ALDH1A1 siRNA (3); the two other ALDH1A1 siRNA targets did not have an effect on 
anoikis. This result may suggest that the role of ALDH1A1 in anoikis is unclear and 
further analysis may need to be carried out to determine its involvement. 
Proliferation assays of ALDH1A1 siRNA transfected Clone #3 cells carried out over 5 
days, determined that loss of ALDH1A1 does not affect cell growth in Clone #3 cells. 
Recent studies have reported that ALDH1A1-/- mice do not exhibit defects in growth and 
survival (Molotkov et al., 2002) or obvious developmental defects in the retina or other 
tissues (Fan et al., 2003).  
 
Difference in drug resistance was also previously observed in our characterisation of the in 
vitro invasive pancreatic cancer cell line model (Chapter 3.3.7). Clone #8 was 
significantly sensitive to a panel of 10 chemotherapeutic drugs tested (Table 3.3.1). Recent 
research has determined a relationship between ALDH1A1 expression and resistance to 
certain chemotherapeutic drugs. To investigate this phenomenon further, we established 
the relative IC50s of MiaPaCa-2, Clone #3 and Clone #8 to 4-hydroxycyclophosphamide 
(4-HC), masfosfamide, 4-diethylaminobenzaldehyde (DEAB) and all-trans retinoic acid. 
ALDH1A1 activity in cancer has been found to be responsible for resistance to 
oxazaphosphorines such as cyclophosphamide. Cyclophosphamide (CPA), an alkylating 
agent, is one of the most widely used drugs in the treatment of breast cancer. CPA is 
metabolised by enzymes in the liver, so its preactivated form, 4-HC and mafosfamide, a 
preactivated cyclophosphamide analogue were used in in vitro chemosensitivity assays. 
Our results show that ALDH1A1 expression correlated with resistance of these drugs. 
Clone #3 was more resistant to 4-HC and mafosfamide than MiaPaCa-2 or Clone #8. 
Although many other molecular enzymes are involved in CPA resistance we showed that 
RNAi-mediated knockdown of ALDH1A1 sensitised Clone #3 cells to the toxic effects of 
4-HC. This result supports numerous studies indicating ALDH1A1s involvement in CPA 
resistance. Sladek et al. (2002) showed by a retrospective study that the ALDH1A1 
expression level was higher in metastatic tumours that did not respond to CPA-based 
treatment than those that did respond to the regime.  
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ALDH1A1 expression has also been reported in lung cancer cell line, A549, where its 
expression along with ALDH1A3 was knocked down by RNAi and determined to mediate 
CPA resistance (Moreb et al., 2007). However, our findings are the first report to show 
ALDH1A1 mediates 4-HC resistance in pancreatic cancer.  
Although no direct evidence exists linking ALDH1A1 mediated drug resistance, invasion 
and the malignant phenotype, studies have shown that increased drug resistance may also 
increase invasion in certain cancers. Liang et al. (2004) used pulse-selections to induce 
drug resistant variants of the lung cancer cell line, DLKP. The cell line was exposed to 
VP-16, vincristine, taxotere, mitoxantrone, 5-fluorouracil, methotrexate, CCNU, BCNU, 
cisplatin and chlorambucil, resulting in resistance to the selecting agents and, in some 
cases, cross-resistance to methotrexate, vincristine, adriamycin and taxotere. A marked 
increase in in vitro invasion and motility was observed with variants pulsed with 
mitoxantrone, 5-fluorouracil, methotrexate, BCNU, cisplatin and chlorambucil suggesting 
that drug exposure may induce not only resistance but also invasiveness in cancer cells. 
Drug selection of RPMI 2650, a non-invasive human nasal epithelium cell line, with the 
chemotherapeutic agents, paclitaxel and melphalan, resulted in multiple drug resistant 
phenotypes and in the case of melphalan but not paclitaxel, a highly invasive phenotype 
(Liang et al., 2001). Glynn et al. (2004) established drug resistant variants using 
doxorubicin and paclitaxel pulse-selection method of an in vitro invasive clonal 
population of the human breast cancer cell line, MDA-MB-435S. A novel 'superinvasive' 
phenotype was observed; this phenotype was characterised by an ability to relocate to 
another surface following invasion through matrigel and membrane pores, by decreased 
adhesion to extracellular matrix proteins and by increased motility. 
 
To further develop our hypothesis linking ALDH1A1 expression and increased invasion in 
pancreatic cancer, we studied the effects of all-trans retinoic acid (ATRA) on Clone #8 
and Clone #3. ALDH1A1 was shown to be 9-fold up-regulated in Clone #3 compared to 
Clone #8 by proteomic profiling. Cells were exposed to ATRA every 72 hrs, as studies 
have shown that ATRA is degraded in vitro every 48-72 hrs.  
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ALDH1A1 is involved in the irreversible oxidisation of retinal to retinoic acid (Duester, 
1996). Retinoic acid (RA) is an acidic derivative of Vitamin A and regulates cell 
differentiation, growth inhibition and apoptosis in many cell types (De luca, 1991). The 
differentiation and anti-proliferative effects of RA has been established in cervical cancer 
(Borutinskaite et al., 2006), hepatoma (Li and Wan, 1998) and breast cancer (Lopez-
Boado et al., 1994). RA inhibits cell proliferation but induces scattering and invasion of 
the pancreatic cancer cell line, Capan-1, through c-met up-regulation (Leelawat et al., 
2004) and also been shown to inhibit adhesion to laminin in pancreatic cancer cells 
through the α6β1 integrin receptor (Rosewicz et al., 1997).  
 
Clone #3 is 2.7-fold more resistant to ATRA than Clone #8, however, ALDH1A1 may not 
involved in the anti-proliferative effects of ATRA. The biological actions of ATRA and 
derivates are mediated by the retinoic acid receptor (RAR) and retinoid X receptor (RXR)  
each with α, β γ isoforms, which are ligand dependent transcription factors expressed in 
the nucleus of cells (Chambon, 1996). These homodimers and heterodimers receptors, 
then bind to specific RA response elements (RARE), and regulate positive/negative 
transcription activities of target genes. ATRA inhibits proliferation of gastric cancer cells 
by up-regulating RARα expression (Liu et al., 2001) and induced G1 cell cycle arrest in 
breast cancer cells (Wilcken et al., 1996) and apoptosis (Mangiarotti et al., 1998). These 
events require ubiquitylation and degradation of Skp2, an F-box protein that targets 
p27Kip1 for degradation and cyclin D (Dow et al., 2001). 
 
RA metabolites are currently used in treatment of colon cancer (Park et al., 2007) and 
leukemia (Huang et al., 1988). Studies have also confirmed the ability of RA to inhibit 
invasion by decreasing expression of proteolytic enzymes and motility factors in 
melanoma cells (Hendrix et al., 1990; Wood et al., 1990) and colonic cancer cells (Park et 
al., 2007). Therefore, conflicting results exist and there is a need for further study into the 
presence of high ALDH1A1 activity, retinoic acid and cancer cell invasion. 
We hypothesised that accumulation of ATRA intracellularly in Clone #3 may reduce 
ALDH1A1 expression and therefore lead to decreased invasion of the cells by a possible 
negative feedback loop. However, we did not observe any decrease in ALDH1A1 protein 
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expression after 5 µM ATRA exposure for 48 hrs or long-term continuous exposure. 
Previous studies have shown that ATRA treatment can decrease ALDH1A1 protein 
expression and enzyme activity, but not corresponding mRNA. This observed decrease 
resulted in a significant increase in toxicity in treated lung cancer cells to 4-HC and 
acetaldehyde, indicating a post-translational mechanism, involving the ubiquitin-
proteasome pathway, through which ATRA decreases ALDH1A1 expression (Moreb et 
al., 2004).  
The lack of ATRA effect on Clone #3 cells may be due to the inherent resistance of these 
cells to ATRA. Although the use of RA is valid in the clinical setting, many cancer cells 
exhibit resistance (Lotan and Nicolson, 1979). ATRA-resistant breast cancer cell lines are 
generally negative for the expression of estrogen receptor-α (ERα) (Fontana, 1987) and 
have low levels of RARs, particularly RARα (Schneider et al., 2000). Tari et al., (2002) 
showed that HER2 over-expression in breast cancer cell lines exhibited resistance to 
ATRA. In pancreatic cancer, Pettersson et al. (2002) reported the involvement of the Bcl-
2 family of proteins in ATRA resistance. Over-expression of Bcl-2 resulted in inhibition 
of apoptosis induced by retinoic acid. Kaiser et al. (1998) reported loss of RARγ 
expression in two pancreatic cancer retinoid-resistant cell lines, suggesting RARγ as a 
predictive marker for retinoid treatment of pancreatic cancer.  
However, Clone #8 (low invasion) cells displayed increased invasion and displayed 
morphological changes of elongated spindle shaped cells after continuous treatment with 
ATRA. Leelawat et al. (2005) determined that the pancreatic cancer cell line, Capan-1 
displayed increased invasion through matrigel after ATRA treatment. The increase in 
invasion of these cells correlated with an up-regulation of c-Met (mesenchymal epithelial 
transition factor), a proto-oncogene that encodes for a tyrosine kinase membrane receptor 
for hepatocyte growth factor/scatter factor (HGF/SF).  
These results suggest that increased ALDH1A1 expression in Clone #3 could potentially 
contribute to the invasive phenotype by the production of RA. 
 
The role of ALDH1A1 activity as a marker for hematopoietic progenitor stem cells is well 
established (Kastan et al., 1990). ALDH1A1 activity appears to be responsible for the 
resistance of hematopoietic progenitor stem cells (HSCs) to cyclophosphamide and 4-
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hydroxyperoxycyclophosphamide (Sahovic et al., 1988). Therefore, these drugs are used 
in purging regimens for autologous bone marrow transplants, as HSCs are capable of 
repopulation (Yeager et al., 1986). Storms et al. (1999) described a fluorescent substrate 
of ALDH (termed Aldefluor) that can be used to isolate cells with increased ALDH 
activity by fluorescence-activated cell sorting (FACS). The substrate is an amino 
acetaldehyde molecule conjugated to a BODIPY (4, 4-difluoro-5, 7-dimethyl-4-bora-3a, 
4adiaza-5-proprionic acid) fluorochrome that is metabolised by ALDH to an aminoacetate 
anion, retained within the cell because of its negative charge. Thus, the amount of 
fluorescent product that accumulates in viable cells correlates to ALDH activity, and cells 
with high ALDH activity can be selected from human umbilical cord blood (UCB). 
Therefore, isolation of stem and progenitor cells based on ALDH activity also represents a 
novel tool to explore the heterogeneity of selected stem cells.  
Cancer stem cells (CSCs) are a distinct sub-population within a tumour that has self-
renewing properties. The existence of CSCs was verified in myelogenous leukaemia 
(Bonnet et al., 1997), breast (Al-Hajj et al., 2003) and brain tumours (Hemmati et al., 
2003). More recently, Li et al. (2007) identified a highly tumourigenic sub-population of 
pancreatic cancer stem cells expressing the cell surface markers CD44, CD24, and 
epithelial-specific antigen (ESA) using a xenograft model in which primary human 
pancreatic adenocarcinomas were grown in immunocompromised mice. Pancreatic cancer 
stem cells with the CD44(+)CD24(+)ESA(+) phenotype (0.2-0.8% of pancreatic cancer 
cells) had a 100-fold increased tumourigenic potential compared with nontumourigenic 
cancer cells. The CD44(+)CD24(+)ESA(+) pancreatic cancer cells, in an orthotopic 
pancreatic mouse model, showed the stem cell properties of self-renewal, the ability to 
produce differentiated progeny, and increased expression of the developmental signalling 
molecule sonic hedgehog (sHh). Feldmann et al. (2007) showed that blockade of Hh by 
cyclopamine treatment in pancreatic cancer significantly reduced invasion in vitro. 
However, in vivo, cyclopamine had no significant effect on primary tumour mass but had 
profound effect on the tumour metastasis of orthotopic xenograft pancreatic cancer mouse 
model. Furthermore, cyclopamine reduced the expression of ALDH (3-fold) in vitro, 
suggesting existence of a sub-population dependent on Hh and therefore, more sensitive to 
cyclopamine specific Hh inhibition. The authors also implied that cyclopamine may 
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inhibit the functional abilities of invading cells through down-regulation of EMT or by 
preferentially targeting the minor proportion of cells capable of tumour initiation within 
the tumour mass, without reducing overall invasive capacity.  
These recent reports along with our own findings linking the expression of ALDH1A1 
with pancreatic cancer cell invasion and drug resistance may warrant further studies as 
identification of pancreatic cancer stem cells markers and further elucidation of the 
signalling pathways that regulate their growth and survival may provide novel therapeutic 
approaches to treat pancreatic cancer, which is highly invasive and metastatic with 
inherent chemotherapy resistance. 
 
4.4.4 Vimentin 
Vimentin (VIM) is the main member of the intermediate filaments (IF) of mesenchymal 
cells and is frequently used as a developmental marker for cells and tissues. IFs are 
important structural features within the cell and along with microtubules, and actin 
microfilaments, make up the cytoskeleton. IF networks form a physical link between the 
plasma membrane and nuclear envelope of the cell (Georgatos et al., 1987) and have been 
suggested to play a role in intracellular transport and signal transduction to the nucleus. 
Vimentin shows a high degree of sequence homology between species (Schaffeld et al., 
2006), indicating an important and evolutionary conserved physiological function. 
Essentially, vimentin is responsible for maintaining cell shape, integrity of the cytoplasm, 
and stabilising cytoskeletal interactions (Goldman et al., 1996). 
 
VIM was chosen as a target for siRNA based on the comparative proteomic data analysis 
which compared protein expression in MiaPaCa-2, Clone #3 and Clone #8. VIM was 
expressed at higher levels in MiaPaCa-2 compared to Clone #8 (2.2-fold), VIM was 2.5-
fold up-regulated in Clone #3 versus MiaPaCa-2 and in the comparison of Clone #3 versus 
Clone #8, VIM was 5.5-fold up-regulated. As the comparisons generated were from high 
to low invasion, the overall status of vimentin expression is increasing as the invasive 
status of the cell lines increase.  
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4.4.4.1 Effect of VIM siRNA in Clone #3 
VIM has a long half-life of 15-17 hrs (Podolin and Prystowsky, 1991) and studies have 
demonstrated that siRNA targeting of proteins with a long half-life may not produce the 
desired phenotypic effect because silencing at the level of transcription will not affect pre-
existing proteins (Pai et al., 2006). However, Western blot analysis of Clone #3 cells 
transfected with VIM siRNA showed efficient protein knockdown. 
Chiu and Goldman (1984) studied the kinetics of synthesis and protein turnover in VIM, 
and observed a fast-decaying pool with a half-life of 12–18 h contributed about 40% of the 
total activity. A major portion, about 60%, however, decayed much more slowly, 
exhibiting a half-life of about 8 days. This may suggest that post-translational 
modifications (phosphorylation) of selective vimentin pools may result in different rates of 
turnover. Several isoforms of VIM were identified in our proteomic analysis. 
Phosphorylation and reorganisation of the vimentin network have been implicated in 
mediating smooth muscle contraction, cell migration and cell mitosis (Li et al., 2006). 
 
Invasion assays carried out 48 hrs after VIM siRNA transfection in our high invasive cell 
line, Clone #3, showed a significant decrease in the total number of invading cells 
(Chapter 3.4.6). Studies of many carcinomas have shown that VIM expression is related to 
high invasion.  
Gilles et al. (1996) showed that VIM expression in vivo is associated with high invasive 
and migratory potential in cervical carcinomas. Furthermore, VIM expression correlates 
with poor prognosis (Kim et al., 2004) and poor survival in breast cancer (Domagala et 
al., 1990). However, another study reported contradictory evidence, Seshadri et al. (1996) 
determined that VIM expression was associated with several features of tumour 
aggressiveness; yet, expression was not associated with increased in risk of relapse or 
death from breast cancer. Nevertheless, the consensus from literature suggests that VIM 
expression is related to high invasive abilities (Sommers et al., 1992; Polette et al., 1998). 
Hendrix et al. (1997) showed the in vitro invasive potential was decreased after 
transfection VIM antisense into MDA-MD-231, a highly invasive, VIM positive cell line. 
These results, along with our own, suggest VIM plays a functional role in cancer cell 
invasion.  
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The functional relationship of VIM expression in our invasive Clone #3 cells, and the 
epithelial to mesenchymal transition (EMT) of the malignant phenotype, was further 
characterised by adhesion, anoikis and proliferations assays.  
Adhesion of VIM siRNA transfected Clone #3 cells to matrigel was significantly 
increased in two out of three independent VIM siRNA targets. These results suggest that 
silencing of VIM expression increases the cells ability to interact with ECM proteins. Loss 
of the epithelial phenotype and disruption of adhesion molecules is a hallmark in the 
epithelial-mesenchymal transition (EMT) reported in several types of cancer. VIM, a 
mesenchymal marker has been implicated in epithelial to mesenchymal transition (EMT) 
in pancreatic cancer (Jungert et al., 2007; Yang et al., 2006). EMT is a process initially 
seen in the development of the embryo, whereby cells lose epithelial characteristics and 
gain a mesenchymal phenotype such as increased invasion and motility. Recent research 
has shown that EMT may be an important factor in cancer progression; epithelial-derived 
tumour cells switch properties to a more mesenchymal phenotype facilitating tumour 
invasion and metastasis. The epithelial state is characterised by E-cadherin expression 
(Ozawa et al., 1990) and cytokeratin expression, such as cytokeratin 18 (Brabletz et al., 
2001). Nakajima et al. (2004) immunohistochemically examined the expression of VIM, 
N- and E- cadherin in pancreatic cancer tissue specimens. In epithelial cells, the loss of E-
cadherin and the increase in N-cadherin expression results in a metastatic phenotype. VIM 
expression was observed in a few cancer cells of pancreatic primary tumours but was 
substantially expressed in liver metastasis of pancreatic tumours. 
McInroy and Määttä (2007) determined that cell adhesion to fibrilliar collagen was 
reduced in VIM siRNA transfected MDA-MD-231 cells; however, VIM knockdown did 
not have an effect on adhesion of SW480 cells. This suggests that the effect of VIM on 
adhesion may be cell specific and that cells that have retained expression of keratins could 
circumvent the requirement of VIM for adhesion. Bühler et al. (2005) transfected the 
human KRT18 gene into MDA-MB-231 cells, which displayed an up-regulation of 
adhesive proteins, dramatic reduction of in vitro invasion and in vivo tumourigenicity. 
Schaller et al. (1996) determined that elevated KRT18 protein expression indicates a 
favourable prognosis in patients with breast cancer. It is interesting to note, that in our 
proteomic analysis, Clone #8 (low invasive cell line) expressed 2.9-fold higher levels of 
 306  
KRT18 compared to Clone #3 (high invasive cell line). The relationship between VIM and 
KRT18 was further described by Thomas et al. (1999), and this study concluded that dual 
expression of KRT18 and VIM in relative amounts characterised breast tumours with the 
poorest prognosis. Melanoma cells transfected with cDNAs for KRT18 and KRT8 co-
expressed VIM, showed increased invasion and migration in vitro and displayed increased 
cytoskeletal interactions at focal contacts within extracellular matrices involving integrin 
cell signaling events (Chu et al., 1996). 
Proliferation assays were carried out on Clone #3 transfected with three independent 
siRNA VIM targets. VIM transfection did not effect growth rate (Chapter 3.4.6), 
indicating that VIM does not play an important role in proliferation of Clone #3.   
Mice homozygous for a null mutation in the VIM gene developed and reproduced without 
an obvious deviant phenotype. No compensatory expression of another intermediate 
filament could be demonstrated, suggesting VIM could play a significant role only in 
pathologic or unusual conditions (Colucci-Guyon et al., 1994). However, Eckes et al. 
(1998) determined that primary fibroblasts derived from vimentin-deficient mouse 
embryos displayed 40% decrease in fibroblast stiffness, reduced mechanical stability, 
motility and directional migration towards different chemo-attractive stimuli compared to 
VIM (+/+) wild-type cells suggesting that absence of VIM does not impair basic cellular 
functions needed for growth but have mechanical instable function.  
In our study, a morphological change in Clone #3 cells after VIM siRNA transfection was 
observed. Cells changed from scattered fibroblast/mesenchymal type to a more epithelial 
tightly connected phenotype. This change in morphology is a common feature observed in 
mesenchymal to epithelial transition (MET) (Kokkinos et al., 2007). During EMT, cell-
cell contact is decreased as cellular motility, invasion and skeletal rearrangement are 
promoted. The reorganisation of the cytoskeleton proteins within cancer cells may have 
significant implications in the invasion and metastasis of pancreatic cancer. Transcription 
factors, TWIST (Cheng et al., 2007) and Sp1 (Jungert et al., 2007) have also been 
associated with EMT phenotype of high VIM and low KRT18 expression. Previous 
studied have also linked the EMT with MMP up-regulation (Taki et al., 2006), down-
regulation of E- cadherin and disruption of adhesion molecules (Blanco et al., 2004). All 
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these characteristics may help to further establish future potential protein markers by 
which aggressive invasive pancreatic cancer can be detected in early stages of malignancy. 
Javle et al. (2007) investigated whether EMT markers (low E-cadherin, high fibronectin 
and VIM) correlated with the activation on P13K and Ras/Erk pathways in pancreatic 
cancer. Fibronectin over-expression correlated with the presence of VIM and activated 
Erk. There was a borderline association of fibronectin with worsening grade, and a 
negative association between vimentin and E-cadherin was observed. Increased 
fibronectin or VIM and decreased E-cadherin correlated with poor survival.  
 
In this thesis, we have investigated the effect of VIM silencing in the invasive cell line, 
Clone #3. We have shown that siRNA knockdown of VIM results in significant reduction 
of invasion through matrigel in an in vitro boyden chamber. Adhesion to matrigel and 
anoikis sensitivity is increased, and we have determined that VIM knockdown does not 
affect the proliferation rate of the cells. These results support the hypothesis that VIM 
expression is associated with a more aggressive invasive phenotype and may be also 
required for loss of adhesion and anoikis resistance. We conclude that targeting VIM 
through RNAi may potentially be effective in modulating pancreatic cancer invasion and 
the malignant EMT phenotype. 
 
4.4.5 Stress-induced phosphoprotein 1 
Stress-induced-phosphoprotein 1 (STIP1, Hop or Hsp70/Hsp90-organising protein) 
mediates the association, and forms a physical complex with the molecular chaperones 
Hsp90 and Hsp70 (Carrigan et al., 2006), which is dependent on the hydrolysis of ATP 
and ADP/ATP exchange. STIP1 optimises the functional co-operation for Hsp70 and 
Hsp90 which require highly co-ordinated interactions for the folding and conformational 
regulation of a variety of proteins, such as steroid hormone receptors and many other 
signal transduction regulators (Hernández et al., 2002).  
 
STIP1 was chosen as a target for siRNA based on the comparative proteomic data analysis 
which compared protein expression in MiaPaCa-2, Clone #3 and Clone #8. STIP1 
expression was higher in MiaPaCa-2 versus Clone #8 (1.3-fold) and 1.5-fold up-regulated 
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in the comparison of Clone #3 to MiaPaCa-2. STIP1 was 2.0-fold higher expressed in 
Clone #3 compared to Clone #8. As the comparisons generated were from high to low 
invasion, the overall status of STIP1 expression is increasing as the invasive status of the 
cell lines increase.  
 
4.4.5.1 Effect of STIP1 siRNA in Clone #3 
STIP1 protein expression was knocked down in Clone #3 cells by siRNA transfection. 
Forty-eight hours post-transfection of three independent STIP1 siRNA targets, invasion, 
adhesion, anoikis and proliferation assays were carried out to investigate the potential role 
of STIP1 in pancreatic cancer invasion and the malignant phenotype. Invasion was 
significantly reduced by all three STIP1 siRNAs in Clone #3 cells. The optimal reduction 
in invasion was observed with STIP1 siRNA (1), which displayed a 2.7-fold decrease in 
invasion of Clone #3 cells. Adhesion to matrigel was statistically significantly increased 
after knockdown of STIP1 protein expression in Clone #3 cells. Increased adhesion was 
observed in 2/3 independent STIP1 siRNAs. Anoikis sensitivity was not altered by STIP1 
siRNA transfection, indicating that STIP1 did not have an effect on anoikis in Clone #3 
cells. Interestingly, proliferation assays of STIP1 siRNA transfected Clone #3 cells carried 
out over 5 days determined that loss STIP1 effected cell growth in Clone #3 cells. 
Proliferation of STIP1 siRNA transfected cells reduced the growth rate between 13-27% 
signifying a role for STIP1 in pancreatic cancer cell proliferation. 
The molecular chaperone complex of Hsp70, Hsp90 and STIP1 is involved in the folding 
and maturation of key regulatory proteins, like steroid hormone receptors, transcription 
factors, and kinases, some of which are involved in cancer progression. The connection 
and interplay between these complexes is of crucial importance for cell viability (Wegele 
et al., 2004). There is increasing evidence that heat shock proteins play an important role 
in the development, maintenance and progression of cancer (Pick et al., 2007).   
Heat shock proteins (Hsp) are highly conserved molecules, which protect cells from 
various environmental damages, including stress and carcinogenesis (Lindquist, 1986). 
Heat shock proteins are activated by the ubiquitin-proteasome pathway. The covalent 
attachment of ubiquitin to protein regulates a number of cellular processes including 
responses to stress. This process is responsible for selective targeting of proteins for 
 309  
degradation. The ubiquitin-proteosome pathway (UPP) can regulate expression of MMPs 
and their tissue inhibitors (TIMPs) in some tissues (Ikebe et al., 1998). The induced HSPs 
play roles as cellular chaperones, and many modulate apoptotic pathways, particularly 
those involving mitochondria, conferring protection from stressful stimuli including 
chemotherapeutic agents.  
The role of STIP1 in cancer invasion is currently unknown; however increasing evidence 
is emerging for the role of heat shock proteins in cancer progression. Ogata et al. (2000) 
examined the expression of Hsp90 and its relationship to pancreatic cancer by IHC, in situ 
hybridisation and RT-PCR. mRNA of Hsp90 was over-expressed in pancreatic tumour 
samples compared to control tissues, and Hsp90 expression correlated with pancreatic 
cancer proliferation. Eustace et al. (2004) showed that Hsp90α interacts with MMP-2 in 
the extracellular compartment of the cell. Inhibition of the extracellular Hsp90α decreases 
MMP-2 activity and invasiveness. Hsp90s association is required for the stability and 
function of multiple mutated, chimeric and over-expressed signalling proteins that 
promote cancer cell growth and/or survival. Hsp90 client proteins include mutated p53, 
Bcr-Abl, Raf-1, Akt, HER2 (ErbB2) and hypoxia inducible factor-1alpha (HIF-1alpha) 
(Powers and Workman, 2006). 
Hsp70 is an anti-apoptotic protein (Jaattela et al., 1998) and is over-expressed in breast, 
(Larazis et al., 1997) lung (Bonay et al., 1994), colorectal (Larazis et al., 1995) and 
pancreatic cancer (Gress et al., 1994), and the level of Hsp70 expression correlates with 
poor clinical outcome in certain cancers (Ciocca and Calderwood, 2005). Hsp70 increases 
tumourigenicity and inhibits apoptosis in pancreatic cancer (Aghdassi et al., 2007). Havik 
et al. (2007) investigated the impact of Hsp70 protein expression and its close family 
member, Hsc70, on breast cancer cell viability and on the activity of the STIP1 
(Hsp90/Hsp70) chaperone complex. Simultaneous blocking of Hsp70, Hsc70 and Hsp90 
reduced breast cancer cell viability. Alone Hsp90 inhibition also displayed low cell 
viability and reduced Hsp70/Hsp90 chaperone complex activity; however, the single or 
mixed reduction in Hsp70 and Hsc70 expression displayed no ability to reduce the activity 
of the Hsp90/Hsp70 chaperone complex. Therefore, targeting the Hsp70/Hsp90 family 
shows greater effect on cancer cell survival, even though their pathways of action are 
separate. Recently, modulators of chaperone activities introduced an emerging field of 
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drug development. Inhibitors of Hsp70’s sister chaperone Hsp90, such as 17-AAG, exhibit 
a broad spectrum of anti-tumour activity and appear promising in clinical trails (Neckers 
and Neckers, 2005). 
 
Our findings determine that STIP1 has a functional effect in invasion and adhesion of 
Clone #3 to matrigel. Functional knockdown of STIP1 failed to induced anoikis 
sensitivity; however, there is little evidence in literature connecting Hsp activation and 
anoikis. Interestingly, loss of STIP1 affected proliferation, indicating that STIP1 
chaperone activity is required for pancreatic cancer cell growth.  
 
4.5 Analysis of effects of CM#3 and CM#8 on MiaPaCa-2 and sub-
populations Clone #3 and Clone #8 
Serum-free conditioned media (CM) collected from Clone #3 and Clone #8 was added 
into the Boyden chamber invasion assay to assess whether secreted factors produced from 
the cells contained in the media would have an effect on invasion. CM#3 significantly 
enhanced the relative level of invasion of MiaPaCa-2, Clone #3 and Clone #8, whereas in 
contrast CM#8 decreased the invasion of MiaPaCa-2 and Clone #3. No obvious decrease 
in invasion was observed in Clone #8, as the cells invade at very low levels, therefore, it 
was difficult to detect a significant reduction in invasion. Adhesion assays showed that 
incubation of CM#3 with MiaPaCa-2, Clone #3 and Clone #8 had no effect on adhesion to 
matrigel; this affect was not altered by addition of CM#8, however, a significant increase 
in adhesion was observed in Clone #8 cells incubated with CM#8. Anoikis was also not 
stimulated in the cells by CM#3 exposure, and CM#8 incubation only statistically reduced 
anoikis resistance in Clone #3 cells. It is evident from these results that factors secreted in 
CM#3 and CM#8 can affect invasion and to a lesser extent adhesion and anoikis.    
We suggest that factors secreted into the CM#3 and CM#8 augment the cell-ECM contact 
and the invasive potential of the cells studied. To address this comment, the parental cell 
line, MiaPaCa-2 was incubated with CM#3 and CM#8 for 24 hrs prior to invasion assay. 
Invasion of MiaPaCa-2 was stimulated with preincubation of CM#3 and inhibited with 
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preincubation of CM#8. These results show that the factors secreted in the CM of both 
Clone #3 and Clone #8 are potentially capable of interacting with the proteins on the cell 
surface, and once secreted into the extracellular media, may induce a series of molecular                     
events leading to modulation of the invasive abilities of the cells. We further demonstrated 
that preincubation of MiaPaCa-2, Clone #3 and Clone #8 with matrigel (reconstituted 
ECM) in the presence of CM#3 showed higher invasive abilities compared to exposure to 
CM#3 alone and induced a phenomenon termed ‘superinvasion’.   In contrast, exposure of 
the cells to matrigel in the presence of CM#8 effectively reduced the invasion, however, 
superinvasion was still observed. During normal in vitro invasion, cells invade to the 
underside of the invasion chamber and are stained at this point, however during 
‘superinvasion’, a large proportion of the cells, invade through the underside of the 
chamber and attach to the bottom of the 24-well plate. This phenomenon of superinvasion, 
first described by Glynn et al. (2004), whereby doxorubicin- and paclitaxel-selected 
variants of an in vitro invasive clonal population of the human breast cancer cell line, 
MDA-MB-435S, were established by pulse selection, and exhibited a novel 'superinvasive' 
phenotype. This phenotype was characterised by an ability to relocate to another surface 
following invasion through matrigel and membrane pores, by decreased adhesion to 
extracellular matrix proteins and by increased motility. 
The occurrence of further increased invasion and superinvasion after exposure of the cell 
lines to matrigel for 24 hrs prior to invasion assays shows that the cell-ECM contact 
stimulates the invasive potential of MiaPaCa-2, Clone #3 and even the low invasive cell 
line, Clone #8. The stimulatory invasive effects of CM#3 were further enhanced when 
combined with cells incubated with matrigel, suggesting that the factor(s) secreted in 
CM#3 interact with cell-matrigel contact. The invasive inhibitory effects of CM#8 in 
combination with cells exposed to matrigel, was not sufficient to eradicate invasion or 
superinvasion completely, and only a modest reduction was observed. These results 
suggest that cell-ECM contact may induce important modulations within the cells, 
creating a highly invasive, superinvasive phenotype. Addition of CM#3 further 
transformed the invasive and superinvasive abilities of the cells, whereas CM#8 modestly 
decreased invasion and superinvasion of the cells similar to that observed in cells exposed 
to matrigel in the presence of control media. Interaction of the cells with matrigel may 
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represent an in vitro model for a step in the metastasis process subsequent to invasion, and 
hence may lead to a better understanding of the metastatic process. 
 
Recent studies have identified that many cancer types can secrete cytokines and growth 
factors to stimulate proliferation and tumourigenesis. The protein, melanoma inhibitory 
activity (MIA) is correlated with tumour progression and development of metastatic 
disease. MIA, secreted by melanoma cells, is known to inhibit tumour cell attachment to 
the extracellular matrix enhancing their invasive potential (Callejo et al., 2004). Barak et 
al. (2007) determined that elevated serum osteopontin (OPN), S-100beta and MIA levels 
correlate with metastatic uveal melanoma (UM) to the liver. OPN is over-expressed in 
metastatic UM, while S-100beta and MIA serum levels are elevated in metastatic 
cutaneous melanoma. In combination, these markers provide a highly sensitive and 
specific method to detect hepatic metastases and therefore provide for earlier therapeutic 
intervention that can prolong survival.  
Tumour cells secreting invasion or tumourigenic inhibitory factors are of critical 
importance. Butt et al. (2003) determined the effect of the insulin-like growth factor-
binding protein (IGFBP)-5 in human breast cancer in vivo and in vitro. Expression of 
IGFBP-5, both by stable transfection and adenoviral-mediated infection, was inhibitory to 
the growth of human breast cancer cell lines over a 13-day period. Secreted IGFBP-5 
when added exogenously to breast cancer cells was not internalised and had no effect on 
cell growth or apoptosis, suggesting that IGFBP-5 may elicit its inhibitory effects via a 
novel, intracrine mechanism.   
WISP3 (WNT-1 inducible signalling pathway protein 3) is secreted into the CM of human 
inflammatory breast cancer (IBC). Once secreted, WISP3 decreases directly or through 
induction of other molecules the IGF-1-induced activation of the IGF-IR, and two of its 
main downstream signalling molecules IRS1 and ERK-1/2, in SUM149 IBC cells. WISP3 
is lost in 80% of human IBC tumours and it has growth- and angiogenesis-inhibitory 
functions in breast cancer in vitro and in vivo. Furthermore, WISP3-containing 
conditioned media decreased the growth rate of SUM149 cells. WISP3 can modulate IGF-
IR signalling pathways and cellular growth in IBC cells (Kleer et al., 2004).   
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The results presented here clearly show that exposure of pancreatic cancer cells to 
exogenous factors secreted in the CM could potentially inhibit or enhance in vitro 
invasion. In general, CM can undergo compositional changes throughout cell cultivation, 
therefore several characteristic experiments were carried out to determine the stability of 
the unknown factor(s) in the CM. Varying the storage conditions determined that both 
CM#3 and CM#8 retained their enhancement/inhibitory affects on MiaPaCa-2 more 
effectively at -80 0C. The ability to dilute the effects of CM#3 and CM#8 in the invasion 
assays were determined by serially diluting CM#3 and CM#8 with normal media and 
observing the effects on invasion of the parental cell line, MiaPaCa-2. The optimal 
dilution factor for both CMs was determined as 1:4, after this dilution point the effects of 
the CM were no longer observed.  
To detect the optimal pH of the factor(s) exhibiting altered affects on invasion in CM#3 
and CM#8, the CMs were exposed to differing pHs for 2 hrs at room temperature and then 
brought back to pH ~7 (the original pH). Invasion assays using these CM #3 pH fractions 
showed that invasion was optimal at pH 5 for the enhancement factor in CM#3 compared 
to normal media under the same conditions. These results suggest that a lower pH is more 
favourable to induce invasion. In contrast, CM#8 exhibited optimal inhibitory effects on 
invasion of MiaPaCa-2 at pH 9-11 compared to control media under the same conditions, 
suggesting alkaline conditions have a favourable effect. These findings are in agreement 
with Kato et al. (1992); this study examined the effect of culture medium pH on the 
secretion of gelatinases from both murine melanoma and human tumour cell lines. 
Gelatinases were not secreted at neutral pHs but at lower pH range of 5.4-6.1, secretion of 
a 103 kDa gelatinase was observed. In vitro invasion assays showed that cells incubated in 
an acidic medium exerted more active migration through collagen type IV than those in a 
neutral medium. These results in conjunction with our own, suggest that an acidic 
environment around tumour cells may be an important factor in invasion and metastasis of 
some cell lines.  It is well established that tumours consistently rely on anaerobic pathways 
to convert glucose to ATP even in the presence of abundant oxygen, resulting in increased 
tumour cell acid production. Tumour cells evolve resistance to acid-induced toxicity 
during carcinogenesis, allowing them to survive and proliferate in low pH 
microenvironments. This permits them to invade the damaged adjacent normal tissue 
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despite the acid gradients (Gatenby et al., 2006). Extracellular pH (pH(e)) is lower in 
many tumours than in the corresponding normal tissue. Melanoma cells cultured at acidic 
pH(e) showed increased secretion of proteinases and proangiogenic factors, enhanced 
invasive and angiogenic potential, and enhanced potential to develop experimental 
metastases (Rofstad et al., 2006).   
The approximate molecular weight range of the factor(s) involved in CM#3 and CM#8 
were determined by concentration of the CMs into fractions of below 10 kDa, between 10-
30 kDa, 30-50 kDa, 50-100 kDa and above 100 kDa. Invasion assays of Clone #3 cells 
with the addition of the molecular weight fractions from CM#3 showed that the highest 
level of enhanced invasion was observed at high molecular weight of between 50-100 kDa 
and above 100 kDa; interestingly, the lower molecular weight fractions (below 10 kDa 
and 10-30 kDa) of CM#3 had an inhibitory effect on invasion of Clone #3 cells. Invasion 
was optimally reduced in Clone #3 cells with the lower molecular weight fractions of 
CM#8 (below 10 kDa and 10-30 kDa); in contrast, invasion was also increased at the high 
molecular weight fractions of CM#8. These results suggest that the enhancement factor of 
invasion secreted by Clone #3 in CM#3 is isolated in the higher molecular weight 
fractions, whereas the inhibitory factor of invasion secreted by Clone #8 in CM#8 is 
contained in the lower molecular weight fractions. The fact that both CMs have opposite 
enhancement and inhibitory effects at different molecular weight fractions could be 
possibly explained by the fact that the cells originate from the same parental cell line, and 
therefore may secrete similar factors into the CM.  The effects of these secreted factors on 
invasion may be due to their relative secreted abundance within the conditioned media and 
isolation of fractions from CM#3 and CM#8 may in fact concentrate factors that may 
otherwise be very low in abundance in the CMs. 
In summary, we present evidence that “hypothetical factor(s)” secreted into the media 
from Clone #3 and Clone #8 modulates the invasive abilities of the cells when co-cultured 
with the CM. The pre-incubation of cells with matrigel in the presence of CM#3 further 
enhanced the in vitro invasion and increased superinvasion, in the presence of CM#8 
invasion and superinvasion were modestly reduced similar to control experiments.  
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Furthermore, characterisation of this ‘factor’ revealed an optimal storage condition of -80 
oC with a maximum diluent ratio of 1:4 with fresh media. The factor(s) secreted into 
CM#3 were found to behave more aggressively at lower pH ranges with a higher 
molecular weight, in the range of between 50-100 kDa and above 100 kDa, while analyses 
of the secreted ‘factors’ in CM#8 revealed the inhibitory effects are more favourable with 
alkaline pHs with a lower molecular weight (mass range below 10 kDa and between 10-30 
kDa).   
At present, we can only speculate to the potential clinical and therapeutic benefit of the 
role of secreted factors in CM#3 and CM#8 in pancreatic cancer invasion and metastasis 
progression. Recently, Ramachandran et al. (2007) identified adrenomedullin as a 
potential secreted autocrine regulator of pancreatic cancer cell line function. Exogenous 
adrenomedullin treatment of Panc-1, BxPC3, and MPanc96 cells in vitro stimulated cell 
proliferation, invasion, and nuclear factor kappaB activity, indicating the ability of the 
cells to respond to adrenomedullin.  Treatment of the cell cultures with an adrenomedullin 
antagonist inhibited basal levels of proliferation and nuclear factor kappaB activity, 
supporting the autocrine function of this molecule. Furthermore, increasing 
adrenomedullin levels by gene transfer to Panc-1 cells increased, whereas adrenomedullin 
small hairpin RNA silencing in MPanc96 cells inhibited, tumour growth and metastasis in      
vivo. Adrenomedullin acts through at least two different receptors, including 
adrenomedullin receptor (ADMR) and calcitonin receptor-like receptor (CRLR).      
Pancreatic cancer cell lines only express ADMR, as determined by Reverse transcription-
PCR and Western blotting. However, cells found in the tumour microenvironment, such as 
primary human pancreatic stellate and endothelial cells, expressed both ADMR and 
CRLR. Silencing of ADMR in pancreatic cancer cells by shRNA blocked adrenomedullin-
induced growth and invasion, demonstrating that this receptor is involved in the autocrine 
actions of adrenomedullin. This data indicates that adrenomedullin acts via ADMR 
increasing the aggressiveness of pancreatic cancer cells and suggests that these molecules 
may be useful therapeutic targets. 
Further analysis and identification of the secreted functions in CM#3 and CM#8 may lead 
to the development of novel biomarkers or therapeutic targets for pancreatic cancer. 
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4.6 Proteomic profiling of conditioned media from CM Mia, CM#3 
and CM#8 
 
The malignant progression of invasive and metastatic pancreatic cancer is a complex and 
poorly understood process. In this study, we established the proteomic profile of proteins 
secreted into the media from pancreatic cancer cell lines with varying invasive and 
malignant transformation characteristics. Identification of secreted proteins from cell lines 
could be an important step toward discovering molecular markers of invasion in 
pancreatic cancer and could potentially form the basis for diagnosis and treatment 
prognosis. Theoretically, proteins secreted by tumour cells are more likely to be detected 
easily in bodily fluids such as urine, blood serum and pancreatic ductal juice. Therefore, 
secreted proteins and their metabolites found in vivo could represent a panel of potential 
bio-markers. 
 
4.6.1 Generation of protein lists 
In this study, secreted proteins were obtained from culture of MiaPaCa-2, Clone #3 and 
Clone #8 in serum-free conditions (SF). Cells were first allowed to attach under normal 
conditions, and once appropriately confluent, cells were adapted to SF conditions for 48 
hrs. SF conditions have the advantage of reducing the abundance of bovine proteins in the 
samples. Three comparative lists of differentially secreted proteins between CM Mia 
versus CM #8, CM #3 versus CM Mia and CM #3 versus CM #8 were established. Bio-
informatic analysis (GO STAT and pathway studio) was applied to all differentially 
secreted proteins between our pancreatic cancer CM model. Gene ontology (GO STAT) 
classified the differentially secreted proteins and their corresponding genes into gene 
categories. Although membrane-bound and extracellular proteins are more likely to be 
cleaved and found in the circulation (Kulasingam and Diamandis, 2007), our GO STAT 
analysis determined that most up-regulated and down-regulated proteins were involved in 
the cytoplasm. However, secreted heat shock proteins and actins, generally viewed as 
cytoplasmic markers, increasingly have been implicated in extracellular functions. 
Altmeyer et al. (1996) showed that gp96 (protypical Hsp) normally resides in the lumen of 
the endoplasmic reticulum (ER), however a significant proportion of intact gp96 molecule 
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is expressed on the cell surface and that this surface expression is not a result of gp96 from 
dead cells. Cell surface expression of gp96 is enhanced by heat shock and exposure to 
reducing agents suggesting that gp96 and perhaps other HSPs are anchored to the cell 
surface as part of larger molecular complexes, which also transport them to the cell 
surface. Wang et al. (2004) showed that beta-actin is present on the extracellular 
membranes of some cancer cells and can mediate plasmin binding to the cell surface and 
autoproteolysis to angiostatin 4.5 (a naturally occurring human angiostatin isoform).  
Eukaryotic protein secretion normally routes through the endoplasmatic reticulum (ER) 
and Golgi, ending up in a secretory vesicle fusing to the cell membrane. Studies have 
shown that the non-classical secretory pathway works independently of the ER–Golgi 
network; the secreted proteins do not enter the ER and have not been glycosylated 
(Bendtsen et al., 2004). Non-classical secretion of proteins was verified by Tanudji et al. 
(2002), whereby the cytosolic green fluorescent protein (GFP) was secreted by cell lines 
experimentally, as export was not hampered by inhibitors of the classical secretory 
pathway, such as monensin and brefeldin A. 
Therefore, it is feasible to include these cytoplasmic proteins as potential secreted bio-
markers in our study. 
 
4.6.2 Invasion specific proteins chosen for siRNA functional analysis 
The greatest fold difference between secreted proteins was observed in the comparison of 
CM#3 versus CM#8, and as CM from these cell lines produced an effective 
inhibitory/enhancement of invasion (Chapter 3.5), we decided to concentrate primarily on 
this comparison for functional analysis. 
Four proteins were chosen for secretion validation in CM Mia, CM#3 and CM#8 by 
Western blot analysis. Gelsolin (GSN), nucleoside diphosphate kinase (NDPK) and 
aldehyde dehydrogenase 1A1 (ALDH1A1) correlated with proteomic data. Galectin-1 
(GAL-1) secretion did not correlate with fold difference determined by proteomic 
profiling; this may have been due to many reasons such as unspecificity of antibody or the 
low fold difference between CM#3 and CM#8 (1.3-fold). 
Two secreted proteins, GSN and ALDH1A1, were chosen for siRNA silencing based on 
specificity to invasion, relevance to cancer/invasion in the literature, fold difference and p-
 318  
value. Table 4.6.1 summarises fold difference between each comparison to the chosen 
target proteins. 
 
Table 4.6.1 Proteins differentially secreted between CM#8 and CM#3 chosen for 
further analysis 
Protein Description CM#8 vs 
CM Mia 
CM Mia vs 
CM#3 
CM#8   vs 
CM#3 
GSN Gelsolin isoform b (a) 2.6 8.0 21.0 
ALDH1A1 Aldehyde dehydrogenase 1A1 -11.4 -6.3 -21.0 
 
4.6.3 Gelsolin (GSN) 
GSN is a calcium-binding protein which binds to and regulates actin filaments. GSN binds 
to the barbed ends of actin filaments and prevents capping (Kumar et al., 2004). Severing 
and capping of actin filament enhances the rate of cell motility and migration 
(Cunningham et al., 1991). Gelsolin is located intracellularly in the cytoplasm and 
mitochondria (Koya et al., 2000) as well as extracellularly in the blood plasma 
(Chaponnier et al., 1979). The intracellular form termed cytoplasmic, and the secreted 
form termed plasma GSN are derived from a single gene by alternative transcription 
initiation sites and differential sequencing (Kwiatkowski et al., 1988). Plasma GSN differs 
to cytoplasmic GSN, in that it is larger (93 kDa and 90 kDa, respectively), contains 25 
extra amino acids at its NH2 terminus, and is more positively charged (Kwiatkowski et al., 
1986). Yin et al. (1984) determined plasma GSN is more highly labelled relative to 
cytoplasmic GSN, suggesting that it is synthesised more rapidly or catabolised more 
slowly. Plasma GSN is removed from the cells more rapidly, consistent with a secreted 
protein, and only the plasma form of GSN is secreted in HepG2, a human hepatoma-
derived cell line.  
 
GSN was chosen as a target for siRNA based on the comparative proteomic data analysis, 
which compared secretion of proteins in the conditioned media of MiaPaCa-2, Clone #3 
and Clone #8. GSN was secreted at lower levels in all three lists (CM Mia vs CM #8 (-2.6-
fold), CM #3 vs CM Mia (-8.0-fold) and CM #3 vs CM #8 (-21-fold)). Therefore, 
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secretion of GSN is highest in the low invasive cell line, Clone #8, and lowest in Clone 
#3.  
 
4.6.3.1 Effect of GSN siRNA in CM#8 
RNAi technology was used to study GSN protein secretion in CM#8. Using two 
independent GSN siRNA target sequences, GSN protein expression was specifically 
down-regulated in Clone #8 cells, resulting in decreased secretion of GSN. The role of 
secreted GSN in invasion was investigated in Clone #8 cells by addition of GSN siRNA 
transfected CM#8 into the invasion chamber. Invasion of Clone #8 was increased after 
addition of GSN siRNA CM#8; however, only one siRNA GSN showed a statistically 
significant increase in invasion. The high standard deviations between triplicate repeats 
may be due to the inherent unevenness of Clone #8 cell invasion, it is possible that GSN 
was not knocked down efficiently enough to observe complete invasion. This may be as a 
result of the high proportion of secreted GSN in CM#8, as in order to observe optimal 
reduction of GSN secretion by Western blot in CM#8, the total amount of protein loaded 
had to be reduced to 5 μg of total protein. This suggests that GSN is highly secreted in 
CM#8.  
 
To address this issue, the level of cytoplasmic GSN was determined by Western blot. 
MiaPaCa-2 and Clone #3 showed no detectable levels of GSN expression, while Clone #8 
expressed low levels of GSN. However, after incubation on matrigel for 24 hrs the 
expression of GSN was increased further in Clone #8 cells. This finding suggests that 
GSN expression is up-regulated due to Clone #8 cell-matrigel contact. Invasion assays of 
siRNA GSN transfected Clone #8 cells showed that loss of cytoplasmic GSN significantly 
increased invasion in both siRNA targets.  
Our results suggest that both plasma and cytoplasmic GSN have functional effects on 
invasion in Clone #8 cells. We showed that cytoplasmic GSN was up-regulated after cell-
matrigel contact. We confirmed that silencing secreted GSN in CM#8 was not sufficient to 
completely increase invasion as the cells in the invasion assays highly express cytoplasmic 
GSN when in contact with an extracellular matrix. Targeting cytoplasmic GSN by siRNA 
was sufficient to statistically increase invasion.   
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Decreased expression of cytoplasmic GSN has been shown in several types of human 
cancers, including urinary bladder carcinogenesis (Tanaka et al., 1995), NSCLC (Dosaka-
Akita et al., 1998), prostatic adenocarcinoma (Lee et al., 1999) and breast (Winston et al., 
2001) suggesting a possible role as a tumour suppressor. Noske et al. (2005) determined 
that reduced expression of GSN in 75 ovarian carcinoma specimens was significantly 
associated with a high tumour grade; this study also showed that up-regulation of GSN in 
ovarian cancer cell lines, OAW42 and ES-2 reduced tumour colony formation. Our studies 
suggest that the inhibitory invasive effects of CM#8 may be in part due to GSN secretion 
and are in agreement with the above findings. Sagawa et al. (2003) suggested that GSN 
expression suppresses the activation of phospholipases C (PLC)/protein kinase C (PKCs) 
involved in phospholipid signalling pathways, thus inhibiting cell proliferation and 
tumourigenicity. Furthermore, Tanaka et al. (2006) functionally knocked down GSN 
expression by siRNA in the human mammary epithelial cell line, MCF10A, and suggested 
that GSN functions as a switch that controls E- and N-cadherin conversion via Snail, and 
demonstrated that its knockdown led to EMT, characterised by fibroblastic morphology, 
loss of contact inhibition, focus formation in monolayer growth and enhanced motility and 
invasiveness in vitro. Therefore, silencing GSN expression could possibly lead to the 
development of human mammary tumours. 
However, Thor et al. (2001) determined the GSN over-expression in 56% of breast 
cancers was associated with the over-expression of EGFR and HER2, as well as a more 
aggressive phenotype. High GSN levels have also been identified as a negative prognostic 
factor in pulmonary carcinomas, stage I non-small cell lung carcinomas (Shieh et al., 
1999), where they have been linked to enhanced cellular motility.  
Several studies have implicated GSN in regulating cell motility. Thompson et al. (2006) 
showed the over-expression of GSN in pancreatic cancer cells and demonstrated that 
reducing the level of GSN decreases the motility of pancreatic cancer cell lines, 
suggesting the marked up-regulation of motility-modulating actin-capping proteins in 
pancreatic cancer cells may have important consequences for the motility and 
consequently the dissemination of these cells. 
 
 321  
GSN secreted in the plasma has an actin-scavenging function, and its level has been 
shown to be reduced in response to increase tissue injury and hepatocellular carcinoma, 
possibly due to an increase in binding and clearance of shed actin (Ito et al., 1992). 
Orchekowski et al. (2005) revealed through antibody microarray profiling of combined 
serum proteins associated with pancreatic cancer a significant reduction of plasma GSN in 
pancreatic cancer serum. Okano et al. (2006) also confirmed the decrease of plasma GSN 
expression in lung cancer serum by proteomic profiling. 
 
In conclusion, the results presented here clearly determine that both cytoplasmic and 
plasma GSN have a role in the invasive potential of pancreatic cancer. GSN may have a 
role as a functional bio-marker for the early detection of invasive/metastatic pancreatic 
cancer. 
 
4.6.4 Aldehyde dehydrogenase 1A1 (ALDH1A1) 
ALDH1A1 as previously discussed in Chapter 4.4 was chosen as a target for siRNA as 
proteomic profiling revealed its secretion highly up-regulated in the CM of the more 
invasive cell line, Clone #3. ALDH1A1 is highly secreted in CM Mia compared to CM#8 
(11.4-fold) and in the comparison of CM#3 compared to CM Mia (6.3-fold change). The 
comparison of CM#3 versus CM#8 showed a 21.0-fold up-regulation of ALDH1A1 
secretion in CM#3. The secretion of ALDH1A1 is higher in the invasive cell line Clone 
#3.  
 
Secreted ALDH1A1 expression was reduced in CM#3 through siRNA sequence targeting 
of three independent sequences of the ALDH1A1 gene. Addition of ALDH1A1 siRNA 
transfected CM#3 into the invasion chamber significantly reduced invasion of Clone #3 
cells. These findings along with our previous analysis of cytosolic ALDH1A1 suggest that 
both secreted and cytosolic ALDH1A1 have an important role to play in pancreatic cancer 
invasion.  
 
No literature is available on the occurrence or incidence of secreted ALDH1A1 in serum 
of cancer patients or conditioned media of cancer cells. Therefore, we can only speculate 
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on its involvement in the pancreatic cancer invasion cascade. The cytosolic form of 
ALDH1A1, expressed in high levels intracellularly, could possibly be secreted into the 
media by active diffusion or transport.  
 
In summary, identification of secreted proteomes from cancer cell lines may serve as an 
ideal and efficient method in the establishment of a panel of potential bio-markers 
correlating to invasion/metastatic cascade of pancreatic cancer. The non-invasive 
detection of bio-markers may be useful for clinical application in early diagnosis and 
prognosis of pancreatic cancer.  
 
 
4.7 Role of EGFR and HER2 in pancreatic carcinoma 
 
Tyrosine kinase growth factor receptors and their ligands act to influence tumour cell 
growth, differentiation, invasion, metastasis and angiogenesis. EGFR over-expression 
occurs in 30% to 50% of pancreatic ductal adenocarcinomas and over-expression is 
thought to often confer a poor prognosis in several malignancies (Garcea et al., 2005). It 
often correlates with poorly differentiated histology and a more advanced stage.  
Increased expression of HER2 has also been observed in pancreatic adenocarcinoma. 
Over-expression is more common in well and moderately differentiated tumours 
compared to poorly differentiated and anaplastic tumours. The oncogene HER2 is over-
expressed in 50-70% of pancreatic cancer cases (Bũchler et al., 2002). Therefore, an agent 
against the combination of EGRF/HER2 is a tempting target for therapeutic strategy in 
pancreatic cancer. 
 
Lapatinib is a reversible, dual EGFR/HER2 tyrosine kinase inhibitor. In vivo and in vitro, 
lapatinib has inhibited EGFR and HER2 phosphorylation, resulting in decreased activation 
and phosphorylation of Erk-1/2 and Akt (Xia et al., 2002).  Lapatinib has shown clinical 
activity in cancers resistant to agents targeted at ErbB receptors. Patients resistant to 
gefinitib or herceptin, experienced minor-partial response to lapatinib treatment (Burris et 
al., 2003; Blackwell et al., 2004). 
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The analysis method of Chou and Talalay was used in this study to calculate the median 
effect and the combination index (CI) equation. The CI method is based on the median-
effect equation, which correlates the drug dose and the cytotoxicity or cytostatic effect 
(Chou and Talalay, 1984). The drugs used in this study have “mutually nonexclusive” 
mechanisms of action (i.e., drugs that are non-competitive inhibitors of each other). The 
CalcuSyn program automatically analyses the data and the CI equation determines the 
additive effect of the drug combinations. Synergism is defined as a greater than expected 
additive effect. 
CI < 0.8 indicates synergism, CI > 0.8 but < 1.2 indicates an additive effect and CI > 1.2 
indicates antagonism. The CI values are presented for each effective dose (ED) tested, 
(e.g., ED25, ED50 and ED75) because the CI values may change with the fraction 
affected in a non-linear manner (Reynolds and Maurer, 2005). ED is the minimal dose that 
produces the desired effect of a drug. The effective dose is determined based on analysing 
the dose-response relationship specific to the drug. The dosage that produces a desired 
effect in half the test population is referred to as the ED-50, for "Effective Dose, 50%". 
 
This study details quantitative interactions between lapatinib and four different 
chemotherapeutic drugs: cisplatin, gemcitabine, taxotere and 5’dFUrd. BxPc-3 and KCI-
MOH1, two pancreatic cancer cell lines that expressed both EGFR and HER2, were tested 
in combination with lapatinib and the cytotoxic drugs. Analysis of the scheduling regime 
identified that pre-incubation of lapatinib 24 hrs prior to chemotherapy was more efficient 
than using the combination together. Wakeling et al. (2002) determined that pre-
incubation with gefitinib prior to EGF treatment inhibited autophosphorylation of EGFR 
TK in a dose-dependent manner in human tumour cell lines from lung, prostate, colon, and 
head and neck cancers and these results correlated with inhibition of tumour xenograft 
growth in vivo. 
Lapatinib was added to the cells 24 hours prior to the addition of cytotoxic drugs, this was 
to ensure the EGFR/HER2 inhibitory effects of lapatinib were maximised. Fixed ratio 
analyses of drug interactions were calculated. Accurate dose-response curves for lapatinib 
and the chemotherapeutic drugs both alone and in combination was generated. Synergy, 
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additivity and antagonism were quantified at different concentrations and effect levels, 
whereby, the maximum anti-tumour efficacy of the combination was determined.  
 
4.7.1 Combination of lapatinib and cisplatin 
In our study, a synergistic to additive interaction was observed between cisplatin and 
lapatinib in both EGFR/HER2 expressing cell lines, BxPc-3 and KCI-MOH1 at ED25-50. 
These results suggest that toxic effects of the lapatinib and cisplatin combination are 
further enhanced compared to either drug alone. Recent studies have supported this 
observation; McHugh et al. (2007) demonstrated a synergistic effect with the combination 
of lapatinib, gemcitabine and cisplatin regime in two bladder cancer cell lines, expressing 
high levels of EGFR/HER2 (RT112) and low levels of EGFR/HER2 (J82). Results 
showed that lapatinib reduced cell viability in both cells lines in a dose-dependent manner, 
and the IC50 results for both cell lines to lapatinib were similar irrespective of their 
EGFR/HER2 expression level. In both cases, addition of lapatinib before or during 
gemcitabine and cisplatin treatment was optimal and resulted in a synergistic effect. Coley 
et al. (2006) showed that the RTK inhibitor GW282974A (an analogue of GW2016; 
lapatinib) is synergistically effective in combination with cisplatin in platinum resistant, 
EGFR over-expressing ovarian cancer cell lines. A reduction in the downstream signalling 
effector phosphorylated ERK was observed when the combination was applied to the 
cells.  
This data, in conjunction with our own work suggests that dual EGFR/HER2 inhibition in 
combination with cisplatin is effective in the chemosensitisation of cancer cell lines. 
   
Baselga et al. (2000) reported responses in patients with head-and-neck cancer treated 
with erbitux (an anti-EGFR antibody) and cisplatin. The interactions between anti-EGFR 
antibodies and cisplatin may be due to inhibition of DNA repair mechanisms, alteration in 
paracrine growth factor production and promotion of apoptotic cell death (Fan and 
Mendelson, 1998). Tanaoka et al. (2007) investigated the effects of combining an anti-
EGFR monoclonal antibody (C225) or an EGFR-selective tyrosine kinase inhibitor 
(AG1478) with cisplatin on the oral SCC (OSCC) cell lines, NA and Ca9-22. OSCC cell 
proliferation was inhibited by C225, AG1478 and cisplatin in a dose-dependent manner. 
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The combination of C225 or AG1478 with cisplatin at concentrations <IC50 synergistically 
inhibited cell proliferation and induced apoptosis in these cells. Furthermore, treatment 
with C225 or AG1478 OSCC reduced phosphorylation of EGFR and Akt, as well as Bad. 
EGFR inhibitors down-regulated expression levels of the anti-apoptotic proteins cellular 
IAP-1 (cIAP-1), X-linked IAP (XIAP), Bcl-2 and Bcl-xL, whereas those of the pro-
apoptotic proteins Bax and Bak were up-regulated. EGFR inhibitors provide partial 
regulation of cisplatin-mediated apoptosis in OSCC cells by modulating expression of 
cIAP-1, XIAP, Bcl-2, Bcl-xL, Bax and Bak.  
 
4.7.2 Combination of lapatinib and gemcitabine 
Our finding show that on average, there was an additive interaction between gemcitabine 
and lapatinib in both cell lines, BxPc-3 and KCI-MOH1 at ED25-75. However, at low 
combination effective doses (ED25) in BxPc-3 cells, there is a synergistic interaction (CI 
value, 0.79 ± 0.23). This may suggest that dosage and treatment regime may be critical in 
the treatment of pancreatic cancer with lapatinib and gemcitabine combinations. 
Baerman et al., (2005) studied the biochemical and biological impact of lapatinib in 
pancreatic cancer cell lines. All cell lines were shown to variably express EGFR, HER2, 
and HER3, while HER4 mRNA levels were lower than other EGFR family members. 
Lapatinib inhibited anchorage-dependent growth in all cell lines and markedly inhibited 
EGF or heregulin initiated phosphorylation of Akt and 44/42 MAPK. This study 
concluded that lapatinib inhibits EGFR dependent proliferation and anchorage-
independent colony formation in pancreatic cancer cell lines through inhibition of MAPK 
and Akt pathways.  A recent two-stage, phase I evaluation of lapatinib, gemcitabine and 
lapatinib, gemcitabine and oxaliplatin (GEMOX) resulted in dramatic responses in 
patients with diffuse liver and peritoneal metastases; this study suggests that EGFR/HER2 
signaling is important in pancreaticobiliary cancers (Safran et al., 2006). Currently, Safran 
and colleagues are recruiting for a phase II study of lapatinib and gemcitabine for patients 
with metastatic pancreatic cancer. 
EGFR inhibition has become an important target in pancreatic carcinoma. Buchsbaum et 
al. (2002) treated pancreatic cancer xenografts with erbitux, an anti-EGFR antibody, 
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gemcitabine and radiation. This study showed the combination had significantly greater 
efficacy over single or double therapies. Erbitux and gemcitabine has previously shown to 
inhibit human pancreatic xenografts in subcutaneous or orthotopically in nude mice and 
reduce metastases (Overholser et al., 2000; Bruns et al., 2000). 
Feng et al. (2006) reported that treatment with gemcitabine stimulates phosphorylation of 
EGFR. As phosphorylation of EGFR is known to precede receptor degradation, 
gemcitabine treatment resulted in EGFR degradation. In two human head and neck cancer 
cell lines, UMSCC-1 and UMSCC-6, an approximately 80% decrease in total EGFR 
levels at 72 h after a 2-h treatment with gemcitabine was demonstrated. Neither cisplatin 
nor 5-fluorouracil, which are used to treat head and neck cancer, caused EGFR 
degradation. EGFR down-regulation did not occur at the level of transcription, as assessed 
by RT-PCR, but instead occurred via phosphorylation and ubiquitination of the receptor 
along a proteosome/lysosome-mediated pathway. Inhibition of EGFR degradation, by 
either pretreatment with the EGFR tyrosine kinase inhibitor, gefitinib or by exposure to 
the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced 
cell death. These results suggest that EGFR degradation may be a novel mechanism for 
gemcitabine-mediated cell death. These findings also indicate that caution should be 
exercised when combining gemcitabine with agents that may prevent EGFR degradation, 
such as EGFR tyrosine kinase inhibitors administered in a suboptimal sequence or 
proteosome inhibitors. 
 
A phase III study determined the effects of combining the EGFR-targeted agent, erlotinib 
with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic 
cancer. Overall survival (OS) was significantly prolonged on the erlotinib/gemcitabine 
arm compared with gemcitabine alone, median survival was 6.25 versus 5.91 months, with 
a one-year survival of 23% versus 17% (Moore et al., 2007). These results led to the FDA 
approval of erlotinib in combination with gemcitabine in advanced, unresectable or 
metastatic pancreatic cancer. 
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Our results in conjunction with recent literature reports, suggest that the combination of 
lapatinib and gemcitabine may be therapeutically more efficient than gemcitabine alone in 
the treatment of pancreatic cancer. 
 
4.7.3 Combination of lapatinib and taxotere 
Lapatinib and taxotere combination in both BxPc-3 and KCIMOH1 cells showed a modest 
interaction, as shown in Chapter 3.7 (Figure 3.7.5). The combination response was not 
evaluated by Calcusyn and CI analysis was not carried out on this data. A perquisite of 
fixed ratio calculations is the generation of an accurate dose response curve of all the 
drugs tested. It is obvious from the graphs that taxotere is a very potent drug and the 
pancreatic cancer cell lines, BxPc-3 and KCI-MOH1, are sensitive to the drug at very low 
concentrations. Therefore, the dynamic range of the assay was not accurate as the 
combination of taxotere and lapatinib were not combined at an equipotent ratio (the ratio 
of the IC50 concentrations). The combination ratio concentration of lapatinib:taxotere used 
was 1:0.01 ng/ml; however, due to the scheduling of the combination including 24 hr pre-
incubation with lapatinib, the overall kill of taxotere alone was higher than expected and 
the anti-proliferative effects of lapatinib were masked. These results highlight the 
importance of lapatinib: taxotere scheduling. It is unclear from this data whether this 
combination would be an effective treatment for pancreatic cancer.  
 
Taxotere has been used in combination with gemcitabine in the treatment of pancreatic 
cancer. The combination in unresectable pancreatic carcinoma has been well tolerated. 
Survival time and 1-year survival rate has proved promising and the regimen appears 
suitable for further evaluation in a prospective phase-III study setting (Ridwelski et al., 
2006; Meyer et al., 2004). 
 
Ignatiadis et al. (2006) evaluated the efficacy and tolerance of the taxotere/gefitinib 
combination as a second-line treatment in patients with advanced pancreatic cancer after 
failure of gemcitabine-based chemotherapy. This study concluded that this combination, 
although safe, did not offer an active salvage treatment. 
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A phase I-II study of lapatinib and taxotere as neoadjuvant treatment for locally advanced 
breast cancer is currently undergoing clinical assessment. 
 
4.7.4 Combination of lapatinib and 5’dFUrd 
Lapatinib in combination with 5’dFUrd (active capecitabine intermediate) shows 
synergism in BxPc-3 cells at ED25, as the concentrations increases the combination 
indices also increases displaying an additive to antagonistic interaction at ED50-75. This 
shows that the combined effect of the two drugs are maximised at lower concentration 
levels. However, the opposite is true for KCIMOH1 cells. Antagonism is observed at 
ED25, and additivity to synergism is observed as the concentration increases (ED50-75). 
These results suggest that synergy is observed in both cell lines with the combination of 
lapatinib and 5’dFUrd, although at different concentration ranges. This may be an 
important consideration in pre-clinical studies. 
Herrmann et al. (2007) in a phase III randomised trial compared the efficacy and safety of 
gemcitabine plus capecitabine versus single-agent gemcitabine alone in 
advanced/metastatic pancreatic cancer. Although the median overall survival (OS) time 
was slightly improved (8.4 compared to 7.2 months), GemCap failed to improve OS 
significantly compared to gemcitabine alone. This study concluded that GemCap may be 
considered as an alternative to single-agent gemcitabine for the treatment of 
advanced/metastatic pancreatic cancer patients with a good performance status.  
Capecitabine in combination with trastuzumab (Herceptin) caused complete remission of a 
patient with recurrent breast cancer and liver metastasis (Morohashi et al., 2007). The 
combination of capecitabine and trastuzumab has been further validated in a phase II study 
of HER2 over-expressing advanced/metastatic breast cancer. Schaller et al. (2007) showed 
that the combination of capecitabine and trastuzumab is highly active in patients with 
HER-2 over-expressing anthracycline- and/or taxane-pretreated breast cancer, with only 
slight restrictions regarding quality of life. These recent studies suggest that the 
combination of capecitabine and EGFR/HER2 targeting therapies could possibly be used 
to treat other cancer at advanced/metastatic stage. Geyer et al. (2006) recently completed a 
clinical trial comparing lapatinib plus capecitabine with capecitabine alone in women with 
 329  
HER2-positive metastatic breast cancer that has progressed after trastuzumab-based 
therapy. The median time to progression was 8.4 months in the combination-therapy 
group as compared with 4.4 months in the monotherapy group. This improvement was 
achieved without an increase in serious toxic effects or symptomatic cardiac events. This 
study concluded that lapatinib plus capecitabine is superior to capecitabine alone in 
women with HER2-positive advanced breast cancer refractive after treatment with 
regimens that included an anthracycline, a taxane, and trastuzumab.  
Clinical trials are now underway investigating the combination of capecitabine with 
gemcitabine and erlotinib for advanced pancreatic cancer. 
 
Our data presents evidence that lapatinib cooperates with cytotoxic drugs and may have a 
therapeutic role in the treatment and management of EGFR/HER2 expressing pancreatic 
cancers. We have demonstrated that the anti-proliferative effect of lapatinib is optimal 
with 24 hrs exposure before addition of chemotherapeutic drug to the cells. Further 
consideration to the optimal scheduling regimes in pre-clinical trials may show a more 




In this thesis, we have successfully established an in vitro pancreatic cancer invasion 
model, which represents the malignant transformation in pancreatic cancer cell lines; this 
model could potentially signify a model of invasion and metastasis in vivo. Novel proteins 
and secreted biomarkers differentially regulated in our model, through identification by 2-
D DIGE proteomics, siRNA and cDNA analysis, showed functional involvement in 
invasion and the malignant phenotype of pancreatic cancer cells. This could possible help 
to further determine key targets/biomarkers in pancreatic cancer patients in an aim to 
therapeutically assist the early detection of the disease. The expression of MDR pumps, P-
gp and MRP-1 in pancreatic cancer specimens showed that these pumps are an important 
mechanism of drug resistance in pancreatic cancer patients. Furthermore, treatment with 
lapatinib in combination with chemotherapeutic lapatinib has shown to exert additive 
effects, and could be used to target EGFR/HER2 expressing pancreatic cancers. 
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Pancreatic cancer is characterised by an inherent drug resistance phenotype with a 
propensity for early invasion and local metastasis. The main focus of this thesis was to 
develop relevant human in vitro models that would allow us search for molecular 
signatures involved in these processes and to identify novel markers that may 
therapeutically assist the detection and treatment of this disease. 
 
5.1.1 Drug resistance profile of pancreatic cancer cell lines and clinical specimens 
Pulse-selection of three pancreatic cancer cell lines with epirubicin, gemcitabine and 
taxotere led to the establishment of eight novel cell lines with relatively low resistance. 
• The low level of resistance observed to the selecting drug may be more clinically 
relevant and better represent acquired resistance observed in vivo.  
• No obvious cross-resistance pattern of variants was observed to a panel of ten 
chemotherapeutic drugs, even with drugs within the same chemical family (e.g. 
taxanes, platinum compounds etc). Inherent or induced expression of the multidrug 
resistant pumps, P-gp or MRP-1 was not obviously detectable in our panel of 
pulsed pancreatic cancer cell lines.  
• Epirubicin and gemcitabine pulse-selected cell lines showed increased invasive 
capacities. The resistance levels, however, did not correlate with invasive abilities 
of the cells, suggesting that even modest resistance can induce a more invasive 
phenotype. In contrast, taxotere-selected variants did not display any increase in 
invasion abilities. 
 
• Pancreatic cancer specimens were stained for the multi-drug resistance pumps, P-
gp and MRP-1. 93% (42/45) of pancreatic cancer specimens stained positive for P-
gp. Approximately 12% (5/42) scored 1+, 10% (4/42) scored 2+, 24% (10/42) 
scored 3+, while 55% (23/42) scored 4+. Weak staining was observed 10% (4/42), 
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intermediate staining in 52% (22/42) and strong staining in 38% (16/42) of cases. 
Three cases showed no P-gp expression. 
• MRP-1 protein was expressed in 31% of pancreatic tumour specimens. 
Approximately 14% (2/14) scored 1+, 14% (2/14) scored 2+, 57% (8/14) scored 
3+ and 14% (2/14) scored 4+. Weak staining was observed in 36% (5/14) of cases, 
intermediate staining in 29% (4/14) and strong staining in 36% (5/14). Sixty-nine 
percent (31/45) of tumours did not show MRP-1 protein expression. 
• Co-expression of multi-drug proteins was observed in 36% of specimens, no cases 
were observed where MRP-1 was expressed independently of MDR-1/P-gp. 
However, 61% stained MDR-1/P-gp positive and MRP-1 negative. 6.7% of cases 
expressed neither drug efflux pumps. 
• These results suggest that P-gp may be functionally more important in the role of 
mediating pancreatic cancer chemotherapy resistance than MRP-1. However, no 
direct link can be made from this data as the chemotherapy resistance history of 
the patients is unknown, therefore, we cannot identify whether this MDR 
phenotype is inherent or acquired.  
• These results show that drug efflux pumps, in particular that of P-gp, are 
frequently expressed in pancreatic cancer. The absence of these pumps in the cell 
lines we used may represent a limitation of the degree in which they model 
pancreatic carcinoma in vivo. This fact should be considered when selecting 
chemotherapy/drug efflux pump inhibitors for future therapies. 
 
5.1.2 Characterisation of sub-populations within the pancreatic cancer cell line, 
MiaPaCa-2 
Heterogeneity within tumours may signify existence of sub-populations with inherent 
invasive/metastatic and drug resistance potentials (Fidler, 1978). 
• Clonal sub-populations of the pancreatic cancer cell line, MiaPaCa-2 which 
displayed variable levels of invasion were established. Clone #3 is 2.5-fold more 
invasive, while Clone #8 is 6-fold less invasive than the parental cell line.  
• Characterisation of these clones revealed that Clone #3 is consistent with the 
malignant transformation phenotype, exhibiting increased invasion through ECM 
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proteins, decreased adhesion to ECM proteins, increased anoikis resistance, ability 
to form colonies in anchorage independent conditions. The reverse of this pattern 
is observed for Clone #8 cells. 
• Integrins β1, α5 and α6 are up-regulated in the less invasive, high adhesive Clone 
#8. Functional knockdown by siRNA of integrin β1 revealed its involvement in the 
invasion and adhesion to matrigel and fibronectin. The loss of integrin β1 
expression also increases motility and anoikis resistance of Clone #8 cells. Our 
results show that integrin β1 may play a role as the main β-chain for the αβ chain 
heterodimer to form a fibronectin receptor. Expression of integrin β1 may act as an 
invasion and motility suppressor and encourage increased adhesiveness and 
anoikis sensitivity. However, invasion and adhesion to laminin was unaltered, 
suggesting that integrin β1 is not the main β-chain involved in laminin binding.  
• Loss of integrin α5 in Clone #8 cells induces increased motility and invasion 
through matrigel, laminin and fibronectin. Silencing of integrin α5 expression 
reduced adhesion to fibronectin. However, no reduction in adhesion was observed 
to matrigel and laminin. Anoikis was not altered when integrin α5 was down-
regulated. Therefore, our results suggest that integrin α5 plays a vital role in 
suppressing motility, invasion through matrigel, laminin and fibronectin, but is 
only involved in increased adhesion to the ECM protein, fibronectin. 
• Loss of integrin α6 in Clone #8 cells increases motility and invasion through 
matrigel and fibronectin, but decreases adhesion to laminin. Anoikis is also 
unaffected by loss of integrin α6. 
• Drug resistance profiling of MiaPaCa-2, Clone #3 and Clone #8 to a panel of ten 
chemotherapeutic drugs suggest a relationship between drug resistance and 
increased invasion in this cell line model. Clone #3 displays significant resistance 
to taxotere and VP-16. Clone #8 shows a significant sensitivity to nine out of ten 
drugs tested compared to the parent, MiaPaCa-2. 
The occurrence of sub-populations within cancer cell lines and the correlation with in vitro 
malignant transformation may offer an important tool for identifying markers of more 
aggressive metastatic cells in vivo. 
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5.1.3 Proteomic profiling of MiaPaCa-2 and sub-populations, Clone #3 and Clone 
#3 
• Proteomic comparative analysis of MiaPaCa-2, Clone #3 and Clone #8 in order of 
high to low invasion of the cell lines (MiaPaCa-2 versus Clone #8, Clone #3 
versus MiaPaCa-2 and Clone #3 versus Clone #8) generated lists of differentially 
expressed proteins. 
• The distinctive design analysis of overlapping the three generated proteins lists to 
specifically identify proteins that were consistently altered (either up-regulated or 
down-regulated) with the invasion status of the cell lines led to the identification of 
three proteins which were verified as having significant roles in invasion and the 
malignant process of pancreatic cancer. 
 
Aldehyde dehydrogenase 1A1 (ALDH1A1) 
ALDH1A1 is a cytosolic enzyme involved in the conversion of aldehydes to their 
corresponding acids by NAD(P)+ dependent reactions. The role of ALDH1A1 in 
mediating resistance to the family of oxazaphosphorines has been clearly demonstrated in 
breast and lung cancer (Sladek et al., 2002; Moreb et al., 2007); however, its role in 
invasion is undefined. ALDH1A1 was found to be up-regulated in the invasive Clone #3 
cell line and subsequent siRNA gene silencing revealed a novel role for this enzyme in 
pancreatic cancer invasion, adhesion and drug resistance. Exogeneous increase of 
ALDH1A1 expression by cDNA transfection in Clone #8 cells further confirmed the 
ability of ALDH1A1 to modulate invasion. ALDH1A1 acts as a catalyst in the oxidation 
of retinal to retinoic acid. We determined no evidence of a negative feedback loop on 
ALDH1A1 expression through ATRA exposure in Clone #3 cells. However, 
morphological changes and increased invasion of Clone #8 were observed after long-term 
continuous ATRA exposure, suggesting a further link to the invasive phenotype 
characterised by pancreatic cancer.  
ALDH1A1 may have dual potential as a therapeutic target as a treatment to inhibit 
invasion as well as sensitising cancer cells to certain chemotherapy regimes. This may be 
especially beneficial since drug resistant cells are refractory to chemotherapy and exhibit 
an aggressive invasive phenotype and highly metastatic cells are inherently more resistant 
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to chemotherapeutic treatment. Thus, targeting ALDH1A1 as an anti-invasive therapy in 
combination with selected chemotherapy may provide a more effective cancer treatment.  
 
Vimentin (VIM) 
VIM is a structural intermediate filament of the cytoskeleton. Its expression confers an 
epithelial to mesenchymal transition (EMT) phenotype characterised by increased 
invasion/metastasis and poorer survival times in many cancers (Gilles et al., 1996; 
Domagala et al., 1990). Our study confirms these previous reports and determined a 
functional role of VIM in pancreatic cancer cell invasion and adhesion; furthermore, the 
silencing of VIM expression in Clone #3 cells by siRNA induced morphological changes 
in the cells consistent with the reversal of the EMT phenotype termed mesenchymal to 
epithelial transition (MET). In agreement with in vivo studies (Colucci-Guyon et al., 1994; 
Eckes et al., 1998) loss of VIM expression did affect cell growth, therefore, VIM could be 
identified as a suitable adjuvant therapy specifically reversing the EMT phenotype while 
targeting cancer invasion and metastasis in conjunction with conventional chemotherapy 
treatment for the solid tumour mass. 
 
Stress-induced phosphoprotein 1 (STIP1) 
STIP1 mediates the association, and forms a physical complex with the molecular 
chaperones Hsp90 and Hsp70 (Carrigan et al., 2006). Little evidence exists determining a 
role for STIP1 in cancer cell invasion and the malignant phenotype. However, STIP1 acts 
as a co-chaperone for Hsp90 and Hsp70, whose involvement in cancer progression, 
development and maintenance has previously been identified (Pick et al., 2007; Aghdassi 
et al., 2007). Through RNAi knockdown of STIP1 expression in the invasive sub-
population, Clone #3, a functional role of STIP1 in invasion, adhesion and proliferation 
was observed in our study. Therefore, further studies on the novel anti-invasive and anti-
proliferative effects of STIP1 as a therapeutic target for pancreatic cancer needs to be 
assessed. Whether or not loss of STIP has functional consequences for Hsp90 and Hsp70, 




5.1.4 Characterisation and proteomic analysis of conditioned media, CM#3 and 
CM#8 
The ability of tumour cells to respond to microenvironmental factors present in the target 
organ may be necessary for successful metastasis. The potential role of secreted factors in 
conditioned media from Clone #3 and Clone #8 on invasion was investigated. 
•   Conditioned media (CM) collected from Clone #3 and Clone #8 and added into the 
in vitro invasion chamber at equal dilution ensuring no gradient (no chemotaxis) 
revealed that CM#3 significantly enhances invasion and CM#8 significantly 
inhibits invasion of MiaPaCa-2, Clone #3 and Clone #8 compared to an invasion 
assay control containing fresh medium. Pre-incubation of the cells with either 
CM#3 or CM#8 24 hrs prior to invasion assays displays the same trends indicating 
that the CMs secrete factor(s) that can modulate invasion. 
• MiaPaCa-2, Clone #3 and Clone #8 grown on matrigel for 24 hrs (in the presence 
of CM#3 and CM#8) prior to invasion assays display further increased invasion 
and superinvasion, suggesting that the cell-ECM contact highly activates 
molecules involved in invasion, and that this pathway may be essential in 
determining potential invasive markers.  
•   Temperature storage stability analysis of CM#3 and CM#8 determined that both 
CM#3 and CM#8 showed better stability in terms of inducing and inhibiting 
invasion when stored at -80o C compared to storage at 4 oC and -20 oC. 
•   The maximum diluent factors for CM#3 and CM#8 to exert their respective 
promotion and inhibitory effects on invasion was determined to be 1:4 with fresh 
media. 
•   pH stability experiments with CM#3 and CM#8 demonstrate that, compared to 
controls (fresh media treated with same pH changes), invasion was promoted to the 
greatest degree when CM#3 was exposed to acidic pH for 2 hrs at RT and brought 
back to pH 7, whereas CM#8 displayed the greatest inhibitory effect on invasion 
when exposed to alkaline pHs for 2 hrs RT and brought back to pH 7, then added 
into the invasion assay chamber.  
• Fractionation of CM#3 and CM#8 showed that invasion was significantly 
increased when higher molecular weight fractions of CM#3 (30-50 kDa, 50-100 
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kDa and 100 kDa) were added to the invasion insert. Invasion was significantly 
decreased when CM#8 fractions 10 kDa and 10-30 kDa were added into the 
invasion insert. Important fractions are secreted into CM#8, acting as an inhibitory 
factor at lower molecular weights, while CM#3 seems to promote invasion at 
higher molecular weight cut off points. 
 
5.1.5 Proteomic profiling of CM Mia, CM#3 and CM#8 
Secreted markers for pancreatic cancer invasion were profiled by proteomic analysis, 
revealing comparative differentially secreted protein between CMs. Emphasis was placed 
on the comparison of CM#3 versus CM#8, as the greatest difference in invasion 
modulation was observed. Two secreted targets chosen for functional analysis showed 
distinct roles in the invasive process of pancreatic cancer. 
 
Gelsolin (GSN) 
GSN is a calcium-binding protein which binds to and regulates actin filaments. The 
majority of work to date shows that GSN may act as a tumour suppressor in many cancer 
tissues. In our study, we confirmed that both cytoplasmic and secreted plasma GSN are 
expressed by Clone #8 and are functionally involved in suppressing pancreatic cancer 
invasion. Gene silencing of GSN reduced plasma and cytoplasmic GSN expression, 
revealing a more invasive phenotype. However, we also determined that cytoplasmic GSN 
expression may have an additional role in invasion suppression. Additional analysis of 
GSN expression and ECM contact, in this cell system may present a clearer picture for 
both cytoplasmic and plasma GSN, as an invasion inhibitory factor. 
 
Aldehyde dehydrogenase 1A1 (ALDH1A1) 
The nature of ALDH1A1 secretion has not been determined in literature. In our model, 
ALDH1A1 was found to be highly secreted in the invasive inducing CM#3. Silencing of 
ALDH1A1 secretion by siRNA in CM#3 significantly reduced the invasive promoting 
activities of CM#3. This study, to our knowledge, is the first report to implicate secreted 
ALDH1A1 as an invasive enhancer and further characterisation and study needs to be 
carried out to verify its effects in other caner types. 
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5.1.6 Role of EGFR and HER2 in pancreatic cancer 
Over-expression of EGFR and HER2 has been associated with reduced overall survival 
and disease free survival in some cancers. The potential use of lapatinib, a dual 
EGFR/HER2 tyrosine kinase inhibitor in combination with chemotherapeutic drugs in 
pancreatic cancer cell lines was assessed.  
• EGFR was expressed in all five of our pancreatic cancer cell lines, as determined 
by western blot and ELISA. HER2 was expressed at low levels in four out of five 
of our pancreatic cell line panel. High expression was observed only in one cell 
line, BxPc-3.  
• Combination assays of lapatinib with four chemotherapeutic drugs, cisplatin, 
gemcitabine, taxotere and 5’dFUrd in BxPc-3 and KCIMOH1 revealed that the 
combination of lapatinib and cisplatin, gemcitabine and 5’dFUrd has an overall 
additive effect compared to either drug alone. The combination of lapatinib and 
taxotere did not show any additivity, possibly because the potent toxicity of 
taxotere masked any additional anti-proliferation effects of lapatinib. 
• The scheduling regime is an important factor, as optimal effects of lapatinib and 
chemotherapeutic drugs was observed after 24 hrs pre-treatment with lapatinib 
followed by addition of chemo-drugs. This may be an important factor in pre-
clinical trials, as optimisation of scheduling regimes may determine a more 













5.2 Future work 
 
1. The proteomic profiling carried out in this thesis generated vast amounts of data. 
Only a fraction of the data was functionally analysed, and consequently, many 
potential targets remain to be examined. The analysis mainly focused on pancreatic 
cancer cell invasion; however, similar analysis could be carried out to determine 
functional involvement of differentially regulated proteins in other parameters 
relevant to cancer such as, adhesion, anoikis, proliferation and drug resistance. 
 
2. The metastatic potential of Clone #3 and Clone #8 will be verified in in vivo 
orthotopic mouse models. Stable transfected cell lines will be established with a 
fluorescent tag, the growth and metastatic spread of the cells will be followed by 
an in vivo fluorescent imager, to correlate metastasis with our in vitro work. 
 
3. ALDH1A1, VIM and STIP1 will be further analysed by transfection of their 
cDNA into the low invasive cell line, Clone #8. It would be interesting to see if 
modulation of the target proteins by cDNA transfection could be capable of 
inducing invasion and if their expression correlates with the invasive phenotype 
without non-specific effects. It is possible that individual silencing of any one of 
protein will not be enough to completely reduce invasion, and therefore, the next 
step would be combined silencing of two or more simultaneously.  
 
4. The role of the selected targets in vivo could be determined by measuring their 
expression in patient tissues sections. 
 
5. Tumour cells expressing CD44, CD24 and ESA have previously been found to 
characterise breast and pancreatic cancer stem cells, therefore ALDH1A1 
expression in pancreatic cancer could also be investigated as a potential marker for 
pancreatic cancer stem cells. 
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6. Identification of secreted targets may be clinically relevant as serum markers. 
Purification of secreted factors involved in the promotion/inhibition of invasion in 
CM of Clone #3 and Clone #8 could determine novel biomarkers and/or 
therapeutic targets. Techniques such as ultrafiltration, size-exclusion, gel-filtration 
and reverse-phase column chromatography could help to purify the secreted 
pancreatic tumour markers in conditioned media and may be applicable to serum 
biomarkers. 
 
7. Proteomic profiling of secreted proteins in CM#3 and CM#8 resulted in the 
identification of two secreted proteins functionally involved in the invasive 
modulation of CM to pancreatic cancer cells. Further validation of these and other 
targets identified in our analysis will be confirmed in pancreatic cancer patient 
serum. Comparison of our secreted factors in CM relating to invasion with patient 
serum may highlight the clinical importance of these ‘secreteomes’ in pancreatic 
cancer invasion. 
 
8. Co-expression of EGFR and HER2 needs to be assessed in pancreatic tumours to 
determine if a sub-population of pancreatic cancer patients exists to which 
lapatinib treatment in combination with chemotherapeutic drugs would be 
clinically applicable. This study will be carried out on paraffin-embedded 
pancreatic cancer tissue sections by immunohistochemistry. 
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Table 7.1 All proteins differentially regulated between MiaPaCa-2 versus Clone #8 





Antiquitin (b) ALDH7A1 gi|34783121| -4.7 *** 
Antiquitin (a) ALDH7A1 gi|34783121| -2.6 *** 
Glyceraldehyde-3-phosphate 
dehydrogenase (b) 
GAPDH gi|31645| -1.9 *** 
Glyceraldehyde-3-phosphate 
dehydrogenase (a) 
GAPDH gi|31645| -1.7 *** 
Profilin 1 PFN1 gi|30582841| -1.6 *** 
Keratin 18 KRT18 gi|12653819| -1.6 * 
Heat shock protein 60 (a) HSPD1 gi|77702086| -1.6 *** 
Heat shock protein 60 (b) HSPD1 gi|77702086| -1.5 * 
Beta actin (c) ACTB gi|15277503| -1.5 *** 
Peroxiredoxin 1 PRDX1 gi|55959887| -1.4 *** 
Peroxiredoxin 2 isoform b PRDX2 gi|33188452| -1.4 *** 
Muscle Fructose 1; 6-Bisphosphate 
Aldolase 
ALDOA gi|4930291| -1.4 ** 
14-3-3 Protein Theta (Human) 
Complexed To Peptide 
YWHAQ gi|71042777| -1.4 *** 
Ubiquinol-cytochrome c reductase 
complex core protein1 
UQCRC1 gi|731047| -1.3 *** 
Heat shock protein 60 (c) HSPD1 gi|77702086| -1.3 * 
Epsilon (Human) Complexed To 
Peptide 
YWHAE gi|67464424| -1.3 * 
Stomatin-like 2 STOML2 gi|6841440| -1.3 ** 
Aldehyde dehydrogenase 1 family; ALDH1B1 gi|30583675| -1.3 * 
381
member B1 
Glutathione synthetase GSS gi|8248826| -1.2 * 
Gamma actin (a) ACTG1 gi|17511847| 1.2 * 
Beta actin (d) ACTB1 gi|15277503| 1.2 * 
Alpha-tubulin TUBA gi|340021| 1.3 * 
Stress-induced-phosphoprotein 1 (a) STIP1 gi|54696884| 1.3 * 
ER-60 protein PDIA3 gi|2245365| 1.3 * 
Tubulin alpha 6 variant TUBA6 gi|62897609| 1.3 ** 
Heat shock 70kDa protein 1A HSPA1A gi|5123454| 1.3 *** 
Glucosidase II GANAB gi|2274968| 1.4 *** 
Eukaryotic translation initiation 
factor 4A; isoform 1 
EIF4A1 gi|40786436| 1.4 * 
Annexin I (a) ANXA1 gi|442631| 1.5 ** 
heat shock 70kDa protein 8 isoform 
1 variant (d) 
HSPA8 gi|62897129| 1.5 *** 
Human rab GDI GDI2 gi|285975| 1.6 *** 
Enolase 1 ENO1 gi|62897945| 1.6 *** 
Heat shock 70kDa protein 8 isoform 
1 variant (a) 
HSPA8 gi|62897129| 1.6 *** 
Ubiquitin-activating enzyme E1 UBE1 gi|57209338| 1.6 ** 
Pyruvate kinase 3 isoform 1 variant 
(a) 
PKM2 gi|62897413| 1.6 *** 
Muscle Pyruvate Kinase (b) PKM2 gi|67464392| 1.6 ** 
Annexin A2 isoform 2 variant ANXA2 gi|62896643| 1.6 *** 
GARS protein GARS gi|12652637| 1.7 *** 
Nucleoside Triphosphate; Nucleoside 
Diphosphate 
NDPK gi|1421614| 1.7 *** 
Chaperonin TCPI, subunit 5 
(epsilon) 
CCT5 gi|58257644| 1.7 *** 
Vimentin (d) VIM gi|57471646| 1.8 ** 
382 
Vinculin VCL gi|24657579| 1.8 *** 
Tryptophanyl-Trna Synthetase WARS gi|50513261| 1.8 *** 
Heat shock 70kDa protein 4 isoform 
a variant 
HSPA4 gi|62087882| 2.0 *** 
Eukaryotic translation elongation 
factor 1 alpha 1 variant (c) 
EEF1A1 gi|62897525| 2.0 *** 
Gamma actin (b) ACTG1 gi|17511847| 2.0 *** 
Eukaryotic translation elongation 
factor 2 
EEF2 gi|33869643| 2.1 *** 
Vimentin (a) VIM gi|57471646| 2.2 *** 
Triosephosphate Isomerase (a) TPI1 gi|66360366| 2.2 *** 
Vimentin (b) VIM gi|57471646| 2.2 *** 
Beta actin (b) ACTB gi|15277503| 2.3 *** 
Aldehyde dehydrogenase 1 (c) ALDH1A1 gi|2183299| 3.8 *** 
Aldehyde dehydrogenase 1 (a) ALDH1A1 gi|2183299| 5.3 *** 

























Table 7.2 All proteins differentially regulated between Clone #3 versus MiaPaCa-2 





Keratin 18 KRT18 gi|12653819| -1.8





annexin A2 isoform 2 variant ANXA2 gi|62896643| -1.3




90kDa heat shock protein HSP90ab1 gi|306891| -1.2








heat shock 70kD protein 9B (mortalin-2) HSPA9 gi|21040386| 1.2





aldehyde dehydrogenase 1 (b) ALDH1A1  gi|2183299| 1.2
transketolase TKT  gi|37267| 1.3




Triosephosphate Isomerase (b) TPI1 (b) gi|999893| 1.3
ACTG1 protein (a) ACTG1  gi|17511847| 1.3
ATP5A1 protein (a) ATP5A1  gi|34782901| 1.3
ATP synthase beta subunit ATPB gi|179279| 1.3
















ACO2 ACO2 gi|49168620| 1.4
Annexin I (b) ANXA1  gi|442631| 1.5
Chain B; 14-3-3 Protein Theta (Human) 
Complexed To Peptide 
YWHAQ 
gi|71042777| 1.5
ER-60 protein PDIA3 gi|2245365| 1.5
translation initiation factor EIF4F gi|496902| 1.5
ATP5A1  ATP5A1  gi|34782901| 1.5
Hydroxyacyl dehydrogenase; subunit B HADHB gi|44890770| 1.5
stress-induced-phosphoprotein 1 (a) STIP1  gi|54696884| 1.5
Glucosidase II GANAB gi|2274968| 1.6
translation elongation factor 1 alpha 1-
like 14 (b) 
EEF1A1 
gi|15277711| 1.6
ubiquitin-activating enzyme E1 UBE1 gi|57209338| 1.6
aldehyde dehydrogenase 1 (a) ALDH1A1  gi|2183299| 1.7
ACTB protein (a) ACTB  gi|15277503| 1.7
Antiquitin (a) ALDH7A1  gi|34783121| 1.7




elongation factor 1-alpha 1 (a) EEF1A1  gi|28848610| 2.0
Antiquitin (b) ALDH7A1 gi|34783121| 2.2
vimentin (a) VIM gi|57471646| 2.5
385 
Table 7.3 All proteins differentially regulated between Clone #3 versus Clone #8 
 






aldehyde dehydrogenase 1 (a) ALDH1A1  gi|2183299| 8.9
aldehyde dehydrogenase 1 (b) ALDH1A1  gi|2183299| 8.4
vimentin (a) VIM  gi|57471646| 5.5
aldehyde dehydrogenase 1 (c) ALDH1A1  gi|2183299| 5.3
Triosephosphate Isomerase (a) TPI1  gi|66360366| 4.0
vimentin (b) VIM  gi|57471646| 2.8
vimentin (c) VIM  gi|37852| 2.7
ubiquitin-activating enzyme E1 UBE1 gi|57209338| 2.6
heat shock 70kDa protein 4 isoform a 
variant 
HSPA4 gi|62087882| 2.4
Chain A; Structure Of Human Muscle 
Pyruvate Kinase (Pkm2) 
PKM2 gi|67464392| 2.4
elongation factor 1-alpha 1 (a) EEF1A1  gi|28848610| 2.4
translation elongation factor 1 alpha 1-
like 14 (b) 
EEF1A1 gi|15277711| 2.2
VCL protein VCL gi|24657579| 2.2
Glucosidase II GANAB gi|2274968| 2.2
ER-60 protein (a) PDIA3 gi|2245365| 2.0
stress-induced-phosphoprotein 1 (a) STIP1  gi|54696884| 2.0
vimentin (d) VIM  gi|57471646| 2.0
EEF2 protein (a) EEF2 gi|33869643| 2.0
pyruvate kinase 3 isoform 1 variant PKM2 gi|62897413| 1.9
heat shock 70kDa protein 8 isoform 1  HSPA8 gi|62897129| 1.9
enolase 1 variant ENO1 gi|62897945| 1.9
386 
eukaryotic translation elongation 
factor 1 alpha 1 variant (c) 
EEF1A1  gi|62897525| 1.8
GARS protein GARS gi|12652637| 1.8
human rab GDI GDI2 gi|285975| 1.8
KIAA0098 protein CCT5 gi|58257644| 1.8
stress-induced-phosphoprotein 1 (b) STIP1  gi|54696884| 1.8
Chain A; Human Cyclophilin A 
Complexed With 2-Thr Cyclosporin 
PPIA gi|3659980| 1.7
tubulin alpha 6 variant (a) TUBA6 gi|62897609| 1.7
heat shock 70kDa protein 8 isoform 1  HSPA8  gi|62897129| 1.7
ER-60 protein (b) PDIA3 gi|2245365| 1.7
MTHSP75 HSPA9 gi|292059| 1.6
beta-tubulin (a) TUBB gi|338695| 1.5
translation initiation factor EIF4A3 gi|496902| 1.5
heat shock 70kDa protein 8 isoform 1 
variant (b) 
HSPA8 gi|62897129| 1.5
ATP5A1 protein ATP5A1 gi|34782901| 1.5
ACTG1 protein (a) ACTG1  gi|17511847| 1.5
tubulin alpha 6 variant (b) TUBA6 gi|62897609| 1.4
Tubulin; beta polypeptide (b) TUBB gi|18088719| 1.4
protein disulfide isomerase-related 
protein 5 
PDIA5 gi|1710248| 1.4
tubulin alpha 6 variant (c) TUBA6 gi|62897609| 1.4
alpha-tubulin TUBA gi|340021| 1.4
Tubulin; beta polypeptide (c) TUBB gi|18088719| 1.4
Fragment Of Human Tryptophanyl-
Trna Synthetase 
WARS gi|50513261| 1.4
MDH2 MDH2 gi|49168580| 1.4
ACO2 ACO2 gi|49168620| 1.3
Bisphosphate Aldolase ALDOA gi|4930291| 1.3











Annexin I (b) ANXA1 gi|442631| 1.3
EEF2 protein EEF2 gi|33869643|               1.2
Mortalin-2 HSPA9 gi|21040386| 1.2
HSPC108 STOML2 gi|6841440| -1.2
Ubiquinol-cytochrome-c reductase 
complex core protein I 
UQCRC1 gi|731047| -1.3
heat shock 70kDa protein 8 isoform 1 
variant (c) 
HSPA8  gi|62897129| -1.3
profilin 1 PFN1 gi|30582841| -1.4
heat shock protein 60 (a) HSPD1  gi|77702086| -1.5
Antiquitin (a) ALDH7A1  gi|34783121| -1.5
ACTB protein (c) ACTB  gi|15277503| -1.6
glyceraldehyde-3-phosphate 
dehydrogenase (a) 
GAPDH  gi|31645| -1.9
Antiquitin (b) ALDH7A1  gi|34783121| -2.2
glyceraldehyde-3-phosphate 
dehydrogenase (b) 
GAPDH  gi|31645| -2.6
Keratin 18 KRT18 gi|12653819| -2.9
388
